Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
33600.0 | 2017-06-15 00:00:00 UTC | Abbott Laboratories Up on EPD & Buyouts, Pediatric Weak | ABT | https://www.nasdaq.com/articles/abbott-laboratories-up-on-epd-buyouts-pediatric-weak-2017-06-15 | nan | nan | On Jun 14, we issued an updated research report on Illinois-based Abbott Laboratories ABT . It is a leading distributor of health care products and services across the globe. The company currently carries a Zacks Rank #2 (Buy).
For the majority of the last one month, Abbott has been trading above the broader Medical - Products industry. The stock has gained 9.0%, compared to the 4.7% gain of the broader industry. Recently, the company received CE mark for its TactiCath Sensor and Confirm Rx ICM products. The company also launched science-based nutrition drinks for faster recovery from surgeries. The company's product diversification plan is expected to drive the share price in the near future.
Notably, Abbott's Established Pharmaceuticals Division (EPD) operates only in emerging markets such as India, Russia and Latin America. The company recently claimed that banking on successful execution of its operating model, EPD is well positioned for sustained growth in many of these growing pharmaceutical markets. Particularly, Latin America, China and several markets in Southeast Asia have demonstrated strong growth of late. We believe, the company's continued focus on enhancing local capabilities and expanding its product portfolio within core therapeutic areas will strengthen its position in these markets.
Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude Medical which was acquired at the start of 2017. The latter has a dominant position in fast-growing areas such as atrial fibrillation, heart failure, structural heart and chronic pain, which will complement Abbott's leading position in the coronary interventions and mitral valve disease markets.
There bodes well for Abbott's investors as the enduring legal battle with its acquisition target Alere seems to be finally over. However, as expected, the financial terms of the deal have been amended in favor of Abbott. Under the altered terms, Abbott will pay $51 per common share to take over Alere, for a new expected equity value of approximately $5.3 billion, reduced from the originally expected equity value of approximately $5.8 billion. Considering the attractive prospects of Point-of-care testing within the in vitro diagnostics market, Abbott is highly optimistic about the Alere deal. According to the company, the acquisition of Alere will significantly expand its diagnostics presence and leadership in this space.
On the flip side, Abbott's sluggish pediatric business in China continues to hamper growth. Management is also concerned about the ongoing economic problem in Venezuela that is expected to remain unresolved in the coming quarters. Foreign exchange headwind continues to plague the stock.
Other Key Picks
Other top-ranked medical stocks are Align Technology, Inc. ALGN , Inogen, Inc. INGN and Accelerate Diagnostics, Inc. AXDX . Notably, Align Technology and Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock added roughly 30.6% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 90.2%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock added roughly 14.2% over the last three months.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Jun 14, we issued an updated research report on Illinois-based Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, Abbott's Established Pharmaceuticals Division (EPD) operates only in emerging markets such as India, Russia and Latin America. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. On Jun 14, we issued an updated research report on Illinois-based Abbott Laboratories ABT . Other Key Picks Other top-ranked medical stocks are Align Technology, Inc. ALGN , Inogen, Inc. INGN and Accelerate Diagnostics, Inc. AXDX . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. On Jun 14, we issued an updated research report on Illinois-based Abbott Laboratories ABT . Under the altered terms, Abbott will pay $51 per common share to take over Alere, for a new expected equity value of approximately $5.3 billion, reduced from the originally expected equity value of approximately $5.8 billion. | On Jun 14, we issued an updated research report on Illinois-based Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Under the altered terms, Abbott will pay $51 per common share to take over Alere, for a new expected equity value of approximately $5.3 billion, reduced from the originally expected equity value of approximately $5.8 billion. |
33601.0 | 2017-06-15 00:00:00 UTC | Health Care Sector Update for 06/15/2017: JNJ, PFE, ABT, MRK, AMGN, CRBP, LNTH | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06152017-jnj-pfe-abt-mrk-amgn-crbp-lnth-2017-06-15 | nan | nan | Top Health Care stocks:
JNJ: +0.6%
PFE: flat
ABT: flat
MRK: +0.1%
AMGN: -0.5
Health care shares were mixed in pre-market trade Thursday.
In health care stocks news, Skyline Medical ( SKLN ) was up 16.6% after it said that its European authorized representative, Emergo Europe BV, has notified the Dutch Competent Authority that the company's Streamway System meets all requirements and can now be affixed with the CE mark and marketed in 32 European countries. The system is described as the first true direct-to-drain fluid disposal system designed specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures.
In other sector news,
(+) CRBP (+2.5%) Plans to commence phase 3 study of anabasum for the treatment of systemic sclerosis in Q4
(-) LNTH (-5.9%) Agrees to sell 3 million shares of its common stock to be offered by certain of its existing stockholders
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat ABT: flat Health care shares were mixed in pre-market trade Thursday. In health care stocks news, Skyline Medical ( SKLN ) was up 16.6% after it said that its European authorized representative, Emergo Europe BV, has notified the Dutch Competent Authority that the company's Streamway System meets all requirements and can now be affixed with the CE mark and marketed in 32 European countries. | PFE: flat ABT: flat In health care stocks news, Skyline Medical ( SKLN ) was up 16.6% after it said that its European authorized representative, Emergo Europe BV, has notified the Dutch Competent Authority that the company's Streamway System meets all requirements and can now be affixed with the CE mark and marketed in 32 European countries. In other sector news, (+) CRBP (+2.5%) Plans to commence phase 3 study of anabasum for the treatment of systemic sclerosis in Q4 (-) LNTH (-5.9%) Agrees to sell 3 million shares of its common stock to be offered by certain of its existing stockholders The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat ABT: flat In health care stocks news, Skyline Medical ( SKLN ) was up 16.6% after it said that its European authorized representative, Emergo Europe BV, has notified the Dutch Competent Authority that the company's Streamway System meets all requirements and can now be affixed with the CE mark and marketed in 32 European countries. In other sector news, (+) CRBP (+2.5%) Plans to commence phase 3 study of anabasum for the treatment of systemic sclerosis in Q4 (-) LNTH (-5.9%) Agrees to sell 3 million shares of its common stock to be offered by certain of its existing stockholders The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat ABT: flat Top Health Care stocks: The system is described as the first true direct-to-drain fluid disposal system designed specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures. |
33602.0 | 2017-06-15 00:00:00 UTC | 3 Dividend Stocks for Astute Investors | ABT | https://www.nasdaq.com/articles/3-dividend-stocks-astute-investors-2017-06-15 | nan | nan | Anyone can buy a dividend-paying stock, but only the most astute investors are able to ferret out those that represent the best combination of income, yield, and growth. Sometimes it takes looking where others fear to go.
We asked three top Motley Fool contributors to highlight a dividend stock that a sharp investor would find advantageous to own. Read on to find out why Hasbro (NASDAQ: HAS) , AbbVie (NYSE: ABBV) , and Best Buy (NYSE: BBY) could be just what an astute investor is looking for.
Dividends can be fun
Demitri Kalogeropoulos ( Hasbro ): At a 2.1% yield, toys and games specialist Hasbro is paying about what you could get by owning a diversified total stock market index fund. There are good reasons to expect this dividend to grow at a market-thumping rate in the years ahead, though.
Its latest quarterly results showed off the strength of Hasbro's deep portfolio of company-owned and -licensed brands. Revenue ticked higher by 2% to meet management's expectations at a time when rival Mattel (NASDAQ: MAT) posted a surprising 15% slump. Yes, profitability fell slightly. But CEO Brian Goldner and his team expect operating margin to rise for the full year thanks to excitement around popular theatrical and TV releases in the Disney Princess, Star Wars , and My Little Pony franchises.
Hasbro raised its dividend by 12% in 2017 to mark the second straight year of accelerating payout growth. The company is no dividend aristocrat, since it had to pause raises in 2009 during the worst of the financial crisis. Yet even including that stumble, Hasbro's dividend has increased at a 14% compound annual rate over the past decade. I'm expecting its core gaming business to continue snatching market share over the next few quarters. Meanwhile, Hasbro should begin generating significant profits from a young entertaining and licensing segment that's just starting to tap into promising areas such as digital gaming. Those positive operating trends imply solid dividend growth for income investors.
More to the story for this biotech dividend stock
Keith Speights ( AbbVie ): A big biotech depends on one drug for 63% of its total revenue. The U.S. Food and Drug Administration approved a biosimilar competitor to that one drug. The biotech's No. 2 drug makes only a little over one-eighth of the top-selling drug that's in jeopardy. Could the dividend the company pays be in trouble? Should investors stay away? Not when the biotech in question is AbbVie.
All of those statements are true, though. AbbVie does depend on Humira for much of its revenue. The FDA did approve Amgen 's (NASDAQ: AMGN) Amjevita, a biosimilar to Humira, last September. Sales for AbbVie's second best-selling drug, Imbruvica, totaled $551 million in the first quarter. That's an impressive amount, but it pales in comparison with the $4.1 billion in sales for Humira.
Astute investors, however, won't be too worried about all of this. They'll understand that AbbVie is in pretty good shape to fend off Amgen and other rivals for quite a while. Although the FDA approved Amjevita, the drug isn't on the market yet. AbbVie has taken Amgen to court over patent infringement. That court date is set for November 2019. AbbVie remains confident that it will protect Humira from U.S. competition through 2022.
Astute investors will also look at AbbVie's growth prospects from new drugs. The company's pipeline is loaded with potential blockbusters, including cancer drugs Rova-T and Veliparib and autoimmune-disease drug ABT-494.
And, of course, these investors will pay attention to AbbVie's dividend. Its yield currently stands at 3.77%. AbbVie has increased its dividend payments by 60% since the company was spun off from parent Abbott Labs (NYSE: ABT) in 2013. With Humira safe for a while and plenty of new drugs on the way, the dividend checks should keep on flowing for a long time to come.
Last man standing
Rich Duprey ( Best Buy ): It was only five years ago that Best Buy was seen as the next Circuit City, a rival electronics superstore that was forced into bankruptcy. Its CEO had resigned amid an investigation into his personal conduct, Amazon.com (NASDAQ: AMZN) was stealing its customers through "showrooming," and its own e-commerce efforts were negligible at best. How far Best Buy has come!
Today, it's pretty much the last man standing, as Radio Shack, hhgregg, and others have also succumbed to the rigors of the marketplace. But not Best Buy. CEO Hubert Joly has transformed the financially troubled electronics retailer into a relatively reliable performer that's even able to challenge Amazon at its own game. Recode recently reported that Best Buy is trialing a new try-before-you-buy service. Now, not just cost-cutting and improved customer service, but also by making its business better than Amazon, it plans to ring up higher sales. Its e-commerce sales may not be on par with the internet's retailing leader, but its rate of growth continues to surpass Amazon.
And next year, Best Buy could become the third biggest appliance retailer, behind Lowe's and Home Depot . According to Twice, Best Buy has cut third-place Sears Holdings ' sales lead from $1.3 billion to just $743 million, meaning, at this pace, it could leapfrog ahead of the ailing retailer.
The market apparently hasn't noticed Best Buy's newfound strength. Although its stock has doubled from its 52-week low, shares still trade at just 15 times earnings and 13 times next year's estimates, and it goes for just a fraction of its sales. It also trades at just 13 times the free cash flow it produces, making it a cheap stock. Considering it pays a dividend of $1.24 per share yielding 2.2%, it makes it a perfect stock for astute income investors looking for overlooked opportunities.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Demitrios Kalogeropoulos owns shares of Hasbro, Home Depot, and Walt Disney. Keith Speights owns shares of AbbVie and Walt Disney. Rich Duprey has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Amazon, Hasbro, and Walt Disney. The Motley Fool recommends Home Depot and Lowe's. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company's pipeline is loaded with potential blockbusters, including cancer drugs Rova-T and Veliparib and autoimmune-disease drug ABT-494. AbbVie has increased its dividend payments by 60% since the company was spun off from parent Abbott Labs (NYSE: ABT) in 2013. But CEO Brian Goldner and his team expect operating margin to rise for the full year thanks to excitement around popular theatrical and TV releases in the Disney Princess, Star Wars , and My Little Pony franchises. | The company's pipeline is loaded with potential blockbusters, including cancer drugs Rova-T and Veliparib and autoimmune-disease drug ABT-494. AbbVie has increased its dividend payments by 60% since the company was spun off from parent Abbott Labs (NYSE: ABT) in 2013. More to the story for this biotech dividend stock Keith Speights ( AbbVie ): A big biotech depends on one drug for 63% of its total revenue. | The company's pipeline is loaded with potential blockbusters, including cancer drugs Rova-T and Veliparib and autoimmune-disease drug ABT-494. AbbVie has increased its dividend payments by 60% since the company was spun off from parent Abbott Labs (NYSE: ABT) in 2013. Read on to find out why Hasbro (NASDAQ: HAS) , AbbVie (NYSE: ABBV) , and Best Buy (NYSE: BBY) could be just what an astute investor is looking for. | The company's pipeline is loaded with potential blockbusters, including cancer drugs Rova-T and Veliparib and autoimmune-disease drug ABT-494. AbbVie has increased its dividend payments by 60% since the company was spun off from parent Abbott Labs (NYSE: ABT) in 2013. AbbVie does depend on Humira for much of its revenue. |
33603.0 | 2017-06-14 00:00:00 UTC | Johnson & Johnson: The Bear Case From a Bull | ABT | https://www.nasdaq.com/articles/johnson-johnson-bear-case-bull-2017-06-14 | nan | nan | You probably couldn't describe me as a raging bull when it comes to Johnson & Johnson (NYSE: JNJ) stock, but I'm a bull nonetheless. With the healthcare giant's shares at all-time highs, I still think the stock will go even higher.
However, I can fully understand why some might not be so bullish on J&J. I can even see why some investors could be bearish on the stock. Here are three key arguments in a bear case against Johnson & Johnson that this bull admits could have some validity.
1. Not enough soon enough from the pipeline
In my opinion, Johnson & Johnson has one of the best pipelines around . Additional indications could be on the way for several current drugs, including Darzalex, Imbruvica, Invokana, Stelara, and Xarelto. J&J also claims promising new products, including psoriasis drug Tremfya (guselkumab) and rheumatoid arthritis drug sirukumab.
The problem, though, is that J&J's pipeline potential might not be enough soon enough to overcome some of the company's challenges. Remicade ranks at the top of that list of challenges. Pfizer (NYSE: PFE) is already marketing a biosimilar to Remicade, branded as Inflectra in the U.S. and as Remsima in Europe. Although Pfizer's first-quarter sales of $78 million for the drug was only a drop in the bucket compared to Remicade's sales of nearly $1.7 billion, it's probably just a matter of time before J&J feels the full brunt of competition.
And Remicade isn't J&J's only problem. Year-over-year sales fell in the first quarter for several other drugs, including Invokana, Procrit, Xarelto, and Zytiga. Total pharmaceuticals sales for the company in the first quarter increased an anemic 0.8% over the prior-year period.
It's great that J&J thinks it will launch or file for regulatory approval for at least 10 new drugs by 2021 that could be blockbusters. The company's current lineup, however, simply isn't delivering significant growth.
2. Consumer and medical devices segments still sluggish
You know there's a problem when Johnson & Johnson's consumer and medical devices business segments outperform its pharmaceuticals segment. But that's exactly what happened in the first quarter -- and the other two segments weren't exactly on fire.
Consumer segment sales grew all of 1% versus the first quarter of 2016. J&J's medical devices segment did a little better, with a year-over-year sales increase of 3%. I don't think those numbers caused any investors to turn cartwheels.
Johnson & Johnson bought some of the growth for these two segments. The company's 2016 acquisition of Vogue International helped improve sales for the consumer segment, while the acquisition of Abbott Medical Optics from Abbott Labs , in February, made a difference for the medical devices segment.
Sales growth is certainly better than the alternative. However, with J&J's pharmaceuticals segment struggling, investors probably shouldn't look to J&J's consumer and medical devices segments to come to the rescue.
3. Positives already baked into the share price
Johnson & Johnson's impressive stock gains in recent months have also driven its valuation higher. J&J's earnings multiple is getting close to the highest level it's been in the last 10 years.
The positives for the company (such as anticipated approval for Tremfya) could already be baked into the share price. If so, J&J's rapid rise this year could be in jeopardy.
Bull to bear?
Are these arguments enough to flip me from a bull to a bear on Johnson & Johnson stock? Not really.
It's best to have a long-term perspective. Over the long run, J&J should perform quite well. Sure, there are stocks that have better growth prospects. There are stocks more attractively valued. There are stocks with higher dividend yields. If investors could only buy one stock, Johnson & Johnson may not be the best choice. But investors aren't restricted to just one stock.
In my view, Johnson & Johnson continues to be a solid pick for nearly any investment portfolio. I'm still a bull on this stock.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Keith Speights owns shares of Pfizer. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Additional indications could be on the way for several current drugs, including Darzalex, Imbruvica, Invokana, Stelara, and Xarelto. Pfizer (NYSE: PFE) is already marketing a biosimilar to Remicade, branded as Inflectra in the U.S. and as Remsima in Europe. Year-over-year sales fell in the first quarter for several other drugs, including Invokana, Procrit, Xarelto, and Zytiga. | Consumer and medical devices segments still sluggish You know there's a problem when Johnson & Johnson's consumer and medical devices business segments outperform its pharmaceuticals segment. Positives already baked into the share price Johnson & Johnson's impressive stock gains in recent months have also driven its valuation higher. The Motley Fool owns shares of and recommends Johnson & Johnson. | You probably couldn't describe me as a raging bull when it comes to Johnson & Johnson (NYSE: JNJ) stock, but I'm a bull nonetheless. Consumer and medical devices segments still sluggish You know there's a problem when Johnson & Johnson's consumer and medical devices business segments outperform its pharmaceuticals segment. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! | And Remicade isn't J&J's only problem. Johnson & Johnson bought some of the growth for these two segments. I'm still a bull on this stock. |
33604.0 | 2017-06-13 00:00:00 UTC | How AbbVie Inc. Makes Most of Its Money | ABT | https://www.nasdaq.com/articles/how-abbvie-inc-makes-most-its-money-2017-06-13 | nan | nan | AbbVie Inc. (NYSE: ABBV) makes a lot of money. In 2016, the big biotech generated revenue totaling $25.6 billion. That's a big jump from the $18.8 billion that AbbVie made in 2013, its first year as a standalone company after being spun off by Abbott Laboratories (NYSE: ABT) .
But for investors, one key question has to be, exactly how does AbbVie make most of that money? Let's dig into the answer for the present, and look at how things could change in the future.
Where AbbVie makes its money now
The primary source for AbbVie's revenue now is the same as it was when the company was spun off from Abbott: Humira. Not only is Humira the top-selling drug for AbbVie, it's also the top-selling drug in the world. How dependent is AbbVie on Humira? The following chart tells the story.
Humira generates roughly 63% of AbbVie's total revenue. The company's No. 2 product, cancer drug Imbruvica, comes in a distant second, contributing 8% of total revenue. Hepatitis C virus (HCV) drug Viekira ranks third, kicking in 4% of AbbVie's revenue.
After these three drugs, AbbVie has several other products that make significant revenue. At the top of the list is Lupron, which generated sales of $821 million last year. The drug is approved for treating prostate cancer, endometriosis, fibroids, and central precocious puberty.
The other way of looking at where AbbVie currently makes its money is by geographical region. AbbVie provides market details only on its drugs listed by name, so the following chart does not include revenue generated by products in the "all other" category.
On an overall basis, AbbVie is heavily dependent on the U.S. market for its revenue. However, it can be a different story depending on individual products. For example, nearly 78% of Viekira sales are made in international markets. All of AbbVie's sales for Synagis, a drug prescribed to help protect children from respiratory syncytial virus (RSV), are in international markets.
A look at AbbVie's potential future
How AbbVie makes money will change dramatically over the next few years. AbbVie thinks that it can hold off biosimilar rivals to Humira in the U.S. through 2022 by asserting its intellectual property rights for the drug. However, Humira will inevitably face competition from biosimilars at some point, which will lead to a significant decrease in sales.
Expect sales for Imbruvica to climb, though. AbbVie has projected that it will make $7 billion in peak annual sales from the cancer drug -- and that doesn't include the revenue that Johnson & Johnson will make from it. Whether or not this lofty goal can be attained will depend in large part on how well several phase 2 and phase 3 clinical studies targeting additional indications go.
At one point, AbbVie predicted sales for Viekira could reach $3 billion. However, HCV patient starts have dropped significantly thanks to several drugs coming on the market that cure hepatitis C. As a result, AbbVie can't depend on Viekira to significantly offset a potential drop in Humira's sales down the road, although the biotech's next-generation HCV treatment could help. The other drugs in AbbVie's current lineup aren't likely to grow sales enough to make a big difference for AbbVie, however.
The good news for AbbVie, though, is that it has several promising pipeline candidates with blockbuster potential. Below is a table showing several of these candidates with peak sales projections.
Data sources: AbbVie and analyst estimates.
While Humira should continue to be a primary source of revenue for AbbVie for years to come, Imbruvica and other drugs likely on the way should become much more important to the company in the future.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | That's a big jump from the $18.8 billion that AbbVie made in 2013, its first year as a standalone company after being spun off by Abbott Laboratories (NYSE: ABT) . All of AbbVie's sales for Synagis, a drug prescribed to help protect children from respiratory syncytial virus (RSV), are in international markets. While Humira should continue to be a primary source of revenue for AbbVie for years to come, Imbruvica and other drugs likely on the way should become much more important to the company in the future. | That's a big jump from the $18.8 billion that AbbVie made in 2013, its first year as a standalone company after being spun off by Abbott Laboratories (NYSE: ABT) . In 2016, the big biotech generated revenue totaling $25.6 billion. AbbVie has projected that it will make $7 billion in peak annual sales from the cancer drug -- and that doesn't include the revenue that Johnson & Johnson will make from it. | That's a big jump from the $18.8 billion that AbbVie made in 2013, its first year as a standalone company after being spun off by Abbott Laboratories (NYSE: ABT) . Where AbbVie makes its money now The primary source for AbbVie's revenue now is the same as it was when the company was spun off from Abbott: Humira. AbbVie has projected that it will make $7 billion in peak annual sales from the cancer drug -- and that doesn't include the revenue that Johnson & Johnson will make from it. | That's a big jump from the $18.8 billion that AbbVie made in 2013, its first year as a standalone company after being spun off by Abbott Laboratories (NYSE: ABT) . How dependent is AbbVie on Humira? After these three drugs, AbbVie has several other products that make significant revenue. |
33605.0 | 2017-06-13 00:00:00 UTC | 111 Actions to Take this Week | ABT | https://www.nasdaq.com/articles/111-actions-take-week-2017-06-13 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
During these busy times, it pays to stay on top of the latest profit opportunities and today's blog post should be a great place to start.
After taking a close look at the latest data on institutional buying pressure and each company's fundamental health, I decided to revise my Portfolio Grader recommendations for 111 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly.
This Week's Ratings Changes:
To stay on top of my latest stock ratings, plug your holdings into Portfolio Grader , my proprietary stock screening tool. You may get started here .
More From InvestorPlace
7 Stocks to Buy in Wall Street's Hottest Industry
7 Stocks With More Upside Than Alphabet
10 Stocks to Buy Before They Finally Join the Rally
The post 111 Actions to Take this Week appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips During these busy times, it pays to stay on top of the latest profit opportunities and today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fundamental health, I decided to revise my Portfolio Grader recommendations for 111 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. This Week's Ratings Changes: To stay on top of my latest stock ratings, plug your holdings into Portfolio Grader , my proprietary stock screening tool. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips During these busy times, it pays to stay on top of the latest profit opportunities and today's blog post should be a great place to start. This Week's Ratings Changes: To stay on top of my latest stock ratings, plug your holdings into Portfolio Grader , my proprietary stock screening tool. More From InvestorPlace 7 Stocks to Buy in Wall Street's Hottest Industry 7 Stocks With More Upside Than Alphabet 10 Stocks to Buy Before They Finally Join the Rally The post 111 Actions to Take this Week appeared first on InvestorPlace . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips During these busy times, it pays to stay on top of the latest profit opportunities and today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fundamental health, I decided to revise my Portfolio Grader recommendations for 111 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. |
33606.0 | 2017-06-13 00:00:00 UTC | Health Care Sector Update for 06/13/2017: JNJ, PFE, ABT, MRK, AMGN, CHRS, IMNP | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06132017-jnj-pfe-abt-mrk-amgn-chrs-imnp-2017-06-13 | nan | nan | Top Health Care stocks:
JNJ: +0.1%
PFE: flat
ABT: flat
MRK: -1.2%
AMGN: flat
Health care shares were mostly flat in pre-market trade Tuesday.
In health care stocks news, Merck & Company ( MRK ) was down 1.2% after it said late Monday it accepted an external data monitoring committee's recommendation to pause new enrollment on Keynote-183 and Keynote-185, two studies exploring Keytruda treatment in combination with other therapies in multiple myeloma. The pause will allow additional information to be collected to understand more reports of death in Keytruda groups, the company said in a statement. Patients currently enrolled in the two studies will continue to receive treatment. Other studies of Keytruda will continue unchanged.
In other sector news,
(+) CHRS (+6.2%) Says FDA requests reanalysis of CHS-1701
IMNP (flat) Monica Luchi resigns from her role as chief medical officer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat ABT: flat In health care stocks news, Merck & Company ( MRK ) was down 1.2% after it said late Monday it accepted an external data monitoring committee's recommendation to pause new enrollment on Keynote-183 and Keynote-185, two studies exploring Keytruda treatment in combination with other therapies in multiple myeloma. The pause will allow additional information to be collected to understand more reports of death in Keytruda groups, the company said in a statement. | PFE: flat ABT: flat In health care stocks news, Merck & Company ( MRK ) was down 1.2% after it said late Monday it accepted an external data monitoring committee's recommendation to pause new enrollment on Keynote-183 and Keynote-185, two studies exploring Keytruda treatment in combination with other therapies in multiple myeloma. In other sector news, (+) CHRS (+6.2%) Says FDA requests reanalysis of CHS-1701 IMNP (flat) Monica Luchi resigns from her role as chief medical officer The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat ABT: flat AMGN: flat Health care shares were mostly flat in pre-market trade Tuesday. In health care stocks news, Merck & Company ( MRK ) was down 1.2% after it said late Monday it accepted an external data monitoring committee's recommendation to pause new enrollment on Keynote-183 and Keynote-185, two studies exploring Keytruda treatment in combination with other therapies in multiple myeloma. | PFE: flat ABT: flat AMGN: flat Health care shares were mostly flat in pre-market trade Tuesday. In health care stocks news, Merck & Company ( MRK ) was down 1.2% after it said late Monday it accepted an external data monitoring committee's recommendation to pause new enrollment on Keynote-183 and Keynote-185, two studies exploring Keytruda treatment in combination with other therapies in multiple myeloma. |
33607.0 | 2017-06-12 00:00:00 UTC | IVE, PFE, ABT, CVS: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/ive-pfe-abt-cvs-large-outflows-detected-etf-2017-06-12 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $73.9 million dollar outflow -- that's a 0.6% decrease week over week (from 127,050,000 to 126,350,000). Among the largest underlying components of IVE, in trading today Pfizer Inc (Symbol: PFE) is up about 1%, Abbott Laboratories (Symbol: ABT) is trading flat, and CVS Health Corporation (Symbol: CVS) is up by about 0.5%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average:
Looking at the chart above, IVE's low point in its 52 week range is $87.88 per share, with $107.75 as the 52 week high point - that compares with a last trade of $105.95. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVE, in trading today Pfizer Inc (Symbol: PFE) is up about 1%, Abbott Laboratories (Symbol: ABT) is trading flat, and CVS Health Corporation (Symbol: CVS) is up by about 0.5%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $87.88 per share, with $107.75 as the 52 week high point - that compares with a last trade of $105.95. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IVE, in trading today Pfizer Inc (Symbol: PFE) is up about 1%, Abbott Laboratories (Symbol: ABT) is trading flat, and CVS Health Corporation (Symbol: CVS) is up by about 0.5%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $87.88 per share, with $107.75 as the 52 week high point - that compares with a last trade of $105.95. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IVE, in trading today Pfizer Inc (Symbol: PFE) is up about 1%, Abbott Laboratories (Symbol: ABT) is trading flat, and CVS Health Corporation (Symbol: CVS) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $73.9 million dollar outflow -- that's a 0.6% decrease week over week (from 127,050,000 to 126,350,000). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $87.88 per share, with $107.75 as the 52 week high point - that compares with a last trade of $105.95. | Among the largest underlying components of IVE, in trading today Pfizer Inc (Symbol: PFE) is up about 1%, Abbott Laboratories (Symbol: ABT) is trading flat, and CVS Health Corporation (Symbol: CVS) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $73.9 million dollar outflow -- that's a 0.6% decrease week over week (from 127,050,000 to 126,350,000). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $87.88 per share, with $107.75 as the 52 week high point - that compares with a last trade of $105.95. |
33608.0 | 2017-06-12 00:00:00 UTC | Health Care Sector Update for 06/12/2017: JNJ, PFE, ABT, MRK, AMGN,CHRS, NVO, AZN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06122017-jnj-pfe-abt-mrk-amgnchrs-nvo-azn-2017-06-12 | nan | nan | Top Health Care stocks:
JNJ: +0.2%
PFE: +0.3%
ABT: flat
MRK: +0.3%
AMGN: +0.9%
Health care shares were mostly higher in pre-market trade Monday.
In health care stocks news, Coherus BioSciences ( CHRS ) was down 31% after it received a complete response letter from the U.S. Food and Drug Administration for its biologics license application for CHS-1701, a pegfilgrastim (Neulasta) biosimilar candidate, under the 351(k) pathway, that will cause a delay in approval. It said the FDA requested a reanalysis of a subset of subject samples with a revised immunogenicity assay, and requested certain additional manufacturing related process information. The FDA did not request a clinical study to be performed in oncology patients. Additionally, the CRL does not indicate additional process qualification lots would be required or raise concerns over the GMP status of CHS-1701 bulk manufacturing and fill-finish vendors.
In other sector news,
(+) NVO, (+1.9%) Says people with type 1 diabetes and type 2 diabetes experienced a significant reduction in HbA1c 6 months after switching to Tresiba from another basal insulin
(-) AZN, (-0.5%) Reports new clinical trial data supporting the safety profile of type 2 diabetes adjunct treatment, Farxiga
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat Health care shares were mostly higher in pre-market trade Monday. In health care stocks news, Coherus BioSciences ( CHRS ) was down 31% after it received a complete response letter from the U.S. Food and Drug Administration for its biologics license application for CHS-1701, a pegfilgrastim (Neulasta) biosimilar candidate, under the 351(k) pathway, that will cause a delay in approval. | ABT: flat In health care stocks news, Coherus BioSciences ( CHRS ) was down 31% after it received a complete response letter from the U.S. Food and Drug Administration for its biologics license application for CHS-1701, a pegfilgrastim (Neulasta) biosimilar candidate, under the 351(k) pathway, that will cause a delay in approval. In other sector news, (+) NVO, (+1.9%) Says people with type 1 diabetes and type 2 diabetes experienced a significant reduction in HbA1c 6 months after switching to Tresiba from another basal insulin (-) AZN, (-0.5%) Reports new clinical trial data supporting the safety profile of type 2 diabetes adjunct treatment, Farxiga The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat In health care stocks news, Coherus BioSciences ( CHRS ) was down 31% after it received a complete response letter from the U.S. Food and Drug Administration for its biologics license application for CHS-1701, a pegfilgrastim (Neulasta) biosimilar candidate, under the 351(k) pathway, that will cause a delay in approval. It said the FDA requested a reanalysis of a subset of subject samples with a revised immunogenicity assay, and requested certain additional manufacturing related process information. | ABT: flat Top Health Care stocks: It said the FDA requested a reanalysis of a subset of subject samples with a revised immunogenicity assay, and requested certain additional manufacturing related process information. |
33609.0 | 2017-06-09 00:00:00 UTC | Health Care Sector Update for 06/09/2017: JNJ, PFE, ABT, MRK, AMGN, ENDP, LXRX, MBOT | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06092017-jnj-pfe-abt-mrk-amgn-endp-lxrx-mbot-2017-06-09 | nan | nan | Top Health Care stocks:
JNJ: +0.3%
PFE: +1.4%
ABT: +0.4%
MRK: +1.34%
AMGN: +1.2%
Health care shares were higher in mid-day trade Friday.
In health care stocks news, Endo International ( ENDP ) fell 14.9% after the company said it is reviewing a request from the U.S. Food and Drug Administration to voluntarily remove its Opana ER opioid pain killer from the U.S. market, that cited the increase in the misuse and abuse of opioid products. The company said it is "evaluating the full range of potential options as we determine the appropriate path forward."
In other sector news,
(+) LXRX, (+4.9%) Says phase 3 trial of its drug sotagliflozin to treat patients with type 1 diabetes met its primary endpoint
(-) MBOT, (-2.2%) Closes registered direct offering of nearly 3.8 million shares of common stock for total gross proceeds of $10.1 million
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Endo International ( ENDP ) fell 14.9% after the company said it is reviewing a request from the U.S. Food and Drug Administration to voluntarily remove its Opana ER opioid pain killer from the U.S. market, that cited the increase in the misuse and abuse of opioid products. The company said it is "evaluating the full range of potential options as we determine the appropriate path forward." In other sector news, (+) LXRX, (+4.9%) Says phase 3 trial of its drug sotagliflozin to treat patients with type 1 diabetes met its primary endpoint (-) MBOT, (-2.2%) Closes registered direct offering of nearly 3.8 million shares of common stock for total gross proceeds of $10.1 million The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Endo International ( ENDP ) fell 14.9% after the company said it is reviewing a request from the U.S. Food and Drug Administration to voluntarily remove its Opana ER opioid pain killer from the U.S. market, that cited the increase in the misuse and abuse of opioid products. In other sector news, (+) LXRX, (+4.9%) Says phase 3 trial of its drug sotagliflozin to treat patients with type 1 diabetes met its primary endpoint (-) MBOT, (-2.2%) Closes registered direct offering of nearly 3.8 million shares of common stock for total gross proceeds of $10.1 million The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Endo International ( ENDP ) fell 14.9% after the company said it is reviewing a request from the U.S. Food and Drug Administration to voluntarily remove its Opana ER opioid pain killer from the U.S. market, that cited the increase in the misuse and abuse of opioid products. In other sector news, (+) LXRX, (+4.9%) Says phase 3 trial of its drug sotagliflozin to treat patients with type 1 diabetes met its primary endpoint (-) MBOT, (-2.2%) Closes registered direct offering of nearly 3.8 million shares of common stock for total gross proceeds of $10.1 million The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved. | Top Health Care stocks: The company said it is "evaluating the full range of potential options as we determine the appropriate path forward." In other sector news, (+) LXRX, (+4.9%) Says phase 3 trial of its drug sotagliflozin to treat patients with type 1 diabetes met its primary endpoint (-) MBOT, (-2.2%) Closes registered direct offering of nearly 3.8 million shares of common stock for total gross proceeds of $10.1 million The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33610.0 | 2017-06-09 00:00:00 UTC | Health Care Sector Update for 06/09/2017: JNJ, PFE, ABT, MRK, AMGN, ENZ, BNTC, SNSS | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06092017-jnj-pfe-abt-mrk-amgn-enz-bntc-snss-2017-06-09 | nan | nan | Top Health Care stocks:
JNJ: +0.5%
PFE: +2.8%
ABT: +0.9%
MRK: +1.9%
AMGN: +1.7%
Health care shares were higher ahead of the close of Friday's session.
In health care stocks news, Enzo Biochem ( ENZ ) was up 13.7% after the company reported breakeven per share for the three months ended April 30, compared to a net loss per share of $0.04. Q3 revenue increased 2% to $27.1 million. An analyst had predicted a net loss per share of $0.01 on $27.5 million in revenue.
In other sector news,
(+) BNTC, (+2.8%) Receives additional AUD636,056 ($478,985) cash refund for 2016 under the Australian Federal Government's research & development tax incentive scheme
(-) SNSS, (-1.9%) Files a shelf registration of securities with an aggregate amount of $200 million.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were higher ahead of the close of Friday's session. In health care stocks news, Enzo Biochem ( ENZ ) was up 13.7% after the company reported breakeven per share for the three months ended April 30, compared to a net loss per share of $0.04. In other sector news, (+) BNTC, (+2.8%) Receives additional AUD636,056 ($478,985) cash refund for 2016 under the Australian Federal Government's research & development tax incentive scheme (-) SNSS, (-1.9%) Files a shelf registration of securities with an aggregate amount of $200 million. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In health care stocks news, Enzo Biochem ( ENZ ) was up 13.7% after the company reported breakeven per share for the three months ended April 30, compared to a net loss per share of $0.04. | In health care stocks news, Enzo Biochem ( ENZ ) was up 13.7% after the company reported breakeven per share for the three months ended April 30, compared to a net loss per share of $0.04. An analyst had predicted a net loss per share of $0.01 on $27.5 million in revenue. In other sector news, (+) BNTC, (+2.8%) Receives additional AUD636,056 ($478,985) cash refund for 2016 under the Australian Federal Government's research & development tax incentive scheme (-) SNSS, (-1.9%) Files a shelf registration of securities with an aggregate amount of $200 million. | In health care stocks news, Enzo Biochem ( ENZ ) was up 13.7% after the company reported breakeven per share for the three months ended April 30, compared to a net loss per share of $0.04. An analyst had predicted a net loss per share of $0.01 on $27.5 million in revenue. In other sector news, (+) BNTC, (+2.8%) Receives additional AUD636,056 ($478,985) cash refund for 2016 under the Australian Federal Government's research & development tax incentive scheme (-) SNSS, (-1.9%) Files a shelf registration of securities with an aggregate amount of $200 million. |
33611.0 | 2017-06-09 00:00:00 UTC | What Traders Can Learn From Professional Horse Betting | ABT | https://www.nasdaq.com/articles/what-traders-can-learn-professional-horse-betting-2017-06-09 | nan | nan | Thegreek.com, a horse racing blog, discusses the "seven deadly sins" losing horse bettors commit. Repeat these sins in your trading, and you'll suffer the same fate as the losers at the track.
Here are the four most important sins to avoid:
Deadly Sin No. 1: The most important thing is picking winners
The few horse bettors good enough to make a living know it's not about picking a winner. It's about identifying positive expected value . Often that means the lower probability play is the better bet.
If an option is currently priced to profit one in 10 times, but you think it'll profit two in 10 times, then buy it. It's a value. It doesn't matter that most of the time the option will expire worthless . Over the long haul, the buyer will walk away profitable.
Deadly Sin No. 3: You should bet more on a horse you really like, such as your 'best bet'
Professional track gamblers understand that bet size is incredibly important. Sizing your bets based on "hunches" leaves you susceptible to accidently betting big on losers and tiny on winners.
Imagine three trades where you're right on the first two and wrong on the last . And since you thought you had a "hot hand," you bet really big on that last loser. This would result in the losses from the last trade canceling out the gains from your first two winners. Your account would end up net negative.
Sizing up has a time and a place in trading. George Soros would bet big when the stars aligned. But you need lots of experience before you can start sizing up on what you think are great trades.
Until you're seasoned and able to determine between a good and great bet, keep your position sizes consistent. If you don't, you risk going broke from bad luck.
Deadly Sin No. 4: Statistical betting trends are important
Ever wonder why those really smart quants with the fancy degrees end up blowing up? It's because they have too much trust in a model tightly fit to past data.
Studying the past can help you figure out what'll happen in the future, but only within reason. If you create a trading model based on the premise that the future will play out exactly like the past, it will fail.
Keep historically based assumptions as simple as possible. That will help thread the needle between useful insight and robustness.
Deadly Sin No. 7: Specialize in certain aspects of the game and pick your spots
That's why our team at Macro Ops trades global macro. If stocks dry up, we have the flexibility to drop into the grains market or currencies or any other market where there's high expected value profit opportunities. The more markets you learn to trade, the easier it is to trade only the most attractive setups.
Warning! GuruFocus has detected 4 Warning Signs with BMY. Click here to check it out.
BMY 15-Year Financial Data
The intrinsic value of BMY
Peter Lynch Chart of BMY
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Until you're seasoned and able to determine between a good and great bet, keep your position sizes consistent. 4: Statistical betting trends are important Ever wonder why those really smart quants with the fancy degrees end up blowing up? If you create a trading model based on the premise that the future will play out exactly like the past, it will fail. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 1: The most important thing is picking winners The few horse bettors good enough to make a living know it's not about picking a winner. | 3: You should bet more on a horse you really like, such as your 'best bet' Professional track gamblers understand that bet size is incredibly important. Sizing your bets based on "hunches" leaves you susceptible to accidently betting big on losers and tiny on winners. BMY 15-Year Financial Data The intrinsic value of BMY Peter Lynch Chart of BMY Premium Members This article first appeared on GuruFocus . | 1: The most important thing is picking winners The few horse bettors good enough to make a living know it's not about picking a winner. 3: You should bet more on a horse you really like, such as your 'best bet' Professional track gamblers understand that bet size is incredibly important. Sizing up has a time and a place in trading. |
33612.0 | 2017-06-09 00:00:00 UTC | Daily Dividend Report: GE, PM, ABT, CL, AMAT, THO, HPP | ABT | https://www.nasdaq.com/articles/daily-dividend-report-ge-pm-abt-cl-amat-tho-hpp-2017-06-09 | nan | nan | GE ( GE ) declared a $0.24 per share dividend on the outstanding stock of the Company payable July 25, 2017 to shareowners of record at the close of business on June 19, 2017. The ex-dividend date is June 15, 2017.
Philip Morris International ( PM ) declared a regular quarterly dividend of $1.04 per common share, payable on July 11, 2017, to shareholders of record as of June 23, 2017. The ex-dividend date is June 21, 2017.
Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. The cash dividend is payable Aug. 15, 2017, to shareholders of record at the close of business on July 14, 2017.
Colgate-Palmolive Company ( CL ) declared a quarterly cash dividend of $0.40 per common share, payable on August 15, 2017, to shareholders of record on July 18, 2017.
Applied Materials has approved a quarterly cash dividend of $0.10 per share payable on the company's common stock. The dividend is payable on September 14, 2017 to shareholders of record as of August 24, 2017.
Thor Industries ( THO ) approved, at their June 8, 2017 meeting, the payment of a regular quarterly dividend of $0.33 per share. The regular dividend is payable on July 12, 2017, to shareholders of record at the close of business on June 23, 2017.
Hudson Pacific Properties (HPP) has declared a quarterly dividend on its common stock of $0.25 per share for the second quarter of 2017. The dividend will be paid on June 30, 2017 to stockholders of record on June 20, 2017.
VIDEO: Daily Dividend Report: GE, PM, ABT, CL, AMAT, THO, HPP
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. VIDEO: Daily Dividend Report: GE, PM, ABT, CL, AMAT, THO, HPP The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Philip Morris International ( PM ) declared a regular quarterly dividend of $1.04 per common share, payable on July 11, 2017, to shareholders of record as of June 23, 2017. | VIDEO: Daily Dividend Report: GE, PM, ABT, CL, AMAT, THO, HPP The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. Philip Morris International ( PM ) declared a regular quarterly dividend of $1.04 per common share, payable on July 11, 2017, to shareholders of record as of June 23, 2017. | Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. VIDEO: Daily Dividend Report: GE, PM, ABT, CL, AMAT, THO, HPP The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. GE ( GE ) declared a $0.24 per share dividend on the outstanding stock of the Company payable July 25, 2017 to shareowners of record at the close of business on June 19, 2017. | Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. VIDEO: Daily Dividend Report: GE, PM, ABT, CL, AMAT, THO, HPP The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Philip Morris International ( PM ) declared a regular quarterly dividend of $1.04 per common share, payable on July 11, 2017, to shareholders of record as of June 23, 2017. |
33613.0 | 2017-06-08 00:00:00 UTC | Health Care Sector Update for 06/08/2017: JNJ, PFE, ABT, MRK, AMGN, CYTR, TGTX, QGEN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06082017-jnj-pfe-abt-mrk-amgn-cytr-tgtx-qgen-2017-06-08 | nan | nan | Top Health Care stocks:
JNJ: +0.1%
PFE: -0.2%
ABT: +0.2%
MRK: -1.4%
AMGN: +0.8
Health care shares were mixed in mid-day trade Thursday.
In health care stocks news, CytRx ( CYTR ) rose 16.1% after the biopharmaceutical research and development company said it plans to submit a rolling new drug application (NDA) to the US Food and Drug Administration for aldoxorubicin as a treatment for soft tissue sarcomas ( STS ). The NDA will be under the 505(b)(2) pathway, which is designed for a new drug that contains the same active ingredient as a previously approved drug, also known as a reference drug. For aldoxorubicin, doxorubicin is the reference drug. The NDA submission is not reliant solely on the recently completed phase 3 clinical trial in STS or overall survival results. Instead, CytRx's completed pharmacokinetic clinical trial, phase 2b and phase 3 trials in STS, along with preclinical safety and efficacy studies, will serve as "scientific bridges" between aldoxorubicin and doxorubicin. These studies, along with the published literature of doxorubicin's effectiveness and safety, will form the basis of the NDA filing for aldoxorubicin under the 505(b)(2) regulations.
In other sector news,
(+) TGTX, (+4.9%) To present clinical abstracts featuring its two therapies targeting hematological malignancies and autoimmune diseases
(-) QGEN, (-0.4%) Says FDA OKs quantiFeron-TB gold plus
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The NDA submission is not reliant solely on the recently completed phase 3 clinical trial in STS or overall survival results. These studies, along with the published literature of doxorubicin's effectiveness and safety, will form the basis of the NDA filing for aldoxorubicin under the 505(b)(2) regulations. In other sector news, (+) TGTX, (+4.9%) To present clinical abstracts featuring its two therapies targeting hematological malignancies and autoimmune diseases (-) QGEN, (-0.4%) Says FDA OKs quantiFeron-TB gold plus The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, CytRx ( CYTR ) rose 16.1% after the biopharmaceutical research and development company said it plans to submit a rolling new drug application (NDA) to the US Food and Drug Administration for aldoxorubicin as a treatment for soft tissue sarcomas ( STS ). The NDA submission is not reliant solely on the recently completed phase 3 clinical trial in STS or overall survival results. Instead, CytRx's completed pharmacokinetic clinical trial, phase 2b and phase 3 trials in STS, along with preclinical safety and efficacy studies, will serve as "scientific bridges" between aldoxorubicin and doxorubicin. | In health care stocks news, CytRx ( CYTR ) rose 16.1% after the biopharmaceutical research and development company said it plans to submit a rolling new drug application (NDA) to the US Food and Drug Administration for aldoxorubicin as a treatment for soft tissue sarcomas ( STS ). Instead, CytRx's completed pharmacokinetic clinical trial, phase 2b and phase 3 trials in STS, along with preclinical safety and efficacy studies, will serve as "scientific bridges" between aldoxorubicin and doxorubicin. In other sector news, (+) TGTX, (+4.9%) To present clinical abstracts featuring its two therapies targeting hematological malignancies and autoimmune diseases (-) QGEN, (-0.4%) Says FDA OKs quantiFeron-TB gold plus The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, CytRx ( CYTR ) rose 16.1% after the biopharmaceutical research and development company said it plans to submit a rolling new drug application (NDA) to the US Food and Drug Administration for aldoxorubicin as a treatment for soft tissue sarcomas ( STS ). For aldoxorubicin, doxorubicin is the reference drug. Instead, CytRx's completed pharmacokinetic clinical trial, phase 2b and phase 3 trials in STS, along with preclinical safety and efficacy studies, will serve as "scientific bridges" between aldoxorubicin and doxorubicin. |
33614.0 | 2017-06-08 00:00:00 UTC | Health Care Sector Update for 06/08/2017: JNJ, PRE, ABT, MRK, AMGN, CHRS, TVTY, AXN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06082017-jnj-pre-abt-mrk-amgn-chrs-tvty-axn-2017-06-08 | nan | nan | Top Health Care stocks:
JNJ: -0.5%
PFE: -0.6%
ABT: +0.3%
MRK: -1.8%
AMGN: +0.2%
Health care shares were mixed ahead of the close of Thursday's session.
In health care stocks news, Coherus BioSciences ( CHRS ) rose 10.1% ahead of the U.S. Food and Drug Administration's June 9 action date on the company's pegfilgrastim, a Neulasta biosimilar. Neulasta is used to reduce the chance of infection due to a low white blood cell count in people with certain types of cancer who receive chemotherapy. It is manufactured by Amgen ( AMGN ).
In other sector news,
(+) TVTY, (+4.8%) Has reportedly received takeover interest from private equity firms
(-) AXN, (-9.6%) Reports an improvement in both Q2 revenue and net income from the year-ago level
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Coherus BioSciences ( CHRS ) rose 10.1% ahead of the U.S. Food and Drug Administration's June 9 action date on the company's pegfilgrastim, a Neulasta biosimilar. Neulasta is used to reduce the chance of infection due to a low white blood cell count in people with certain types of cancer who receive chemotherapy. In other sector news, (+) TVTY, (+4.8%) Has reportedly received takeover interest from private equity firms (-) AXN, (-9.6%) Reports an improvement in both Q2 revenue and net income from the year-ago level The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Coherus BioSciences ( CHRS ) rose 10.1% ahead of the U.S. Food and Drug Administration's June 9 action date on the company's pegfilgrastim, a Neulasta biosimilar. In other sector news, (+) TVTY, (+4.8%) Has reportedly received takeover interest from private equity firms (-) AXN, (-9.6%) Reports an improvement in both Q2 revenue and net income from the year-ago level The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Coherus BioSciences ( CHRS ) rose 10.1% ahead of the U.S. Food and Drug Administration's June 9 action date on the company's pegfilgrastim, a Neulasta biosimilar. In other sector news, (+) TVTY, (+4.8%) Has reportedly received takeover interest from private equity firms (-) AXN, (-9.6%) Reports an improvement in both Q2 revenue and net income from the year-ago level The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved. | Top Health Care stocks: Health care shares were mixed ahead of the close of Thursday's session. In health care stocks news, Coherus BioSciences ( CHRS ) rose 10.1% ahead of the U.S. Food and Drug Administration's June 9 action date on the company's pegfilgrastim, a Neulasta biosimilar. |
33615.0 | 2017-06-07 00:00:00 UTC | Health Care Sector Update for 06/07/2017: JNJ, PFE, ABT, MRK, AMGN, CALA, ALOG, CERS | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06072017-jnj-pfe-abt-mrk-amgn-cala-alog-cers-2017-06-07 | nan | nan | Top Health Care stocks:
JNJ: -0.1%
PFE: -0.2%
ABT: -0.1%
MRK: -0.6%
AMGN: +0.9
Health care shares were mostly lower in mid-day trade Wednesday.
In health care stocks news, Calithera Biosciences ( CALA ) was up 13.6% after it said that the U.S. Food and Drug Administration has granted fast track designation to CB-839 in combination with everolimus, for the treatment of patients with metastatic renal cell carcinoma who have received two or more prior lines of therapy. CB-839 is a first-in-class, oral, selective, potent inhibitor of glutaminase being evaluated in phase 1/2 clinical trials for the treatment of solid tumors including renal cell carcinoma, triple negative breast cancer, non-small cell lung cancer, and melanoma. The company said that it will be imitating a global randomized trial of CB-839 in combination with everolimus for the treatment of renal cell carcinoma in H2.
In other sector news,
(+) CERS, (+12.3%) Says the expected shortage of platelet additive solution from Fresenius Kabi could be less disruptive to the blood center production of the company's Intercept platelets than initially anticipated
(-) ALOG, (-10.1%) Guides FY17 earnings below Street as fiscal Q3 results beat estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Calithera Biosciences ( CALA ) was up 13.6% after it said that the U.S. Food and Drug Administration has granted fast track designation to CB-839 in combination with everolimus, for the treatment of patients with metastatic renal cell carcinoma who have received two or more prior lines of therapy. The company said that it will be imitating a global randomized trial of CB-839 in combination with everolimus for the treatment of renal cell carcinoma in H2. In other sector news, (+) CERS, (+12.3%) Says the expected shortage of platelet additive solution from Fresenius Kabi could be less disruptive to the blood center production of the company's Intercept platelets than initially anticipated (-) ALOG, (-10.1%) Guides FY17 earnings below Street as fiscal Q3 results beat estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Calithera Biosciences ( CALA ) was up 13.6% after it said that the U.S. Food and Drug Administration has granted fast track designation to CB-839 in combination with everolimus, for the treatment of patients with metastatic renal cell carcinoma who have received two or more prior lines of therapy. In other sector news, (+) CERS, (+12.3%) Says the expected shortage of platelet additive solution from Fresenius Kabi could be less disruptive to the blood center production of the company's Intercept platelets than initially anticipated (-) ALOG, (-10.1%) Guides FY17 earnings below Street as fiscal Q3 results beat estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Calithera Biosciences ( CALA ) was up 13.6% after it said that the U.S. Food and Drug Administration has granted fast track designation to CB-839 in combination with everolimus, for the treatment of patients with metastatic renal cell carcinoma who have received two or more prior lines of therapy. CB-839 is a first-in-class, oral, selective, potent inhibitor of glutaminase being evaluated in phase 1/2 clinical trials for the treatment of solid tumors including renal cell carcinoma, triple negative breast cancer, non-small cell lung cancer, and melanoma. In other sector news, (+) CERS, (+12.3%) Says the expected shortage of platelet additive solution from Fresenius Kabi could be less disruptive to the blood center production of the company's Intercept platelets than initially anticipated (-) ALOG, (-10.1%) Guides FY17 earnings below Street as fiscal Q3 results beat estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care stocks: In health care stocks news, Calithera Biosciences ( CALA ) was up 13.6% after it said that the U.S. Food and Drug Administration has granted fast track designation to CB-839 in combination with everolimus, for the treatment of patients with metastatic renal cell carcinoma who have received two or more prior lines of therapy. The company said that it will be imitating a global randomized trial of CB-839 in combination with everolimus for the treatment of renal cell carcinoma in H2. |
33616.0 | 2017-06-07 00:00:00 UTC | Health Care Sector Update for 06/07/2017: JNJ, PFE, ABT, MRK, AMGN, KMDA, JAZZ, EXAS | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06072017-jnj-pfe-abt-mrk-amgn-kmda-jazz-exas-2017-06-07 | nan | nan | Top Health Care stocks:
JNJ: +0.1%
PFE: -0.5%
ABT: +0.5%
MRK: -0.9%
AMGN: +1.2%
Health care shares were mixed ahead of the close of Wednesday's session.
In health care stocks news, Kamada ( KMDA ) was down 6.1% following the transfer of full ownership and responsibility for the clinical development of Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (GvHD) from Shire ( SHPG ). An investigational new drug (IND) application approved by the U.S. Food and Drug Administration for the phase 2/3 study evaluating the drug will be transferred from Shire to Kamada, the company said in a press release. Shire has been leading the G1-AAT IV GvHD program in the U.S., while Kamada was leading the program in the EU. Shire decided to transfer the IND to Kamada due to pipeline prioritization and slow recruitment rate in its current U.S. study. Kamada will assume control of, and onward funding for the full G1-AAT IV program, and intends to conduct an integrated clinical development program across both territories--the U.S. and the EU. As the result of this decision, the current part 1 of the phase 2/3 study conducted in the U.S. is being halted by Shire. SHPG shares were down 2.1%.
In other sector news,
(+) JAZZ, (+4.8%) Says JZP-110 could be an important treatment option for patients suffering from excessive sleepiness as a result of narcolepsy
(-) EXAS, (-5%) Prices an offering of 7.0 million common shares at $35 each, equal to a 4.3% discount relative to Tuesday's closing price
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Kamada ( KMDA ) was down 6.1% following the transfer of full ownership and responsibility for the clinical development of Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (GvHD) from Shire ( SHPG ). Shire decided to transfer the IND to Kamada due to pipeline prioritization and slow recruitment rate in its current U.S. study. In other sector news, (+) JAZZ, (+4.8%) Says JZP-110 could be an important treatment option for patients suffering from excessive sleepiness as a result of narcolepsy (-) EXAS, (-5%) Prices an offering of 7.0 million common shares at $35 each, equal to a 4.3% discount relative to Tuesday's closing price The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Kamada ( KMDA ) was down 6.1% following the transfer of full ownership and responsibility for the clinical development of Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (GvHD) from Shire ( SHPG ). Shire has been leading the G1-AAT IV GvHD program in the U.S., while Kamada was leading the program in the EU. In other sector news, (+) JAZZ, (+4.8%) Says JZP-110 could be an important treatment option for patients suffering from excessive sleepiness as a result of narcolepsy (-) EXAS, (-5%) Prices an offering of 7.0 million common shares at $35 each, equal to a 4.3% discount relative to Tuesday's closing price The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Kamada ( KMDA ) was down 6.1% following the transfer of full ownership and responsibility for the clinical development of Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (GvHD) from Shire ( SHPG ). An investigational new drug (IND) application approved by the U.S. Food and Drug Administration for the phase 2/3 study evaluating the drug will be transferred from Shire to Kamada, the company said in a press release. In other sector news, (+) JAZZ, (+4.8%) Says JZP-110 could be an important treatment option for patients suffering from excessive sleepiness as a result of narcolepsy (-) EXAS, (-5%) Prices an offering of 7.0 million common shares at $35 each, equal to a 4.3% discount relative to Tuesday's closing price The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were mixed ahead of the close of Wednesday's session. In health care stocks news, Kamada ( KMDA ) was down 6.1% following the transfer of full ownership and responsibility for the clinical development of Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (GvHD) from Shire ( SHPG ). An investigational new drug (IND) application approved by the U.S. Food and Drug Administration for the phase 2/3 study evaluating the drug will be transferred from Shire to Kamada, the company said in a press release. |
33617.0 | 2017-06-06 00:00:00 UTC | Health Care Sector Update for 06/06/2017: JNJ, PFE, ABT, MRK, AMGN, NOVT, SNOA, EGLT | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06062017-jnj-pfe-abt-mrk-amgn-novt-snoa-eglt-2017-06-06 | nan | nan | Top Health Care stocks:
JNJ: +0.4%
PFE: -0.9%
ABT: -0.4%
MRK: -0.8%
AMGN: +0.1%
Most health care shares were on track to close Tuesday's session lower.
In health care stocks news, Egalet ( EGLT ) was up 15.3% after the company said one of the largest payers in the United States will provide coverage of its Arymo extended-release tablets, an abuse-deterrent morphine product for the treatment of chronic pain. Egalet did not identify the payer but said it has over 24 million members. The new drug coverage is effective immediately, the company said. Oxaydo tablets and Sprix nasal spray will also be covered through 2018.
In other sector news,
(+) NOVT, (+5.1%) To acquire privately-held World of Medicine GmbH for EUR115 million ($129.4 million) in cash
(-) SNOA, (-7.8%) Reports wider-than-expected Q4 loss and revenue that beat the single analyst estimate on Capital IQ
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Most health care shares were on track to close Tuesday's session lower. In health care stocks news, Egalet ( EGLT ) was up 15.3% after the company said one of the largest payers in the United States will provide coverage of its Arymo extended-release tablets, an abuse-deterrent morphine product for the treatment of chronic pain. In other sector news, (+) NOVT, (+5.1%) To acquire privately-held World of Medicine GmbH for EUR115 million ($129.4 million) in cash (-) SNOA, (-7.8%) Reports wider-than-expected Q4 loss and revenue that beat the single analyst estimate on Capital IQ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Egalet ( EGLT ) was up 15.3% after the company said one of the largest payers in the United States will provide coverage of its Arymo extended-release tablets, an abuse-deterrent morphine product for the treatment of chronic pain. In other sector news, (+) NOVT, (+5.1%) To acquire privately-held World of Medicine GmbH for EUR115 million ($129.4 million) in cash (-) SNOA, (-7.8%) Reports wider-than-expected Q4 loss and revenue that beat the single analyst estimate on Capital IQ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Egalet ( EGLT ) was up 15.3% after the company said one of the largest payers in the United States will provide coverage of its Arymo extended-release tablets, an abuse-deterrent morphine product for the treatment of chronic pain. In other sector news, (+) NOVT, (+5.1%) To acquire privately-held World of Medicine GmbH for EUR115 million ($129.4 million) in cash (-) SNOA, (-7.8%) Reports wider-than-expected Q4 loss and revenue that beat the single analyst estimate on Capital IQ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved. | Top Health Care stocks: In health care stocks news, Egalet ( EGLT ) was up 15.3% after the company said one of the largest payers in the United States will provide coverage of its Arymo extended-release tablets, an abuse-deterrent morphine product for the treatment of chronic pain. In other sector news, (+) NOVT, (+5.1%) To acquire privately-held World of Medicine GmbH for EUR115 million ($129.4 million) in cash (-) SNOA, (-7.8%) Reports wider-than-expected Q4 loss and revenue that beat the single analyst estimate on Capital IQ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33618.0 | 2017-06-05 00:00:00 UTC | Health Care Sector Update for 06/05/2017: JNJ, PFE, ABT, MRK, AMGN, CLSN, MBOT, LOXO | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06052017-jnj-pfe-abt-mrk-amgn-clsn-mbot-loxo-2017-06-05 | nan | nan | Top Health Care stocks:
JNJ: +0.1%
PFE: -0.8%
ABT: +0.3%
MRK: -1.1%
AMGN: +0.1%
Health care shares were mostly higher in mid-day trade Monday.
In health care stocks news, Loxo Oncology ( LOXO ) rose 46% to a new 52-week high after the company said data from three ongoing trials of larotrectinib demonstrated a 76% objective response rate in treating tumors.The studies evaluated adults and pediatric patients whose tumors harbor tropomyosin receptor kinase fusions. The company said 93% of all responding patients either remain on drug or received surgery with curative intent. A total of all patients enrolled either remain on drug or received surgery with curative intent. Loxo also said it published a research brief in Cancer Discovery outlining the preclinical rationale for LOXO-195 and clinical proof-of-concept data from the first two patients treated. LOXO-195 was developed to treat patients with TRK fusion cancers who become resistant while receiving another TRK inhibitor, such as Loxo Oncology's larotrectinib.
In other sector news,
(+) CLSN, (+55.6%) Study shows 86% response rate to ovarian cancer drug combination;
(-) MBOT, (-29.1%) Agrees to sell 3.8 million shares of common stock to three institutional investors for $10.1 million.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Loxo Oncology ( LOXO ) rose 46% to a new 52-week high after the company said data from three ongoing trials of larotrectinib demonstrated a 76% objective response rate in treating tumors.The studies evaluated adults and pediatric patients whose tumors harbor tropomyosin receptor kinase fusions. The company said 93% of all responding patients either remain on drug or received surgery with curative intent. Loxo also said it published a research brief in Cancer Discovery outlining the preclinical rationale for LOXO-195 and clinical proof-of-concept data from the first two patients treated. | In health care stocks news, Loxo Oncology ( LOXO ) rose 46% to a new 52-week high after the company said data from three ongoing trials of larotrectinib demonstrated a 76% objective response rate in treating tumors.The studies evaluated adults and pediatric patients whose tumors harbor tropomyosin receptor kinase fusions. The company said 93% of all responding patients either remain on drug or received surgery with curative intent. LOXO-195 was developed to treat patients with TRK fusion cancers who become resistant while receiving another TRK inhibitor, such as Loxo Oncology's larotrectinib. | In health care stocks news, Loxo Oncology ( LOXO ) rose 46% to a new 52-week high after the company said data from three ongoing trials of larotrectinib demonstrated a 76% objective response rate in treating tumors.The studies evaluated adults and pediatric patients whose tumors harbor tropomyosin receptor kinase fusions. LOXO-195 was developed to treat patients with TRK fusion cancers who become resistant while receiving another TRK inhibitor, such as Loxo Oncology's larotrectinib. In other sector news, (+) CLSN, (+55.6%) Study shows 86% response rate to ovarian cancer drug combination; (-) MBOT, (-29.1%) Agrees to sell 3.8 million shares of common stock to three institutional investors for $10.1 million. | Top Health Care stocks: In health care stocks news, Loxo Oncology ( LOXO ) rose 46% to a new 52-week high after the company said data from three ongoing trials of larotrectinib demonstrated a 76% objective response rate in treating tumors.The studies evaluated adults and pediatric patients whose tumors harbor tropomyosin receptor kinase fusions. The company said 93% of all responding patients either remain on drug or received surgery with curative intent. |
33619.0 | 2017-06-05 00:00:00 UTC | Abbott Laboratories at 52-Week High on Product Line, Buyouts | ABT | https://www.nasdaq.com/articles/abbott-laboratories-at-52-week-high-on-product-line-buyouts-2017-06-05 | nan | nan | Share price of IL-based Abbott LaboratoriesABT scaled a new 52-week high of $46.55 on Jun 2, eventually closing a bit lower at $46.50. The stock has a market cap of $80.69 billion.
Over the last one year, this Zacks Rank #2 (Buy) company has steadily outshined the Zacks categorized Medical - Products with respect to share price. The stock has climbed 18.7%, way higher than the broader industry's gain of 10.5%. The share price trend has also outweighed the S&P 500's gain of 15.8% over the same period.
Further, the company's estimate revision trend for the current year is favorable. In the past 60 days, five estimates have moved up with no downward revision. The magnitude of estimate revision over the same time period inched up roughly 1% to $2.47 per share.
The company also has a trailing four-quarter average positive earnings surprise of 4.67%.
Abbott Laboratories Price and Consensus
Abbott Laboratories Price and Consensus | Abbott Laboratories Quote
Growth Catalysts
The latest 52-week high came on the back of extensive product expansion and diversification. Recently, Abbott Laboratories announced CE mark and first use of Confirm Rx Insertable Cardiac Monitor (ICM). It has been touted to be the world's first smartphone compatible ICM that will help physicians identify cardiac arrhythmias to help guide therapy. Management claims that post approval, adoption of the device has been strong and implants have taken place in 10 countries across Europe.
This apart, the company has received CE mark for its TactiCath Contact Force Ablation Catheter, which has been developed to help physicians treat atrial fibrillation, a condition in which the upper chambers of the heart beat very fast, more effectively.
Abbott Laboratories has also introduced two science-based nutrition drinks for patients undergoing surgery - EnsureSurgery Immunonutrition Shake and EnsurePre-Surgery Clear Nutrition Drink.
Meanwhile, we expect the company to benefit from the ongoing integration and synergy achievement at St. Jude Medical. The combined portfolio will deliver greater value to customers and payors with products like EnSite Precision, ConfirmRx, HeartMate 3, Portico Transcatheter Aortic Heart Valves and Proclaim DRG system. In terms of the integration of St. Jude Medical into AbbottLaboratories, the consolidated company has started to generate positive outcome.
Thus, the above-mentioned factors are expected to drive the company's share price in the days ahead.
We are also looking forward to the company's impending acquisition of Alere which has been extended to Sep 30, 2017. The buyout has attractive prospects for AbbottLaboratories' Point-of-care testing within the in vitro diagnostics market.
Other Key Picks
Other top-ranked medical stocks include Align Technology, Inc. ALGN , Inogen, Inc. INGN and Accelerate Diagnostics, Inc. AXDX . Notably, Align Technologyand Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Align Technologyhas an expected long-term adjusted earnings growth of almost 22.8%. The stock added roughly 45.7% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 79.7%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock added roughly 14% over the last three months.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Share price of IL-based Abbott LaboratoriesABT scaled a new 52-week high of $46.55 on Jun 2, eventually closing a bit lower at $46.50. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. This apart, the company has received CE mark for its TactiCath Contact Force Ablation Catheter, which has been developed to help physicians treat atrial fibrillation, a condition in which the upper chambers of the heart beat very fast, more effectively. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Share price of IL-based Abbott LaboratoriesABT scaled a new 52-week high of $46.55 on Jun 2, eventually closing a bit lower at $46.50. Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote Growth Catalysts The latest 52-week high came on the back of extensive product expansion and diversification. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Share price of IL-based Abbott LaboratoriesABT scaled a new 52-week high of $46.55 on Jun 2, eventually closing a bit lower at $46.50. Over the last one year, this Zacks Rank #2 (Buy) company has steadily outshined the Zacks categorized Medical - Products with respect to share price. | Share price of IL-based Abbott LaboratoriesABT scaled a new 52-week high of $46.55 on Jun 2, eventually closing a bit lower at $46.50. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. The share price trend has also outweighed the S&P 500's gain of 15.8% over the same period. |
33620.0 | 2017-06-05 00:00:00 UTC | Health Care Sector Update for 06/05/2017: JNJ, PFE, ABT, MRK, AMGN, NLNK, RDUS, BPMC | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06052017-jnj-pfe-abt-mrk-amgn-nlnk-rdus-bpmc-2017-06-05 | nan | nan | Top Health Care stocks:
JNJ: +0.1%
PFE: -0.8%
ABT: +0.2%
MRK: -0.8%
AMGN: +0.9%
Health care shares were on track to close Monday's session higher.
In health care stocks news,NewLink Genetics ( NLNK ) fell 11.7% after the company said a phase 2 study of indoximod in combination with the therapeutic cancer vaccine Provenge for patients with metastatic castration resistant prostate cancer didn't show a statistical difference in the primary endpoint of ELISPOT assay immune response to PA2024, the Provenge-related fusion protein, in the 35 of 46 patients who had clinical samples available for testing. However, the commpany said the study showed a statistically significant improvement in radiographic progression-free survival compared to placebo and was well tolerated.
In other sector news,
(+) RDUS, (+10.8%) Results from a phase 1 study of its elacestrant showed five confirmed partial responses in patients with estrogen receptor positive breast cancer
(-) BPMC, (-8.5%) Phase 1 data on BLU-285 foR patients with advanced gastrointestinal stromal tumors showed a 60% objective response rate and an estimated 9-month progression free survival of 87%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news,NewLink Genetics ( NLNK ) fell 11.7% after the company said a phase 2 study of indoximod in combination with the therapeutic cancer vaccine Provenge for patients with metastatic castration resistant prostate cancer didn't show a statistical difference in the primary endpoint of ELISPOT assay immune response to PA2024, the Provenge-related fusion protein, in the 35 of 46 patients who had clinical samples available for testing. However, the commpany said the study showed a statistically significant improvement in radiographic progression-free survival compared to placebo and was well tolerated. In other sector news, (+) RDUS, (+10.8%) Results from a phase 1 study of its elacestrant showed five confirmed partial responses in patients with estrogen receptor positive breast cancer (-) BPMC, (-8.5%) Phase 1 data on BLU-285 foR patients with advanced gastrointestinal stromal tumors showed a 60% objective response rate and an estimated 9-month progression free survival of 87% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news,NewLink Genetics ( NLNK ) fell 11.7% after the company said a phase 2 study of indoximod in combination with the therapeutic cancer vaccine Provenge for patients with metastatic castration resistant prostate cancer didn't show a statistical difference in the primary endpoint of ELISPOT assay immune response to PA2024, the Provenge-related fusion protein, in the 35 of 46 patients who had clinical samples available for testing. In other sector news, (+) RDUS, (+10.8%) Results from a phase 1 study of its elacestrant showed five confirmed partial responses in patients with estrogen receptor positive breast cancer (-) BPMC, (-8.5%) Phase 1 data on BLU-285 foR patients with advanced gastrointestinal stromal tumors showed a 60% objective response rate and an estimated 9-month progression free survival of 87% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news,NewLink Genetics ( NLNK ) fell 11.7% after the company said a phase 2 study of indoximod in combination with the therapeutic cancer vaccine Provenge for patients with metastatic castration resistant prostate cancer didn't show a statistical difference in the primary endpoint of ELISPOT assay immune response to PA2024, the Provenge-related fusion protein, in the 35 of 46 patients who had clinical samples available for testing. In other sector news, (+) RDUS, (+10.8%) Results from a phase 1 study of its elacestrant showed five confirmed partial responses in patients with estrogen receptor positive breast cancer (-) BPMC, (-8.5%) Phase 1 data on BLU-285 foR patients with advanced gastrointestinal stromal tumors showed a 60% objective response rate and an estimated 9-month progression free survival of 87% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved. | Top Health Care stocks: In health care stocks news,NewLink Genetics ( NLNK ) fell 11.7% after the company said a phase 2 study of indoximod in combination with the therapeutic cancer vaccine Provenge for patients with metastatic castration resistant prostate cancer didn't show a statistical difference in the primary endpoint of ELISPOT assay immune response to PA2024, the Provenge-related fusion protein, in the 35 of 46 patients who had clinical samples available for testing. In other sector news, (+) RDUS, (+10.8%) Results from a phase 1 study of its elacestrant showed five confirmed partial responses in patients with estrogen receptor positive breast cancer (-) BPMC, (-8.5%) Phase 1 data on BLU-285 foR patients with advanced gastrointestinal stromal tumors showed a 60% objective response rate and an estimated 9-month progression free survival of 87% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33621.0 | 2017-06-03 00:00:00 UTC | 3 Best Dividend Stocks in the Medical Device Industry | ABT | https://www.nasdaq.com/articles/3-best-dividend-stocks-medical-device-industry-2017-06-03 | nan | nan | Although biotech and pharmaceutical stocks get more attention, there are plenty of medical device stocks that have plenty to offer to investors. According to a report by strategic consulting and market research firm Lucintel, the aging population and increasing health awareness are a couple of key factors expected to drive growth for the medical device industry in the next few years.
Some medical device stocks promise solid dividends in addition to growth. The three best dividend stocks in the medical device industry right now are Abbott Laboratories (NYSE: ABT) , Medtronic PLC (NYSE: MDT) , and Smith & Nephew PLC (NYSE: SNN) . Here's why.
Abbott Laboratories
Abbott Laboratories markets a broad line of medical devices, including coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular disease, electrophysiology devices, and devices for eye surgeries. The company also has a large established pharmaceuticals business and is a major player in the nutritionals and diagnostics markets. In 2016, Abbott generated revenue of $20.8 billion, with earnings totaling $1.4 billion.
The company's dividend currently yields 2.32%. Abbott is a member of the elite Dividend Aristocrats , a group of companies that have increased their dividends for at least 25 consecutive years. For Abbott, the streak of raising dividends is an impressive 45 years. The company has paid a dividend every quarter of every year since 1924.
At first glance, investors might think there could be a problem for Abbott in keeping its dividend streak going. The company has been spending more to fund its dividend program than it has made in profits. However, Abbott's solid cash flow should allow it to keep the dividend checks flowing.
In addition, the company's earnings outlook is positive. Abbott completed the acquisition of medical device maker St. Jude Medical earlier this year, a move that should boost its revenue and earnings. Wall Street analysts project the company will grow earnings by an average annual rate of 11% over the next five years.
Medtronic
Medtronic is one of the largest medical device companies in the world. The company has four business segments: cardiac and vascular, minimally invasive therapies, restorative therapies, and diabetes. Each of these segments develops and markets medical devices and other products focused on their respective therapeutic areas. Medtronic reported revenue last year of $28.8 billion, with earnings of $3.5 billion.
The company's dividend yield stands at 2.04%. Like Abbott, Medtronic is a member of the Dividend Aristocrats. It has increased its dividend for 39 years in a row, with especially significant dividend growth over the last 10 years.
Medtronic's dividend payout ratio is 59.01%. This indicates that the company shouldn't have significant problems continuing to pay out dividends to shareholders.
Analysts expect Medtronic to grow earnings by an average of 7% annually over the next five years. The company intends to elbow its way into the lucrative market for robotic surgical systems late next year, a move that could pay off significantly over time.
Smith & Nephew
Smith & Nephew is a global medical device company that sells hip and knee implants, products supporting minimally invasive surgery of joints, and advanced wound devices, as well as other products. The company made $4.7 billion in revenue last year and reported a profit of just over $1 billion.
Its dividend currently yields 2.1%, ranking Smith & Nephew just ahead of Medtronic among medical device companies. Although Smith & Nephew isn't a member of the Dividend Aristocrats, the company has a good overall track record of dividend increases. It has also paid a dividend each year since 1937.
Smith & Nephew's payout ratio is below 36%. This low ratio indicates that the company should be able to keep the dividends coming without much trouble.
Wall Street doesn't have great expectations for growth from Smith & Nephew. Analysts project average annual earnings growth of around 5% over the next few years. However, the company has made some acquisitions that could help drive growth down the road, including the purchase last year of Blue Belt Technologies, which makes the Navio orthopedic robotic-assisted surgery system.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Keith Speights has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The three best dividend stocks in the medical device industry right now are Abbott Laboratories (NYSE: ABT) , Medtronic PLC (NYSE: MDT) , and Smith & Nephew PLC (NYSE: SNN) . According to a report by strategic consulting and market research firm Lucintel, the aging population and increasing health awareness are a couple of key factors expected to drive growth for the medical device industry in the next few years. The company intends to elbow its way into the lucrative market for robotic surgical systems late next year, a move that could pay off significantly over time. | The three best dividend stocks in the medical device industry right now are Abbott Laboratories (NYSE: ABT) , Medtronic PLC (NYSE: MDT) , and Smith & Nephew PLC (NYSE: SNN) . Wall Street analysts project the company will grow earnings by an average annual rate of 11% over the next five years. Analysts project average annual earnings growth of around 5% over the next few years. | The three best dividend stocks in the medical device industry right now are Abbott Laboratories (NYSE: ABT) , Medtronic PLC (NYSE: MDT) , and Smith & Nephew PLC (NYSE: SNN) . Abbott Laboratories Abbott Laboratories markets a broad line of medical devices, including coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular disease, electrophysiology devices, and devices for eye surgeries. Abbott is a member of the elite Dividend Aristocrats , a group of companies that have increased their dividends for at least 25 consecutive years. | The three best dividend stocks in the medical device industry right now are Abbott Laboratories (NYSE: ABT) , Medtronic PLC (NYSE: MDT) , and Smith & Nephew PLC (NYSE: SNN) . Some medical device stocks promise solid dividends in addition to growth. It has increased its dividend for 39 years in a row, with especially significant dividend growth over the last 10 years. |
33622.0 | 2017-06-02 00:00:00 UTC | Noteworthy ETF Outflows: IVE, CVS, ABT, MDLZ | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-ive-cvs-abt-mdlz-2017-06-02 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $160.6 million dollar outflow -- that's a 1.2% decrease week over week (from 128,600,000 to 127,050,000). Among the largest underlying components of IVE, in trading today CVS Health Corporation (Symbol: CVS) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Mondelez International Inc (Symbol: MDLZ) is up by about 0.2%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average:
Looking at the chart above, IVE's low point in its 52 week range is $87.88 per share, with $107.75 as the 52 week high point - that compares with a last trade of $104.42. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVE, in trading today CVS Health Corporation (Symbol: CVS) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Mondelez International Inc (Symbol: MDLZ) is up by about 0.2%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $87.88 per share, with $107.75 as the 52 week high point - that compares with a last trade of $104.42. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IVE, in trading today CVS Health Corporation (Symbol: CVS) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Mondelez International Inc (Symbol: MDLZ) is up by about 0.2%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $87.88 per share, with $107.75 as the 52 week high point - that compares with a last trade of $104.42. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVE, in trading today CVS Health Corporation (Symbol: CVS) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Mondelez International Inc (Symbol: MDLZ) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $160.6 million dollar outflow -- that's a 1.2% decrease week over week (from 128,600,000 to 127,050,000). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $87.88 per share, with $107.75 as the 52 week high point - that compares with a last trade of $104.42. | Among the largest underlying components of IVE, in trading today CVS Health Corporation (Symbol: CVS) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Mondelez International Inc (Symbol: MDLZ) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $160.6 million dollar outflow -- that's a 1.2% decrease week over week (from 128,600,000 to 127,050,000). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $87.88 per share, with $107.75 as the 52 week high point - that compares with a last trade of $104.42. |
33623.0 | 2017-06-02 00:00:00 UTC | The Zacks Analyst Blog Highlights: McCormick & Company, S&P Global, Sherwin-Williams, 3M and Abbott Laboratories | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-mccormick-company-sp-global-sherwin-williams-3m-and | nan | nan | For Immediate Release
Chicago, IL -June 02, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include McCormick & Company, Incorporated (NYSE: MKC - Free Report ), S&P Global Inc (NYSE: SPGI - Free Report ), Sherwin-Williams Co (NYSE: SHW - Free Report ), 3M Co (NYSE: MMM - Free Report ) and Abbott Laboratories (NYSE: ABT - Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday's Analyst Blog:
5 Top High-Yield Aristocrat Stocks to Buy
Summer months in the stock market through June are known to be notorious for sluggish price movements. Last year, Brexit affected the markets while Greece's debt crisis had rattled theglobal marketin the year before. And prior to that, investors had to bear the brunt of Fed scaling back its stimulus program or a downgrade of America's credit rating or early signs that the investment banking giant Lehman Bros was on the brink of a collapse.
This time around, if the Congress fails to pass the much anticipated tax reforms, the markets might be in trouble. Fed could also pose a problem for the markets if economic conditions don't start looking up. Moreover, even if the markets have gained strength on the back of strong earnings growth, it is at a high valuation level. This could restrict the markets from moving further north in the near term.
Lest we forget, financials had already taken a hit after two of the largest U.S. banks signaled at a trading slowdown, while drop in oil prices and FBI Director Comey to testify about President Trump's confrontations could lead to a market sell-off. With such uncertainty around the corner, investing in dividend aristocrats seems to be prudent. These stocks provide higher returns at lower risks, which are undoubtedly the 'holy grail' of investing.
June is Notorious for Sluggish Price Action
The equity market in June is on average flattish, while it is also the fourth worst month in terms of the S&P 500's performance. While September is historically the worst month, August has been the second followed by February.
Over the last 50 years, the benchmark index has recorded an average return of 0.11% during the month of June. The returns have been fairly evenly split between gains and losses, with the average June advance being 2.39 and the average loss 2.79%. However, the average gain in June is the second lowest in all the 12 months.
Stock Market's Summer Concerns
The market isn't void of risks this June. Following are possible sources of trouble that investors should look out for:
Trump Trade Deflates
Trump terminated and removed FBI Director Comey on May 9, a development that few saw coming. This decision made equity strategists emphasize that the days of Trump trade in the market isn't anymore. For now, investors should refrain from betting on any quick legislation around trade, budget, healthcare or infrastructure.
According to Michael Arone, Chief Investment Strategist at State Street Global Advisors, "Investors are realizing that the fiscal policy agenda is being pushed out farther on the horizon". Trump's pro-business tax, regulation and infrastructural polices are anyhow taking longer to translate into action than investors had hoped.
Fed Rate Hike Amid Soft Economy
The Federal Reserve's Beige Books said that the economy is still growing at a "modest or moderate" pace, appearing to support a June rate increase. Minutes from the Federal Reserve's May 2-3 meeting also showed that officials believe that an interest rate hike is in the cards "soon".
U.S. GDP growth, in the meanwhile, was revised up to 1.2% for the first three months of the year. Despite the uptick, most of Wall Street wasn't in a celebratory mood as it is still a disappointing outcome, mainly caused by a slowdown in consumer spending and inventories. Analysts noted that data doesn't signal at a strong rebound in the second quarter and that the Fed had made up its mind about monetary policy long before the GDP figures were released.
Upbeat Earnings Performance, Stretched Valuations
Earnings growth, did, scale to the highest level in over five years during the first quarter. It was also driven across various sectors and not concentrated in one area. But, we shouldn't forget that U.S. equities have rallied sharply since last November, making them substantially more expensive when compared to profits.
Such equities are very stretched in terms of most valuation measures, which could lead up to a stock market bubble. After all, a highly valued stock market is more likely to result in lower returns.
Financial and Energy Sectors Bleed
Two major U.S. banks, J.P. Morgan Chase and Bank of America, expressed caution over weakening trading in the second quarter, which eventually had a negative impact on the broader financial sector. J.P. Morgan's second-quarter trading is so far down about 15% compared with a year ago, while Bank of America's second-quarter trading revenue is expected to be down slightly from a year ago.
Energy shares, in the meantime, continued their downtrend with U.S. crude-oil prices dipping below $48 and settling 2.7% lower at $48.32 a barrel. Investors doubt that the extended-production caps by major producers and the summer-driving season in the U.S. won't do enough to reduce concerns about global supplies.
Buy 5 Best Dividend Aristocrats for Better Returns
With so many concerns on investors' minds, dividend paying stocks are tempting options at the moment. These stocks have tremendous financial strength and are immune to market vagaries, while stocks that pay dividends are willing to reward shareholders with cash payments. This is a sign that management is shareholder friendly.
But, why dividend aristocrats? This is because this category of stocks outperforms other dividend payers on better quality business. They have also raked in solid risk-adjusted returns this year, with the S&P High Yield Dividend Aristocrats Index rallying 3.4%.
We have, thus, selected five dividend aristocrats to boost your returns. Such stocks also possess a Zacks Rank #2 (Buy). The favorable Zacks Rank should help these stocks gain further this year as well. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
McCormick & Company, Incorporated (NYSE: MKC - Free Report ) is engaged in manufacturing, marketing and distributing spices, seasoning mixes, condiments and other flavorful products to the food industry. The company has raised its dividend annually for the past 30 consecutive years.
McCormick has a dividend yield of 1.81%, while its five-year average dividend yield is pegged at 8.53%. The company's expected growth rate for the current year is 7.8%, higher than the Food - Miscellaneous industry's estimated gain of 7.7%.
S&P Global Inc (NYSE: SPGI - Free Report ) is a provider of ratings, benchmarks, analytics and data to the capital and commodity markets around the world. The company marked its 43rd consecutive annual dividend increase.
S&P Global has a dividend yield of 1.15%, while its five-year average dividend yield is pegged at 9.27%. The company's expected growth rate for the current year is 15.2%, higher than the Business - Information Services industry's estimated rise of 10.2%.
Sherwin-Williams Co (NYSE: SHW - Free Report ) is engaged in the development, manufacture, distribution and sale of paint, coatings and related products. The company has raised its dividend payments for 37 consecutive years.
Sherwin-Williams has a dividend yield of 1.02%, while its five-year average dividend yield is pegged at 19%. The company's expected growth rate for the current year is 14.4%, higher than the Paints and Related Products industry's estimated increase of 2%.
3M Co (NYSE: MMM - Free Report ) is a technology company. The company raised its dividend for more than 58 consecutive years, while it has paid dividends for 100 years.
3M has a dividend yield of 2.30%, while its five-year average dividend yield is pegged at 18.28%. The company, which belongs to the Diversified Operations industry, is expected to yield a steady return of 9.3%.
Abbott Laboratories (NYSE: ABT - Free Report ) is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The company has increased its dividend payments for 44 consecutive years.
Abbott has a dividend yield of 2.32%, while it has a positive five-year average dividend yield. The company's expected growth rate for the current year is 12%, higher than the Medical - Products industry's estimated rise of 10.3%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>
Get the full Report on MKC - FREE
Get the full Report on SPGI - FREE
Get the full Report on SHW - FREE
Get the full Report on MMM - FREE
Get the full Report on ABT - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
McCormick & Company, Incorporated (MKC): Free Stock Analysis Report
S&P Global Inc. (SPGI): Free Stock Analysis Report
Sherwin-Williams Company (The) (SHW): Free Stock Analysis Report
3M Company (MMM): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include McCormick & Company, Incorporated (NYSE: MKC - Free Report ), S&P Global Inc (NYSE: SPGI - Free Report ), Sherwin-Williams Co (NYSE: SHW - Free Report ), 3M Co (NYSE: MMM - Free Report ) and Abbott Laboratories (NYSE: ABT - Free Report ). Abbott Laboratories (NYSE: ABT - Free Report ) is engaged in the discovery, development, manufacture and sale of a range of healthcare products. See these high-potential stocks free >> Get the full Report on MKC - FREE Get the full Report on SPGI - FREE Get the full Report on SHW - FREE Get the full Report on MMM - FREE Get the full Report on ABT - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. | Stocks recently featured in the blog include McCormick & Company, Incorporated (NYSE: MKC - Free Report ), S&P Global Inc (NYSE: SPGI - Free Report ), Sherwin-Williams Co (NYSE: SHW - Free Report ), 3M Co (NYSE: MMM - Free Report ) and Abbott Laboratories (NYSE: ABT - Free Report ). See these high-potential stocks free >> Get the full Report on MKC - FREE Get the full Report on SPGI - FREE Get the full Report on SHW - FREE Get the full Report on MMM - FREE Get the full Report on ABT - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report S&P Global Inc. (SPGI): Free Stock Analysis Report Sherwin-Williams Company (The) (SHW): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include McCormick & Company, Incorporated (NYSE: MKC - Free Report ), S&P Global Inc (NYSE: SPGI - Free Report ), Sherwin-Williams Co (NYSE: SHW - Free Report ), 3M Co (NYSE: MMM - Free Report ) and Abbott Laboratories (NYSE: ABT - Free Report ). See these high-potential stocks free >> Get the full Report on MKC - FREE Get the full Report on SPGI - FREE Get the full Report on SHW - FREE Get the full Report on MMM - FREE Get the full Report on ABT - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report S&P Global Inc. (SPGI): Free Stock Analysis Report Sherwin-Williams Company (The) (SHW): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include McCormick & Company, Incorporated (NYSE: MKC - Free Report ), S&P Global Inc (NYSE: SPGI - Free Report ), Sherwin-Williams Co (NYSE: SHW - Free Report ), 3M Co (NYSE: MMM - Free Report ) and Abbott Laboratories (NYSE: ABT - Free Report ). Abbott Laboratories (NYSE: ABT - Free Report ) is engaged in the discovery, development, manufacture and sale of a range of healthcare products. See these high-potential stocks free >> Get the full Report on MKC - FREE Get the full Report on SPGI - FREE Get the full Report on SHW - FREE Get the full Report on MMM - FREE Get the full Report on ABT - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. |
33624.0 | 2017-06-01 00:00:00 UTC | 5 Top High-Yield Dividend Aristocrats to Buy in June | ABT | https://www.nasdaq.com/articles/5-top-high-yield-dividend-aristocrats-buy-june-2017-06-01 | nan | nan | Summer months in the stock market through June are known to be notorious for sluggish price movements. Last year, Brexit affected the markets while Greece's debt crisis had rattled theglobal marketin the year before. And prior to that, investors had to bear the brunt of Fed scaling back its stimulus program or a downgrade of America's credit rating or early signs that the investment banking giant Lehman Bros was on the brink of a collapse.
This time around, if the Congress fails to pass the much anticipated tax reforms, the markets might be in trouble. Fed could also pose a problem for the markets if economic conditions don't start looking up. Moreover, even if the markets have gained strength on the back of strong earnings growth, it is at a high valuation level. This could restrict the markets from moving further north in the near term.
Lest we forget, financials had already taken a hit after two of the largest U.S. banks signaled at a trading slowdown, while drop in oil prices and FBI Director Comey to testify about President Trump's confrontations could lead to a market sell-off. With such uncertainty around the corner, investing in dividend aristocrats seems to be prudent. These stocks provide higher returns at lower risks, which are undoubtedly the 'holy grail' of investing.
June is Notorious for Sluggish Price Action
The equity market in June is on average flattish, while it is also the fourth worst month in terms of the S&P 500's performance. While September is historically the worst month, August has been the second followed by February.
Over the last 50 years, the benchmark index has recorded an average return of 0.11% during the month of June. The returns have been fairly evenly split between gains and losses, with the average June advance being 2.39 and the average loss 2.79%. However, the average gain in June is the second lowest in all the 12 months. Take a look at the table on the S&P 500's average monthly returns over the past 50 years:
Stock Market's Summer Concerns
The market isn't void of risks this June. Following are possible sources of trouble that investors should look out for:
Trump Trade Deflates
Trump terminated and removed FBI Director Comey on May 9, a development that few saw coming. This decision made equity strategists emphasize that the days of Trump trade in the market isn't anymore. For now, investors should refrain from betting on any quick legislation around trade, budget, healthcare or infrastructure.
According to Michael Arone, Chief Investment Strategist at State Street Global Advisors, "Investors are realizing that the fiscal policy agenda is being pushed out farther on the horizon". Trump's pro-business tax, regulation and infrastructural polices are anyhow taking longer to translate into action than investors had hoped.
Fed Rate Hike Amid Soft Economy
The Federal Reserve's Beige Books said that the economy is still growing at a "modest or moderate" pace, appearing to support a June rate increase. Minutes from the Federal Reserve's May 2-3 meeting also showed that officials believe that an interest rate hike is in the cards "soon".
U.S. GDP growth, in the meanwhile, was revised up to 1.2% for the first three months of the year. Despite the uptick, most of Wall Street wasn't in a celebratory mood as it is still a disappointing outcome, mainly caused by a slowdown in consumer spending and inventories. Analysts noted that data doesn't signal at a strong rebound in the second quarter and that the Fed had made up its mind about monetary policy long before the GDP figures were released.
Upbeat Earnings Performance, Stretched Valuations
Earnings growth, did, scale to the highest level in over five years during the first quarter. It was also driven across various sectors and not concentrated in one area. But, we shouldn't forget that U.S. equities have rallied sharply since last November, making them substantially more expensive when compared to profits.
Such equities are very stretched in terms of most valuation measures, which could lead up to a stock market bubble. After all, a highly valued stock market is more likely to result in lower returns.
Financial and Energy Sectors Bleed
Two major U.S. banks, J.P. Morgan Chase & Co. JPM and Bank of America BAC expressed caution over weakening trading in the second quarter, which eventually had a negative impact on the broader financial sector. J.P. Morgan's second-quarter trading is so far down about 15% compared with a year ago, while Bank of America's second-quarter trading revenue is expected to be down slightly from a year ago.
Energy shares, in the meantime, continued their downtrend with U.S. crude-oil prices dipping below $48 and settling 2.7% lower at $48.32 a barrel. Investors doubt that the extended-production caps by major producers and the summer-driving season in the U.S. won't do enough to reduce concerns about global supplies.
Buy 5 Best Dividend Aristocrats for Better Returns
With so many concerns on investors' minds, dividend paying stocks are tempting options at the moment. These stocks have tremendous financial strength and are immune to market vagaries, while stocks that pay dividends are willing to reward shareholders with cash payments. This is a sign that management is shareholder friendly.
But, why dividend aristocrats? This is because this category of stocks outperforms other dividend payers on better quality business. They have also raked in solid risk-adjusted returns this year, with the S&P High Yield Dividend Aristocrats Index rallying 3.4%.
We have, thus, selected five dividend aristocrats to boost your returns. Such stocks also possess a Zacks Rank #2 (Buy). The favorable Zacks Rank should help these stocks gain further this year as well. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
McCormick & Company, IncorporatedMKC is engaged in manufacturing, marketing and distributing spices, seasoning mixes, condiments and other flavorful products to the food industry. The company has raised its dividend annually for the past 30 consecutive years.
McCormick has a dividend yield of 1.81%, while its five-year average dividend yield is pegged at 8.53%. The company's expected growth rate for the current year is 7.8%, higher than the Food - Miscellaneous industry's estimated gain of 7.7%.
S&P Global IncSPGI is a provider of ratings, benchmarks, analytics and data to the capital and commodity markets around the world. The company marked its 43rd consecutive annual dividend increase.
S&P Global has a dividend yield of 1.15%, while its five-year average dividend yield is pegged at 9.27%. The company's expected growth rate for the current year is 15.2%, higher than the Business - Information Services industry's estimated rise of 10.2%.
Sherwin-Williams CoSHW is engaged in the development, manufacture, distribution and sale of paint, coatings and related products. The company has raised its dividend payments for 37 consecutive years.
Sherwin-Williams has a dividend yield of 1.02%, while its five-year average dividend yield is pegged at 19%. The company's expected growth rate for the current year is 14.4%, higher than the Paints and Related Products industry's estimated increase of 2%.
3M CoMMM is a technology company. The company raised its dividend for more than 58 consecutive years, while it has paid dividends for 100 years.
3M has a dividend yield of 2.30%, while its five-year average dividend yield is pegged at 18.28%. The company, which belongs to the Diversified Operations industry, is expected to yield a steady return of 9.3%.
Abbott LaboratoriesABT is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The company has increased its dividend payments for 44 consecutive years.
Abbott has a dividend yield of 2.32%, while it has a positive five-year average dividend yield. The company's expected growth rate for the current year is 12%, higher than the Medical - Products industry's estimated rise of 10.3%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
J P Morgan Chase & Co (JPM): Free Stock Analysis Report
Bank of America Corporation (BAC): Free Stock Analysis Report
S&P Global Inc. (SPGI): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
3M Company (MMM): Free Stock Analysis Report
McCormick & Company, Incorporated (MKC): Free Stock Analysis Report
Sherwin-Williams Company (The) (SHW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is engaged in the discovery, development, manufacture and sale of a range of healthcare products. Click to get this free report J P Morgan Chase & Co (JPM): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report S&P Global Inc. (SPGI): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report Sherwin-Williams Company (The) (SHW): Free Stock Analysis Report To read this article on Zacks.com click here. And prior to that, investors had to bear the brunt of Fed scaling back its stimulus program or a downgrade of America's credit rating or early signs that the investment banking giant Lehman Bros was on the brink of a collapse. | Click to get this free report J P Morgan Chase & Co (JPM): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report S&P Global Inc. (SPGI): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report Sherwin-Williams Company (The) (SHW): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is engaged in the discovery, development, manufacture and sale of a range of healthcare products. Take a look at the table on the S&P 500's average monthly returns over the past 50 years: Stock Market's Summer Concerns The market isn't void of risks this June. | Click to get this free report J P Morgan Chase & Co (JPM): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report S&P Global Inc. (SPGI): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report Sherwin-Williams Company (The) (SHW): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is engaged in the discovery, development, manufacture and sale of a range of healthcare products. Take a look at the table on the S&P 500's average monthly returns over the past 50 years: Stock Market's Summer Concerns The market isn't void of risks this June. | Abbott LaboratoriesABT is engaged in the discovery, development, manufacture and sale of a range of healthcare products. Click to get this free report J P Morgan Chase & Co (JPM): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report S&P Global Inc. (SPGI): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report Sherwin-Williams Company (The) (SHW): Free Stock Analysis Report To read this article on Zacks.com click here. Take a look at the table on the S&P 500's average monthly returns over the past 50 years: Stock Market's Summer Concerns The market isn't void of risks this June. |
33625.0 | 2017-06-01 00:00:00 UTC | Insider Bets Paying Off At ABT As New 52-Week High Reached | ABT | https://www.nasdaq.com/articles/insider-bets-paying-abt-new-52-week-high-reached-2017-06-01 | nan | nan | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) touched a new 52-week high of $46.02/share. That's a 25.19% rise, or $9.26000000000001 per share from the 52-week low of $36.76 set back on 06/27/2016. That means at today's intraday high, any investor who purchased ABT stock any time over the past 52 weeks has an unrealized gain, including company insiders.
Over the past six months, insiders have been scooping up shares, and those bets are now paying off handsomely. As summarized by the table below, ABT has seen 3 different instances of insiders buying over the trailing six month period.
The chart below shows where ABT has traded over the past year, with the 50-day and 200-day moving averages included.
In afternoon trading on Thursday, ABT shares are changing hands at $45.83/share, slightly below the new 52-week high.
Ten Bargains You Can Buy Cheaper Than The Insiders Did »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) touched a new 52-week high of $46.02/share. That means at today's intraday high, any investor who purchased ABT stock any time over the past 52 weeks has an unrealized gain, including company insiders. In afternoon trading on Thursday, ABT shares are changing hands at $45.83/share, slightly below the new 52-week high. | In afternoon trading on Thursday, ABT shares are changing hands at $45.83/share, slightly below the new 52-week high. In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) touched a new 52-week high of $46.02/share. That means at today's intraday high, any investor who purchased ABT stock any time over the past 52 weeks has an unrealized gain, including company insiders. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) touched a new 52-week high of $46.02/share. That means at today's intraday high, any investor who purchased ABT stock any time over the past 52 weeks has an unrealized gain, including company insiders. As summarized by the table below, ABT has seen 3 different instances of insiders buying over the trailing six month period. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) touched a new 52-week high of $46.02/share. That means at today's intraday high, any investor who purchased ABT stock any time over the past 52 weeks has an unrealized gain, including company insiders. As summarized by the table below, ABT has seen 3 different instances of insiders buying over the trailing six month period. |
33626.0 | 2017-05-30 00:00:00 UTC | 3 Big Stock Charts for Tuesday: Boeing Co (BA), Caterpillar Inc. (CAT) and Abbott Laboratories (ABT) | ABT | https://www.nasdaq.com/articles/3-big-stock-charts-for-tuesday%3A-boeing-co-ba-caterpillar-inc.-cat-and-abbott-laboratories | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The market has been able to maintain its low-volatility trend move higher as we get into what are typically the more quiet days of summer trading.
Abbott Laboratories (NYSE: ABT ), Boeing Co (NYSE: BA ) and Caterpillar Inc. (NYSE: CAT ) are three of the large-cap companies on our technical radar screens today as all three companies are part of the market's melt-up as stocks continue to push to new highs.
Abbott Laboratories (ABT)
Abbott stock surged on Friday with relatively heavy volume, pushing the stock towards a bullish technical trigger. ABT shares were pushed forward on a break above the stock's 50-day moving average. This initiated a technical buy signal and thus the heavy volume.
The move came close to seeing Abbott shares break above their top Bollinger Band, a move that would have accelerated and extended the rally of this biotech company.
ABT stock will run into a little resistance at $45 from past chart resistance and the fact that the top Bollinger Band still resides at this price.
10 Stocks That Won't Exist in a Decade
A move above $45 will give traders a boost of confidence that this market leader is ready to take it to the next level with a price target of $50 from there.
Boeing Co (BA)
The continued political headlines have caused many of the air and defense stocks to start seeing selling as doubt over the Administration's agenda, including defense spending, grew unsteady. This was the fundamental reason for the weakness in Boeing stock through March and April.
After this consolidation, BA shares are beginning to build momentum again as the stock is headed towards $200 with a head of steam building.
Chart watchers have been eyeing $185 as historical resistance as the stock has been stopped in its ascent at that price a number of times. Now, the break above this price has traders increasing their volume trading on Boeing.
From a short-term perspective, BA shares are likely to become overbought as they approach $200. That will combine with the round-numbered resistance that comes naturally from a price point like $200. Expect to see the stock pause due to these factors. However, Boeing should be able to make a momentum move through this price and continue its leadership role in the market.
Caterpillar Inc. (CAT)
Another group of companies that have been affected by doubt around the Trump administration's ability to move their agenda forward are the heavy machinery industrial companies.
Caterpillar shares declined more than 10% into a short-term bottom in May, giving investors an opportunity to buy this stock "on sale". CAT shares have regained their price of $105 and are wrestling with chart resistance in trying to break higher.
Short interest in the latest report showed that the bears have been selling out of their positions, helping to fuel the rally higher. The short interest of 4.0 now indicates that we've probably seen the majority of short covering help the stock higher.
Look for a little rest as the stock takes a breather before breaking above $105, but from there, the momentum will move this heavy equipment manufacturer higher towards the $115-mark.
As of this writing, Johnson Research Group did not hold a position in any of the aforementioned securities.
More From InvestorPlace
7 Stocks That Will Get Crushed in the Next Crash
7 Stocks to Buy Now for BIG Summer Outperformance
7 Stocks to Sell Thanks to TERRIBLE Seasonality
The post 3 Big Stock Charts for Tuesday: Boeing Co (BA), Caterpillar Inc. (CAT) and Abbott Laboratories (ABT) appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT ), Boeing Co (NYSE: BA ) and Caterpillar Inc. (NYSE: CAT ) are three of the large-cap companies on our technical radar screens today as all three companies are part of the market's melt-up as stocks continue to push to new highs. Abbott Laboratories (ABT) Abbott stock surged on Friday with relatively heavy volume, pushing the stock towards a bullish technical trigger. ABT shares were pushed forward on a break above the stock's 50-day moving average. | Abbott Laboratories (NYSE: ABT ), Boeing Co (NYSE: BA ) and Caterpillar Inc. (NYSE: CAT ) are three of the large-cap companies on our technical radar screens today as all three companies are part of the market's melt-up as stocks continue to push to new highs. Abbott Laboratories (ABT) Abbott stock surged on Friday with relatively heavy volume, pushing the stock towards a bullish technical trigger. More From InvestorPlace 7 Stocks That Will Get Crushed in the Next Crash 7 Stocks to Buy Now for BIG Summer Outperformance 7 Stocks to Sell Thanks to TERRIBLE Seasonality The post 3 Big Stock Charts for Tuesday: Boeing Co (BA), Caterpillar Inc. (CAT) and Abbott Laboratories (ABT) appeared first on InvestorPlace . | Abbott Laboratories (NYSE: ABT ), Boeing Co (NYSE: BA ) and Caterpillar Inc. (NYSE: CAT ) are three of the large-cap companies on our technical radar screens today as all three companies are part of the market's melt-up as stocks continue to push to new highs. More From InvestorPlace 7 Stocks That Will Get Crushed in the Next Crash 7 Stocks to Buy Now for BIG Summer Outperformance 7 Stocks to Sell Thanks to TERRIBLE Seasonality The post 3 Big Stock Charts for Tuesday: Boeing Co (BA), Caterpillar Inc. (CAT) and Abbott Laboratories (ABT) appeared first on InvestorPlace . Abbott Laboratories (ABT) Abbott stock surged on Friday with relatively heavy volume, pushing the stock towards a bullish technical trigger. | Abbott Laboratories (NYSE: ABT ), Boeing Co (NYSE: BA ) and Caterpillar Inc. (NYSE: CAT ) are three of the large-cap companies on our technical radar screens today as all three companies are part of the market's melt-up as stocks continue to push to new highs. Abbott Laboratories (ABT) Abbott stock surged on Friday with relatively heavy volume, pushing the stock towards a bullish technical trigger. ABT shares were pushed forward on a break above the stock's 50-day moving average. |
33627.0 | 2017-05-30 00:00:00 UTC | The Zacks Analyst Blog Highlights: Visa, General Electric, GlaxoSmithKline, Morgan Stanley and Abbott Laboratories | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-visa-general-electric-glaxosmithkline-morgan-stanley | nan | nan | For Immediate Release
Chicago, IL - May 30, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Visa (NYSE: V- Free Report ), General Electric Company (NYSE: GE- Free Report ), GlaxoSmithKline plc (NYSE: GSK- Free Report ), Morgan Stanley (NYSE: MS- Free Report ) and Abbott Laboratories (NYSE: ABT- Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Friday's Analyst Blog:
Top Analyst Reports for Tuesday: Visa, GE, Glaxo & More
Today's Research Daily features new research reports on 16 major stocks, including Visa (NYSE: V- Free Report ), General Electric Company (NYSE: GE- Free Report ) and GlaxoSmithKline plc (NYSE: GSK- Free Report ). You can see all of today's research reports here >>>
Visa shares have outperformed the Zacks Financial Transaction Services industry as well as MasterCard in the year-to-date period (Visa is up +21.7% vs. +17.8% gain for MA and +16.8% for the industry). Driving this momentum is the acknowledgement that Visa's brand, global network, and leading market share position it to be a key beneficiary of the secular global shift to electronic transactions. Initial concerns about a changing competitive landscape, large on account of new payment options, have also started receding. The company's strong results in recent quarters reflect this favorable backdrop. On the flip side, forex volatility, increased client incentives and global economic uncertainty are some of the headwinds (You can read the full research report on Visa here >>> ).
General Electric shares have been laggards for a while now; the stock has underperformed the S&P 500 index in the year-to-date (-13.2% vs. +8.2%), trailing one year, 2 years or even 5-year periods. This has rattled long-term investors and made them skeptical of management plans to turn the conglomerate around. The stock was down following the Q1 earnings release and management's cautious commentary about the business outlook since then hasn't helped matters much. The Baker Hughes purchase should close soon, but management has been less than enthusiastic about that business' near-term outlook despite indications that activity levels may have bottomed in the oil patch already. As gloomy as all of this looks, we have acknowledge the limited downside risks at this stage, given the very attractive dividend (currently yielding a juicy 3.5%) and very reasonable valuation. The stock has historically traded in-line with the S&P 500 index, but currently trades at a big discount to the index. (You can read the full research report on General Electric here >>> ).
GlaxoSmithKline shares have performed in-line with the Zacks Large Cap Pharmaceuticals industry over the year-to-date period, gaining +10.7% versus the industry's +10.7% increase. Persistent challenges like stiff competition, genericization and pricing pressure along with slowing growth in emerging markets have been impacting the company's performance. In particular, pricing dynamics and competitive pressure are hurting sales of its top-selling drug Advair. On the other hand, the Zacks analyst pointed out that performance of its new products as well as of those acquired from Novartis has been encouraging. Glaxo reported mixed Q1 results with earnings meeting the mark and sales beating the same (You can read the full research report on GlaxoSmithKline here >>> ).
Other noteworthy reports we are featuring today include Morgan Stanley (NYSE: MS- Free Report ) and Abbott Laboratories (NYSE: ABT- Free Report ).
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on V - FREE
Get the full Report on GE - FREE
Get the full Report on GSK - FREE
Get the full Report on MS - FREE
Get the full Report on ABT - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Visa Inc. (V): Free Stock Analysis Report
General Electric Company (GE): Free Stock Analysis Report
GlaxoSmithKline PLC (GSK): Free Stock Analysis Report
Morgan Stanley (MS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include Visa (NYSE: V- Free Report ), General Electric Company (NYSE: GE- Free Report ), GlaxoSmithKline plc (NYSE: GSK- Free Report ), Morgan Stanley (NYSE: MS- Free Report ) and Abbott Laboratories (NYSE: ABT- Free Report ). Other noteworthy reports we are featuring today include Morgan Stanley (NYSE: MS- Free Report ) and Abbott Laboratories (NYSE: ABT- Free Report ). Get the full Report on V - FREE Get the full Report on GE - FREE Get the full Report on GSK - FREE Get the full Report on MS - FREE Get the full Report on ABT - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. | Stocks recently featured in the blog include Visa (NYSE: V- Free Report ), General Electric Company (NYSE: GE- Free Report ), GlaxoSmithKline plc (NYSE: GSK- Free Report ), Morgan Stanley (NYSE: MS- Free Report ) and Abbott Laboratories (NYSE: ABT- Free Report ). Click to get this free report Visa Inc. (V): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Morgan Stanley (NYSE: MS- Free Report ) and Abbott Laboratories (NYSE: ABT- Free Report ). | Stocks recently featured in the blog include Visa (NYSE: V- Free Report ), General Electric Company (NYSE: GE- Free Report ), GlaxoSmithKline plc (NYSE: GSK- Free Report ), Morgan Stanley (NYSE: MS- Free Report ) and Abbott Laboratories (NYSE: ABT- Free Report ). Get the full Report on V - FREE Get the full Report on GE - FREE Get the full Report on GSK - FREE Get the full Report on MS - FREE Get the full Report on ABT - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Visa Inc. (V): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Visa Inc. (V): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Visa (NYSE: V- Free Report ), General Electric Company (NYSE: GE- Free Report ), GlaxoSmithKline plc (NYSE: GSK- Free Report ), Morgan Stanley (NYSE: MS- Free Report ) and Abbott Laboratories (NYSE: ABT- Free Report ). Other noteworthy reports we are featuring today include Morgan Stanley (NYSE: MS- Free Report ) and Abbott Laboratories (NYSE: ABT- Free Report ). |
33628.0 | 2017-05-25 00:00:00 UTC | The Zacks Analyst Blog Highlights: Alphabet, Morgan Stanley, Abbott, Waste Management, General Mills and Raytheon | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alphabet-morgan-stanley-abbott-waste-management-general | nan | nan | For Immediate Release
Chicago, IL - May 25, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Alphabet (NASDAQ: GOOGL- Free Report ), Morgan Stanley (NYSE: MS- Free Report ), Abbott (NYSE: ABT- Free Report ), Waste Management (NYSE: WM- Free Report ), General Mills (NYSE: GIS- Free Report ) and Raytheon (NYSE: RTN- Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday's Analyst Blog:
Analyst Reports for Alphabet, Morgan Stanley, Abbott & Others
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (NASDAQ: GOOGL- Free Report ), Morgan Stanley (NYSE: MS- Free Report ) and Abbott (NYSE: ABT- Free Report ). You can see all of today's research reports here >>>
Buy rated Alphabet shares are up +22.4% in the year-to-date period vs. the +15% gain for the Zacks Technology sector and +7.4% gain for the S&P 500 index, with the stock getting a boost from the better than expected Q1 earnings report on April 27th (the stock has gained in excess of +10% since then). The Zacks analyst points out the company's good execution to date, more or less maintaining its dominant share in the competitive, fast-growing search market. The company's focus on innovation, strategic acquisitions and Android OS should continue to generate strong cash flows. However, the promise of Google's non-search businesses continue getting pushed into future even as the company's spending keeps rising. (You can read the full research report on Alphabet here >>> )
Morgan Stanley shares have outperformed the Zacks Finance sector over the last one year, gaining +52.5% versus the sector's +16% increase. In comparison, Goldman Sachs shares are up +36.4% in that time period. The Zacks analyst likes the company's efforts to offload its non-core assets to lower balance-sheet risks and shift focus toward less capital-intensive businesses. Moreover, it remains on track to achieve its expense saving target of $1 billion by the end of this year. However, equity trading income distress, new regulatory requirements and intense pricing competition are concerns though the regulatory burden is expected to come down going forward. (You can read the full research report on Morgan Stanley here >>> )
Abbott shares have outperformed the Zacks Medical sector in the year-to-date period (the stock is up +13.6% vs. +7.2% gain for the sector) on the back of greater appreciation for the company's strategic repositioning through acquisitions/divestitures. The St. Jude Medical buyout will complement its cardiovascular devices business. Also, the company's plans to focus on selling its portfolio in core therapeutic areas. Meanwhile, weakness in the nutrition business in China and sluggish growth in the Venezuelan market is a concern. (You can read the full research report on Abbott here >>> )
Other noteworthy reports we are featuring today include Waste Management (NYSE: WM- Free Report ), General Mills (NYSE: GIS- Free Report ) and Raytheon (NYSE: RTN- Free Report ).
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on GOOGL - FREE
Get the full Report on MS - FREE
Get the full Report on ABT - FREE
Get the full Report on WM - FREE
Get the full Report on GIS - FREE
Get the full Report on RTN - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alphabet Inc. (GOOGL): Free Stock Analysis Report
Morgan Stanley (MS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Waste Management, Inc. (WM): Free Stock Analysis Report
General Mills, Inc. (GIS): Free Stock Analysis Report
Raytheon Company (RTN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include Alphabet (NASDAQ: GOOGL- Free Report ), Morgan Stanley (NYSE: MS- Free Report ), Abbott (NYSE: ABT- Free Report ), Waste Management (NYSE: WM- Free Report ), General Mills (NYSE: GIS- Free Report ) and Raytheon (NYSE: RTN- Free Report ). Here are highlights from Wednesday's Analyst Blog: Analyst Reports for Alphabet, Morgan Stanley, Abbott & Others Today's Research Daily features new research reports on 16 major stocks, including Alphabet (NASDAQ: GOOGL- Free Report ), Morgan Stanley (NYSE: MS- Free Report ) and Abbott (NYSE: ABT- Free Report ). Get the full Report on GOOGL - FREE Get the full Report on MS - FREE Get the full Report on ABT - FREE Get the full Report on WM - FREE Get the full Report on GIS - FREE Get the full Report on RTN - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. | Stocks recently featured in the blog include Alphabet (NASDAQ: GOOGL- Free Report ), Morgan Stanley (NYSE: MS- Free Report ), Abbott (NYSE: ABT- Free Report ), Waste Management (NYSE: WM- Free Report ), General Mills (NYSE: GIS- Free Report ) and Raytheon (NYSE: RTN- Free Report ). Here are highlights from Wednesday's Analyst Blog: Analyst Reports for Alphabet, Morgan Stanley, Abbott & Others Today's Research Daily features new research reports on 16 major stocks, including Alphabet (NASDAQ: GOOGL- Free Report ), Morgan Stanley (NYSE: MS- Free Report ) and Abbott (NYSE: ABT- Free Report ). Click to get this free report Alphabet Inc. (GOOGL): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Waste Management, Inc. (WM): Free Stock Analysis Report General Mills, Inc. (GIS): Free Stock Analysis Report Raytheon Company (RTN): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include Alphabet (NASDAQ: GOOGL- Free Report ), Morgan Stanley (NYSE: MS- Free Report ), Abbott (NYSE: ABT- Free Report ), Waste Management (NYSE: WM- Free Report ), General Mills (NYSE: GIS- Free Report ) and Raytheon (NYSE: RTN- Free Report ). Get the full Report on GOOGL - FREE Get the full Report on MS - FREE Get the full Report on ABT - FREE Get the full Report on WM - FREE Get the full Report on GIS - FREE Get the full Report on RTN - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Alphabet Inc. (GOOGL): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Waste Management, Inc. (WM): Free Stock Analysis Report General Mills, Inc. (GIS): Free Stock Analysis Report Raytheon Company (RTN): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include Alphabet (NASDAQ: GOOGL- Free Report ), Morgan Stanley (NYSE: MS- Free Report ), Abbott (NYSE: ABT- Free Report ), Waste Management (NYSE: WM- Free Report ), General Mills (NYSE: GIS- Free Report ) and Raytheon (NYSE: RTN- Free Report ). Here are highlights from Wednesday's Analyst Blog: Analyst Reports for Alphabet, Morgan Stanley, Abbott & Others Today's Research Daily features new research reports on 16 major stocks, including Alphabet (NASDAQ: GOOGL- Free Report ), Morgan Stanley (NYSE: MS- Free Report ) and Abbott (NYSE: ABT- Free Report ). Get the full Report on GOOGL - FREE Get the full Report on MS - FREE Get the full Report on ABT - FREE Get the full Report on WM - FREE Get the full Report on GIS - FREE Get the full Report on RTN - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. |
33629.0 | 2017-05-24 00:00:00 UTC | Say Congratulations with a Gift That Keeps on GROWING: 5 Great DRIPs to Buy | ABT | https://www.nasdaq.com/articles/say-congratulations-gift-keeps-growing-5-great-drips-buy-2017-05-24 | nan | nan | Spring is in the air and summer is around the corner. Both seasons mark significant milestones for many younger people. There are graduations and weddings -- events that mark important accomplishments and lifelong commitments. These are occasions that deserve to be commemorated with significant gifts.
SEE ALSO: 7 Things You Need to Know About Mutual Funds
For the past several years the editors at Moneypaper have offered an alternative to the traditional cash gift -- where your gift is distinguished from the next only by the dollar amount. That gift is a five-stock portfolio held in dividend reinvestment plans (DRIPs).
Your total investment cost to set up such a gift portfolio is somewhere between $400 and $500 (depending on the current share prices of the stocks). In addition to the financial benefit, which has the potential to compound to substantial wealth over the long-term, this gift will provide the recipient a first-hand experience with a logical approach to building wealth by investing in stocks.
By "saving" in the stock of the companies in this DRIPs portfolio, your young investor has the opportunity to build wealth by participating in the growth of the economy with cash investments of as little as $25 at a time. These small investments are likely to compound into real wealth over the long-term.
An Astounding Nest Egg at Retirement
Let's assume that the graduate or the newlywed (or you on their behalf), invests $1,500 a year for the next five years -- that's $125 a month spread evenly among the five high-quality, dividend-paying companies in the portfolio ($25 in each company every month). Let's also say that no further investments are EVER going to be made into those accounts. Based on the historical returns of the stock market over long periods of time, the results would be astounding.
What would the total $7,500 (invested over five years) turn into? The answer will surprise you...
Assuming a 7% return compounded annually, you'll have $8,801 at the end of your first five years. Leave that alone and make no more contributions and your investment would grow to $259,251 in 50 years assuming a 7% annual average return compounded.
Now, let's use a more optimistic assumption: that is that the average annualized growth is 10%, which approximates the long-term return achieved by the market as a whole as calculated by the Ibbotson organization.
Assuming a 10% return compounded annually, you'll have $9,359 at the end of your first five years. Leave that alone and make no more contributions and your investment would grow to $1,098,661 in 50 years.
Now that's a substantial gift!
5 Companies for Your Consideration
Every year the editors of Moneypaper pick five companies worthy of your consideration for such a gift. To make our list, these companies have consistently paid dividends for 10+ years, offer a company-sponsored DRIP where your dividends can be automatically reinvested and shares can be purchased directly without paying fees or commissions. With such a portfolio, your long-term results are likely to exceed the results achieved by the market as a whole.
Hormel (ticker symbol HRL) is a food service company that produces a wide range of meat products, including pepperoni, Spam and Jennie-O turkey, as well as Skippy peanut butter.
MDU Resources (MDU) is a diversified natural resource company with business operations in energy delivery and construction.
Polaris Industries (PII) designs, engineers and manufactures off-road vehicles including all-terrain vehicles (ATV) and side-by-side vehicles for recreational and utility use, snowmobiles, motorcycles and global adjacent markets vehicles, together with the related parts, garments and accessories.
3M Company (MMM) is a diversified technology company with brands including household names like Post-it Notes and Scotch Tape.
Abbott Laboratories (ABT) is a health care company engaged in the discovery, development, manufacture and sale of a diversified line of health care products, including Similac baby formula and Glucerna nutrition drinks.
The best way to set up this portfolio is to purchase the stock directly by enrolling in the company's DRIP. That way you won't pay commissions and your dividends will be automatically reinvested to compound over the years. Enrollment in these companies is available through the Temper Enrollment Service with the purchase of a single share of company stock. For a full list of no-fee DRIPs, click here .
See Also: 3 Warning Signs It is Time to Sell a Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) is a health care company engaged in the discovery, development, manufacture and sale of a diversified line of health care products, including Similac baby formula and Glucerna nutrition drinks. By "saving" in the stock of the companies in this DRIPs portfolio, your young investor has the opportunity to build wealth by participating in the growth of the economy with cash investments of as little as $25 at a time. Now, let's use a more optimistic assumption: that is that the average annualized growth is 10%, which approximates the long-term return achieved by the market as a whole as calculated by the Ibbotson organization. | Abbott Laboratories (ABT) is a health care company engaged in the discovery, development, manufacture and sale of a diversified line of health care products, including Similac baby formula and Glucerna nutrition drinks. Leave that alone and make no more contributions and your investment would grow to $259,251 in 50 years assuming a 7% annual average return compounded. To make our list, these companies have consistently paid dividends for 10+ years, offer a company-sponsored DRIP where your dividends can be automatically reinvested and shares can be purchased directly without paying fees or commissions. | Abbott Laboratories (ABT) is a health care company engaged in the discovery, development, manufacture and sale of a diversified line of health care products, including Similac baby formula and Glucerna nutrition drinks. An Astounding Nest Egg at Retirement Let's assume that the graduate or the newlywed (or you on their behalf), invests $1,500 a year for the next five years -- that's $125 a month spread evenly among the five high-quality, dividend-paying companies in the portfolio ($25 in each company every month). 5 Companies for Your Consideration Every year the editors of Moneypaper pick five companies worthy of your consideration for such a gift. | Abbott Laboratories (ABT) is a health care company engaged in the discovery, development, manufacture and sale of a diversified line of health care products, including Similac baby formula and Glucerna nutrition drinks. Leave that alone and make no more contributions and your investment would grow to $259,251 in 50 years assuming a 7% annual average return compounded. Now that's a substantial gift! |
33630.0 | 2017-05-23 00:00:00 UTC | Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna | ABT | https://www.nasdaq.com/articles/edward-owens-buys-abbott-labs-sells-allergan-amgen-aetna-2017-05-23 | nan | nan | Edward Owens has managed the Vanguard Health Care Fund ( Trades , Portfolio ) since its inception in May 1984. It invests primarily in health care companies.
Owens' strategy is characterized by a long-term focus and careful attention to valuations. During the first quarter the guru traded shares in the following stocks:
The fund closed its position in St. Jude Medical Inc. ( STJ ) with an impact of -1.18% on the portfolio.
The company develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.
GuruFocus gives the stock a profitability and growth rating of 6 out of 10. The return on equity (ROE) of 15.74% and return on assets (ROA) of 5.33% are outperforming 70% of the companies in the Global Medical Devices industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.07 is below the industry median of 2.55.
The guru raised its shares in Abbott Laboratories ( ABT ) by 63.66% impacting the portfolio by 0.68%.
The company discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the U.S.
GuruFocus gives the stock a profitability and growth rating of 4 out of 10. The ROE of 6.59% and ROA of 3.10% are outperforming 61% of the companies in the Global Medical Devices industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.37 is below the industry median of 2.55.
Vanguard Health Care Fund is the largest shareholder among the gurus with 1.02% of outstanding shares followed by PRIMECAP Management (Trades, Portfolio) with 0.85%, Diamond Hill Capital (Trades, Portfolio) with 0.71%, Jeremy Grantham (Trades, Portfolio) with 0.29%, Mairs and Power (Trades, Portfolio) with 0.25% and Jim Simons (Trades, Portfolio) with 0.18%.
The investor reduced his shares in Incyte Corp. ( INCY ) by 20.45%. The trade had an impact of -0.57% on the portfolio.
It is a biopharmaceutical company that discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.
GuruFocus gives the stock a profitability and growth rating of 5 out of 10. The ROE of -23.44% and ROA of -7.31% are outperforming 89% of the companies in the Global Biotechnology industry. Financial strength has a rating of 7 out of 10. The cash-debt ratio of 12.31 is below the industry median of 54.02.
Frank Sands (Trades, Portfolio) is another notable shareholder among the gurus with 4.52% of outstanding shares followed by Pioneer Investments (Trades, Portfolio) with 0.27%, Andreas Halvorsen (Trades, Portfolio) with 0.21%, Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) with 0.1%, Manning & Napier Advisors Inc. with 0.03%, Joel Greenblatt (Trades, Portfolio) with 0.03%, John Burbank (Trades, Portfolio) with 0.01% and Ken Fisher (Trades, Portfolio) with 0.01%.
The guru reduced his position in Allergan PLC ( AGN ) by 22.55%. The transaction had an impact of -0.45% on the portfolio.
It is a specialty pharmaceutical company that is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.
GuruFocus gives the stock a profitability and growth rating of 6 out of 10. The ROE of 15.02% and ROA of 9.09% are outperforming 81% of the companies in the Global Drug Manufacturers - Specialty and Generic industry. Financial strength has a rating of 4 out of 10. The cash-debt ratio of 0.28 is below the industry median of 3.09.
The largest shareholder among the gurus Is John Paulson (Trades, Portfolio) with 3.48% of outstanding shares followed by David Tepper (Trades, Portfolio) with 0.87%, Seth Klarman (Trades, Portfolio) with 0.72%, John Griffin (Trades, Portfolio) with 0.57%, Spiros Segalas (Trades, Portfolio) with 0.45% and Pioneer Investments with 0.37%.
The guru reduced his position in Amgen Inc. ( AMGN ) by 71.47%. The trade had an impact of -0.46% on the portfolio.
It is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. The company's business segment is human therapeutics.
GuruFocus gives the stock a profitability and growth rating of 9 out of 10. The ROE of 26.29% and ROA of 10.27% are outperforming 91% of the companies in the Global Biotechnology industry. Financial strength has a rating of 6 out of 10. The cash-debt ratio of 1.13 is below the industry median of 54.02.
PRIMECAP Management is the largest shareholder among the gurus with 3.28% of outstanding shares followed by Simons with 0.33%, David Carlson (Trades, Portfolio) with 0.06%, Greenblatt with 0.05%, Third Avenue Management (Trades, Portfolio) with 0.03% and Steven Cohen (Trades, Portfolio) with 0.02%.
The firm reduced its shares in Aetna Inc.( AET) by 22.55% with an impact of -0.45% on the portfolio.
It is a health care benefit company. It offers traditional and consumer-directed health insurance products and related services including medical, pharmacy, dental, behavioral health, group life and disability plans.
GuruFocus gives the stock a profitability and growth rating of 8 out of 10. While the ROE of 6.79% is outperforming the sector, ROA of 1.78% is underperforming 61% of the companies in the Global Health Care Plans industry. Financial strength has a rating of 6 out of 10. The cash-debt ratio of 0.74 is below the industry median of 1.12.
Another notable shareholder among the gurus is Larry Robbins (Trades, Portfolio) with 1.52% of outstanding shares followed by Chris Davis (Trades, Portfolio) with 1.26%, Simons with 0.94%, Diamond Hill Capital with 0.5%, Jana Partners (Trades, Portfolio) with 0.44%, Lee Ainslie (Trades, Portfolio) with 0.3% and Cohen with 0.07%.
The guru reduced his holding in Merck & Co. Inc. ( MRK ) by 8.27% impacting the portfolio by -0.41%.
It is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health.
GuruFocus gives the stock a profitability and growth rating of 5 out of 10. The ROE of 10.30% and ROA of 4.47% are outperforming 53% of the companies in the Global Drug Manufacturers - Major industry. Financial strength has a rating of 6 out of 10. The cash-debt ratio of 0.54 is below the industry median of 3.09.
Barrow, Hanley, Mewhinney & Strauss is another notable shareholder among the gurus with 0.58% of outstanding shares followed by Dodge & Cox with 0.5%, Simons with 0.27%, Fisher with 0.25%, PRIMECAP Management with 0.18%, T Rowe Price Equity Income Fund (Trades, Portfolio) with 0.12% and Charles Brandes (Trades, Portfolio) with 0.1%.
The investor reduced his position in UnitedHealth Group Inc. (UNH) by 4.20% with an impact of -0.25% on the portfolio.
The company designs products, provides services and applies technologies that improve access to health and well-being services, simplify the health care experience and make health care more affordable.
GuruFocus gives the stock a profitability and growth rating of 7 out of 10. The ROE of 20.01% and ROA of 6.10% are outperforming 74% of the companies in the Global Health Care Plans industry. Financial strength has a rating of 6 out of 10. The cash-debt ratio of 0.57 is below the industry median of 1.12.
The largest shareholder among the gurus is Dodge & Cox with 1.55% of outstanding shares followed by Halvorsen with 0.37%, Grantham with 0.37%, Davis with 0.3% and Bill Nygren (Trades, Portfolio) with 0.23%.
The firm purchased a 642,725-share position in Tesaro Inc. (TSRO) with an impact of 0.22% on the portfolio.
It is an oncology-focused biopharmaceutical company engaged in improving the lives of cancer patients. It develops oncology-related product candidates including rolapitant, niraparib and the product candidates under the immuno-oncology platform.
GuruFocus gives the stock a profitability and growth rating of 4 out of 10. The ROE of -110.69% and ROA of -72.44% are underperforming 85% of the companies in the Global Biotechnology industry. Financial strength has a rating of 3 out of 10. The cash-debt ratio of 5.00 is below the industry median of 54.02.
The largest shareholder among the gurus is Cohen with 0.93% of outstanding shares followed by Pioneer Investments with 0.2%, Leon Cooperman (Trades, Portfolio) with 0.05% and Paul Tudor Jones (Trades, Portfolio) with 0.01%.
Disclosure: I do not own any shares of any stocks mentioned in this article.
Start a free seven-day trial of Premium Membership to GuruFocus.
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The guru raised its shares in Abbott Laboratories ( ABT ) by 63.66% impacting the portfolio by 0.68%. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the U.S. GuruFocus gives the stock a profitability and growth rating of 4 out of 10. It is a biopharmaceutical company that discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology. | The guru raised its shares in Abbott Laboratories ( ABT ) by 63.66% impacting the portfolio by 0.68%. Vanguard Health Care Fund is the largest shareholder among the gurus with 1.02% of outstanding shares followed by PRIMECAP Management (Trades, Portfolio) with 0.85%, Diamond Hill Capital (Trades, Portfolio) with 0.71%, Jeremy Grantham (Trades, Portfolio) with 0.29%, Mairs and Power (Trades, Portfolio) with 0.25% and Jim Simons (Trades, Portfolio) with 0.18%. The largest shareholder among the gurus Is John Paulson (Trades, Portfolio) with 3.48% of outstanding shares followed by David Tepper (Trades, Portfolio) with 0.87%, Seth Klarman (Trades, Portfolio) with 0.72%, John Griffin (Trades, Portfolio) with 0.57%, Spiros Segalas (Trades, Portfolio) with 0.45% and Pioneer Investments with 0.37%. | The guru raised its shares in Abbott Laboratories ( ABT ) by 63.66% impacting the portfolio by 0.68%. Vanguard Health Care Fund is the largest shareholder among the gurus with 1.02% of outstanding shares followed by PRIMECAP Management (Trades, Portfolio) with 0.85%, Diamond Hill Capital (Trades, Portfolio) with 0.71%, Jeremy Grantham (Trades, Portfolio) with 0.29%, Mairs and Power (Trades, Portfolio) with 0.25% and Jim Simons (Trades, Portfolio) with 0.18%. Frank Sands (Trades, Portfolio) is another notable shareholder among the gurus with 4.52% of outstanding shares followed by Pioneer Investments (Trades, Portfolio) with 0.27%, Andreas Halvorsen (Trades, Portfolio) with 0.21%, Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) with 0.1%, Manning & Napier Advisors Inc. with 0.03%, Joel Greenblatt (Trades, Portfolio) with 0.03%, John Burbank (Trades, Portfolio) with 0.01% and Ken Fisher (Trades, Portfolio) with 0.01%. | The guru raised its shares in Abbott Laboratories ( ABT ) by 63.66% impacting the portfolio by 0.68%. Edward Owens has managed the Vanguard Health Care Fund ( Trades , Portfolio ) since its inception in May 1984. During the first quarter the guru traded shares in the following stocks: The fund closed its position in St. Jude Medical Inc. ( STJ ) with an impact of -1.18% on the portfolio. |
33631.0 | 2017-05-18 00:00:00 UTC | VTV, ABT, MDLZ, AET: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/vtv-abt-mdlz-aet-large-outflows-detected-etf-2017-05-18 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $134.6 million dollar outflow -- that's a 0.4% decrease week over week (from 320,386,298 to 318,950,101). Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, Mondelez International Inc (Symbol: MDLZ) is up about 0.5%, and Aetna Inc. (Symbol: AET) is up by about 0.8%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average:
Looking at the chart above, VTV's low point in its 52 week range is $80.43 per share, with $98.50 as the 52 week high point - that compares with a last trade of $93.93. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, Mondelez International Inc (Symbol: MDLZ) is up about 0.5%, and Aetna Inc. (Symbol: AET) is up by about 0.8%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $80.43 per share, with $98.50 as the 52 week high point - that compares with a last trade of $93.93. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, Mondelez International Inc (Symbol: MDLZ) is up about 0.5%, and Aetna Inc. (Symbol: AET) is up by about 0.8%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $80.43 per share, with $98.50 as the 52 week high point - that compares with a last trade of $93.93. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, Mondelez International Inc (Symbol: MDLZ) is up about 0.5%, and Aetna Inc. (Symbol: AET) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $134.6 million dollar outflow -- that's a 0.4% decrease week over week (from 320,386,298 to 318,950,101). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $80.43 per share, with $98.50 as the 52 week high point - that compares with a last trade of $93.93. | Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, Mondelez International Inc (Symbol: MDLZ) is up about 0.5%, and Aetna Inc. (Symbol: AET) is up by about 0.8%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $80.43 per share, with $98.50 as the 52 week high point - that compares with a last trade of $93.93. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33632.0 | 2017-05-18 00:00:00 UTC | AbbVie Inc (ABBV) Stock STILL Has Much More Room to Run Higher | ABT | https://www.nasdaq.com/articles/abbvie-inc-abbv-stock-still-has-much-more-room-to-run-higher-2017-05-18 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) is the maker of the world's best selling pharmaceutical, Humira. In late 2012, Abbott Laboratories (NYSE: ABT ) spun off AbbVie with one drug and a lot of its accumulated debt. At the time, it looked like ABBV stock was being set up to fail so ABT could offload a lot of debt.
Source: Black Stripe via Wikimedia (Modified)
But now it looks like ABT might have some spinoff remorse now that the drug AbbVie was left with is doing about $16 billion a year in revenue.
Instead of getting sucked into the black hole of all the debt, ABBV stock has become a shining star in the biotech world.
Now that it has been averaging about 25% growth a year some analysts are throwing up caution signs because Humira's patent ran out in 2016. They talk about the nearly three dozen cheap generics and biosimlars that are ready to eat its lunch.
Why ABBV Stock Still Has Strength
AbbVie relies heavily on Humira revenue and anything that significantly eats into that revenue is cause for concern. But one of the strength of ABBV stock is the fact that it's backed by a company that is not only fighting hard to keep the would-be competitors out of its markets using legal tactics, it's also showing analysts that Humira still has some good years left.
It has raised the price of the drug by 8% and yet, according to its own numbers, saw sales growth in the U.S. of nearly 23% in the past quarter compared to the same quarter a year ago. International sales were up 15%.
7 Stocks to Buy Now for BIG Summer Outperformance
Speaking of Q1 numbers, revenue and earnings beat estimates handily. These are strong signals that AbbVie is not going down quickly. The company currently estimates it has about three years until Humira revenue starts dropping off. Part of what's keeping Humira alive is the fact that ABBV is also expanding its uses for the drug and it expects to bring in $20 billion on Humira in 2020.
But the biggest ace AbbVie has up its sleeve is its late-stage drug pipeline. The company estimates that eight of its drugs that are either in the market now or will be in the next year or two will bring in another $25 to $30 billion annually by 2020.
Spinraza for spinal muscular atrophy was just approved. There are two others in the phase 3 trials for Alzheimer's and 11 other drugs in phase 2 trials. The point is, ABBV stock is more than a one-trick pony.
The other nice component that AbbVie offers is a solid dividend. Even trading near its 52-week highs, the stock is still delivering an impressive 3.8% dividend. Coupled with the stock's near-5% rise year-to-date, that's a solid return for 2017.
The stock looks to be taking a breather right now and the bulls and bears are both tugging at it. This is a good time to get in on ABBV stock while neither side has the advantage and it is trading at a very reasonable price.
Richard Band'sProfitable Investing advisory service helps retirement savers outperform the market without losing a minute of sleep along the way. His straightforward style and low-risk value approach has won seven Best Financial Advisory awards from the Newsletter and Electronic Publishers Foundation.
More From InvestorPlace
7 Stocks That Will Get Crushed in the Next Crash
7 Stocks to Buy on the Next Big Market Dip
7 Stocks to Sell Thanks to TERRIBLE Seasonality
The post AbbVie Inc (ABBV) Stock STILL Has Much More Room to Run Higher appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Source: Black Stripe via Wikimedia (Modified) But now it looks like ABT might have some spinoff remorse now that the drug AbbVie was left with is doing about $16 billion a year in revenue. In late 2012, Abbott Laboratories (NYSE: ABT ) spun off AbbVie with one drug and a lot of its accumulated debt. At the time, it looked like ABBV stock was being set up to fail so ABT could offload a lot of debt. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In late 2012, Abbott Laboratories (NYSE: ABT ) spun off AbbVie with one drug and a lot of its accumulated debt. At the time, it looked like ABBV stock was being set up to fail so ABT could offload a lot of debt. | In late 2012, Abbott Laboratories (NYSE: ABT ) spun off AbbVie with one drug and a lot of its accumulated debt. At the time, it looked like ABBV stock was being set up to fail so ABT could offload a lot of debt. Source: Black Stripe via Wikimedia (Modified) But now it looks like ABT might have some spinoff remorse now that the drug AbbVie was left with is doing about $16 billion a year in revenue. | In late 2012, Abbott Laboratories (NYSE: ABT ) spun off AbbVie with one drug and a lot of its accumulated debt. At the time, it looked like ABBV stock was being set up to fail so ABT could offload a lot of debt. Source: Black Stripe via Wikimedia (Modified) But now it looks like ABT might have some spinoff remorse now that the drug AbbVie was left with is doing about $16 billion a year in revenue. |
33633.0 | 2017-05-17 00:00:00 UTC | The Zacks Analyst Blog Highlights: General Dynamics, EOG Resources, Abbott, Northrop Grumman and Symantec | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-general-dynamics-eog-resources-abbott-northrop-grumman | nan | nan | For Immediate Release
Chicago, IL - May 17, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include General Dynamics (NYSE: GD- Free Report ), EOG Resources (NYSE: EOG- Free Report ), Abbott (NYSE: ABT- Free Report ), Northrop Grumman (NYSE: NOC- Free Report ) and Symantec (NASDAQ: SYMC- Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Tuesday's Analyst Blog:
Analyst Reports for Abbott Labs, EOG Resources, General Dynamics & More
Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (NYSE: GD- Free Report ), EOG Resources (NYSE: EOG- Free Report ) and Abbott (NYSE: ABT- Free Report ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today's research reports here >>>
General Dynamics ' shares have gained +34.6% over the last one year, outperforming the Zacks Aerospace - Defense industry, which increased +20.8% over the same period. The Zacks analyst likes the improved outlook for the company's broad portfolio of products and services given the administration's plans for material spending increases. The expectation is for solid growth momentum post 2017, following the introduction of G500 in 2018, major revenue recognition from Combat Systems' huge backlog and the Ohio-class Replacement (ORP) submarine program, which should add substantially to the top line by 2019. On the flip side, any slip up in the Trump administration's commitment to raise defense spending remains a headwind for this company as well as many of its peers. Valuation has become an issue as well following the stock's aforementioned run up. (You can read the full research report on General Dynamics here >>> )
EOG Resources shares have gained around +16.1% over the last one year, outperforming the Zacks Oil & Gas E&P Industry, which has lost -9.3% over the same period. The Zacks analyst likes the fact that EOG Resources has premium acreages in three prospective oil plays in the U.S like Permian, Bakken and Eagle Ford shale plays. The company has also decided to complete more wells in 2017, which should contribute to production growth. However, significantly higher exploration expenses incurred during the first three months of this year is cause for concern even though Q1 results were better than expected on the back of volume gains and improved realizations. (You can read the full research report on EOG Resources here >>> )
Abbott shares have outperformed the Zacks Medical sector in the year-to-date period (the stock is up +14% vs. +7.7% gain for the sector) on the back of greater appreciation for the company's strategic repositioning through acquisitions/divestitures. The St. Jude Medical buyout will complement its cardiovascular devices business. Also, the company's plans to focus on selling its portfolio in core therapeutic areas. Meanwhile, weakness in the nutrition business in China and sluggish growth in the Venezuelan market is a concern. (You can read the full research report on Abbott here >>> )
Other noteworthy reports we are featuring today include Northrop Grumman (NYSE: NOC- Free Report ) and Symantec (NASDAQ: SYMC- Free Report ).
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on GD - FREE
Get the full Report on EOG - FREE
Get the full Report on ABT - FREE
Get the full Report on NOC - FREE
Get the full Report on SYMC - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
General Dynamics Corporation (GD): Free Stock Analysis Report
EOG Resources, Inc. (EOG): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Northrop Grumman Corporation (NOC): Free Stock Analysis Report
Symantec Corporation (SYMC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include General Dynamics (NYSE: GD- Free Report ), EOG Resources (NYSE: EOG- Free Report ), Abbott (NYSE: ABT- Free Report ), Northrop Grumman (NYSE: NOC- Free Report ) and Symantec (NASDAQ: SYMC- Free Report ). Here are highlights from Tuesday's Analyst Blog: Analyst Reports for Abbott Labs, EOG Resources, General Dynamics & More Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (NYSE: GD- Free Report ), EOG Resources (NYSE: EOG- Free Report ) and Abbott (NYSE: ABT- Free Report ). Get the full Report on GD - FREE Get the full Report on EOG - FREE Get the full Report on ABT - FREE Get the full Report on NOC - FREE Get the full Report on SYMC - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. | Stocks recently featured in the blog include General Dynamics (NYSE: GD- Free Report ), EOG Resources (NYSE: EOG- Free Report ), Abbott (NYSE: ABT- Free Report ), Northrop Grumman (NYSE: NOC- Free Report ) and Symantec (NASDAQ: SYMC- Free Report ). Here are highlights from Tuesday's Analyst Blog: Analyst Reports for Abbott Labs, EOG Resources, General Dynamics & More Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (NYSE: GD- Free Report ), EOG Resources (NYSE: EOG- Free Report ) and Abbott (NYSE: ABT- Free Report ). Click to get this free report General Dynamics Corporation (GD): Free Stock Analysis Report EOG Resources, Inc. (EOG): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Northrop Grumman Corporation (NOC): Free Stock Analysis Report Symantec Corporation (SYMC): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Tuesday's Analyst Blog: Analyst Reports for Abbott Labs, EOG Resources, General Dynamics & More Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (NYSE: GD- Free Report ), EOG Resources (NYSE: EOG- Free Report ) and Abbott (NYSE: ABT- Free Report ). Get the full Report on GD - FREE Get the full Report on EOG - FREE Get the full Report on ABT - FREE Get the full Report on NOC - FREE Get the full Report on SYMC - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report General Dynamics Corporation (GD): Free Stock Analysis Report EOG Resources, Inc. (EOG): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Northrop Grumman Corporation (NOC): Free Stock Analysis Report Symantec Corporation (SYMC): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include General Dynamics (NYSE: GD- Free Report ), EOG Resources (NYSE: EOG- Free Report ), Abbott (NYSE: ABT- Free Report ), Northrop Grumman (NYSE: NOC- Free Report ) and Symantec (NASDAQ: SYMC- Free Report ). Here are highlights from Tuesday's Analyst Blog: Analyst Reports for Abbott Labs, EOG Resources, General Dynamics & More Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (NYSE: GD- Free Report ), EOG Resources (NYSE: EOG- Free Report ) and Abbott (NYSE: ABT- Free Report ). Get the full Report on GD - FREE Get the full Report on EOG - FREE Get the full Report on ABT - FREE Get the full Report on NOC - FREE Get the full Report on SYMC - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. |
33634.0 | 2017-05-17 00:00:00 UTC | Abbott Lab Well Poised on Strong EPD, St. Jude Integration | ABT | https://www.nasdaq.com/articles/abbott-lab-well-poised-on-strong-epd-st.-jude-integration-2017-05-17 | nan | nan | On May 17, we issued an updated research report on Abbott LaboratoriesABT . The stock currently carries a Zacks Rank #2 (Buy).
Abbott exceeded the Zacks Consensus Estimate on both earnings and sales front in first-quarter 2017. We are particularly optimistic about its strong and consistent Established Pharmaceuticals Division (EPD) and Medical Devices performance.
The company recently noted that, banking on successful execution of its operating model, EPD is well positioned for sustained growth in many of these growing pharmaceutical markets. Particularly, Latin America, China and several markets in Southeast Asia have demonstrated strong growth of late.
Overall, Abbott stands to benefit from the ongoing integration and synergy achievement of St. Jude. The consolidated company has already started to generate positive outcome. The company remains focused on achieving its new product milestones, synergy targets, and financial objectives for 2017.
Abbott is also highly optimistic about the Alere deal. According to the company, the acquisition of Alere will significantly expand its diagnostics presence and leadership in this space. We are also looking forward to the company's plans to focus on selling portfolio in core therapeutic areas. Very recently, Abbott also received CE mark for its TactiCath Sensor and Confirm Rx ICM products.
However, for the last three months, the company traded below the Zacks categorized Large Cap Pharmaceuticals industry. Dull international pediatric business on challenging market conditions in China continues to hamper growth. The stock has lost 2.24% during this period as against 4.81% gain of the broader industry. Also economic problems in Venezuela are expected to remain unresolved in the coming quarters.
Key Picks
Other stocks worth considering in the broader medical sector include Luminex Corporation LMNX , Hologic, Inc. HOLX and Edward Lifesciences, Inc. EW . Luminex sports a Zacks Rank #1 (Strong Buy), while Hologic and Edward Lifesciences carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 17.0% over the last three months.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a solid one-year return of roughly 30.5%.
Edward Lifesciences recorded a stellar EPS growth rate of almost 16% (last three-five years of actual earnings).
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think. See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Hologic, Inc. (HOLX): Free Stock Analysis Report
Luminex Corporation (LMNX): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On May 17, we issued an updated research report on Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently noted that, banking on successful execution of its operating model, EPD is well positioned for sustained growth in many of these growing pharmaceutical markets. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. On May 17, we issued an updated research report on Abbott LaboratoriesABT . Key Picks Other stocks worth considering in the broader medical sector include Luminex Corporation LMNX , Hologic, Inc. HOLX and Edward Lifesciences, Inc. EW . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. On May 17, we issued an updated research report on Abbott LaboratoriesABT . Luminex sports a Zacks Rank #1 (Strong Buy), while Hologic and Edward Lifesciences carry a Zacks Rank #2. | On May 17, we issued an updated research report on Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. The stock currently carries a Zacks Rank #2 (Buy). |
33635.0 | 2017-05-10 00:00:00 UTC | IYY, AGN, ABT, MDLZ: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/iyy-agn-abt-mdlz-large-outflows-detected-etf-2017-05-10 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Dow Jones U.S. ETF (Symbol: IYY) where we have detected an approximate $30.0 million dollar outflow -- that's a 2.7% decrease week over week (from 9,300,000 to 9,050,000). Among the largest underlying components of IYY, in trading today Allergan PLC (Symbol: AGN) is down about 3.4%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Mondelez International Inc (Symbol: MDLZ) is lower by about 0.3%. For a complete list of holdings, visit the IYY Holdings page » The chart below shows the one year price performance of IYY, versus its 200 day moving average:
Looking at the chart above, IYY's low point in its 52 week range is $99.15 per share, with $120.51 as the 52 week high point - that compares with a last trade of $119.86. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- | Among the largest underlying components of IYY, in trading today Allergan PLC (Symbol: AGN) is down about 3.4%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Mondelez International Inc (Symbol: MDLZ) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Dow Jones U.S. ETF (Symbol: IYY) where we have detected an approximate $30.0 million dollar outflow -- that's a 2.7% decrease week over week (from 9,300,000 to 9,050,000). For a complete list of holdings, visit the IYY Holdings page » The chart below shows the one year price performance of IYY, versus its 200 day moving average: Looking at the chart above, IYY's low point in its 52 week range is $99.15 per share, with $120.51 as the 52 week high point - that compares with a last trade of $119.86. | Among the largest underlying components of IYY, in trading today Allergan PLC (Symbol: AGN) is down about 3.4%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Mondelez International Inc (Symbol: MDLZ) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Dow Jones U.S. ETF (Symbol: IYY) where we have detected an approximate $30.0 million dollar outflow -- that's a 2.7% decrease week over week (from 9,300,000 to 9,050,000). For a complete list of holdings, visit the IYY Holdings page » The chart below shows the one year price performance of IYY, versus its 200 day moving average: Looking at the chart above, IYY's low point in its 52 week range is $99.15 per share, with $120.51 as the 52 week high point - that compares with a last trade of $119.86. | Among the largest underlying components of IYY, in trading today Allergan PLC (Symbol: AGN) is down about 3.4%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Mondelez International Inc (Symbol: MDLZ) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Dow Jones U.S. ETF (Symbol: IYY) where we have detected an approximate $30.0 million dollar outflow -- that's a 2.7% decrease week over week (from 9,300,000 to 9,050,000). For a complete list of holdings, visit the IYY Holdings page » The chart below shows the one year price performance of IYY, versus its 200 day moving average: Looking at the chart above, IYY's low point in its 52 week range is $99.15 per share, with $120.51 as the 52 week high point - that compares with a last trade of $119.86. | Among the largest underlying components of IYY, in trading today Allergan PLC (Symbol: AGN) is down about 3.4%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Mondelez International Inc (Symbol: MDLZ) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Dow Jones U.S. ETF (Symbol: IYY) where we have detected an approximate $30.0 million dollar outflow -- that's a 2.7% decrease week over week (from 9,300,000 to 9,050,000). For a complete list of holdings, visit the IYY Holdings page » The chart below shows the one year price performance of IYY, versus its 200 day moving average: Looking at the chart above, IYY's low point in its 52 week range is $99.15 per share, with $120.51 as the 52 week high point - that compares with a last trade of $119.86. |
33636.0 | 2017-05-09 00:00:00 UTC | 7 Stocks to Buy Now for BIG Summer Outperformance | ABT | https://www.nasdaq.com/articles/7-stocks-to-buy-now-for-big-summer-outperformance-2017-05-09 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If you're not looking for stocks to buy right now because you're worried about jumping on the "sell in May and go away" bandwagon, you're making a rookie mistake.
Source: Shutterstock
Investing isn't really as easy as selling in may and walking away, which is one of the most well-worn sayings in investing. The idea is simple, sure. If you keep your money in stocks from October through May, then pull it out and take the summer off, boom - you beat the market. Depending on the person analyzing the data and how they present it, this can be true, but remember:
The devil is in the details.
We recently showed you seven stocks to sell that follow that trend and in fact are worthy of ditching in May. But that doesn't mean they're all garbage, and in fact, there are a number of stocks you should jump on before the month is through.
The best stocks to buy in May are particularly resilient, typically posting gains when the market is busy snoozing. The S&P 500 itself has average a return of just 0.6% for the month of May over the past five years. Believe it or not, that's only slightly below average. Moreover, only one year has actually been down in that time - that's four up years in the past five!
We've compiled a list of 16 companies that our data models identified as "Buy in May Stocks." This was based on the number of years each company has seen buying vs. selling, and the degree of positive returns. Of course, seasonality doesn't determine everything, so we've filtered this down to the seven stocks with the strongest overall bull cases.
The 10 Best Cheap Stocks to Buy for $10 or Less
Let's hop in and look at this list of seven stocks you should absolutely buy in May.
Stocks to Buy Now: Sherwin-Williams (SHW)
Source: Shutterstock
3-Month Upside: 11%
Sherwin-Williams Co (NYSE: SHW ) shares have cruised more than 25% higher year-to-date, outpacing the market by more than threefold as investors maintain a bullish outlook for homebuilding-related companies.
Sherwin-Williams averages a return of 3.9% for the month of May over the past five years, and hasn't missed a beat, posting gains in each of those years. The consistency makes sense - not only do homebuilding crews ramp up work, but the house-painting business thrives during the summer months.
SHW is trading in technically strong territory and currently holds a "Buy" recommendation from our models. The company surged in April after a positive earnings report, breaking back into a long-term bullish trend channel that now targets a price of $375.
Stocks to Buy Now: Regeneron (REGN)
Source: Mark Bellusci via Vimeo
3-Month Upside: 17%
It's the right time for pharmaceutical and biotech companies to hit seasonality, right as the Trump administration is getting a little traction on the healthcare reform the market expected.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) just made a 7% move higher after its most recent earnings report. That rally has seen some traders take profits, but seasonality suggests now is the time to grab shares … not sell them.
We should see support at $420, and REGN has has upside potential first to $460, which chart resistance should lie.
10 Dividend Stocks That Will Deliver Double-Digit Returns Every Year
Past that, we believe Regeneron will target $500 after a break above the $460 level as momentum continues to build.
Stocks to Buy Now: Quest Diagnostics (DGX)
Source: Ed Uthman via Flickr (Modified)
3-Month Upside: 12%
Quest Diagnostics Inc (NYSE: DGX ) is one of those stocks that has been on our model's bullish lists for the past three years. The fundamental story is simple and sound: Lab work, regardless of healthcare reform, will continue to grow in demand. Nothing's stopping that.
DGX shares broke above $100 after their last earnings report, putting them on the radar of many traders that are now trying to squeeze into the stock without sending it through the roof.
Speaking of squeezing, the short interest ratio on Quest Diagnostics is a lofty 9.1, meaning that these new highs are causing a lot of pain for those that hold the stock short. DGX is set for a short squeeze even higher because of that.
Our models target a move to $120 over the intermediate-term (three to four months).
Stocks to Buy Now: Abbott Laboratories (ABT)
Source: Open Grid Scheduler Via Flickr
3-Month Outlook: 12%
Abbott Laboratories (NYSE: ABT ) is another embattled biotech name that's on this list of seasonally strong stocks to buy now.
Abbott Labs just enjoyed a boost from a better-than-expected quarterly earnings report, moving the stock from $43.50 to $44.70. But it's a turn of the technical tide that should help shares the most this May.
Abbott Labs shares are now trading above their 50-day moving average again. In addition, this trendline is beginning to transition into a bullish outlook as it is edging toward an uptrend itself. Bottom line: The technicians are about get really bullish on ABT.
The 10 Best Growth Stocks You Can Buy Right Now
Watch for some round-numbered resistance at $45. Otherwise, our seasonality and the bullish outlook suggests that Abbott Labs is likely to beat the "sell in May" rule and head toward $50.
Stocks to Buy Now: Apple (AAPL)
Source: Shutterstock
3-Month Upside: 6%
It almost pains us to cover Apple Inc. (NASDAQ:AAPL) with a bullish tint.
Apple, which is at all-time highs and sits at more than $820 billion in market capitalization , is one of the most crowded trades on Wall Street - something we dislike as a general rule. Nonetheless, the data tells us that Apple shares have averaged a move of 3.8% over the past five Mays.
Just so we can be a little skeptical, Apple is set to host the WWDC event in the beginning of June, and a lot of hoopla goes into this event. This suggests that Apple's strength in May is probably attributable to "buy the rumor" activity attached to the early June event.
Put the event aside. Apple shares are trading in a new bullish channel after last quarter's earnings report. For now, AAPL is likely to remain a leader in the tech sector with a target of (gulp) $163.
Stocks to Buy Now: Mohawk Industries (MHK)
Source: Shutterstock
3-Month Upside: 11%
Following the same theme as Sherwin-Williams, Mohawk Industries, Inc. (NYSE: MHK ) is a consistently strong performer in May based in part on the increase in homebuilding seen during this season.
Our technical models love Mohawk Industries due to the strong trends, and the fact that they're being maintained at lower volatility levels than the very sleepy market. Currently, the 50- and 200-day trendlines are in bullish patterns themselves, suggesting dedicated support on pullbacks.
Mohawk Industries recently pulled back following the company's most recent earnings report. The increase in buying as the stock approached its 50-day moving average, however, suggests that May is likely to follow the already established trend.
10 Simply Safe Dividend Stocks to Buy for Retirement
Look for shares to punch higher to roughly $260.
Stocks to Buy Now: Darden Restaurants (DRI)
Source: Mike Mozart via Flickr (Modified)
3-Month Upside: 7%
Finally, another long-time favorite of our modeling is Darden Restaurants, Inc. (NYSE: DRI ). The company announced a great earnings report in March that propelled the stock back into new high territory, and investors are still trying to catch up to the shares.
Short sellers are still on the wrong side of this stock, indicating that the new high status of Darden Restaurants is likely to draw even more buyers into the fold.
Currently, our models maintain a "Buy" on the stock through the summer with a target to add to positions if the stock were to pull back to $85.
DRI averages 3.5% over the month of May for the past five years. With a target of $93, our models expect 2017 to repeat its strong May performance.
As of this writing, Johnson Research Group did not hold a position in any of the aforementioned securities.
The post 7 Stocks to Buy Now for BIG Summer Outperformance appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks to Buy Now: Abbott Laboratories (ABT) Source: Open Grid Scheduler Via Flickr 3-Month Outlook: 12% Abbott Laboratories (NYSE: ABT ) is another embattled biotech name that's on this list of seasonally strong stocks to buy now. Bottom line: The technicians are about get really bullish on ABT. Stocks to Buy Now: Regeneron (REGN) Source: Mark Bellusci via Vimeo 3-Month Upside: 17% It's the right time for pharmaceutical and biotech companies to hit seasonality, right as the Trump administration is getting a little traction on the healthcare reform the market expected. | Stocks to Buy Now: Abbott Laboratories (ABT) Source: Open Grid Scheduler Via Flickr 3-Month Outlook: 12% Abbott Laboratories (NYSE: ABT ) is another embattled biotech name that's on this list of seasonally strong stocks to buy now. Bottom line: The technicians are about get really bullish on ABT. Stocks to Buy Now: Sherwin-Williams (SHW) Source: Shutterstock 3-Month Upside: 11% Sherwin-Williams Co (NYSE: SHW ) shares have cruised more than 25% higher year-to-date, outpacing the market by more than threefold as investors maintain a bullish outlook for homebuilding-related companies. | Stocks to Buy Now: Abbott Laboratories (ABT) Source: Open Grid Scheduler Via Flickr 3-Month Outlook: 12% Abbott Laboratories (NYSE: ABT ) is another embattled biotech name that's on this list of seasonally strong stocks to buy now. Bottom line: The technicians are about get really bullish on ABT. InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you're not looking for stocks to buy right now because you're worried about jumping on the "sell in May and go away" bandwagon, you're making a rookie mistake. | Stocks to Buy Now: Abbott Laboratories (ABT) Source: Open Grid Scheduler Via Flickr 3-Month Outlook: 12% Abbott Laboratories (NYSE: ABT ) is another embattled biotech name that's on this list of seasonally strong stocks to buy now. Bottom line: The technicians are about get really bullish on ABT. Sherwin-Williams averages a return of 3.9% for the month of May over the past five years, and hasn't missed a beat, posting gains in each of those years. |
33637.0 | 2017-04-25 00:00:00 UTC | Health Care Sector Update for 04/25/2017: BIIB, ESRX, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-04252017-biib-esrx-jnj-pfe-abt-mrk-amgn-2017-04-25 | nan | nan | Top Health Care stocks:
JNJ: +01%
PFE: +1%
ABT: -2.5%
MRK: flat
AMGN: +0.8%
Health care shares were mostly higher in pre-market trade Tuesday.
In health care stocks news, Express Scripts Holding Company ( ESRX ) shares fell 12.6%, on track to sink below its 52-week low, after it said it has been notified that Anthem ANTM) has decided to not renew the pharmacy benefit management contract with Express when it expires at the end of 2019. In 2016, Express Scripts revenue attributable to Anthem was $17.08 billion of the group total of $100.29 billion. Adjusted EBITDA attributable to Anthem was $2.25 billion, or approximately 31% of the group total figure. Express said it had proposed providing as much as $1 billion in annual value in the form of price concessions for 2017-2019 in connection with a negotiated contract extension for the period beyond 2019 at prevailing market rates but ultimately Anthem was not interested in these or in receiving the company's proposed pricing for the period beyond 2019. Express said that Anthem's contribution to its profitability, as a percentage of total EBITDA and adjusted EBITDA, has grown and it expects it will continue to increase and exceed its contribution to its revenues, as a percentage of our total revenues, and that revenues, EBITDA and adjusted EBITDA attributable to Anthem will increase as the contract nears its termination in 2019.
And, Biogen ( BIIB ) was up 4% after it said it had Q1 revenues of $2.81 billion, up 3% from $2.73 billion in the same quarter a year earlier and beating analysts' consensus estimate of $2.73 billion. The company also said it had adjusted net diluted net income of $5.20 per share, up 9% from $4.79 per share a year ago and beating analysts' consensus estimate of $4.97 per share.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Express Scripts Holding Company ( ESRX ) shares fell 12.6%, on track to sink below its 52-week low, after it said it has been notified that Anthem ANTM) has decided to not renew the pharmacy benefit management contract with Express when it expires at the end of 2019. Adjusted EBITDA attributable to Anthem was $2.25 billion, or approximately 31% of the group total figure. Express said it had proposed providing as much as $1 billion in annual value in the form of price concessions for 2017-2019 in connection with a negotiated contract extension for the period beyond 2019 at prevailing market rates but ultimately Anthem was not interested in these or in receiving the company's proposed pricing for the period beyond 2019. | In 2016, Express Scripts revenue attributable to Anthem was $17.08 billion of the group total of $100.29 billion. Express said that Anthem's contribution to its profitability, as a percentage of total EBITDA and adjusted EBITDA, has grown and it expects it will continue to increase and exceed its contribution to its revenues, as a percentage of our total revenues, and that revenues, EBITDA and adjusted EBITDA attributable to Anthem will increase as the contract nears its termination in 2019. The company also said it had adjusted net diluted net income of $5.20 per share, up 9% from $4.79 per share a year ago and beating analysts' consensus estimate of $4.97 per share. | In health care stocks news, Express Scripts Holding Company ( ESRX ) shares fell 12.6%, on track to sink below its 52-week low, after it said it has been notified that Anthem ANTM) has decided to not renew the pharmacy benefit management contract with Express when it expires at the end of 2019. In 2016, Express Scripts revenue attributable to Anthem was $17.08 billion of the group total of $100.29 billion. Express said that Anthem's contribution to its profitability, as a percentage of total EBITDA and adjusted EBITDA, has grown and it expects it will continue to increase and exceed its contribution to its revenues, as a percentage of our total revenues, and that revenues, EBITDA and adjusted EBITDA attributable to Anthem will increase as the contract nears its termination in 2019. | Health care shares were mostly higher in pre-market trade Tuesday. In health care stocks news, Express Scripts Holding Company ( ESRX ) shares fell 12.6%, on track to sink below its 52-week low, after it said it has been notified that Anthem ANTM) has decided to not renew the pharmacy benefit management contract with Express when it expires at the end of 2019. In 2016, Express Scripts revenue attributable to Anthem was $17.08 billion of the group total of $100.29 billion. |
33638.0 | 2017-04-21 00:00:00 UTC | The Zacks Analyst Blog Highlights: IBM, Abbott, Dow Chemical, Delta Air Lines and Exelon | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-ibm-abbott-dow-chemical-delta-air-lines-and-exelon-2017 | nan | nan | For Immediate Release
Chicago, IL - April 21, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include IBM (NYSE: IBM- Free Report ), Abbott (NYSE: ABT- Free Report ), Dow Chemical (NYSE: DOW- Free Report ), Delta Air Lines (NYSE: DAL- Free Report ) and Exelon (NYSE: EXC- Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday's Analyst Blog:
Q1 Earnings and Research Reports for Friday
The Zacks Research Daily features the best research output of our analyst team. In today's write-up, we are featuring analyst reports on 16 major stocks, including reports on IBM (NYSE: IBM- Free Report ), Abbott (NYSE: ABT- Free Report ) and Dow Chemical (NYSE: DOW- Free Report ). These reports have been hand-picked from amongst the 70 or so stock research reports published by our analyst team today. You can see all of today's research reports here >>
In addition to these stock research reports, we are also giving you a real-time scorecard of the ongoing Q1 earnings season. You can read more about our views about this earnings season in the weekly Earnings Trends report >>>Q1 Earnings Season Off to a Solid Start
Q1Earnings Scorecard (as of Thursday, April 20 th )
Including all of this morning's releases, we now have Q1 results from 82 S&P 500 members that combined account for 21% of the index's total market capitalization. Total earnings for these 82 index members are up +15.4% on +4.9% higher revenues, with 72% beating EPS estimates and 59.8% beating revenue estimates.
This is better earnings and revenue growth performance than we have seen from this group of 82 S&P 500 members in other recent periods, even after adjusting for the strong growth from the Finance sector which has a heavy presence in the results at this stage.
For the Finance sector, we now have Q1 results from 47.7% of the sector's market capitalization in the S&P 500 index. Total earnings for these Finance companies are up +23.4% from the same period last year on +7.7% higher revenues, with 69.2% beating EPS estimates and 57.7% beating revenue estimates. This is better earnings and revenue growth rate for the Finance sector than we have seen in other recent periods, though most of these stocks have been struggling lately as a result of the downtrend in interest rates.
Excluding the Finance sector, total earnings for the rest of the S&P 500 companies that have reported would be up +8.7% on +3.7% higher revenues from the year-earlier level.
Looking at Q1 as a whole, combining the actual results from the 82 index members with estimates from the still-to-come 418 companies, total earnings are expected to be up +8.8% from the same period last year on +6.2% higher revenues, the best earnings and revenue growth pace in more than two years.
Today's Research Daily features new research reports on 16 major stocks, including IBM, Abbott and Dow Chemical.
IBM shares did reasonably well this year, but the stock has lost ground following the disappointing quraterly report that appear to have raised fresh doubts about the company's ability to reposition itself for the changing technological landscape. Although IBM has been expanding product portfolio into newer technologies like Blockchain, Quantum computing and Containers through frequent acquisitions, these are still in a nascent stage and will take some time to contribute meaningfully towards top-line growth. However, sluggish IT spending particularly on on-premise and data center hardware and foreign exchange volatility remain concerns. (You can read the full research report on IBM here >> )
Shares of Abbott have gained +8.1% over the last three months, outperforming the Zacks Large-Cap Pharma sector which has gained +5.7% over the same period. Abbott exceeded expectations on both the earnings and sales fronts during the first quarter. The Zacks analyst likes how Abbott has been reshaping its portfolio through strategic acquisitions/divestitures for long-term growth. The St. Jude Medical buyout will complement its cardiovascular devices business. Also, the company's plans to focus on selling its portfolio in core therapeutic areas. Meanwhile, weakness in the nutrition business in China and sluggish growth in the Venezuelan market is a concern. (You can read the full research report on Abbott here >> )
Dow Chemical shares have gained +7.7% over the past three months, outperforming the Zacks Chemicals Diversified industry (up +3.6% over the same period). The Zacks analyst likes the planned merger with DuPont, which is expected to create significant synergies. Dow should also gain from cost synergies associated with Dow Corning Silicones business and its strategic investments in the U.S. Gulf Coast and the Middle East. Estimates for first-quarter 2017 have also been stable of late. However, Dow's agriculture business remains affected by depressed crop commodity prices. The company also faces pricing headwinds, feedstock cost pressure as well as weak demand in the energy market. Earnings estimate for the first-quarter 2017 has been stable of late. (You can read the full research report on Dow Chemical here >> )
Other noteworthy reports we are featuring today include Delta Air Lines (NYSE: DAL- Free Report ) and Exelon (NYSE: EXC- Free Report ).
Now See All Our Private Trades
While today's Zacks Rank #1 new additions are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for all Zacks trades >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on IBM - FREE
Get the full Report on ABT - FREE
Get the full Report on DOW - FREE
Get the full Report on DAL - FREE
Get the full Report on EXC - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
International Business Machines Corporation (IBM): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Dow Chemical Company (The) (DOW): Free Stock Analysis Report
Delta Air Lines, Inc. (DAL): Free Stock Analysis Report
Exelon Corporation (EXC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include IBM (NYSE: IBM- Free Report ), Abbott (NYSE: ABT- Free Report ), Dow Chemical (NYSE: DOW- Free Report ), Delta Air Lines (NYSE: DAL- Free Report ) and Exelon (NYSE: EXC- Free Report ). In today's write-up, we are featuring analyst reports on 16 major stocks, including reports on IBM (NYSE: IBM- Free Report ), Abbott (NYSE: ABT- Free Report ) and Dow Chemical (NYSE: DOW- Free Report ). Get the full Report on IBM - FREE Get the full Report on ABT - FREE Get the full Report on DOW - FREE Get the full Report on DAL - FREE Get the full Report on EXC - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. | Stocks recently featured in the blog include IBM (NYSE: IBM- Free Report ), Abbott (NYSE: ABT- Free Report ), Dow Chemical (NYSE: DOW- Free Report ), Delta Air Lines (NYSE: DAL- Free Report ) and Exelon (NYSE: EXC- Free Report ). In today's write-up, we are featuring analyst reports on 16 major stocks, including reports on IBM (NYSE: IBM- Free Report ), Abbott (NYSE: ABT- Free Report ) and Dow Chemical (NYSE: DOW- Free Report ). Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Dow Chemical Company (The) (DOW): Free Stock Analysis Report Delta Air Lines, Inc. (DAL): Free Stock Analysis Report Exelon Corporation (EXC): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include IBM (NYSE: IBM- Free Report ), Abbott (NYSE: ABT- Free Report ), Dow Chemical (NYSE: DOW- Free Report ), Delta Air Lines (NYSE: DAL- Free Report ) and Exelon (NYSE: EXC- Free Report ). Get the full Report on IBM - FREE Get the full Report on ABT - FREE Get the full Report on DOW - FREE Get the full Report on DAL - FREE Get the full Report on EXC - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Dow Chemical Company (The) (DOW): Free Stock Analysis Report Delta Air Lines, Inc. (DAL): Free Stock Analysis Report Exelon Corporation (EXC): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include IBM (NYSE: IBM- Free Report ), Abbott (NYSE: ABT- Free Report ), Dow Chemical (NYSE: DOW- Free Report ), Delta Air Lines (NYSE: DAL- Free Report ) and Exelon (NYSE: EXC- Free Report ). In today's write-up, we are featuring analyst reports on 16 major stocks, including reports on IBM (NYSE: IBM- Free Report ), Abbott (NYSE: ABT- Free Report ) and Dow Chemical (NYSE: DOW- Free Report ). Get the full Report on IBM - FREE Get the full Report on ABT - FREE Get the full Report on DOW - FREE Get the full Report on DAL - FREE Get the full Report on EXC - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. |
33639.0 | 2017-04-21 00:00:00 UTC | Procedure Growth Likely To Remain Strong For Intuitive Surgical | ABT | https://www.nasdaq.com/articles/procedure-growth-likely-remain-strong-intuitive-surgical-2017-04-21 | nan | nan | Intuitive Surgical's ( ISRG ) stock jumped nearly 6.5% following its Q1 2017 earnings announcement. So, was the investor enthusiasm justified? We think so, considering that the growth in the number of procedures performed using da Vinci surgical systems accelerated to 18% in the first quarter. This is critical because the growth in instruments and accessories revenue closely follows the growth in the number of procedures, and is a recurring source of revenue. According to our estimates, this revenue source accounts for nearly 50% of Intuitive Surgical's value. We had stated in an earlier note that Q1 2017 results should be seen as an important catalyst which can set expectations for the rest of the year. Needless to say, the results catalyzed investor activity and Intuitive exceeded our growth expectations. This wasn't an easy task, considering that Intuitive's performance has been mixed in China and Brazil, which are key growth markets, and more instruments are being placed under operating leases. While we don't expect such stellar growth in the remaining quarters of the year, we believe that Intuitive has offered an optimistic outlook for da Vinci's adoption.
Our price estimate of $747 for Intuitive Surgical is nearly 10% below the market. We are reviewing our price estimate in light of recent earnings and will update it shortly.
The growth in procedures was not just driven by mature categories such as urology and gynecology, but also the emerging category of general surgery. The company has observed strong surgeon interest and an encouraging utilization rate of da Vinci systems in general surgery. Overall, procedures grew at a healthy rate in international markets including Europe, Korea and China this quarter. In addition, the company also saw its revenue per procedure increase to nearly $1,840 compared to $1,830 in Q1 2016. It plans to invest in a new technology upgrade - da Vinci X - over the next few quarters, contingent on regulatory approvals. The company hasn't given much information on the price point at this time but it appears that da Vinci's adoption is likely to expand at a healthy rate.
Let us know your views by commenting in the box below.
See More at Trefis|View Interactive Institutional Research(Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This wasn't an easy task, considering that Intuitive's performance has been mixed in China and Brazil, which are key growth markets, and more instruments are being placed under operating leases. While we don't expect such stellar growth in the remaining quarters of the year, we believe that Intuitive has offered an optimistic outlook for da Vinci's adoption. The company has observed strong surgeon interest and an encouraging utilization rate of da Vinci systems in general surgery. | We think so, considering that the growth in the number of procedures performed using da Vinci surgical systems accelerated to 18% in the first quarter. The company has observed strong surgeon interest and an encouraging utilization rate of da Vinci systems in general surgery. See More at Trefis|View Interactive Institutional Research(Powered by Trefis) Get Trefis Technology The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We think so, considering that the growth in the number of procedures performed using da Vinci surgical systems accelerated to 18% in the first quarter. This is critical because the growth in instruments and accessories revenue closely follows the growth in the number of procedures, and is a recurring source of revenue. While we don't expect such stellar growth in the remaining quarters of the year, we believe that Intuitive has offered an optimistic outlook for da Vinci's adoption. | We think so, considering that the growth in the number of procedures performed using da Vinci surgical systems accelerated to 18% in the first quarter. While we don't expect such stellar growth in the remaining quarters of the year, we believe that Intuitive has offered an optimistic outlook for da Vinci's adoption. Our price estimate of $747 for Intuitive Surgical is nearly 10% below the market. |
33640.0 | 2017-04-20 00:00:00 UTC | Company News for April 20, 2017 | ABT | https://www.nasdaq.com/articles/company-news-for-april-20-2017-2017-04-20 | nan | nan | • Shares of Lam Research Corporation LRCX gained 6.9% after the company reported third-quarter fiscal 2017 non-GAAP earnings of $2.80 per share, which surpassed the Zacks Consensus Estimate of $2.54
• Facebook's FB shares advanced 0.9% after it announced a new cameras-based augmented reality platform.
• Shares of Ultragenyx Pharmaceutical Inc RARE gained 1.4% after the company declared positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH)
• Abbott Laboratories' ABT shares gained 0.4% after the company reported first quarter revenues of $6.33 billion which has surpassed the Zacks Consensus Estimate for revenues of $6.11 billion
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Facebook, Inc. (FB): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report
Lam Research Corporation (LRCX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Ultragenyx Pharmaceutical Inc RARE gained 1.4% after the company declared positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH) • Abbott Laboratories' ABT shares gained 0.4% after the company reported first quarter revenues of $6.33 billion which has surpassed the Zacks Consensus Estimate for revenues of $6.11 billion Want the latest recommendations from Zacks Investment Research? Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report To read this article on Zacks.com click here. • Shares of Lam Research Corporation LRCX gained 6.9% after the company reported third-quarter fiscal 2017 non-GAAP earnings of $2.80 per share, which surpassed the Zacks Consensus Estimate of $2.54 • Facebook's FB shares advanced 0.9% after it announced a new cameras-based augmented reality platform. | • Shares of Ultragenyx Pharmaceutical Inc RARE gained 1.4% after the company declared positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH) • Abbott Laboratories' ABT shares gained 0.4% after the company reported first quarter revenues of $6.33 billion which has surpassed the Zacks Consensus Estimate for revenues of $6.11 billion Want the latest recommendations from Zacks Investment Research? Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report To read this article on Zacks.com click here. • Shares of Lam Research Corporation LRCX gained 6.9% after the company reported third-quarter fiscal 2017 non-GAAP earnings of $2.80 per share, which surpassed the Zacks Consensus Estimate of $2.54 • Facebook's FB shares advanced 0.9% after it announced a new cameras-based augmented reality platform. | • Shares of Ultragenyx Pharmaceutical Inc RARE gained 1.4% after the company declared positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH) • Abbott Laboratories' ABT shares gained 0.4% after the company reported first quarter revenues of $6.33 billion which has surpassed the Zacks Consensus Estimate for revenues of $6.11 billion Want the latest recommendations from Zacks Investment Research? Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Ultragenyx Pharmaceutical Inc RARE gained 1.4% after the company declared positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH) • Abbott Laboratories' ABT shares gained 0.4% after the company reported first quarter revenues of $6.33 billion which has surpassed the Zacks Consensus Estimate for revenues of $6.11 billion Want the latest recommendations from Zacks Investment Research? Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report To read this article on Zacks.com click here. • Shares of Lam Research Corporation LRCX gained 6.9% after the company reported third-quarter fiscal 2017 non-GAAP earnings of $2.80 per share, which surpassed the Zacks Consensus Estimate of $2.54 • Facebook's FB shares advanced 0.9% after it announced a new cameras-based augmented reality platform. |
33641.0 | 2017-04-19 00:00:00 UTC | Earnings Reaction History: Abbott Laboratories, 50.0% Follow-Through Indicator, 2.4% Sensitive | ABT | https://www.nasdaq.com/articles/earnings-reaction-history-abbott-laboratories-500-follow-through-indicator-24-sensitive-0 | nan | nan | Expected Earnings Release: 04/19/2017, Premarket
Avg. Extended-Hours Dollar Volume: $574,475
Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 42.9%
Average next regular session additional gain: 2.4%
Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 42.9% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 66.7%
Average next regular session additional loss: 2.7%
Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 42.9% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 42.9% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $574,475 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 42.9% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 42.9% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $574,475 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 42.9% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 42.9% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $574,475 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $574,475 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 42.9% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 42.9% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. |
33642.0 | 2017-04-19 00:00:00 UTC | Granite Investment Advisors, Inc. Buys Abbott Laboratories, Danone SA, AT&T, Sells Corning, ... | ABT | https://www.nasdaq.com/articles/granite-investment-advisors-inc-buys-abbott-laboratories-danone-sa-att-sells-corning-2017 | nan | nan | Granite Investment Advisors, Inc.
New Purchases: BK , VIAB , RIG , XLF, BSV, OEF, PEP, EEM, SNY, SPY,
Added Positions:ABT, DANOY, T, MRK, WMT, RDS.B, BRK.B, AAPL, UTX, UL,
Reduced Positions:GLW, AIG, GIS, UNH, FAX, KO, WY, TU, NSRGY, BLX,
Sold Out:CAT,
For the details of Granite Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Granite+Investment+Advisors%2C+Inc.
These are the top 5 holdings of Granite Investment Advisors, Inc.
Berkshire Hathaway Inc (BRK.B) - 113,181 shares, 3.41% of the total portfolio. Shares added by 11.27%
Johnson & Johnson ( JNJ ) - 145,403 shares, 3.28% of the total portfolio. Shares added by 2.09%
Unilever PLC ( UL ) - 345,489 shares, 3.08% of the total portfolio. Shares added by 9.76%
Abbott Laboratories ( ABT ) - 351,289 shares, 2.82% of the total portfolio. Shares added by 298.60%
Apple Inc ( AAPL ) - 104,966 shares, 2.73% of the total portfolio. Shares added by 13.71%
New Purchase: Bank of New York Mellon Corp ( BK )
Granite Investment Advisors, Inc. initiated holdings in Bank of New York Mellon Corp. The purchase prices were between $43.87 and $48.71, with an estimated average price of $46.77. The stock is now traded at around $46.77. The impact to the portfolio due to this purchase was 1.15%. The holdings were 134,986 shares as of 2017-03-31.
New Purchase: Viacom Inc (VIAB)
Granite Investment Advisors, Inc. initiated holdings in Viacom Inc. The purchase prices were between $35.9 and $46.62, with an estimated average price of $42.21. The stock is now traded at around $44.54. The impact to the portfolio due to this purchase was 0.96%. The holdings were 113,931 shares as of 2017-03-31.
New Purchase: Transocean Ltd (RIG)
Granite Investment Advisors, Inc. initiated holdings in Transocean Ltd. The purchase prices were between $11.99 and $15.84, with an estimated average price of $13.74. The stock is now traded at around $11.27. The impact to the portfolio due to this purchase was 0.61%. The holdings were 271,916 shares as of 2017-03-31.
New Purchase: SPDR Select Sector Fund - Financial (XLF)
Granite Investment Advisors, Inc. initiated holdings in SPDR Select Sector Fund - Financial. The purchase prices were between $22.95 and $25.24, with an estimated average price of $23.95. The stock is now traded at around $23.06. The impact to the portfolio due to this purchase was 0.06%. The holdings were 14,313 shares as of 2017-03-31.
New Purchase: Vanguard Short-Term Bond (BSV)
Granite Investment Advisors, Inc. initiated holdings in Vanguard Short-Term Bond. The purchase prices were between $79.27 and $79.92, with an estimated average price of $79.59. The stock is now traded at around $80.01. The impact to the portfolio due to this purchase was 0.05%. The holdings were 3,231 shares as of 2017-03-31.
New Purchase: PepsiCo Inc (PEP)
Granite Investment Advisors, Inc. initiated holdings in PepsiCo Inc. The purchase prices were between $101.55 and $112.45, with an estimated average price of $107.29. The stock is now traded at around $113.74. The impact to the portfolio due to this purchase was 0.04%. The holdings were 1,820 shares as of 2017-03-31.
Added: Abbott Laboratories ( ABT )
Granite Investment Advisors, Inc. added to the holdings in Abbott Laboratories by 298.60%. The purchase prices were between $39.05 and $45.72, with an estimated average price of $43.23. The stock is now traded at around $43.67. The impact to the portfolio due to this purchase was 2.11%. The holdings were 351,289 shares as of 2017-03-31.
Added: Danone SA (DANOY)
Granite Investment Advisors, Inc. added to the holdings in Danone SA by 174.91%. The purchase prices were between $12.53 and $13.98, with an estimated average price of $13.1. The stock is now traded at around $13.63. The impact to the portfolio due to this purchase was 1.7%. The holdings were 1,079,766 shares as of 2017-03-31.
Added: AT&T Inc (T)
Granite Investment Advisors, Inc. added to the holdings in AT&T Inc by 98.78%. The purchase prices were between $40.61 and $43.02, with an estimated average price of $41.67. The stock is now traded at around $40.24. The impact to the portfolio due to this purchase was 1.16%. The holdings were 311,792 shares as of 2017-03-31.
Added: Merck & Co Inc (MRK)
Granite Investment Advisors, Inc. added to the holdings in Merck & Co Inc by 82.84%. The purchase prices were between $59.92 and $66.58, with an estimated average price of $63.58. The stock is now traded at around $62.56. The impact to the portfolio due to this purchase was 0.98%. The holdings were 187,810 shares as of 2017-03-31.
Added: Wal-Mart Stores Inc (WMT)
Granite Investment Advisors, Inc. added to the holdings in Wal-Mart Stores Inc by 23.41%. The purchase prices were between $65.66 and $72.39, with an estimated average price of $69.04. The stock is now traded at around $74.20. The impact to the portfolio due to this purchase was 0.49%. The holdings were 198,263 shares as of 2017-03-31.
Added: United Technologies Corp (UTX)
Granite Investment Advisors, Inc. added to the holdings in United Technologies Corp by 23.40%. The purchase prices were between $108.18 and $113.68, with an estimated average price of $111.49. The stock is now traded at around $112.97. The impact to the portfolio due to this purchase was 0.32%. The holdings were 83,768 shares as of 2017-03-31.
Sold Out: Caterpillar Inc (CAT)
Granite Investment Advisors, Inc. sold out the holdings in Caterpillar Inc. The sale prices were between $91.39 and $99.02, with an estimated average price of $94.66.
Warning! GuruFocus has detected 7 Warning Signs with ABT. Click here to check it out.
ABT 15-Year Financial Data
The intrinsic value of ABT
Peter Lynch Chart of ABT
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Granite Investment Advisors, Inc. New Purchases: BK , VIAB , RIG , XLF, BSV, OEF, PEP, EEM, SNY, SPY, Added Positions:ABT, DANOY, T, MRK, WMT, RDS.B, BRK.B, AAPL, UTX, UL, Reduced Positions:GLW, AIG, GIS, UNH, FAX, KO, WY, TU, NSRGY, BLX, Sold Out:CAT, For the details of Granite Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Granite+Investment+Advisors%2C+Inc. Shares added by 9.76% Abbott Laboratories ( ABT ) - 351,289 shares, 2.82% of the total portfolio. Added: Abbott Laboratories ( ABT ) Granite Investment Advisors, Inc. added to the holdings in Abbott Laboratories by 298.60%. | Granite Investment Advisors, Inc. New Purchases: BK , VIAB , RIG , XLF, BSV, OEF, PEP, EEM, SNY, SPY, Added Positions:ABT, DANOY, T, MRK, WMT, RDS.B, BRK.B, AAPL, UTX, UL, Reduced Positions:GLW, AIG, GIS, UNH, FAX, KO, WY, TU, NSRGY, BLX, Sold Out:CAT, For the details of Granite Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Granite+Investment+Advisors%2C+Inc. Shares added by 9.76% Abbott Laboratories ( ABT ) - 351,289 shares, 2.82% of the total portfolio. Added: Abbott Laboratories ( ABT ) Granite Investment Advisors, Inc. added to the holdings in Abbott Laboratories by 298.60%. | Granite Investment Advisors, Inc. New Purchases: BK , VIAB , RIG , XLF, BSV, OEF, PEP, EEM, SNY, SPY, Added Positions:ABT, DANOY, T, MRK, WMT, RDS.B, BRK.B, AAPL, UTX, UL, Reduced Positions:GLW, AIG, GIS, UNH, FAX, KO, WY, TU, NSRGY, BLX, Sold Out:CAT, For the details of Granite Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Granite+Investment+Advisors%2C+Inc. Added: Abbott Laboratories ( ABT ) Granite Investment Advisors, Inc. added to the holdings in Abbott Laboratories by 298.60%. Shares added by 9.76% Abbott Laboratories ( ABT ) - 351,289 shares, 2.82% of the total portfolio. | Shares added by 9.76% Abbott Laboratories ( ABT ) - 351,289 shares, 2.82% of the total portfolio. Granite Investment Advisors, Inc. New Purchases: BK , VIAB , RIG , XLF, BSV, OEF, PEP, EEM, SNY, SPY, Added Positions:ABT, DANOY, T, MRK, WMT, RDS.B, BRK.B, AAPL, UTX, UL, Reduced Positions:GLW, AIG, GIS, UNH, FAX, KO, WY, TU, NSRGY, BLX, Sold Out:CAT, For the details of Granite Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Granite+Investment+Advisors%2C+Inc. Added: Abbott Laboratories ( ABT ) Granite Investment Advisors, Inc. added to the holdings in Abbott Laboratories by 298.60%. |
33643.0 | 2017-04-19 00:00:00 UTC | The Pressure Is on D.R. Horton, Inc. (DHI) Ahead of Q1 Earnings | ABT | https://www.nasdaq.com/articles/the-pressure-is-on-d.r.-horton-inc.-dhi-ahead-of-q1-earnings-2017-04-19 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
D.R. Horton, Inc. (NYSE: DHI ) is one of the leading homebuilders in the country, so investors will pay close attention to the company's earnings before the bell on Thursday. I also watch DHI stock closely because of the building millennial mega-trend that will affect housing and many other industries for years to come.
Analysts are looking for earnings to increased 13.5% to $0.59 a share on nearly 12% revenue growth of $3.09 billion. Keep in mind that DHI has beaten estimates three of the last four quarters with an average earnings surprise of 6.3%.
Housing is a critical part of the economy, and homebuilders in general have been outperforming the market this year. Take a look at the iShares U.S. Home Construction ETF (NYSEARCA: ITB ) - which features DHI stock as its top holding, along with heavy weights in LennarCorporation (NYSE: LEN ) and NVR, Inc. (NYSE: NVR ) - and you'll see that it's up 18.5% year-to-date, way ahead of the S&P 500's 5% gain. DHI has done even better, jumping 25% already in 2017.
Demand for homes is getting a boost from an increasing number of new buyers (aka the millennials as they form families) and a stronger jobs market. Add in the fact that interest rates are at their lowest of the year - despite the Fed raising short-term rates - and you have an added bonus for potential homebuyers.
10 Stocks That Won't Exist in a Decade
In terms of DHI stock itself, it's a question mark heading into earnings and a bit risky to own.
D.R. Horton is trading right around its 11-year high of $34.56 set last July, and unless we see a major move over these last few hours, it will head into Thursday morning's report trading just below what is significant resistance.
The pressure is on to beat expectations and provide solid guidance for a breakout to new highs. Anything less will likely hit DHI hard.
Matthew McCall is founder and president of Penn Financial Group, an investment advisory firm. Matt also is Editor of FUTR Stocks and the ETF Bulletin. Earlier this year, Matt and Hilary Kramer teamed up onBreakout Stockswhere Matt serves as the Co-Editor. Most recently, Matt and Hilary joined forces again. This time, they are helping individual investors make money trading ETFs. For more on their latest project, visitwww.etfedgesummit.com.
More From InvestorPlace
3 Reasons Twilio Inc (TWLO) Stock Is Still Dead Money
EBay Inc (EBAY) Is a 'Wait-and-See' Stock Before Earnings
Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results
The post The Pressure Is on D.R. Horton, Inc. (DHI) Ahead of Q1 Earnings appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | More From InvestorPlace 3 Reasons Twilio Inc (TWLO) Stock Is Still Dead Money EBay Inc (EBAY) Is a 'Wait-and-See' Stock Before Earnings Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results The post The Pressure Is on D.R. Horton, Inc. (NYSE: DHI ) is one of the leading homebuilders in the country, so investors will pay close attention to the company's earnings before the bell on Thursday. I also watch DHI stock closely because of the building millennial mega-trend that will affect housing and many other industries for years to come. | More From InvestorPlace 3 Reasons Twilio Inc (TWLO) Stock Is Still Dead Money EBay Inc (EBAY) Is a 'Wait-and-See' Stock Before Earnings Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results The post The Pressure Is on D.R. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | More From InvestorPlace 3 Reasons Twilio Inc (TWLO) Stock Is Still Dead Money EBay Inc (EBAY) Is a 'Wait-and-See' Stock Before Earnings Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results The post The Pressure Is on D.R. Take a look at the iShares U.S. Home Construction ETF (NYSEARCA: ITB ) - which features DHI stock as its top holding, along with heavy weights in LennarCorporation (NYSE: LEN ) and NVR, Inc. (NYSE: NVR ) - and you'll see that it's up 18.5% year-to-date, way ahead of the S&P 500's 5% gain. 10 Stocks That Won't Exist in a Decade In terms of DHI stock itself, it's a question mark heading into earnings and a bit risky to own. | More From InvestorPlace 3 Reasons Twilio Inc (TWLO) Stock Is Still Dead Money EBay Inc (EBAY) Is a 'Wait-and-See' Stock Before Earnings Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results The post The Pressure Is on D.R. InvestorPlace - Stock Market News, Stock Advice & Trading Tips D.R. Horton is trading right around its 11-year high of $34.56 set last July, and unless we see a major move over these last few hours, it will head into Thursday morning's report trading just below what is significant resistance. |
33644.0 | 2017-04-19 00:00:00 UTC | 3 Big Stock Charts for Wednesday: Intuitive Surgical, Inc. (ISRG), Abbott Laboratories (ABT) and Huntington Bancshares Incorporated (HBAN) | ABT | https://www.nasdaq.com/articles/3-big-stock-charts-for-wednesday%3A-intuitive-surgical-inc.-isrg-abbott-laboratories-abt-and | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Earnings will take a lot of the spotlight not only on the news wire, but also on the screens of technical traders as this once quarterly event always has the potential to change the trajectory of a stock.
Today's three big stock charts look at three companies who's earnings results hit the tape this morning, Intuitive Surgical, Inc. (NASDAQ: ISRG ), Abbott Laboratories (NYSE: ABT ) and Huntington Bancshares Incorporated (NASDAQ: HBAN ) and the effect of their results on the charts.
Intuitive Surgical, Inc. (ISRG)
Intuitive Surgical came out with earnings numbers that beat analyst expectations last night after the close. The company beat earnings-per-share estimates by $0.11 and handily beat their revenue target while showing 13% year-over-year growth.
Shares of ISRG are surging more than 7% this morning on the good news, sending the stock on a new bullish trajectory.
Intuitive Surgical shares spent much of the first quarter in a low volatility rally that set the tone for an intermediate-term bullish move in the future. This morning's rally shifts this rally into high gear driven in part by upgrades from the analyst community.
10 Stocks That Won't Exist in a Decade
This shift is marked by the stock's rally straight through the $800-price and into new high territory. From a long-term chart perspective, ISRG stock has yet to match other long-term overbought readings, meaning this rally has room to run higher.
Helping the rally is the catalyst of Intuitive Surgical moving above its top Bollinger Band on the morning trade. This is causing an increase in trading volume as the market is now trying to catch-up with the new valuation suggested by the earnings beat.
For now, we may see shares cool as some profit-taking is likely to take place, but as long as this stock is outside of its Bollinger Band range, we expect it to continue its short-term surge.
Abbott Laboratories (ABT)
Abbott Labs beat expectations with its earnings report, but the stock's reaction is less than ensuring as the stock is trading back into the red. There's a reason in the charts for the price movement that suggests that lower prices are on the horizon.
First, ABT stock headed into earnings registering an oversold signal from its RSI.
Our studies on S&P 500 companies shows that a stock is more likely to rally (about 75% of the time) after their earnings release when this is the case.
The bad part, the clear majority of these rallies turn lower in very short order. Abbott Labs is following that game plan today.
Looking at the trends, Abbott Labs shares are positioned between their 50-day moving average which is overhead and the 100- and 200-day moving averages that are converging at $42-below current prices. This makes reading the next big move easy.
The rollover in the 50-day suggests that ABT shares are likely to start seeing more selling pressure.
The $42-price-level is turning critical for Abbott Labs stock. A break of this price will encroach the 100- and 200-day, while the stock would be breaking the consolidation level from early February trading. Breaking this triple technical threat level would result in a trip to $38 for this well-known health care name.
Huntington Bancshares Incorporated (HBAN)
Financials have had a mixed earnings season so far, though it is still very early. Huntington Bancshares released their earnings to a cool reception from traders.
HBAN stock sits at a dangerous spot on the chart.
Currently at $12.58, Huntington Bancorp shares are teetering on the brink of a technical breakdown that could surrender 10% to 15%.
Why Amazon.com, Inc. (AMZN) Stock Is Still "The Next Big Thing"
First, HBAN stock is preparing to break below its lower Bollinger Band. This will result in a volatility selling situation that will pressure shares lower.
Second, the stock's 50-day moving average is preparing to cross below its 100-day. While not as sexy sounding as the "Death Cross" (when the 50-day moves below the 200-day), it does confirm an intermediate-term bearish trend for the stock.
Finally, as indicated by the red horizontal line, the $12.50-price has been historical chart support as traders have used crosses above this price as a catalyst for buying and selling.
All-in-all, traders need to watch for a bounce from $12.50 on Huntington Bancorp shares. Failure for this level to hold will target a rapid decline lower.
As of this writing, Johnson Research Group did not hold a position in any of the aforementioned securities.
More From InvestorPlace
10 Hopeless Stocks to Wash From Your Portfolio Forever
7 Top Emerging Markets Stocks to Buy Now
Ford Motor Company (F) Stock Has a Secret Weapon
The post 3 Big Stock Charts for Wednesday: Intuitive Surgical, Inc. (ISRG), Abbott Laboratories (ABT) and Huntington Bancshares Incorporated (HBAN) appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Today's three big stock charts look at three companies who's earnings results hit the tape this morning, Intuitive Surgical, Inc. (NASDAQ: ISRG ), Abbott Laboratories (NYSE: ABT ) and Huntington Bancshares Incorporated (NASDAQ: HBAN ) and the effect of their results on the charts. Abbott Laboratories (ABT) Abbott Labs beat expectations with its earnings report, but the stock's reaction is less than ensuring as the stock is trading back into the red. First, ABT stock headed into earnings registering an oversold signal from its RSI. | Today's three big stock charts look at three companies who's earnings results hit the tape this morning, Intuitive Surgical, Inc. (NASDAQ: ISRG ), Abbott Laboratories (NYSE: ABT ) and Huntington Bancshares Incorporated (NASDAQ: HBAN ) and the effect of their results on the charts. More From InvestorPlace 10 Hopeless Stocks to Wash From Your Portfolio Forever 7 Top Emerging Markets Stocks to Buy Now Ford Motor Company (F) Stock Has a Secret Weapon The post 3 Big Stock Charts for Wednesday: Intuitive Surgical, Inc. (ISRG), Abbott Laboratories (ABT) and Huntington Bancshares Incorporated (HBAN) appeared first on InvestorPlace . Abbott Laboratories (ABT) Abbott Labs beat expectations with its earnings report, but the stock's reaction is less than ensuring as the stock is trading back into the red. | Today's three big stock charts look at three companies who's earnings results hit the tape this morning, Intuitive Surgical, Inc. (NASDAQ: ISRG ), Abbott Laboratories (NYSE: ABT ) and Huntington Bancshares Incorporated (NASDAQ: HBAN ) and the effect of their results on the charts. More From InvestorPlace 10 Hopeless Stocks to Wash From Your Portfolio Forever 7 Top Emerging Markets Stocks to Buy Now Ford Motor Company (F) Stock Has a Secret Weapon The post 3 Big Stock Charts for Wednesday: Intuitive Surgical, Inc. (ISRG), Abbott Laboratories (ABT) and Huntington Bancshares Incorporated (HBAN) appeared first on InvestorPlace . Abbott Laboratories (ABT) Abbott Labs beat expectations with its earnings report, but the stock's reaction is less than ensuring as the stock is trading back into the red. | Today's three big stock charts look at three companies who's earnings results hit the tape this morning, Intuitive Surgical, Inc. (NASDAQ: ISRG ), Abbott Laboratories (NYSE: ABT ) and Huntington Bancshares Incorporated (NASDAQ: HBAN ) and the effect of their results on the charts. Abbott Laboratories (ABT) Abbott Labs beat expectations with its earnings report, but the stock's reaction is less than ensuring as the stock is trading back into the red. First, ABT stock headed into earnings registering an oversold signal from its RSI. |
33645.0 | 2017-04-19 00:00:00 UTC | Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-posts-better-expected-earnings-results-2017-04-19 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Abbott Laboratories (NYSE: ABT ) has released its earnings report for the first quarter of 2017.
Revenue reported by Abbott Laboratories in the first quarter of the year was $$6.34 billion. This is an increase over its revenue of $4.89 billion that it reported in the first quarter of 2017. It also came in above Wall Street's revenue estimate of $6.15 billion for the quarter.
During the first quarter of 2017, Abbott Laboratories reported earnings per share of 48 cents. This is up from its earnings per share of 41 cents that was reported during the same time last year. It also beat out analysts' earnings per share estimate of 43 cents for the first quarter of the year.
Abbott Laboratories reported an operating loss of $202 million during the first quarter of 2017. This is a decrease from the operating income of $524 million that was reported during the same period of the year prior.
Net income reported by Abbott Laboratories was $419 million . The healthcare product developer and seller reported a net income of $316 million during the first quarter of the previous year.
Abbott Laboratories will also be paying a quarterly cash dividend to investors. This dividend will be 26.5 cents per share. It will be payable on May 15, 2017 to shareholders that were on record as of April 14, 2017.
10 Blue-Chip Stocks That Will Bleed for the Rest of 2017
Abbott Laboratories also says that its guidance for the full year of 2017 remains unchanged. It continues to expects earnings per share to range from $2.40 to $2.50 for the year. Wall Street is looking for the company to report earnings per share of $2.45 in 2017.
ABT stock remained largely unchanged as of Wednesday morning following the release of its Q1 earnings report.
More From InvestorPlace
7 High-Yield Stocks That Could Wreck Your Retirement
7 Energy Stocks That Will Turn 2017 on Its Head
10 Hopeless Stocks to Wash From Your Portfolio Forever
The post Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT stock remained largely unchanged as of Wednesday morning following the release of its Q1 earnings report. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) has released its earnings report for the first quarter of 2017. More From InvestorPlace 7 High-Yield Stocks That Could Wreck Your Retirement 7 Energy Stocks That Will Turn 2017 on Its Head 10 Hopeless Stocks to Wash From Your Portfolio Forever The post Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results appeared first on InvestorPlace . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) has released its earnings report for the first quarter of 2017. More From InvestorPlace 7 High-Yield Stocks That Could Wreck Your Retirement 7 Energy Stocks That Will Turn 2017 on Its Head 10 Hopeless Stocks to Wash From Your Portfolio Forever The post Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results appeared first on InvestorPlace . ABT stock remained largely unchanged as of Wednesday morning following the release of its Q1 earnings report. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) has released its earnings report for the first quarter of 2017. ABT stock remained largely unchanged as of Wednesday morning following the release of its Q1 earnings report. More From InvestorPlace 7 High-Yield Stocks That Could Wreck Your Retirement 7 Energy Stocks That Will Turn 2017 on Its Head 10 Hopeless Stocks to Wash From Your Portfolio Forever The post Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results appeared first on InvestorPlace . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) has released its earnings report for the first quarter of 2017. ABT stock remained largely unchanged as of Wednesday morning following the release of its Q1 earnings report. More From InvestorPlace 7 High-Yield Stocks That Could Wreck Your Retirement 7 Energy Stocks That Will Turn 2017 on Its Head 10 Hopeless Stocks to Wash From Your Portfolio Forever The post Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results appeared first on InvestorPlace . |
33646.0 | 2017-04-19 00:00:00 UTC | Abbott (ABT) Tops Q1 Earnings on Strong EPD, Medical Device | ABT | https://www.nasdaq.com/articles/abbott-abt-tops-q1-earnings-on-strong-epd-medical-device-2017-04-19 | nan | nan | Abbott LaboratoriesABT reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, 11.6% higher than the Zacks Consensus Estimate and up 17.1% year over year.
Reported earnings for the quarter came in at 22 cents per share, way ahead of the year-ago number of 4 cents.
First-quarter worldwide sales came in at $6.33 billion, up 29.7% year over year on a reported basis. The quarterly figure also remains ahead of the Zacks Consensus Estimate of $6.11 billion.
On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments) sales increased 3.2% year over year in the reported quarter.
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote
Quarter in Detail
Abbott Labs operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
EPD sales were up 7% on a reported basis (up 5.7% on comparable operational basis) to $950 billion. There was a positive impact of 1.3% due to currency fluctuations. Sales in key emerging markets increased 15.2% (up 12.5%) driven by commercial initiatives and locally relevant portfolio expansion. Sales in Other segment declined 13.4% (down 11.3%) to $220 million on poor Venezuelan operations.
The Medical Devices business sales spiked 100.2% on a reported basis on St. Jude inclusion to $2.39 billion. However, on a comparable operational basis, sales increased 4.5%.
Cardiovascular and Neuromodulation sales increased 207% on a reported basis (up 2.4% on comparable operational basis) on double-digit growth in Electrophysiology, Structural Heart and Neuromodulation. Vascular product sales were up 0.1% on a comparable operational basis on the back of double-digit growth in MitraClip. Also, strong sales growth in Abbott's Endovascular business was driven by vessel closure products and Supera.
Diabetes Care sales increased 20.2% on a reported basis (up 22.9%), driven by double-digit international sales growth led by continued consumer uptake of FreeStyle Libre, Abbott's revolutionary continuous glucose monitoring system.
Nutrition sales decreased 1.7% year over year on a reported basis (down 1% on a comparable operational basis). Unfavorable foreign exchange impacted sales by 0.7%. Pediatric Nutrition sales decreased 3.3% on a comparable operational basis. Adult Nutrition sales however, increased 2% on a comparable operational basis.
Diagnostics sales increased 3.6% year over year (up 4.7% on a comparable operational basis). While Core Laboratory sales increased 4.3%, Point of Care Diagnostics sales increased 7.5%, both on a comparable operational basis. Molecular Diagnostics sales were up 3.9% as strong growth in the infectious disease testing business was partially offset by the planned scale-down of the genetics business.
2017 Guidance
Abbott Labs reiterated its full-year 2017 guidance. The company still forecasts earnings per share from continuing operations to remain within the range of 92 cents to $1.02. Adjusting certain net specified items for the full year of approximately $1.48 per share, adjusted earnings per share from continuing operations is expected to stay within the range of $2.40 to $2.50. The current Zacks Consensus Estimate is pegged at $2.45, at the midpoint of the projected range.
Our Take
One more time, Abbott Labs successfully exceeded the Zacks Consensus Estimate on both earnings and sales front. We are optimistic about the company's strong and consistent EPD and Medical Devices performance. However, these strong performances were to some extent offset by sluggish Nutrition business.
However, the company stands to benefit from the recently completed acquisition of St. Jude Medical, which has already started offering it an industry leading pipeline across cardiovascular, neuromodulation, diabetes and vision care.
In 2017, the company plans to execute its existing operating model which focuses on selling portfolio in core therapeutic areas. This will lead to the creation of unique channel opportunities in differentiated relationships with physicians, retailers and pharmacies that are looking to offer a complete line of solutions to treat prominent local health conditions. Also, Abbott Labs has plans to beef up its development capabilities with an expanded EPD innovation center in India.
Moreover, the sale of Abbott Medical Optics to Johnson & Johnson will help the company in reshaping its portfolio in order to focus on gaining leadership positions in cardiovascular devices and expanding diagnostics.
Abbott Labs currently carries a Zacks Rank #3 (Hold).
Stocks to Consider
Better-ranked stocks in the broader medical sector include Inogen Inc. INGN , Hologic, Inc. HOLX and Sunshine Heart Inc SSH . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Inogen has a long-term expected earnings growth rate of 17.50%. The stock registered an impressive one-year return of 64.2%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock registered a solid one-year return of roughly 21.3%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock has a stellar EPS growth record (last three-five years of actual earnings) of almost 22%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Hologic, Inc. (HOLX): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
Sunshine Heart Inc (SSH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, 11.6% higher than the Zacks Consensus Estimate and up 17.1% year over year. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Sunshine Heart Inc (SSH): Free Stock Analysis Report To read this article on Zacks.com click here. However, the company stands to benefit from the recently completed acquisition of St. Jude Medical, which has already started offering it an industry leading pipeline across cardiovascular, neuromodulation, diabetes and vision care. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Sunshine Heart Inc (SSH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, 11.6% higher than the Zacks Consensus Estimate and up 17.1% year over year. On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments) sales increased 3.2% year over year in the reported quarter. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Sunshine Heart Inc (SSH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, 11.6% higher than the Zacks Consensus Estimate and up 17.1% year over year. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote Quarter in Detail Abbott Labs operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics. | Abbott LaboratoriesABT reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, 11.6% higher than the Zacks Consensus Estimate and up 17.1% year over year. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Sunshine Heart Inc (SSH): Free Stock Analysis Report To read this article on Zacks.com click here. However, on a comparable operational basis, sales increased 4.5%. |
33647.0 | 2017-04-19 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABT | https://www.nasdaq.com/articles/5-dividend-growth-stocks-upside-analyst-targets-2017-04-19 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
Another consideration with dividend growth stocks is just how much the dividend is growing . We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
These five stocks are part of our full Dividend Aristocrats List . The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com .
Get the latest Zacks research report on ABT - FREE
Get the latest Zacks research report on PPG - FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Get the latest Zacks research report on ABT - FREE Get the latest Zacks research report on PPG - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . | Get the latest Zacks research report on ABT - FREE Get the latest Zacks research report on PPG - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. | Get the latest Zacks research report on ABT - FREE Get the latest Zacks research report on PPG - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. | Get the latest Zacks research report on ABT - FREE Get the latest Zacks research report on PPG - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. |
33648.0 | 2017-04-19 00:00:00 UTC | Perkins Capital Management Inc Buys LeMaitre Vascular, Abbott Laboratories, ANI ... | ABT | https://www.nasdaq.com/articles/perkins-capital-management-inc-buys-lemaitre-vascular-abbott-laboratories-ani-2017-04-19 | nan | nan | Perkins Capital Management Inc
New Purchases: LMAT , ANIP , STX , DLX, RIG, BX, SRCI, TCB, VG, INTC,
Added Positions:ABT, CYRX, MMSI, JBLU, EDAP, CVS, RMTI, CSII, PFIE, ATRC,
Reduced Positions:NVDA, PIP, SNAK, CGNT, GE, XTNT, CEMI, NEO, GSK, USAT,
Sold Out:STJ, SVU, SRDX, DTLK, BMY, DLTH, MSTX,
For the details of PERKINS CAPITAL MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERKINS+CAPITAL+MANAGEMENT+INC
These are the top 5 holdings of PERKINS CAPITAL MANAGEMENT INC
AxoGen Inc ( AXGN ) - 592,167 shares, 6.44% of the total portfolio. Shares reduced by 0.63%
NeoGenomics Inc ( NEO ) - 520,275 shares, 4.27% of the total portfolio. Shares reduced by 1.87%
Cardiovascular Systems Inc ( CSII ) - 136,050 shares, 4% of the total portfolio. Shares added by 6.66%
Abbott Laboratories ( ABT ) - 83,546 shares, 3.86% of the total portfolio. Shares added by 197.58%
Cancer Genetics Inc ( CGIX ) - 836,908 shares, 3.57% of the total portfolio. Shares reduced by 3.09%
New Purchase: LeMaitre Vascular Inc (LMAT)
Perkins Capital Management Inc initiated holdings in LeMaitre Vascular Inc. The purchase prices were between $21.9 and $26.59, with an estimated average price of $23.48. The stock is now traded at around $25.18. The impact to the portfolio due to this purchase was 2.79%. The holdings were 108,675 shares as of 2017-03-31.
New Purchase: ANI Pharmaceuticals Inc (ANIP)
Perkins Capital Management Inc initiated holdings in ANI Pharmaceuticals Inc. The purchase prices were between $45.01 and $65.55, with an estimated average price of $56.15. The stock is now traded at around $51.07. The impact to the portfolio due to this purchase was 1.14%. The holdings were 22,150 shares as of 2017-03-31.
New Purchase: Seagate Technology PLC (STX)
Perkins Capital Management Inc initiated holdings in Seagate Technology PLC. The purchase prices were between $36.34 and $49.48, with an estimated average price of $44.38. The stock is now traded at around $48.84. The impact to the portfolio due to this purchase was 1.02%. The holdings were 21,350 shares as of 2017-03-31.
New Purchase: Deluxe Corp (DLX)
Perkins Capital Management Inc initiated holdings in Deluxe Corp. The purchase prices were between $70.62 and $75.79, with an estimated average price of $73.24. The stock is now traded at around $70.17. The impact to the portfolio due to this purchase was 1%. The holdings were 13,333 shares as of 2017-03-31.
New Purchase: Transocean Ltd (RIG)
Perkins Capital Management Inc initiated holdings in Transocean Ltd. The purchase prices were between $11.99 and $15.84, with an estimated average price of $13.74. The stock is now traded at around $11.47. The impact to the portfolio due to this purchase was 0.77%. The holdings were 59,700 shares as of 2017-03-31.
New Purchase: Blackstone Group LP (BX)
Perkins Capital Management Inc initiated holdings in Blackstone Group LP. The purchase prices were between $28.12 and $31.3, with an estimated average price of $30.08. The stock is now traded at around $30.22. The impact to the portfolio due to this purchase was 0.5%. The holdings were 16,150 shares as of 2017-03-31.
Added: Abbott Laboratories ( ABT )
Perkins Capital Management Inc added to the holdings in Abbott Laboratories by 197.58%. The purchase prices were between $39.05 and $45.72, with an estimated average price of $43.23. The stock is now traded at around $43.47. The impact to the portfolio due to this purchase was 2.56%. The holdings were 83,546 shares as of 2017-03-31.
Added: CryoPort Inc (CYRX)
Perkins Capital Management Inc added to the holdings in CryoPort Inc by 652.78%. The purchase prices were between $2.01 and $3.91, with an estimated average price of $3.28. The stock is now traded at around $2.28. The impact to the portfolio due to this purchase was 0.88%. The holdings were 410,606 shares as of 2017-03-31.
Added: Merit Medical Systems Inc (MMSI)
Perkins Capital Management Inc added to the holdings in Merit Medical Systems Inc by 188.57%. The purchase prices were between $24.7 and $31.55, with an estimated average price of $28. The stock is now traded at around $28.73. The impact to the portfolio due to this purchase was 0.59%. The holdings were 30,300 shares as of 2017-03-31.
Added: JetBlue Airways Corp (JBLU)
Perkins Capital Management Inc added to the holdings in JetBlue Airways Corp by 127.27%. The purchase prices were between $18.86 and $22.78, with an estimated average price of $20.39. The stock is now traded at around $21.23. The impact to the portfolio due to this purchase was 0.53%. The holdings were 43,750 shares as of 2017-03-31.
Added: Edap TMS SA (EDAP)
Perkins Capital Management Inc added to the holdings in Edap TMS SA by 184.32%. The purchase prices were between $2.55 and $3.51, with an estimated average price of $3.02. The stock is now traded at around $2.54. The impact to the portfolio due to this purchase was 0.52%. The holdings were 276,500 shares as of 2017-03-31.
Added: CVS Health Corp (CVS)
Perkins Capital Management Inc added to the holdings in CVS Health Corp by 31.63%. The purchase prices were between $74.8 and $83.92, with an estimated average price of $79.83. The stock is now traded at around $77.71. The impact to the portfolio due to this purchase was 0.29%. The holdings were 14,983 shares as of 2017-03-31.
Sold Out: St Jude Medical Inc (STJ)
Perkins Capital Management Inc sold out the holdings in St Jude Medical Inc. The sale prices were between $80.69 and $80.82, with an estimated average price of $80.76.
Sold Out: SUPERVALU Inc (SVU)
Perkins Capital Management Inc sold out the holdings in SUPERVALU Inc. The sale prices were between $3.26 and $4.91, with an estimated average price of $3.9.
Sold Out: Surmodics Inc (SRDX)
Perkins Capital Management Inc sold out the holdings in Surmodics Inc. The sale prices were between $23.15 and $26.4, with an estimated average price of $24.51.
Sold Out: Datalink Corp (DTLK)
Perkins Capital Management Inc sold out the holdings in Datalink Corp. The sale prices were between $11.24 and $11.26, with an estimated average price of $11.25.
Sold Out: Bristol-Myers Squibb Company (BMY)
Perkins Capital Management Inc sold out the holdings in Bristol-Myers Squibb Company. The sale prices were between $46.82 and $60.13, with an estimated average price of $54.85.
Sold Out: Duluth Holdings Inc (DLTH)
Perkins Capital Management Inc sold out the holdings in Duluth Holdings Inc. The sale prices were between $18.43 and $26.77, with an estimated average price of $22.25.
Reduced: NVIDIA Corp (NVDA)
Perkins Capital Management Inc reduced to the holdings in NVIDIA Corp by 69.8%. The sale prices were between $97.67 and $119.13, with an estimated average price of $106.43. The stock is now traded at around $100.59. The impact to the portfolio due to this sale was -0.8%. Perkins Capital Management Inc still held 2,937 shares as of 2017-03-31.
Reduced: PharmAthene Inc (PIP)
Perkins Capital Management Inc reduced to the holdings in PharmAthene Inc by 26.56%. The sale prices were between $0.63 and $3.4, with an estimated average price of $1.78. The stock is now traded at around $0.80. The impact to the portfolio due to this sale was -0.67%. Perkins Capital Management Inc still held 520,000 shares as of 2017-03-31.
Reduced: General Electric Co (GE)
Perkins Capital Management Inc reduced to the holdings in General Electric Co by 29.51%. The sale prices were between $29.39 and $31.7, with an estimated average price of $30.2. The stock is now traded at around $29.95. The impact to the portfolio due to this sale was -0.18%. Perkins Capital Management Inc still held 12,660 shares as of 2017-03-31.
Reduced: Xtant Medical Holdings Inc (XTNT)
Perkins Capital Management Inc reduced to the holdings in Xtant Medical Holdings Inc by 29.45%. The sale prices were between $0.33 and $0.95, with an estimated average price of $0.51. The stock is now traded at around $0.59. The impact to the portfolio due to this sale was -0.17%. Perkins Capital Management Inc still held 685,104 shares as of 2017-03-31.
Reduced: Chembio Diagnostics Inc (CEMI)
Perkins Capital Management Inc reduced to the holdings in Chembio Diagnostics Inc by 27.33%. The sale prices were between $5.25 and $6.65, with an estimated average price of $5.82. The stock is now traded at around $6.02. The impact to the portfolio due to this sale was -0.14%. Perkins Capital Management Inc still held 49,450 shares as of 2017-03-31.
Reduced: Craft Brew Alliance Inc (BREW)
Perkins Capital Management Inc reduced to the holdings in Craft Brew Alliance Inc by 22.19%. The sale prices were between $12.4 and $17.25, with an estimated average price of $14.91. The stock is now traded at around $12.90. The impact to the portfolio due to this sale was -0.07%. Perkins Capital Management Inc still held 12,450 shares as of 2017-03-31.
Warning! GuruFocus has detected 7 Warning Signs with ABT. Click here to check it out.
ABT 15-Year Financial Data
The intrinsic value of ABT
Peter Lynch Chart of ABT
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Perkins Capital Management Inc New Purchases: LMAT , ANIP , STX , DLX, RIG, BX, SRCI, TCB, VG, INTC, Added Positions:ABT, CYRX, MMSI, JBLU, EDAP, CVS, RMTI, CSII, PFIE, ATRC, Reduced Positions:NVDA, PIP, SNAK, CGNT, GE, XTNT, CEMI, NEO, GSK, USAT, Sold Out:STJ, SVU, SRDX, DTLK, BMY, DLTH, MSTX, For the details of PERKINS CAPITAL MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERKINS+CAPITAL+MANAGEMENT+INC These are the top 5 holdings of PERKINS CAPITAL MANAGEMENT INC AxoGen Inc ( AXGN ) - 592,167 shares, 6.44% of the total portfolio. Shares added by 6.66% Abbott Laboratories ( ABT ) - 83,546 shares, 3.86% of the total portfolio. Added: Abbott Laboratories ( ABT ) Perkins Capital Management Inc added to the holdings in Abbott Laboratories by 197.58%. | Perkins Capital Management Inc New Purchases: LMAT , ANIP , STX , DLX, RIG, BX, SRCI, TCB, VG, INTC, Added Positions:ABT, CYRX, MMSI, JBLU, EDAP, CVS, RMTI, CSII, PFIE, ATRC, Reduced Positions:NVDA, PIP, SNAK, CGNT, GE, XTNT, CEMI, NEO, GSK, USAT, Sold Out:STJ, SVU, SRDX, DTLK, BMY, DLTH, MSTX, For the details of PERKINS CAPITAL MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERKINS+CAPITAL+MANAGEMENT+INC These are the top 5 holdings of PERKINS CAPITAL MANAGEMENT INC AxoGen Inc ( AXGN ) - 592,167 shares, 6.44% of the total portfolio. Shares added by 6.66% Abbott Laboratories ( ABT ) - 83,546 shares, 3.86% of the total portfolio. Added: Abbott Laboratories ( ABT ) Perkins Capital Management Inc added to the holdings in Abbott Laboratories by 197.58%. | Perkins Capital Management Inc New Purchases: LMAT , ANIP , STX , DLX, RIG, BX, SRCI, TCB, VG, INTC, Added Positions:ABT, CYRX, MMSI, JBLU, EDAP, CVS, RMTI, CSII, PFIE, ATRC, Reduced Positions:NVDA, PIP, SNAK, CGNT, GE, XTNT, CEMI, NEO, GSK, USAT, Sold Out:STJ, SVU, SRDX, DTLK, BMY, DLTH, MSTX, For the details of PERKINS CAPITAL MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERKINS+CAPITAL+MANAGEMENT+INC These are the top 5 holdings of PERKINS CAPITAL MANAGEMENT INC AxoGen Inc ( AXGN ) - 592,167 shares, 6.44% of the total portfolio. Shares added by 6.66% Abbott Laboratories ( ABT ) - 83,546 shares, 3.86% of the total portfolio. Added: Abbott Laboratories ( ABT ) Perkins Capital Management Inc added to the holdings in Abbott Laboratories by 197.58%. | Perkins Capital Management Inc New Purchases: LMAT , ANIP , STX , DLX, RIG, BX, SRCI, TCB, VG, INTC, Added Positions:ABT, CYRX, MMSI, JBLU, EDAP, CVS, RMTI, CSII, PFIE, ATRC, Reduced Positions:NVDA, PIP, SNAK, CGNT, GE, XTNT, CEMI, NEO, GSK, USAT, Sold Out:STJ, SVU, SRDX, DTLK, BMY, DLTH, MSTX, For the details of PERKINS CAPITAL MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERKINS+CAPITAL+MANAGEMENT+INC These are the top 5 holdings of PERKINS CAPITAL MANAGEMENT INC AxoGen Inc ( AXGN ) - 592,167 shares, 6.44% of the total portfolio. Shares added by 6.66% Abbott Laboratories ( ABT ) - 83,546 shares, 3.86% of the total portfolio. Added: Abbott Laboratories ( ABT ) Perkins Capital Management Inc added to the holdings in Abbott Laboratories by 197.58%. |
33649.0 | 2017-04-18 00:00:00 UTC | High-Yield Healthcare Investments You Can Buy Right Now | ABT | https://www.nasdaq.com/articles/high-yield-healthcare-investments-you-can-buy-right-now-2017-04-18 | nan | nan | If you're looking for high-yield investments, you might want to consider the sector that accounts for nearly one-fifth of the nation's economy. I'm talking about healthcare, of course.
Three healthcare stocks in particular boast high dividend yields and good overall prospects. Here's why AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Novo Nordisk (NYSE: NVO) are high-yield healthcare investments you can buy right now.
AbbVie: Great dividend and a strong pipeline
AbbVie's dividend currently yields 3.91%. What makes the biotech's dividend even more attractive is that AbbVie has increased its dividend by 60% since 2013, when it was spun off from parent Abbott Laboratories (NYSE: ABT) . AbbVie uses around 63% of its earnings to pay out dividends, which leaves room for more increases in the future.
The company's earnings picture could improve quite a bit over the next few years. Sales for several of AbbVie's current products are growing. That's especially true for cancer drug Imbruvica, which saw sales more than double in 2016. AbbVie should also enjoy success with another cancer drug approved last year, Venclexta.
AbbVie's pipeline could produce multiple big winners. Elagolix is in late-stage clinical studies for the treatment of endometriosis and uterine fibroids. Two late-stage candidates for treating autoimmune diseases, risankizumab and ABT-494, also hold significant potential.
The biggest knock against AbbVie is that Humira could face heavier competition in the days ahead. One biosimilar to Humira has already won regulatory approval in the U.S. and Europe, although AbbVie is attempting to use the court system to fend off the rival in the U.S.
Pfizer: Ibrance and acquisitions leading the way
Pfizer isn't too far behind AbbVie, with a dividend yield of 3.75%. The big drugmaker's dividend has increased by 60% since 2011. Although Pfizer is currently paying out more in dividends than it's making in profit, that should change in the near future.
At least a dozen of Pfizer's top products enjoyed double-digit percentage sales increases in 2016. The fastest growth belonged to cancer drug Ibrance, which became the company's fourth best-selling drug in only its second full year on the market. Pfizer also experienced exceptionally strong revenue growth for rheumatoid arthritis drug Xeljanz.
Thanks in part to several acquisitions, Pfizer looks to be in good shape for more growth in the future. The company's purchase of Anacor in 2016 has already resulted in an approved product, atopic dermatitis drug Eucrisa. Pfizer also bought Medivation last year, gaining prostate cancer drug Xtandi. The drugmaker's pipeline is loaded with promising candidates, including cancer drug avelumab, which recently won approval for its first indication.
The most significant headwind for Pfizer is declining sales for products that have either lost patent exclusivity or will soon do so. Fall revenue for blockbuster cholesterol drug Lipitor is especially problematic. However, Pfizer's newer drugs and growing sterile injectables businesses should continue to offset these sales decreases.
Novo Nordisk: High-yield dividend and a winning diabetes franchise
Novo Nordisk claims a nice dividend yield of 3.15%. The drugmaker's dividend seems likely to increase in the future, since Novo Nordisk currently uses just over 62% of earnings to fund its dividend program.
Diabetes is the company's primary focus. Sales for Novo Nordisk's newer insulin products, particularly Tresiba, are growing. Type-2 diabetes drug Victoza also continues to perform well. In addition, growth hormone therapy Norditropin is enjoying considerable success.
Novo Nordisk has high expectations for Xultophy, which is a once-daily single-injection combination of Tresiba and Victoza. The drugmaker awaits regulatory approval for two other diabetes treatments, fast-acting insulin aspart and semaglutide.
The company's hemophilia business hasn't performed all that well recently. However, Novo Nordisk could see better results with hemophilia drug N9-GP wins approval. Another hemophilia candidate, N8-GP, is in a late-stage clinical study. The company also faces pricing pressure in the U.S. for its diabetes and growth hormone products. Still, Wall Street analysts expect Novo Nordisk to grow earnings by an average annual rate of nearly 10% over the next few years.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What makes the biotech's dividend even more attractive is that AbbVie has increased its dividend by 60% since 2013, when it was spun off from parent Abbott Laboratories (NYSE: ABT) . Two late-stage candidates for treating autoimmune diseases, risankizumab and ABT-494, also hold significant potential. The drugmaker's pipeline is loaded with promising candidates, including cancer drug avelumab, which recently won approval for its first indication. | What makes the biotech's dividend even more attractive is that AbbVie has increased its dividend by 60% since 2013, when it was spun off from parent Abbott Laboratories (NYSE: ABT) . Two late-stage candidates for treating autoimmune diseases, risankizumab and ABT-494, also hold significant potential. Here's why AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Novo Nordisk (NYSE: NVO) are high-yield healthcare investments you can buy right now. | What makes the biotech's dividend even more attractive is that AbbVie has increased its dividend by 60% since 2013, when it was spun off from parent Abbott Laboratories (NYSE: ABT) . Two late-stage candidates for treating autoimmune diseases, risankizumab and ABT-494, also hold significant potential. Here's why AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Novo Nordisk (NYSE: NVO) are high-yield healthcare investments you can buy right now. | What makes the biotech's dividend even more attractive is that AbbVie has increased its dividend by 60% since 2013, when it was spun off from parent Abbott Laboratories (NYSE: ABT) . Two late-stage candidates for treating autoimmune diseases, risankizumab and ABT-494, also hold significant potential. AbbVie: Great dividend and a strong pipeline AbbVie's dividend currently yields 3.91%. |
33650.0 | 2017-04-18 00:00:00 UTC | Company News for April 18, 2017 | ABT | https://www.nasdaq.com/articles/company-news-for-april-18-2017-2017-04-18 | nan | nan | • Shares of Moneygram International Inc MGI rose 7.8% after Ant Financial hiked its bid for MoneyGram, valuing the company at $1.2 billion
• Eli Lilly and Company's LLY shares declined 4.1% after the company's drug to treat rheumatoid arthritis was rejected by Food and Drug Administration
• Shares of Ashland Global Holdings Inc. ASH advanced 2% after the company agreed to purchase Pharmachem Laboratories Inc. for $660 million
• Alere Inc's ALR shares gained 15.9% after Abbott Laboratories ABT agreed to acquire the company
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Ashland Global Holdings Inc. (ASH): Free Stock Analysis Report
Moneygram International, Inc. (MGI): Free Stock Analysis Report
Alere Inc. (ALR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Moneygram International Inc MGI rose 7.8% after Ant Financial hiked its bid for MoneyGram, valuing the company at $1.2 billion • Eli Lilly and Company's LLY shares declined 4.1% after the company's drug to treat rheumatoid arthritis was rejected by Food and Drug Administration • Shares of Ashland Global Holdings Inc. ASH advanced 2% after the company agreed to purchase Pharmachem Laboratories Inc. for $660 million • Alere Inc's ALR shares gained 15.9% after Abbott Laboratories ABT agreed to acquire the company Want the latest recommendations from Zacks Investment Research? Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Ashland Global Holdings Inc. (ASH): Free Stock Analysis Report Moneygram International, Inc. (MGI): Free Stock Analysis Report Alere Inc. (ALR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Moneygram International Inc MGI rose 7.8% after Ant Financial hiked its bid for MoneyGram, valuing the company at $1.2 billion • Eli Lilly and Company's LLY shares declined 4.1% after the company's drug to treat rheumatoid arthritis was rejected by Food and Drug Administration • Shares of Ashland Global Holdings Inc. ASH advanced 2% after the company agreed to purchase Pharmachem Laboratories Inc. for $660 million • Alere Inc's ALR shares gained 15.9% after Abbott Laboratories ABT agreed to acquire the company Want the latest recommendations from Zacks Investment Research? Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Ashland Global Holdings Inc. (ASH): Free Stock Analysis Report Moneygram International, Inc. (MGI): Free Stock Analysis Report Alere Inc. (ALR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Moneygram International Inc MGI rose 7.8% after Ant Financial hiked its bid for MoneyGram, valuing the company at $1.2 billion • Eli Lilly and Company's LLY shares declined 4.1% after the company's drug to treat rheumatoid arthritis was rejected by Food and Drug Administration • Shares of Ashland Global Holdings Inc. ASH advanced 2% after the company agreed to purchase Pharmachem Laboratories Inc. for $660 million • Alere Inc's ALR shares gained 15.9% after Abbott Laboratories ABT agreed to acquire the company Want the latest recommendations from Zacks Investment Research? Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Ashland Global Holdings Inc. (ASH): Free Stock Analysis Report Moneygram International, Inc. (MGI): Free Stock Analysis Report Alere Inc. (ALR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Moneygram International Inc MGI rose 7.8% after Ant Financial hiked its bid for MoneyGram, valuing the company at $1.2 billion • Eli Lilly and Company's LLY shares declined 4.1% after the company's drug to treat rheumatoid arthritis was rejected by Food and Drug Administration • Shares of Ashland Global Holdings Inc. ASH advanced 2% after the company agreed to purchase Pharmachem Laboratories Inc. for $660 million • Alere Inc's ALR shares gained 15.9% after Abbott Laboratories ABT agreed to acquire the company Want the latest recommendations from Zacks Investment Research? Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Ashland Global Holdings Inc. (ASH): Free Stock Analysis Report Moneygram International, Inc. (MGI): Free Stock Analysis Report Alere Inc. (ALR): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
33651.0 | 2017-04-18 00:00:00 UTC | Pre-Market Earnings Report for April 19, 2017 : USB, MS, ABT, BLK, ASML, HBAN, GPC, TXT, SBNY, LAD, UBSH | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-april-19-2017-usb-ms-abt-blk-asml-hban-gpc-txt-sbny-lad-ubsh | nan | nan | The following companies are expected to report earnings prior to market open on 04/19/2017. Visit our Earnings Calendar for a full list of expected earnings releases.
U.S. Bancorp ( USB ) is reporting for the quarter ending March 31, 2017. The bank company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.80. This value represents a 5.26% increase compared to the same quarter last year. In the past year USB has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for USB is 14.52 vs. an industry ratio of 14.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Morgan Stanley ( MS ) is reporting for the quarter ending March 31, 2017. The investment bankers company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.90. This value represents a 63.64% increase compared to the same quarter last year. In the past year MS has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 24.62%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for MS is 12.31 vs. an industry ratio of 17.90.
Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2017. The large cap pharmaceutical company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.43. This value represents a 4.88% increase compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 1.56%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 17.68 vs. an industry ratio of 16.60, implying that they will have a higher earnings growth than their competitors in the same industry.
BlackRock, Inc. ( BLK ) is reporting for the quarter ending March 31, 2017. The finance/investment management company's consensus earnings per share forecast from the 7 analysts that follow the stock is $4.94. This value represents a 16.24% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for BLK is 17.66 vs. an industry ratio of 12.40, implying that they will have a higher earnings growth than their competitors in the same industry.
ASML Holding N.V. ( ASML ) is reporting for the quarter ending March 31, 2017. The capital goods company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.99. This value represents a 94.12% increase compared to the same quarter last year. ASML missed the consensus earnings per share in the 3rd calendar quarter of 2016 by -2.8%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ASML is 28.99 vs. an industry ratio of 18.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Huntington Bancshares Incorporated ( HBAN ) is reporting for the quarter ending March 31, 2017. The bank (midwest) company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.22. This value represents a 10.00% increase compared to the same quarter last year. In the past year HBAN has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for HBAN is 13.31 vs. an industry ratio of 16.80.
Genuine Parts Company ( GPC ) is reporting for the quarter ending March 31, 2017. The auto (truck) company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.05. This value represents a no change for the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for GPC is 18.97 vs. an industry ratio of 15.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Textron Inc. ( TXT ) is reporting for the quarter ending March 31, 2017. The aerospace and defense company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.46. This value represents a 16.36% decrease compared to the same quarter last year. TXT missed the consensus earnings per share in the 4th calendar quarter of 2016 by -8.05%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for TXT is 18.30 vs. an industry ratio of 14.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Signature Bank ( SBNY ) is reporting for the quarter ending March 31, 2017. The bank (northeast) company's consensus earnings per share forecast from the 16 analysts that follow the stock is $2.10. This value represents a 7.14% increase compared to the same quarter last year. SBNY missed the consensus earnings per share in the 2nd calendar quarter of 2016 by -4.04%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for SBNY is 15.09 vs. an industry ratio of 17.70.
Lithia Motors, Inc. ( LAD ) is reporting for the quarter ending March 31, 2017. The retail company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.77. This value represents a 14.19% increase compared to the same quarter last year. The last two quarters LAD had negative earnings surprises; the latest report they missed by -0.53%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for LAD is 10.13 vs. an industry ratio of 64.40.
Union Bankshares Corporation ( UBSH ) is reporting for the quarter ending March 31, 2017. The banks (southeast) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.43. This value represents a 13.16% increase compared to the same quarter last year. In the past year UBSH has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 6.67%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for UBSH is 17.40 vs. an industry ratio of 19.70.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2017. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 17.68 vs. an industry ratio of 16.60, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 17.68 vs. an industry ratio of 16.60, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2017. In the past year ABT has beat the expectations every quarter. | Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 17.68 vs. an industry ratio of 16.60, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2017. In the past year ABT has beat the expectations every quarter. | In the past year ABT has beat the expectations every quarter. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2017. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 17.68 vs. an industry ratio of 16.60, implying that they will have a higher earnings growth than their competitors in the same industry. |
33652.0 | 2017-04-18 00:00:00 UTC | Abbott Labs: What To Look For In Q1 Earnings | ABT | https://www.nasdaq.com/articles/abbott-labs-what-look-q1-earnings-2017-04-18 | nan | nan | Abbott Labs ( ABT ) will report its Q1 2017 earnings on April 19. We believe that some of the key trends observed in the previous quarter are likely to continue. Our primary concern is Abbott's nutritional segment's performance in China. There is an oversupply in China's nutrition market, and the situation is exacerbated by discounts being offered by local players to clear inventory in the wake of the government's new safety regulations. Additionally, there is likely to be near-term pressure on sales due to the shift to the e-commerce sales channel. To add to this, Abbott recently received a warning letter from the FDA regarding the manufacturing practices of one of the facilities of St. Jude Medical, which it acquired recently. Investors expect significant synergies from the St. Jude acquisition in the next 2-3 years, and the additional costs of addressing the regulatory concerns could cause a minor dent. We also look forward to more color on Abbott's acquisition of Alere. The company recently sealed the deal for $4.4 billion.
Our price estimate of $46.50 for Abbott Laboratories is slightly above the market.
Despite the aforementioned concerns, there is a lot going well for Abbott. Its point-of-care diagnostics products are growing well, and saw a nearly 8.5% increase in their sales in Q4 2016. This was driven by strong adoption of the i-STAT handheld system in the U.S. and international markets. Abbott has also obtained CE approval for four new major diagnostics systems, which include "Alinity s" for blood and plasma screening, "Alinity i" for immunoassay diagnostics, "Alinity c" for clinical chemistry diagnostics and "i-STAT Alinity" for point of care blood testing. In the diabetes segment, Freestyle Libre is expected to do well. Abbott has also streamlined its established pharma business through sale of its developed markets business and acquisition of CFR Pharmaceuticals and Veropharm. We expect the segment's operational growth to be strong.
Please let us know your views by commenting in the box below.
See More at Trefis|View Interactive Institutional Research(Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) will report its Q1 2017 earnings on April 19. There is an oversupply in China's nutrition market, and the situation is exacerbated by discounts being offered by local players to clear inventory in the wake of the government's new safety regulations. Investors expect significant synergies from the St. Jude acquisition in the next 2-3 years, and the additional costs of addressing the regulatory concerns could cause a minor dent. | Abbott Labs ( ABT ) will report its Q1 2017 earnings on April 19. Our primary concern is Abbott's nutritional segment's performance in China. See More at Trefis|View Interactive Institutional Research(Powered by Trefis) Get Trefis Technology The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) will report its Q1 2017 earnings on April 19. Abbott has also obtained CE approval for four new major diagnostics systems, which include "Alinity s" for blood and plasma screening, "Alinity i" for immunoassay diagnostics, "Alinity c" for clinical chemistry diagnostics and "i-STAT Alinity" for point of care blood testing. Abbott has also streamlined its established pharma business through sale of its developed markets business and acquisition of CFR Pharmaceuticals and Veropharm. | Abbott Labs ( ABT ) will report its Q1 2017 earnings on April 19. Our primary concern is Abbott's nutritional segment's performance in China. Its point-of-care diagnostics products are growing well, and saw a nearly 8.5% increase in their sales in Q4 2016. |
33653.0 | 2017-04-17 00:00:00 UTC | Company News for April 17, 2017 | ABT | https://www.nasdaq.com/articles/company-news-for-april-17-2017-2017-04-17 | nan | nan | • Shares of Abbott Laboratories ABT fell 1.9% after the company received a warning letter from Food and Drug Administration related to its implantable heart defibrillators
• United Continental Holdings, Inc.'s UAL shares declined 1.2% after the company removed a couple from a flight to Costa Rica on Saturday
• Shares of Goldman Sachs Group Inc GS fell 1.1% after a U.S. District Court judge in Manhattan rejected the company's bid to shorten a gender bias lawsuit
• Pier 1 Imports, Inc.'s PIR shares declined 9.1% after the company's quarterly revenue declined 2.6% year over year, to $528.4 million
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
United Continental Holdings, Inc. (UAL): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Goldman Sachs Group, Inc. (The) (GS): Free Stock Analysis Report
Pier 1 Imports, Inc. (PIR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ABT fell 1.9% after the company received a warning letter from Food and Drug Administration related to its implantable heart defibrillators • United Continental Holdings, Inc.'s UAL shares declined 1.2% after the company removed a couple from a flight to Costa Rica on Saturday • Shares of Goldman Sachs Group Inc GS fell 1.1% after a U.S. District Court judge in Manhattan rejected the company's bid to shorten a gender bias lawsuit • Pier 1 Imports, Inc.'s PIR shares declined 9.1% after the company's quarterly revenue declined 2.6% year over year, to $528.4 million Want the latest recommendations from Zacks Investment Research? Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Goldman Sachs Group, Inc. (The) (GS): Free Stock Analysis Report Pier 1 Imports, Inc. (PIR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ABT fell 1.9% after the company received a warning letter from Food and Drug Administration related to its implantable heart defibrillators • United Continental Holdings, Inc.'s UAL shares declined 1.2% after the company removed a couple from a flight to Costa Rica on Saturday • Shares of Goldman Sachs Group Inc GS fell 1.1% after a U.S. District Court judge in Manhattan rejected the company's bid to shorten a gender bias lawsuit • Pier 1 Imports, Inc.'s PIR shares declined 9.1% after the company's quarterly revenue declined 2.6% year over year, to $528.4 million Want the latest recommendations from Zacks Investment Research? Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Goldman Sachs Group, Inc. (The) (GS): Free Stock Analysis Report Pier 1 Imports, Inc. (PIR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ABT fell 1.9% after the company received a warning letter from Food and Drug Administration related to its implantable heart defibrillators • United Continental Holdings, Inc.'s UAL shares declined 1.2% after the company removed a couple from a flight to Costa Rica on Saturday • Shares of Goldman Sachs Group Inc GS fell 1.1% after a U.S. District Court judge in Manhattan rejected the company's bid to shorten a gender bias lawsuit • Pier 1 Imports, Inc.'s PIR shares declined 9.1% after the company's quarterly revenue declined 2.6% year over year, to $528.4 million Want the latest recommendations from Zacks Investment Research? Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Goldman Sachs Group, Inc. (The) (GS): Free Stock Analysis Report Pier 1 Imports, Inc. (PIR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ABT fell 1.9% after the company received a warning letter from Food and Drug Administration related to its implantable heart defibrillators • United Continental Holdings, Inc.'s UAL shares declined 1.2% after the company removed a couple from a flight to Costa Rica on Saturday • Shares of Goldman Sachs Group Inc GS fell 1.1% after a U.S. District Court judge in Manhattan rejected the company's bid to shorten a gender bias lawsuit • Pier 1 Imports, Inc.'s PIR shares declined 9.1% after the company's quarterly revenue declined 2.6% year over year, to $528.4 million Want the latest recommendations from Zacks Investment Research? Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Goldman Sachs Group, Inc. (The) (GS): Free Stock Analysis Report Pier 1 Imports, Inc. (PIR): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
33654.0 | 2017-04-17 00:00:00 UTC | Stock Futures Turn Positive; Empire State Manufacturing Index Dives in April | ABT | https://www.nasdaq.com/articles/stock-futures-turn-positive-empire-state-manufacturing-index-dives-april-2017-04-17 | nan | nan | Futures flipped to the plus column ahead of Monday's open as Wall Street struggles for direction amid lingering geopolitical tensions against the backdrop of Q1 earnings. Early pressure on futures associated with continued saber-rattling in North Korean and bearish U.S. economic data Friday has dissipated before the NYSE open with Dow futures currently 18 points above fair value.
Markets shrugged of more downbeat economic news after last Friday's miss on both consumer prices and retail sales. The Empire State manufacturing index dropped to 5.20 in April from 16.4 in March, well below estimates for a decline to 15.0, and the largest decline in the indicator in nearly a year.
At 10:00 a.m. ET, the National Association of Home Builders housing market index is expected to drop to 70 from 71 in March.
Most European markets were closed for the Easter holiday, but Asian markets were mixed as bullish Chinese GDP and production data was overshadowed by recent events on the Korean peninsula leaving the Shanghai and Hang Seng lower. The Nikkei closed higher despite continued gains in the yen.
-Dow Jones Industrial up 0.23%
-S&P 500 futures up 0.17%
-Nasdaq 100 futures up 0.22%
SENTIMENT
Nikkei up 0.11%
Hang Seng down 0.21%
Shanghai Composite down 0.75%
FTSE-100 Closed
DAX-30 Closed
PRE-MARKET SECTOR WATCH
(+/-) Large cap tech: Higher
(+/-) Chip stocks: Higher
(+/-) Software stocks: Flat
(+/-) Hardware stocks: Higher
(+/-) Internet stocks: Higher
(+/-) Oil stocks: Higher
(+/-) Biotech stocks: Mixed
(+/-) Drug stocks: Flat
(+/-) Financial stocks: Higher
(+/-) Retail stocks: Flat
(+/-) Industrial stocks: Higher
(+/-) Airlines: Higher
(+/-) Autos: Higher
UPSIDE MOVERS:
(+) WPRT (+31.13%) Sold its APU assets for $70 million
(+) HTGM (+22.03%) Complete master service agreement with Daiichi Sankyo
(+) ALR (+16.76%) To be acquired by Abbott Labs ( ABT ) for $51 per share
(+) MGI (+8.00%) Ant Financial raised its bid for Moneygram to $18 per share
DOWNSIDE MOVERS:
(-) OMED (-21.90%) Company will conduct portfolio prioritization after lung cancer study missed endpoint
(-) INCY (-10.18%) and Eli Lilly ( LLY ) were denied FDA approval for Baricitinig for rheumatoid arthritis
(-) BAX (-3.29%) mployee received Justice Department subpoena regarding sales practices of intravenous saline
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) WPRT (+31.13%) Sold its APU assets for $70 million (+) HTGM (+22.03%) Complete master service agreement with Daiichi Sankyo (+) ALR (+16.76%) To be acquired by Abbott Labs ( ABT ) for $51 per share (+) MGI (+8.00%) Ant Financial raised its bid for Moneygram to $18 per share Futures flipped to the plus column ahead of Monday's open as Wall Street struggles for direction amid lingering geopolitical tensions against the backdrop of Q1 earnings. Markets shrugged of more downbeat economic news after last Friday's miss on both consumer prices and retail sales. | (+) WPRT (+31.13%) Sold its APU assets for $70 million (+) HTGM (+22.03%) Complete master service agreement with Daiichi Sankyo (+) ALR (+16.76%) To be acquired by Abbott Labs ( ABT ) for $51 per share (+) MGI (+8.00%) Ant Financial raised its bid for Moneygram to $18 per share (+/-) Large cap tech: Higher (+/-) Chip stocks: Higher (+/-) Software stocks: Flat (+/-) Hardware stocks: Higher (+/-) Internet stocks: Higher (+/-) Oil stocks: Higher (+/-) Biotech stocks: Mixed (+/-) Drug stocks: Flat (+/-) Financial stocks: Higher (+/-) Retail stocks: Flat (+/-) Industrial stocks: Higher (+/-) Airlines: Higher (+/-) Autos: Higher (-) OMED (-21.90%) Company will conduct portfolio prioritization after lung cancer study missed endpoint (-) INCY (-10.18%) and Eli Lilly ( LLY ) were denied FDA approval for Baricitinig for rheumatoid arthritis (-) BAX (-3.29%) mployee received Justice Department subpoena regarding sales practices of intravenous saline The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) WPRT (+31.13%) Sold its APU assets for $70 million (+) HTGM (+22.03%) Complete master service agreement with Daiichi Sankyo (+) ALR (+16.76%) To be acquired by Abbott Labs ( ABT ) for $51 per share (+) MGI (+8.00%) Ant Financial raised its bid for Moneygram to $18 per share Most European markets were closed for the Easter holiday, but Asian markets were mixed as bullish Chinese GDP and production data was overshadowed by recent events on the Korean peninsula leaving the Shanghai and Hang Seng lower. (+/-) Large cap tech: Higher (+/-) Chip stocks: Higher (+/-) Software stocks: Flat (+/-) Hardware stocks: Higher (+/-) Internet stocks: Higher (+/-) Oil stocks: Higher (+/-) Biotech stocks: Mixed (+/-) Drug stocks: Flat (+/-) Financial stocks: Higher (+/-) Retail stocks: Flat (+/-) Industrial stocks: Higher (+/-) Airlines: Higher (+/-) Autos: Higher | (+) WPRT (+31.13%) Sold its APU assets for $70 million (+) HTGM (+22.03%) Complete master service agreement with Daiichi Sankyo (+) ALR (+16.76%) To be acquired by Abbott Labs ( ABT ) for $51 per share (+) MGI (+8.00%) Ant Financial raised its bid for Moneygram to $18 per share Early pressure on futures associated with continued saber-rattling in North Korean and bearish U.S. economic data Friday has dissipated before the NYSE open with Dow futures currently 18 points above fair value. The Nikkei closed higher despite continued gains in the yen. |
33655.0 | 2017-04-17 00:00:00 UTC | Abbott Laboratories Agrees to Acquire Alere at Lower Price | ABT | https://www.nasdaq.com/articles/abbott-laboratories-agrees-to-acquire-alere-at-lower-price-2017-04-17 | nan | nan | Finally the much contentious merger of Abbott LaboratoriesABT with Alere is nearing its close. As expected, the financial terms of the deal have been amended.
Amended Terms
Per the amended terms of the agreement, Abbott has agreed to pay $51 per common share to acquire Alere, a reduction from earlier deal of $56 per common share in cash upon the completion of the transaction. This results in a new expected equity value of approximately $5.3 billion, reduced from the originally expected equity value of approximately $5.8 billion.
The transaction, which was inked on 1 Feb 2016, is now expected to close by the end of the third quarter of 2017, subject to the approval of Alere shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. Notably, the company also extended the last date of receiving necessary regulatory approvals from Apr 30, 2017 to Sep 30, 2017.
Also, both the companies, which were engaged in legal battles with each other on issues regarding the pending merger, agreed to dismiss their respective lawsuits.
The Legal Battle
Notably, the legal battle came into spotlight last August when for Alere filed a complaint against Abbott Labs in the Delaware Chancery Court. It wanted to force Abbott Labs to take all the necessary actions to obtain anti-trust approvals and fulfill its obligations under the terms of the merger agreement.
Alere's accusation was based on Abbott Labs' reluctance to complete the deal. In fact, Abbott Labs even requested to call it off in Apr 2016.
Abbott's version was that, it had serious concerns regarding the accuracy of various representations, warranties and covenants made by Alere in their merger agreement. It also agreed to pay the legal costs in the range of $30-$50 million in respect to Alere's transaction expenses, which was rejected by the latter.
Against Alere's lawsuit, in December, Abbott filed a lawsuit to terminate its $5.8 billion purchase of the former quoting a substantial loss in the value of Alere's stock since they struck the deal.
With the legal actions finally dropped now, according to a Bloomberge article, "The renegotiated price was better than many on Wall Street expected."
Share Price Performance
In this regard we note that, Abbott's shares underperformed the Zacks classified Large Cap Pharmaceuticals industry over the past month on litigation qualms with Alere. The stock lost 5.14% during this period compared with 1.65% loss of the broader industry. The resolution of the matter is likely to boost the company's stock price in the future.
Our Take
Earlier, Abbott Labs said that it expects its total diagnostics sales to exceed $7 billion post the closure of the transaction. The company will also become a lead player in the $5.5 billion point-of-care diagnostic segment.
We are upbeat about the fact that Alere integration will enable Abbott Labs to gain access to new channels and geographies. Although Alere generated more than half of its total sales of $2.5 billion from the U.S. alone, the company has a growing presence in key international markets, which should further strengthen Abbott Labs' business in these territories. It will also add Alere's complementary portfolio of diagnostic products, which comprises tests for infections such as HIV, tuberculosis, malaria and dengue.
Zacks Rank & Key Picks
Abbott Labs currently carries a Zacks Rank #4 (Sell). Better-ranked stocks in the broader Medical space include Inogen, Inc. INGN , Orasure Technologies, Inc. OSUR and Hill-Rom Holdings, Inc. HRC . While Inogen sports a Zacks Rank #1 (Strong Buy), Orasure and Hill-Rom carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Inogen gained 62.2% in the last one year compared with the S&P 500's gain of 15.1%. The company reported a stellar four-quarter positive average earnings surprise of over 49.08%.
Orasure surged 73.9% in the last one year compared with the S&P 500's gain. Its four-quarter average earnings surprise was a positive 123.5%.
Hill-Rom gained over 33.9% in the past one year, better than the S&P 500 mark. It posted a trailing four-quarter positive average earnings surprise of 12.03%.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500. See today's Zacks "Strong Sells" absolutely free >>.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report
Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Finally the much contentious merger of Abbott LaboratoriesABT with Alere is nearing its close. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report To read this article on Zacks.com click here. Although Alere generated more than half of its total sales of $2.5 billion from the U.S. alone, the company has a growing presence in key international markets, which should further strengthen Abbott Labs' business in these territories. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report To read this article on Zacks.com click here. Finally the much contentious merger of Abbott LaboratoriesABT with Alere is nearing its close. Amended Terms Per the amended terms of the agreement, Abbott has agreed to pay $51 per common share to acquire Alere, a reduction from earlier deal of $56 per common share in cash upon the completion of the transaction. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report To read this article on Zacks.com click here. Finally the much contentious merger of Abbott LaboratoriesABT with Alere is nearing its close. Against Alere's lawsuit, in December, Abbott filed a lawsuit to terminate its $5.8 billion purchase of the former quoting a substantial loss in the value of Alere's stock since they struck the deal. | Finally the much contentious merger of Abbott LaboratoriesABT with Alere is nearing its close. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report To read this article on Zacks.com click here. Our Take Earlier, Abbott Labs said that it expects its total diagnostics sales to exceed $7 billion post the closure of the transaction. |
33656.0 | 2017-04-17 00:00:00 UTC | Alere Inc. Shares Surge After Renewed Commitment From Abbott Laboratories | ABT | https://www.nasdaq.com/articles/alere-inc-shares-surge-after-renewed-commitment-abbott-laboratories-2017-04-17 | nan | nan | What happened
Shares of Alere Inc. (NYSE: ALR) popped this morning in response an announcement that Abbott Laboratories (NYSE: ABT) will acquire the point-of-care diagnostics manufacturer. Renewed hope the delayed deal will be completed has lifted the stock 16.2% as of 10:45 a.m. EDT during Monday's trading session.
So what
Over a year ago, Abbott announced its intent to acquire Alere at $56 per share for a total expected value of about $5.8 billion. Abbott's diagnostics segment is already one of the industry's largest, and Alere's burgeoning point-of-care operations seemed like a perfect fit.
Last week's announcement that Abbott will purchase the company for $51 per share allays a lot of fears. Shortly after announcing its intent in early 2016, it started looking like Abbott was getting cold feet. Last April, Abbott requested termination of the deal in return for a fee between $30 million and $50 million, which Alere didn't accept. Not much later, Alere stock suffered its worst single-day drop after it revealed a U.S. Justice Department investigation into its foreign revenue recognition practices.
Now what
If antitrust regulators green-light the transaction, it could close sometime in the third quarter. Although it looks like the deal will indeed go through, I'll be surprised if it becomes nearly as accretive as Abbott hopes.
Alere has been characteristically slow to file its annual report for 2016, but during the nine-month period ended last September, it reported an operating profit of just $54.2 million from $1.77 billion in total revenue. That's an awfully slim margin to work with, and I find it hard to believe Abbott will see a significant return from the acquisition, now valued at about $5.3 billion.
Most people don't know who performed the tests on the last blood sample their healthcare provider sent out, and few are willing to pay more to have the results generated in-house. Large, centralized laboratories enjoy economies of scale that will make marketing point-of-care diagnostic devices an uphill battle.
10 stocks we like better than Alere
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Alere wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Alere Inc. (NYSE: ALR) popped this morning in response an announcement that Abbott Laboratories (NYSE: ABT) will acquire the point-of-care diagnostics manufacturer. So what Over a year ago, Abbott announced its intent to acquire Alere at $56 per share for a total expected value of about $5.8 billion. Not much later, Alere stock suffered its worst single-day drop after it revealed a U.S. Justice Department investigation into its foreign revenue recognition practices. | What happened Shares of Alere Inc. (NYSE: ALR) popped this morning in response an announcement that Abbott Laboratories (NYSE: ABT) will acquire the point-of-care diagnostics manufacturer. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Alere Inc. (NYSE: ALR) popped this morning in response an announcement that Abbott Laboratories (NYSE: ABT) will acquire the point-of-care diagnostics manufacturer. 10 stocks we like better than Alere When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. *Stock Advisor returns as of April 3, 2017 Cory Renauer has no position in any stocks mentioned. | What happened Shares of Alere Inc. (NYSE: ALR) popped this morning in response an announcement that Abbott Laboratories (NYSE: ABT) will acquire the point-of-care diagnostics manufacturer. So what Over a year ago, Abbott announced its intent to acquire Alere at $56 per share for a total expected value of about $5.8 billion. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Alere wasn't one of them! |
33657.0 | 2017-04-17 00:00:00 UTC | Midday Update: Market Averages Trade Higher as Bargain-Hunting Overshadows Geopolitical Risks | ABT | https://www.nasdaq.com/articles/midday-update-market-averages-trade-higher-bargain-hunting-overshadows-geopolitical-risks | nan | nan | The S&P 500 was higher for the first time in four days as Wall Street shifts its focus to Q1 earnings reports and away from recent geopolitical tensions and downbeat U.S. economic data. Although flows into most safe-havens continues, bargain-hunting in beaten down sectors like financials and technology was boosting the blue-chip index by more than 100 points.
Stocks were slightly lower ahead of the open as investors digested bearish consumer price and retail sales data on Friday with more saber-rattling between North Korea and the U.S. As the open approached, the major indices flipped into positive territory as geopolitical pressures dissipated and investors dismissed bearish economic data.
The Empire State manufacturing index tumbled to 5.20 from 16.4 in March, the largest one-month decline in nearly a year. Additionally, the National Association of Home Builder's housing market index backed up to 68 in April from 71 in March, missing 70 estimates.
European markets are closed for the Easter holiday on Monday.
Crude oil was down $0.47 to $52.71 per barrel. Natural gas was down $0.02 to $3.29 per 1 million BTU. Gold was up $1.50 to $1,290.10 an ounce, while silver was down $0.01 to $18.50 an ounce. Copper was down $0.05 to $11.08 per pound.
Among energy ETFs, the United States Oil Fund was down 0.45% to $11.08 with the United States Natural Gas Fund was down 0.85% to $7.59. Amongst precious-metal funds, the Market Vectors Gold Miners ETF was down 0.41% to 24.44 while SPDR Gold Shares were unchanged at $122.60. The iShares Silver Trust was down 0.23% to $17.49.
Here's where the markets stand at mid-day:
US MARKETS
NYSE Composite Index was up 59.53 points (+0.53%) to 11,384.91
Dow Jones Industrial Index was up 123.25 points (+0.60%) to 20,577.10
S&P 500 was up 13.52 points (+0.58%) to 2,342.45
Nasdaq Composite Index was up 34.49 points (+0.59%) to 5,838.87
GLOBAL SENTIMENT
FTSE 100 was Closed
DAX was Closed
CAC 40 was Closed
Nikkei 225 was up 19.63 points (+0.11%) to 18,355.26
Hang Seng Index was down 51.84 points (-0.21%) to 24,261.66
Shanghai China Composite Index was down 23.90 points (-0.74%) to 3,222.17
NYSE SECTOR INDICES
NYSE Energy Sector Index was up 18.51 points (+0.17%) to 10,753.26
NYSE Financial Sector Index was up 57.59 points (+0.82%) to 7,092.21
NYSE Healthcare Sector Index was up 16.99 points (+0.14%) to 12,673.59
UPSIDE MOVERS
(+) CBLI (+77.64%) FDA completed review of two formulations of entolimod
(+) MOCO (+37.30%) To be acquired by AMETEK ( AME ) for $30 per share
(+) WPRT (+17.07%) Sold its APU assets for $70 million
(+) ALR (+16.19%) To be acquired by Abbott Labs ( ABT ) for $51 per share
DOWNSIDE MOVERS
(-) SKY (-24.50%) Fiscal Q3 loss widens, revenues increase
(-) VNCE (-23.08%) Delays release of fiscal Q4, year-end results on unanticipated delays in compiling financial reports
(-) OMED (-19.21%) Company will conduct portfolio prioritization after lung cancer study missed endpoint
(-) INCY (-11.25%) and Eli Lilly ( LLY ) were denied FDA approval for Baricitinig for rheumatoid arthritis
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) CBLI (+77.64%) FDA completed review of two formulations of entolimod (+) MOCO (+37.30%) To be acquired by AMETEK ( AME ) for $30 per share (+) WPRT (+17.07%) Sold its APU assets for $70 million (+) ALR (+16.19%) To be acquired by Abbott Labs ( ABT ) for $51 per share The S&P 500 was higher for the first time in four days as Wall Street shifts its focus to Q1 earnings reports and away from recent geopolitical tensions and downbeat U.S. economic data. Stocks were slightly lower ahead of the open as investors digested bearish consumer price and retail sales data on Friday with more saber-rattling between North Korea and the U.S. As the open approached, the major indices flipped into positive territory as geopolitical pressures dissipated and investors dismissed bearish economic data. | (+) CBLI (+77.64%) FDA completed review of two formulations of entolimod (+) MOCO (+37.30%) To be acquired by AMETEK ( AME ) for $30 per share (+) WPRT (+17.07%) Sold its APU assets for $70 million (+) ALR (+16.19%) To be acquired by Abbott Labs ( ABT ) for $51 per share Among energy ETFs, the United States Oil Fund was down 0.45% to $11.08 with the United States Natural Gas Fund was down 0.85% to $7.59. NYSE Energy Sector Index was up 18.51 points (+0.17%) to 10,753.26 NYSE Financial Sector Index was up 57.59 points (+0.82%) to 7,092.21 NYSE Healthcare Sector Index was up 16.99 points (+0.14%) to 12,673.59 | (+) CBLI (+77.64%) FDA completed review of two formulations of entolimod (+) MOCO (+37.30%) To be acquired by AMETEK ( AME ) for $30 per share (+) WPRT (+17.07%) Sold its APU assets for $70 million (+) ALR (+16.19%) To be acquired by Abbott Labs ( ABT ) for $51 per share NYSE Composite Index was up 59.53 points (+0.53%) to 11,384.91 Dow Jones Industrial Index was up 123.25 points (+0.60%) to 20,577.10 S&P 500 was up 13.52 points (+0.58%) to 2,342.45 Nasdaq Composite Index was up 34.49 points (+0.59%) to 5,838.87 FTSE 100 was Closed DAX was Closed CAC 40 was Closed Nikkei 225 was up 19.63 points (+0.11%) to 18,355.26 Hang Seng Index was down 51.84 points (-0.21%) to 24,261.66 Shanghai China Composite Index was down 23.90 points (-0.74%) to 3,222.17 | (+) CBLI (+77.64%) FDA completed review of two formulations of entolimod (+) MOCO (+37.30%) To be acquired by AMETEK ( AME ) for $30 per share (+) WPRT (+17.07%) Sold its APU assets for $70 million (+) ALR (+16.19%) To be acquired by Abbott Labs ( ABT ) for $51 per share Gold was up $1.50 to $1,290.10 an ounce, while silver was down $0.01 to $18.50 an ounce. Among energy ETFs, the United States Oil Fund was down 0.45% to $11.08 with the United States Natural Gas Fund was down 0.85% to $7.59. |
33658.0 | 2017-04-17 00:00:00 UTC | Close Update: Stocks Rally as Bargain-Hunting Overshadows Geopolitical Tensions | ABT | https://www.nasdaq.com/articles/close-update-stocks-rally-bargain-hunting-overshadows-geopolitical-tensions-2017-04-17 | nan | nan | Buoyed by bargain-hunting and expectations for upbeat Q1 earnings from Wall Street heavyhitters this week starting with Bank of America ( BAC ) and Johnson & Johnson ( JNJ ) Tuesday, the benchmark averages closed substantially higher on Monday with the Nasdaq Composite in the green for the first time in five sessions. The blue chip index closed near its session high with financials and industrial stocks leading Dow advancers.
Stocks were slightly lower ahead of the open as investors digested bearish consumer price and retail sales data on Friday with more saber-rattling between North Korea and the U.S. As the open approached, the major indices flipped into positive territory as geopolitical pressures dissipated and investors swapped safe-havens like gold and U.S. Treasury securities for cheaper equity assets.
At 8:30am ET, the New York Fed reported a significant drop in the Empire State manufacturing index to 5.20 in April from 16.4 previously, the largest one-month decline in nearly a year. Additionally, the National Association of Home Builder's housing market index backed up to 68 in April from 71 in March, missing 70 estimates.
Besides earnings, Wall Street gets a look at industrial production and housing market data on Tuesday. March industrial production is expected to show a modest 0.4% gain with capacity utilization at 76.0% from 75.4% in February.
Housing starts are expected to decline 2% to a seasonally-adjusted annual rate (SAAR) of 1.262 million while permits should rise 3% to a SAAR of 1.250 million.
Here's where the markets stood at the close:
US MARKETS
Dow Jones Industrial Index was up 183.67 points (+0.90%)
S&P 500 was up 20.06 points (+0.86%)
Nasdaq Composite Index was up 51.64 points (+0.89%)
GLOBAL SENTIMENT
FTSE 100 was closed
Nikkei 225 was up 0.11%
Hang Seng Index was down 0.21%
Shanghai China Composite Index was down 0.74%
UPSIDE MOVERS
(+) CBLI (+107.69%) FDA completed review of two formulations of entolimod
(+) MOCO (+37.18%) To be acquired by AMETEK ( AME ) for $30 per share
(+) WPRT (+19.81%) Sold its APU assets for $70 million
(+) ALR (+15.93%) To be acquired by Abbott Labs ( ABT ) for $51 per share
DOWNSIDE MOVERS
(-) SKY (-27.81%) Fiscal Q3 loss widens, revenues increase
(-) VNCE (-19.23%) Delays release of fiscal Q4, year-end results on unanticipated delays in compiling financial reports
(-) OMED (-17.15%) Company will conduct portfolio prioritization after lung cancer study missed endpoint
(-) INCY (-10.49%) and Eli Lilly ( LLY ) were denied FDA approval for Baricitinig for rheumatoid arthritis
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) CBLI (+107.69%) FDA completed review of two formulations of entolimod (+) MOCO (+37.18%) To be acquired by AMETEK ( AME ) for $30 per share (+) WPRT (+19.81%) Sold its APU assets for $70 million (+) ALR (+15.93%) To be acquired by Abbott Labs ( ABT ) for $51 per share Stocks were slightly lower ahead of the open as investors digested bearish consumer price and retail sales data on Friday with more saber-rattling between North Korea and the U.S. As the open approached, the major indices flipped into positive territory as geopolitical pressures dissipated and investors swapped safe-havens like gold and U.S. Treasury securities for cheaper equity assets. At 8:30am ET, the New York Fed reported a significant drop in the Empire State manufacturing index to 5.20 in April from 16.4 previously, the largest one-month decline in nearly a year. | (+) CBLI (+107.69%) FDA completed review of two formulations of entolimod (+) MOCO (+37.18%) To be acquired by AMETEK ( AME ) for $30 per share (+) WPRT (+19.81%) Sold its APU assets for $70 million (+) ALR (+15.93%) To be acquired by Abbott Labs ( ABT ) for $51 per share Besides earnings, Wall Street gets a look at industrial production and housing market data on Tuesday. (-) SKY (-27.81%) Fiscal Q3 loss widens, revenues increase (-) VNCE (-19.23%) Delays release of fiscal Q4, year-end results on unanticipated delays in compiling financial reports (-) OMED (-17.15%) Company will conduct portfolio prioritization after lung cancer study missed endpoint (-) INCY (-10.49%) and Eli Lilly ( LLY ) were denied FDA approval for Baricitinig for rheumatoid arthritis The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) CBLI (+107.69%) FDA completed review of two formulations of entolimod (+) MOCO (+37.18%) To be acquired by AMETEK ( AME ) for $30 per share (+) WPRT (+19.81%) Sold its APU assets for $70 million (+) ALR (+15.93%) To be acquired by Abbott Labs ( ABT ) for $51 per share Buoyed by bargain-hunting and expectations for upbeat Q1 earnings from Wall Street heavyhitters this week starting with Bank of America ( BAC ) and Johnson & Johnson ( JNJ ) Tuesday, the benchmark averages closed substantially higher on Monday with the Nasdaq Composite in the green for the first time in five sessions. Dow Jones Industrial Index was up 183.67 points (+0.90%) S&P 500 was up 20.06 points (+0.86%) Nasdaq Composite Index was up 51.64 points (+0.89%) | (+) CBLI (+107.69%) FDA completed review of two formulations of entolimod (+) MOCO (+37.18%) To be acquired by AMETEK ( AME ) for $30 per share (+) WPRT (+19.81%) Sold its APU assets for $70 million (+) ALR (+15.93%) To be acquired by Abbott Labs ( ABT ) for $51 per share Stocks were slightly lower ahead of the open as investors digested bearish consumer price and retail sales data on Friday with more saber-rattling between North Korea and the U.S. As the open approached, the major indices flipped into positive territory as geopolitical pressures dissipated and investors swapped safe-havens like gold and U.S. Treasury securities for cheaper equity assets. Besides earnings, Wall Street gets a look at industrial production and housing market data on Tuesday. |
33659.0 | 2017-04-17 00:00:00 UTC | Why Straight Path Communications, Alere, and MoneyGram International Jumped Today | ABT | https://www.nasdaq.com/articles/why-straight-path-communications-alere-and-moneygram-international-jumped-today-2017-04-17 | nan | nan | Monday was a strong day for the stock market, which came off the three-day weekend with a solid advance. Major benchmarks rose as much as 1% as investors looked beyond geopolitical tensions in North Korea and around the world and instead focused on the positive prospects for corporate earnings. Despite some concerns about the releases of results from major banks last week, market participants seem generally upbeat about the chances for key players in the economy to produce positive earnings surprises. Indeed, some good news has already surfaced for a few individual companies, and Straight Path Communications (NYSEMKT: STRP) , Alere (NYSE: ALR) , and MoneyGram International (NASDAQ: MGI) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well.
Straight Path hopes for a bidding war
Shares of Straight Path Communications jumped another 20%, adding to their impressive upward move last week. A week ago, Straight Path shares soared almost 150% after AT&T (NYSE: T) announced a deal to acquire the owner of substantial wireless spectrum assets. Yet today, some market participants believe that Straight Path might get a competing bid from rival Verizon Communications (NYSE: VZ) or another player in the telecommunications space, and that could push shares of Straight Path even higher. At this point, the stock has climbed so far that it's essential that Straight Path actually negotiate a better deal. Otherwise, those who seek to buy into the small industry player could end up getting burned even if an acquisition in fact takes place.
Alere's deal is still on
Alere stock jumped 16% after the diagnostic test provider announced an amended merger agreement with Abbott Labs (NYSE: ABT) . More than a year ago, Abbott and Alere had agreed to a combination, but legal battles emerged and threatened the deal. Over the weekend, Alere and Abbott said that rather than continuing to pursue legal action, they had instead decided to amend the terms of the merger agreement. Now, Alere shareholders will have to accept $51 per share from Abbott, which is down from the original $56-per-share deal. Nevertheless, with Alere stock having traded as low as $35 per share as investors grew more skeptical that any merger would ever take place, even the reduced offer was good news for long-nervous shareholders in the diagnostic specialist.
MoneyGram gets a better bid
Finally, shares of MoneyGram International climbed 8%. The company received a higher buyout bid from China's Ant Financial, which raised its offer by more than a third to $1.2 billion. The deal, which would amount to $18 per share for MoneyGram shareholders, exceeds the bid that rival Euronet Worldwide had made for the payment specialist. As MoneyGram executive chair Pamela Patsley said, "We are pleased to offer even more value to our stockholders through the amendment of our merger agreement with Ant Financial." Most now believe that Euronet won't try to counter again, but the share price is close enough to the new $18 offer to raise at least the possibility of further bidding.
Offer from The Motley Fool: The 10 best stocks to buy now
Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Fool Stock Advisor , has tripled the S&P 500!*
Tom and David just revealed their ten top stock picks for investors to buy right now.
Click here to get access to the full list!
* Stock Advisor returns as of 4/3/2017.
Dan Caplinger has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Verizon Communications. The Motley Fool recommends EEFT. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Alere's deal is still on Alere stock jumped 16% after the diagnostic test provider announced an amended merger agreement with Abbott Labs (NYSE: ABT) . Despite some concerns about the releases of results from major banks last week, market participants seem generally upbeat about the chances for key players in the economy to produce positive earnings surprises. Indeed, some good news has already surfaced for a few individual companies, and Straight Path Communications (NYSEMKT: STRP) , Alere (NYSE: ALR) , and MoneyGram International (NASDAQ: MGI) were among the best performers on the day. | Alere's deal is still on Alere stock jumped 16% after the diagnostic test provider announced an amended merger agreement with Abbott Labs (NYSE: ABT) . Indeed, some good news has already surfaced for a few individual companies, and Straight Path Communications (NYSEMKT: STRP) , Alere (NYSE: ALR) , and MoneyGram International (NASDAQ: MGI) were among the best performers on the day. A week ago, Straight Path shares soared almost 150% after AT&T (NYSE: T) announced a deal to acquire the owner of substantial wireless spectrum assets. | Alere's deal is still on Alere stock jumped 16% after the diagnostic test provider announced an amended merger agreement with Abbott Labs (NYSE: ABT) . Yet today, some market participants believe that Straight Path might get a competing bid from rival Verizon Communications (NYSE: VZ) or another player in the telecommunications space, and that could push shares of Straight Path even higher. Offer from The Motley Fool: The 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. | Alere's deal is still on Alere stock jumped 16% after the diagnostic test provider announced an amended merger agreement with Abbott Labs (NYSE: ABT) . Yet today, some market participants believe that Straight Path might get a competing bid from rival Verizon Communications (NYSE: VZ) or another player in the telecommunications space, and that could push shares of Straight Path even higher. Offer from The Motley Fool: The 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. |
33660.0 | 2017-04-12 00:00:00 UTC | Will Abbott Lab (ABT) Surprise Estimates in Q1 Earnings? | ABT | https://www.nasdaq.com/articles/will-abbott-lab-abt-surprise-estimates-in-q1-earnings-2017-04-12 | nan | nan | Abbott LaboratoriesABT is scheduled to report first-quarter 2017 results before the opening bell on Apr 19. Last quarter, the company's earnings exceeded the Zacks Consensus Estimate by 1.56%. Also, the company posted an average beat of 3.05% in the trailing four quarters. Let's see how things are shaping up prior to this announcement.
Factors at Play
We are optimistic about Abbott's strong and consistent Established Pharmaceuticals Division (EPD) and Medical Devices performances.
Within EPD, through a series of strategic actions, including the sale of Abbott's developed markets business, the acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia, the company already achieved double-digit operational sales growth in fourth-quarter and full-year 2016. The company expects the same momentum to continue in the yet-to-be reported quarter.
With a leading market position in several geographies, including India, Russia and Latin America, EPD is believed to be well positioned for sustained above-market growth in some of the largest and fastest growing pharmaceutical markets in the world.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
In 2017, the company plans to execute its existing operating model which focuses on portfolio selling in core therapeutic areas which will lead to the creation of unique channel opportunities in differentiated relationships with physicians, retailers and pharmacies that are looking to offer a complete line of solutions to treat prominent local health conditions.
Also, Abbott has plans to beef up its development capabilities with an expanded EPD innovation center in India. The center will act as a hub, shipping products to over 30 countries that will further develop differentiated products to suit local needs. Ffirst quarter onward, we expect a few of these executions to take place successfully, resulting in a top-line accretion.
Within medical device, we are looking forward to Abbott's ongoing integration synergy, related to the St. Jude acquisition, which closed in January. The acquisition of St. Jude represents a major strategic move that establishes Abbott as a premier medical device business comprising cardiovascular, neuromodulation and diabetes care. These represent some of the largest and fastest growing areas of healthcare. We expect to see the ongoing synergy to ramp up the top line from the first quarter itself.
Notably, Abbott anticipates annual pre-tax synergies of $500 million by 2020, including revenue expansion opportunities as well as operational and SG&A efficiencies.
Overall, for the first quarter 2017, the company forecast adjusted earnings per share within 42 cents to 44 cents. Comparable operational sales growth for the quarter is expected in low single digits.
Earnings Whispers
Our proven model does not conclusively show that Abbott Laboratories is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: Abbott's Earnings ESP is 0.00% since both the Most Accurate estimate and the Zacks Consensus Estimate stand at 43 cents.
Zacks Rank: Abbott has a Zacks Rank #4 (Sell), which fails to increase the predictive power of ESP.
Also, we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are three companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter:
Applied Materials, Inc. AMAT has an Earnings ESP of +1.32% and a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here .
The Chemours Company CC has an Earnings ESP of +4.08% and a Zacks Rank #1.
You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Hill-Rom Holdings, Inc. HRC has an Earnings ESP of +1.27% and a Zacks Rank #2.
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Chemours Company (The) (CC): Free Stock Analysis Report
Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report
Applied Materials, Inc. (AMAT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is scheduled to report first-quarter 2017 results before the opening bell on Apr 19. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Chemours Company (The) (CC): Free Stock Analysis Report Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play We are optimistic about Abbott's strong and consistent Established Pharmaceuticals Division (EPD) and Medical Devices performances. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Chemours Company (The) (CC): Free Stock Analysis Report Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report first-quarter 2017 results before the opening bell on Apr 19. Within EPD, through a series of strategic actions, including the sale of Abbott's developed markets business, the acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia, the company already achieved double-digit operational sales growth in fourth-quarter and full-year 2016. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Chemours Company (The) (CC): Free Stock Analysis Report Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report first-quarter 2017 results before the opening bell on Apr 19. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote In 2017, the company plans to execute its existing operating model which focuses on portfolio selling in core therapeutic areas which will lead to the creation of unique channel opportunities in differentiated relationships with physicians, retailers and pharmacies that are looking to offer a complete line of solutions to treat prominent local health conditions. | Abbott LaboratoriesABT is scheduled to report first-quarter 2017 results before the opening bell on Apr 19. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Chemours Company (The) (CC): Free Stock Analysis Report Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report To read this article on Zacks.com click here. The company expects the same momentum to continue in the yet-to-be reported quarter. |
33661.0 | 2017-04-12 00:00:00 UTC | Market Lower After US Treasury Budget Report | ABT | https://www.nasdaq.com/articles/market-lower-after-us-treasury-budget-report-2017-04-12 | nan | nan | The U.S. Treasury released its monthly budget report for March on Wednesday.
According to the report, the Treasury reported a deficit of $176.2 billion for March, bringing the current deficit for fiscal 2017 to $526.9 billion.
The government's deficit is 15% higher from March 2016. Excluding special factors like calendar timing of receipts and payments, the year-to-date deficit would be 23% above last year at $564 billion.
Tax receipts are down 0.2% and include an 18% decline in corporate income taxes. Outlays are up 3.3% with net interest up 15%, which reflects a higher interest rate environment, and Medicare gaining 4.8%.
After the announcement, the overall market was down with the Dow Jones Industrial Average down 0.17%, the Nasdaq down 0.48% and the Standard & Poor's 500 down 0.40%.
The monthly Treasury budget tracks the changes in federal policy on spending and taxation for the fiscal year, which begins in October.
For investors, this report is an indicator of the state of the economy. The higher the deficit, the more bonds the government must sell in order to operate. If demand is constant, this leads to a higher number of available bonds at lower prices. Conversely, if the deficit decreases, the supply decreases and prices increase. Due to an increasing deficit over the past several years, more Treasury bonds have become available in the marketplace.
Additionally, higher deficits often lead to higher interest rates for Treasury securities, which is what the U.S. is currently seeing from the Federal Reserve with its rate hikes. In turn, these higher interest rates impact interest rate-bearing securities, creating a bearish environment for stocks.
The government's tax receipts also reflect the state of the economy. While higher tax receipts reflect an improved deficit situation when economic conditions are strong, lower tax receipts indicate a slow economic environment.
The Treasury's budget report for April will be released on May 10.
Start afree 7-day trial of Premium Membershipto GuruFocus.
Warning! GuruFocus has detected 4 Warning Signs with UA. Click here to check it out.
UA 15-Year Financial Data
The intrinsic value of UA
Peter Lynch Chart of UA
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Excluding special factors like calendar timing of receipts and payments, the year-to-date deficit would be 23% above last year at $564 billion. After the announcement, the overall market was down with the Dow Jones Industrial Average down 0.17%, the Nasdaq down 0.48% and the Standard & Poor's 500 down 0.40%. The monthly Treasury budget tracks the changes in federal policy on spending and taxation for the fiscal year, which begins in October. | The U.S. Treasury released its monthly budget report for March on Wednesday. Additionally, higher deficits often lead to higher interest rates for Treasury securities, which is what the U.S. is currently seeing from the Federal Reserve with its rate hikes. While higher tax receipts reflect an improved deficit situation when economic conditions are strong, lower tax receipts indicate a slow economic environment. | According to the report, the Treasury reported a deficit of $176.2 billion for March, bringing the current deficit for fiscal 2017 to $526.9 billion. Additionally, higher deficits often lead to higher interest rates for Treasury securities, which is what the U.S. is currently seeing from the Federal Reserve with its rate hikes. While higher tax receipts reflect an improved deficit situation when economic conditions are strong, lower tax receipts indicate a slow economic environment. | Additionally, higher deficits often lead to higher interest rates for Treasury securities, which is what the U.S. is currently seeing from the Federal Reserve with its rate hikes. The government's tax receipts also reflect the state of the economy. GuruFocus has detected 4 Warning Signs with UA. |
33662.0 | 2017-04-10 00:00:00 UTC | XLV, LLY, ABT, AET: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/xlv-lly-abt-aet-etf-inflow-alert-2017-04-10 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $89.3 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 212,715,324 to 213,915,324). Among the largest underlying components of XLV, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is trading flat, and Aetna Inc. (Symbol: AET) is higher by about 1.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $76.75 as the 52 week high point - that compares with a last trade of $74.51. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is trading flat, and Aetna Inc. (Symbol: AET) is higher by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $89.3 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 212,715,324 to 213,915,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is trading flat, and Aetna Inc. (Symbol: AET) is higher by about 1.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $76.75 as the 52 week high point - that compares with a last trade of $74.51. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is trading flat, and Aetna Inc. (Symbol: AET) is higher by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $89.3 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 212,715,324 to 213,915,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $76.75 as the 52 week high point - that compares with a last trade of $74.51. | Among the largest underlying components of XLV, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is trading flat, and Aetna Inc. (Symbol: AET) is higher by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $89.3 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 212,715,324 to 213,915,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $76.75 as the 52 week high point - that compares with a last trade of $74.51. |
33663.0 | 2017-04-10 00:00:00 UTC | The Zacks Analyst Blog Highlights: Johnson & Johnson, Verizon, Visa, General Dynamics and Abbott | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-johnson-johnson-verizon-visa-general-dynamics-and | nan | nan | For Immediate Release
Chicago, IL - April 10, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Johnson & Johnson (NYSE: JNJ- Free Report ), Verizon (NYSE: VZ- Free Report ), Visa (NYSE: V- Free Report ), General Dynamics (NYSE: GD- Free Report ) and Abbott (NYSE: ABT- Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Friday's Analyst Blog:
Top Research Reports for Monday: JNJ, VZ, V
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (NYSE: JNJ- Free Report ), Verizon (NYSE: VZ- Free Report ) and Visa (NYSE: V- Free Report ).
Johnson & Johnson shares have gained +14.6% over the last year, widely outperforming the large-cap pharma space (up +2.1%). While the company is faced with a number of headwinds like unfavorable currency movements, increased competition from generics, pricing pressures and an uncertain global macroeconomic backdrop, the Zacks analyst believes that JNJ's diversified business model, deep product pipeline, lack of cyclicality and financial strength position it for continued momentum going forward.
Also, the potential Actelion buyout, though expensive, will bolster J&J's long-term growth. However, in 2017, growth in J&J's Pharma segment is expected to suffer as key growth drivers have slowed down due to competition. Estimates have remained mostly stable lately ahead of the Q1 earnings results. (You can read the full research report on Johnson & Johnson here . )
Shares of Verizon have been laggards over the past year- the stock is down -7.2% over the past 12 months vs. AT&T's +5.5% gain and the +14.4% gain for the S&P 500 index. Verizon has started conducting 5G wireless network trials in 11 U.S. cities and plans to deploy its fixed wireless version in 2018. The company's decision to launch FiOS Prepaid plan, FiOS Internet service and to zero-rate its data on FiOS Mobile App should help it gain subscribers while unlimited data plans have heated up the wireless industry.
The Verizon-Yahoo deal underwent a discount revision of $350 million. But it will likely take a while before these actions bear fruit. In the updated research report issued today, the Zacks analyst discusses the pros & cons of investing in Verizon shares at this stage. (You can read the full research report on Verizon here. )
Buy rated Visa 's shares have marginally underperformed the Zacks Financial Transaction Services industry over the past one year, gaining +14.2% vs. +14.8%. The Zacks analyst likes the company's strategic acquisitions and alliances, technology upgrades and effective marketing efforts.
Visa is experiencing growth from acquisition of Visa Europe and solid growth in payments volume as well as processed transactions. In addition, global economic uncertainty and legal headwinds are major concerns. Higher client incentives also pose a risk on profitability. (You can read the full research report on Visa here. )
Other noteworthy reports we are featuring today include General Dynamics (NYSE: GD- Free Report ) and Abbott (NYSE: ABT- Free Report ).
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 11X worse than the market. See these critical buys and sells free >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on JNJ - FREE
Get the full Report on VZ - FREE
Get the full Report on V - FREE
Get the full Report on GD - FREE
Get the full Report on ABT - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Verizon Communications Inc. (VZ): Free Stock Analysis Report
Visa Inc. (V): Free Stock Analysis Report
General Dynamics Corporation (GD): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include Johnson & Johnson (NYSE: JNJ- Free Report ), Verizon (NYSE: VZ- Free Report ), Visa (NYSE: V- Free Report ), General Dynamics (NYSE: GD- Free Report ) and Abbott (NYSE: ABT- Free Report ). Other noteworthy reports we are featuring today include General Dynamics (NYSE: GD- Free Report ) and Abbott (NYSE: ABT- Free Report ). Get the full Report on JNJ - FREE Get the full Report on VZ - FREE Get the full Report on V - FREE Get the full Report on GD - FREE Get the full Report on ABT - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. | Stocks recently featured in the blog include Johnson & Johnson (NYSE: JNJ- Free Report ), Verizon (NYSE: VZ- Free Report ), Visa (NYSE: V- Free Report ), General Dynamics (NYSE: GD- Free Report ) and Abbott (NYSE: ABT- Free Report ). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Verizon Communications Inc. (VZ): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include General Dynamics (NYSE: GD- Free Report ) and Abbott (NYSE: ABT- Free Report ). | Get the full Report on JNJ - FREE Get the full Report on VZ - FREE Get the full Report on V - FREE Get the full Report on GD - FREE Get the full Report on ABT - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Verizon Communications Inc. (VZ): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Johnson & Johnson (NYSE: JNJ- Free Report ), Verizon (NYSE: VZ- Free Report ), Visa (NYSE: V- Free Report ), General Dynamics (NYSE: GD- Free Report ) and Abbott (NYSE: ABT- Free Report ). | Stocks recently featured in the blog include Johnson & Johnson (NYSE: JNJ- Free Report ), Verizon (NYSE: VZ- Free Report ), Visa (NYSE: V- Free Report ), General Dynamics (NYSE: GD- Free Report ) and Abbott (NYSE: ABT- Free Report ). Other noteworthy reports we are featuring today include General Dynamics (NYSE: GD- Free Report ) and Abbott (NYSE: ABT- Free Report ). Get the full Report on JNJ - FREE Get the full Report on VZ - FREE Get the full Report on V - FREE Get the full Report on GD - FREE Get the full Report on ABT - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. |
33664.0 | 2017-04-10 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 11, 2017 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-april-11-2017-2017-04-10 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 11, 2017. A cash dividend payment of $0.265 per share is scheduled to be paid on May 15, 2017. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 1.92% increase over prior dividend payment. At the current stock price of $43.83, the dividend yield is 2.42%.
The previous trading day's last sale of ABT was $43.83, representing a -4.38% decrease from the 52 week high of $45.84 and a 19.23% increase over the 52 week low of $36.76.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Pfizer, Inc. ( PFE ). ABT's current earnings per share, an indicator of a company's profitability, is $.93. Zacks Investment Research reports ABT's forecasted earnings growth in 2017 as 11.25%, compared to an industry average of 1.7%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares U.S. Medical Devices ETF ( IHI )
SPDR S&P Health Care Equipment ( XHE )
First Trust VL Dividend ( FVD )
First Trust Health Care AlphaDEX ( FXH )
First Trust CBOE S&P 500 VIX Tail Hedge Fund ( VIXH ).
The top-performing ETF of this group is XHE with an increase of 14.25% over the last 100 days. IHI has the highest percent weighting of ABT at 9.48%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2017 as 11.25%, compared to an industry average of 1.7%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ) First Trust VL Dividend ( FVD ) First Trust Health Care AlphaDEX ( FXH ) First Trust CBOE S&P 500 VIX Tail Hedge Fund ( VIXH ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 11, 2017. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ) First Trust VL Dividend ( FVD ) First Trust Health Care AlphaDEX ( FXH ) First Trust CBOE S&P 500 VIX Tail Hedge Fund ( VIXH ). | ABT's current earnings per share, an indicator of a company's profitability, is $.93. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ) First Trust VL Dividend ( FVD ) First Trust Health Care AlphaDEX ( FXH ) First Trust CBOE S&P 500 VIX Tail Hedge Fund ( VIXH ). Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 11, 2017. |
33665.0 | 2017-04-09 00:00:00 UTC | 5 Pharmaceutical Stocks With the Most Reliable Dividends | ABT | https://www.nasdaq.com/articles/5-pharmaceutical-stocks-most-reliable-dividends-2017-04-09 | nan | nan | What's the one thing that dividend-seeking investors value the most? Several answers could arguably be correct, but I suspect that the best answer of all is reliability. If you're looking for dividend stocks , you want their dividends to be reliable.
Several pharmaceutical stocks claim impressive track records of consistently paying and increasing dividends. Here's why Johnson & Johnson (NYSE: JNJ) , Abbott Laboratories (NYSE: ABT) , AbbVie (NYSE: ABBV) , Novo Nordisk (NYSE: NVO) , and Novartis (NYSE: NVS) rank as the pharmaceutical stocks with the most reliable dividends, with Eli Lilly (NYSE: LLY) receiving an honorable mention.
Johnson & Johnson
Fifty-four years. That's how long Johnson & Johnson has increased its dividend, year in and year out. The Beatles hadn't even made it to America yet when J&J began this remarkable streak.
After all of this growth, Johnson & Johnson's dividend now yields 2.57%. Investors don't have to worry about J&J tarnishing its record, either. The company uses a little over half of its earnings to fund the dividend. That leaves plenty of room for more increases in the future.
Even though Johnson & Johnson isn't growing its earnings tremendously, the bottom line is nonetheless improving. The company's consumer and medical device segments aren't growing like J&J's pharmaceutical segment is. However, all three segments remain quite profitable and generate solid cash flow, which should allow dividend-seeking shareholders to sleep easy at night.
Abbott Laboratories and AbbVie
Abbott Laboratories and AbbVie are listed together, since they share so much history. Abbott spun off AbbVie in 2013. If we give AbbVie credit for the time that it was part of Abbott Labs, both companies have increased their dividends for 44 years in a row.
Abbott's dividend yield currently stands at 2.38%, while AbbVie claims an impressive yield of 3.94%. Although Abbott spent more on dividends last year than it made in profits, the company's cash flow remains strong, so its dividend shouldn't be in jeopardy anytime soon. As for AbbVie, the biotech used roughly 63% of its earnings to fund its dividend program.
Both companies should also grow earnings in the future. Abbott's focus is more on medical devices than pharmaceuticals. The company's acquisition of St. Jude Medical could fuel more growth. While AbbVie faces some uncertainty related to biosimilar challengers to top-selling Humira, the company claims a couple of impressive cancer drugs (Imbruvica and Venclexta) and multiple pipeline candidates with strong potential, including elagolix and Rova-T.
Novo Nordisk and Novartis
Novo Nordisk and Novartis have both steadily grown their dividends for 20 years in a row. While the two drugmakers tie in terms of the number of consecutive dividend increases, Novo Nordisk wins the prize for the biggest increase during that period.
Novo Nordisk's dividend yield now stands at 3.25%, while Novartis' yield is 3.69%. Although both companies should be able to continue paying and raising dividends, Novo Nordisk seems to be in better position to do so. The company used around 62% of its earnings last year to fund the dividend, while Novartis used 95% of its earnings to pay out dividends.
The situation could improve for Novartis, however. With more than 200 clinical programs in its pipeline, the Swiss pharmaceutical company appears to be poised to grow earnings despite facing loss of patent exclusivity for several key drugs. Novo Nordisk doesn't claim nearly as large of a pipeline, but the company's problems aren't as big as those Novartis must address.
Honorable mention
Eli Lilly doesn't have the long track record of increasing its dividends like these other drugmakers do. However, Lilly certainly deserves an honorable mention for sheer longevity of its dividend program. The company paid out its first dividend way back in 1885 and has paid dividends in every year since then.
Lilly's dividend currently yields a respectable 2.46%. Although Lilly, like Novartis, faces loss of patent exclusivity for some of its top drugs in the next few years, the company should be in good shape to keep the dividends flowing for a long time to come. A sesquicentennial celebration of Lilly's dividend could very well be in store in a few years.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here's why Johnson & Johnson (NYSE: JNJ) , Abbott Laboratories (NYSE: ABT) , AbbVie (NYSE: ABBV) , Novo Nordisk (NYSE: NVO) , and Novartis (NYSE: NVS) rank as the pharmaceutical stocks with the most reliable dividends, with Eli Lilly (NYSE: LLY) receiving an honorable mention. While AbbVie faces some uncertainty related to biosimilar challengers to top-selling Humira, the company claims a couple of impressive cancer drugs (Imbruvica and Venclexta) and multiple pipeline candidates with strong potential, including elagolix and Rova-T. Novo Nordisk and Novartis Novo Nordisk and Novartis have both steadily grown their dividends for 20 years in a row. With more than 200 clinical programs in its pipeline, the Swiss pharmaceutical company appears to be poised to grow earnings despite facing loss of patent exclusivity for several key drugs. | Here's why Johnson & Johnson (NYSE: JNJ) , Abbott Laboratories (NYSE: ABT) , AbbVie (NYSE: ABBV) , Novo Nordisk (NYSE: NVO) , and Novartis (NYSE: NVS) rank as the pharmaceutical stocks with the most reliable dividends, with Eli Lilly (NYSE: LLY) receiving an honorable mention. Several pharmaceutical stocks claim impressive track records of consistently paying and increasing dividends. Honorable mention Eli Lilly doesn't have the long track record of increasing its dividends like these other drugmakers do. | Here's why Johnson & Johnson (NYSE: JNJ) , Abbott Laboratories (NYSE: ABT) , AbbVie (NYSE: ABBV) , Novo Nordisk (NYSE: NVO) , and Novartis (NYSE: NVS) rank as the pharmaceutical stocks with the most reliable dividends, with Eli Lilly (NYSE: LLY) receiving an honorable mention. While AbbVie faces some uncertainty related to biosimilar challengers to top-selling Humira, the company claims a couple of impressive cancer drugs (Imbruvica and Venclexta) and multiple pipeline candidates with strong potential, including elagolix and Rova-T. Novo Nordisk and Novartis Novo Nordisk and Novartis have both steadily grown their dividends for 20 years in a row. The company used around 62% of its earnings last year to fund the dividend, while Novartis used 95% of its earnings to pay out dividends. | Here's why Johnson & Johnson (NYSE: JNJ) , Abbott Laboratories (NYSE: ABT) , AbbVie (NYSE: ABBV) , Novo Nordisk (NYSE: NVO) , and Novartis (NYSE: NVS) rank as the pharmaceutical stocks with the most reliable dividends, with Eli Lilly (NYSE: LLY) receiving an honorable mention. That's how long Johnson & Johnson has increased its dividend, year in and year out. The company used around 62% of its earnings last year to fund the dividend, while Novartis used 95% of its earnings to pay out dividends. |
33666.0 | 2017-04-06 00:00:00 UTC | Abbott Laboratories Enters Oversold Territory | ABT | https://www.nasdaq.com/articles/abbott-laboratories-enters-oversold-territory-2017-04-06 | nan | nan | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks , according to a proprietary formula designed to identify those stocks that combine two important characteristics - strong fundamentals and a valuation that looks inexpensive. Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.
But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABT entered into oversold territory, changing hands as low as $43.35 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Abbott Laboratories, the RSI reading has hit 28.1 - by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 50.4. A falling stock price - all else being equal - creates a better opportunity for dividend investors to capture a higher yield. Indeed, ABT's recent annualized dividend of 1.06/share (currently paid in quarterly installments) works out to an annual yield of 2.43% based upon the recent $43.80 share price.
A bullish investor could look at ABT's 28.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABT is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue.
According to the ETF Finder at ETF Channel, ABT makes up 8.46% of the iShares U.S. Medical Devices ETF (Symbol: IHI) which is trading lower by about 0.2% on the day Thursday.
Click here to find out what 9 other oversold dividend stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A bullish investor could look at ABT's 28.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABT entered into oversold territory, changing hands as low as $43.35 per share. | Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. Indeed, ABT's recent annualized dividend of 1.06/share (currently paid in quarterly installments) works out to an annual yield of 2.43% based upon the recent $43.80 share price. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABT entered into oversold territory, changing hands as low as $43.35 per share. | Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABT entered into oversold territory, changing hands as low as $43.35 per share. Indeed, ABT's recent annualized dividend of 1.06/share (currently paid in quarterly installments) works out to an annual yield of 2.43% based upon the recent $43.80 share price. | But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABT entered into oversold territory, changing hands as low as $43.35 per share. Indeed, ABT's recent annualized dividend of 1.06/share (currently paid in quarterly installments) works out to an annual yield of 2.43% based upon the recent $43.80 share price. Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. |
33667.0 | 2017-04-06 00:00:00 UTC | 4 Big Reasons Mylan N.V. Shares Fell 7% in March | ABT | https://www.nasdaq.com/articles/4-big-reasons-mylan-nv-shares-fell-7-march-2017-04-06 | nan | nan | What happened
Shares of Mylan (NASDAQ: MYL) , an embattled branded and generic drug developer perhaps best-known for its allergic reaction injectable medication EpiPen, fell 7% in March, according to data from S&P Global Market Intelligence . Worries continue to mount for Mylan, with four factors weighing on its shares last month.
So what
First and foremost, Mylan is dealing with recalls of its EpiPen both outside and within the United States. It was reported on March 22 that 81,000 EpiPens outside the U.S. were being recalled for being ineffective, and the number of recalls has since swelled. This isn't good news for a company whose image has been tarnished lately by its pricing practices on EpiPen, and it's possible these recalls could wind up a | What happened Shares of Mylan (NASDAQ: MYL) , an embattled branded and generic drug developer perhaps best-known for its allergic reaction injectable medication EpiPen, fell 7% in March, according to data from S&P Global Market Intelligence . Worries continue to mount for Mylan, with four factors weighing on its shares last month. This isn't good news for a company whose image has been tarnished lately by its pricing practices on EpiPen, and it's possible these recalls could wind up a | What happened Shares of Mylan (NASDAQ: MYL) , an embattled branded and generic drug developer perhaps best-known for its allergic reaction injectable medication EpiPen, fell 7% in March, according to data from S&P Global Market Intelligence . So what First and foremost, Mylan is dealing with recalls of its EpiPen both outside and within the United States. It was reported on March 22 that 81,000 EpiPens outside the U.S. were being recalled for being ineffective, and the number of recalls has since swelled. | What happened Shares of Mylan (NASDAQ: MYL) , an embattled branded and generic drug developer perhaps best-known for its allergic reaction injectable medication EpiPen, fell 7% in March, according to data from S&P Global Market Intelligence . So what First and foremost, Mylan is dealing with recalls of its EpiPen both outside and within the United States. It was reported on March 22 that 81,000 EpiPens outside the U.S. were being recalled for being ineffective, and the number of recalls has since swelled. | What happened Shares of Mylan (NASDAQ: MYL) , an embattled branded and generic drug developer perhaps best-known for its allergic reaction injectable medication EpiPen, fell 7% in March, according to data from S&P Global Market Intelligence . Worries continue to mount for Mylan, with four factors weighing on its shares last month. So what First and foremost, Mylan is dealing with recalls of its EpiPen both outside and within the United States. |
33668.0 | 2017-04-05 00:00:00 UTC | Significant Insider Buying Registered in Holdings of FTXH | ABT | https://www.nasdaq.com/articles/significant-insider-buying-registered-holdings-ftxh-2017-04-05 | nan | nan | A look at the weighted underlying holdings of the First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) shows an impressive 20.1% of holdings on a weighted basis have experienced insider buying within the past six months.
Abbott Laboratories (Symbol: ABT), which makes up 7.93% of the First Trust Nasdaq Pharmaceuticals ETF ( FTXH ), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $157,717 worth of ABT, making it the #4 largest holding. The table below details the recent insider buying activity observed at ABT:
ABT - last trade: $44.18 - Recent Insider Buys:
10 ETFs With Stocks That Insiders Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (Symbol: ABT), which makes up 7.93% of the First Trust Nasdaq Pharmaceuticals ETF ( FTXH ), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABT: ABT - last trade: $44.18 - Recent Insider Buys: 10 ETFs With Stocks That Insiders Are Buying » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ETF holds a total of $157,717 worth of ABT, making it the #4 largest holding. | Abbott Laboratories (Symbol: ABT), which makes up 7.93% of the First Trust Nasdaq Pharmaceuticals ETF ( FTXH ), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABT: ABT - last trade: $44.18 - Recent Insider Buys: 10 ETFs With Stocks That Insiders Are Buying » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ETF holds a total of $157,717 worth of ABT, making it the #4 largest holding. | Abbott Laboratories (Symbol: ABT), which makes up 7.93% of the First Trust Nasdaq Pharmaceuticals ETF ( FTXH ), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABT: ABT - last trade: $44.18 - Recent Insider Buys: 10 ETFs With Stocks That Insiders Are Buying » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ETF holds a total of $157,717 worth of ABT, making it the #4 largest holding. | The table below details the recent insider buying activity observed at ABT: ABT - last trade: $44.18 - Recent Insider Buys: 10 ETFs With Stocks That Insiders Are Buying » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories (Symbol: ABT), which makes up 7.93% of the First Trust Nasdaq Pharmaceuticals ETF ( FTXH ), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $157,717 worth of ABT, making it the #4 largest holding. |
33669.0 | 2017-04-05 00:00:00 UTC | Close Update: Stocks Give Back Gains After Minutes Show Fed Considering Balance Sheet Unwinding | ABT | https://www.nasdaq.com/articles/close-update-stocks-give-back-gains-after-minutes-show-fed-considering-balance-sheet | nan | nan | Wall Street gave back gains on Wednesday afternoon, with the main indices ending in the red after the release of the Federal Open Market Committee's minutes from its meeting last month that showed most participants could see a change in the reinvestment policy later in 2017.
Markets earlier surged, with the Nasdaq touching a record intraday high, after Automated Data Processing figures showed a better-than-expected 263,000 increase in private payrolls, nearly 100,000 more than what was expected. But talk from the FOMC about unwinding its $4.5 trillion balance sheet brought selling pressure on equities as bond prices rose.
"Provided that the economy continued to perform about as expected, most participants anticipated that gradual increases in the federal funds rate would continue and judged that a change to the committee's reinvestment policy would likely be appropriate later this year," according to the minutes. New York Fed President William Dudley said last week normalizing the balance sheet could be a substitute for short-term rate hikes.
Nearly all the S&P sectors turned negative, with losses led by financials, falling 0.5%. Defensive utilities posted a 0.5% increase. On the Nasdaq, Tesla ( TSLA ) snapped a recent rally with a 2.9% decline while 18 of the 30 Dow components were lower by the close. JPMorgan Chase ( JPM ) fell 1.3% in the steepest decline. Goldman Sachs ( GS ) fell 0.7% to be among the blue chips that reversed their gains.
Also late in the session, comments by House Speaker Paul Ryan that tax reform will take longer to accomplish than health care reform would weighed on markets and left them solidly in the red by the bell.
Here's where the markets stood at the close:
US MARKETS
Dow Jones Industrial Average was down 41.09 (-0.20%)
S&P 500 was down 7.21 (-0.31%)
Nasdaq Composite Index was down 34.13 (-0.58%)
GLOBAL SENTIMENT
FTSE 100 was up 0.13%
Nikkei 225 was up 0.27%
Hang Seng Index was up 0.57%
Shanghai China Composite Index was up 1.48%
UPSIDE MOVERS
(+) INNL (+20.3%) Agrees to be acquired by Gurnet Point for up to $6.65 per share
(+) PNRA (+14.2%) Signs merger deal with JAB Holding
(+) NVCN (+12.4%) Ladenburg Thalmann upgrades to buy from neutral with $4 price target
(+) NEOT (+12.3%) Gets U.S. patent for LIPO-202 lead clinical asset
(+) ALR (+9.5%) Investors anticipate ruling on dispute with would-be acquirer Abbott ( ABT )
DOWNSIDE MOVERS
(-) UNIS (-75.3%) Seeks bridge financing, doesn't have enough cash to fund operations beyond this week
(-) OHRP (-14.3%) Priced 20.25 million stock offering at 9% discount
(-) CGI (-13.3%) Prescience Point Research Group said stock does not have any tangible book value
(-) AAOI (-12.7%) Chinese unit gets notice of release related to land use rights, buildings pledged as collateral for credit facilities
(-) QTNT (-10.8%) Prices stock offering at 10.4% discount
(-) IPHS (-8.5%) Reaffirms guidance, unveiled five-year plan to boost revenue
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) INNL (+20.3%) Agrees to be acquired by Gurnet Point for up to $6.65 per share (+) PNRA (+14.2%) Signs merger deal with JAB Holding (+) NVCN (+12.4%) Ladenburg Thalmann upgrades to buy from neutral with $4 price target (+) NEOT (+12.3%) Gets U.S. patent for LIPO-202 lead clinical asset (+) ALR (+9.5%) Investors anticipate ruling on dispute with would-be acquirer Abbott ( ABT ) Wall Street gave back gains on Wednesday afternoon, with the main indices ending in the red after the release of the Federal Open Market Committee's minutes from its meeting last month that showed most participants could see a change in the reinvestment policy later in 2017. Markets earlier surged, with the Nasdaq touching a record intraday high, after Automated Data Processing figures showed a better-than-expected 263,000 increase in private payrolls, nearly 100,000 more than what was expected. | (+) INNL (+20.3%) Agrees to be acquired by Gurnet Point for up to $6.65 per share (+) PNRA (+14.2%) Signs merger deal with JAB Holding (+) NVCN (+12.4%) Ladenburg Thalmann upgrades to buy from neutral with $4 price target (+) NEOT (+12.3%) Gets U.S. patent for LIPO-202 lead clinical asset (+) ALR (+9.5%) Investors anticipate ruling on dispute with would-be acquirer Abbott ( ABT ) "Provided that the economy continued to perform about as expected, most participants anticipated that gradual increases in the federal funds rate would continue and judged that a change to the committee's reinvestment policy would likely be appropriate later this year," according to the minutes. (-) UNIS (-75.3%) Seeks bridge financing, doesn't have enough cash to fund operations beyond this week (-) OHRP (-14.3%) Priced 20.25 million stock offering at 9% discount (-) CGI (-13.3%) Prescience Point Research Group said stock does not have any tangible book value (-) AAOI (-12.7%) Chinese unit gets notice of release related to land use rights, buildings pledged as collateral for credit facilities (-) QTNT (-10.8%) Prices stock offering at 10.4% discount (-) IPHS (-8.5%) Reaffirms guidance, unveiled five-year plan to boost revenue The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) INNL (+20.3%) Agrees to be acquired by Gurnet Point for up to $6.65 per share (+) PNRA (+14.2%) Signs merger deal with JAB Holding (+) NVCN (+12.4%) Ladenburg Thalmann upgrades to buy from neutral with $4 price target (+) NEOT (+12.3%) Gets U.S. patent for LIPO-202 lead clinical asset (+) ALR (+9.5%) Investors anticipate ruling on dispute with would-be acquirer Abbott ( ABT ) Wall Street gave back gains on Wednesday afternoon, with the main indices ending in the red after the release of the Federal Open Market Committee's minutes from its meeting last month that showed most participants could see a change in the reinvestment policy later in 2017. "Provided that the economy continued to perform about as expected, most participants anticipated that gradual increases in the federal funds rate would continue and judged that a change to the committee's reinvestment policy would likely be appropriate later this year," according to the minutes. | (+) INNL (+20.3%) Agrees to be acquired by Gurnet Point for up to $6.65 per share (+) PNRA (+14.2%) Signs merger deal with JAB Holding (+) NVCN (+12.4%) Ladenburg Thalmann upgrades to buy from neutral with $4 price target (+) NEOT (+12.3%) Gets U.S. patent for LIPO-202 lead clinical asset (+) ALR (+9.5%) Investors anticipate ruling on dispute with would-be acquirer Abbott ( ABT ) Wall Street gave back gains on Wednesday afternoon, with the main indices ending in the red after the release of the Federal Open Market Committee's minutes from its meeting last month that showed most participants could see a change in the reinvestment policy later in 2017. On the Nasdaq, Tesla ( TSLA ) snapped a recent rally with a 2.9% decline while 18 of the 30 Dow components were lower by the close. |
33670.0 | 2017-03-31 00:00:00 UTC | Abbott's St Jude Buyout to Boost Business, Risks Remain | ABT | https://www.nasdaq.com/articles/abbotts-st-jude-buyout-to-boost-business-risks-remain-2017-03-31 | nan | nan | On Mar 31, we updated our research report on medical device major, Abbott LaboratoriesABT . The stock currently carries a Zacks Rank #3 (Hold).
We are encouraged by Abbott's initiative to realign the Established Pharmaceuticals Division (EPD) segment, which was a step in the right direction given the challenging market conditions faced by the division. The company's EPD business operates solely in emerging geographies, with leading positions in many of the largest and fastest growing pharmaceutical markets for branded generics in the world. These markets include India, Russia and Latin America. The company recently stated that, banking on successful execution of its operating model, EPD is well positioned for sustained above-market growth in some of these growing pharmaceutical markets.
We are also looking forward to Abbott's recently completed acquisition of St. Jude Medical, a leading player in fast-growing areas such as atrial fibrillation, heart failure, structural heart and chronic pain. The deal will complement Abbott's leading position in the coronary interventions and mitral valve disease markets.
However, over the past month, Abbott's shares underperformed the Zacks classified Large Cap Pharmaceuticals industry on litigation qualms related to its former takeover target Alere. Almost a year after the $5.8 billion deal was inked, Abbott filed a suit to terminate the purchase of Alere. The stock lost 2.28% during this period compared with 0.34% gainfor the industry.
We are also concerned about the sluggish Nutrition business performance, especially in China and Venezuela.
This apart, a comparative analysis of the company's forward P/E (F12M basis) multiple reflects a relatively gloomy picture that might be a cause for investors' concern. The stock's valuation looks stretched when compared with its industry. Abbott currently trades at a P/E ratio of 17.65, overvalued compared with 15.72 for the broader industry. In fact, comparing the company's current P/E level, with its own range (median of 18.0), depicts that the stock is tad overvalued in this respect as well.
Stocks to Consider
Some better-ranked stocks in the medical product industry include Inogen, Inc. INGN , Orasure Technologies, Inc. OSUR and ZELTIQ Aesthetics, Inc. ZLTQ . While Inogen sports a Zacks Rank #1 (Strong Buy), Orasure and ZELTIQ Aesthetics carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Inogen returned 83.2% in the last one year compared with the S&P 500's gain of 14.3%. The company posted a stellar four-quarter positive average earnings surprise of over 49.08%.
Orasure surged 76.8% in the last one year compared with the S&P 500's gain. It reported a four-quarter positive average earnings surprise of 123.5%.
ZELTIQ Aesthetics gained over 100% in the past one year, better than the S&P 500 mark. Its trailing four-quarter average earnings surprise was a positive 12.03%.
Zacks' Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report
ZELTIQ Aesthetics, Inc. (ZLTQ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Mar 31, we updated our research report on medical device major, Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report ZELTIQ Aesthetics, Inc. (ZLTQ): Free Stock Analysis Report To read this article on Zacks.com click here. The company's EPD business operates solely in emerging geographies, with leading positions in many of the largest and fastest growing pharmaceutical markets for branded generics in the world. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report ZELTIQ Aesthetics, Inc. (ZLTQ): Free Stock Analysis Report To read this article on Zacks.com click here. On Mar 31, we updated our research report on medical device major, Abbott LaboratoriesABT . Stocks to Consider Some better-ranked stocks in the medical product industry include Inogen, Inc. INGN , Orasure Technologies, Inc. OSUR and ZELTIQ Aesthetics, Inc. ZLTQ . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report ZELTIQ Aesthetics, Inc. (ZLTQ): Free Stock Analysis Report To read this article on Zacks.com click here. On Mar 31, we updated our research report on medical device major, Abbott LaboratoriesABT . Stocks to Consider Some better-ranked stocks in the medical product industry include Inogen, Inc. INGN , Orasure Technologies, Inc. OSUR and ZELTIQ Aesthetics, Inc. ZLTQ . | On Mar 31, we updated our research report on medical device major, Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report ZELTIQ Aesthetics, Inc. (ZLTQ): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider Some better-ranked stocks in the medical product industry include Inogen, Inc. INGN , Orasure Technologies, Inc. OSUR and ZELTIQ Aesthetics, Inc. ZLTQ . |
33671.0 | 2017-03-29 00:00:00 UTC | Noteworthy ETF Outflows: IYH, MDT, LLY, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-iyh-mdt-lly-abt-2017-03-29 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $39.0 million dollar outflow -- that's a 2.1% decrease week over week (from 12,050,000 to 11,800,000). Among the largest underlying components of IYH, in trading today Medtronic PLC (Symbol: MDT) is down about 0.1%, Lilly (Eli) & Co (Symbol: LLY) is down about 0.3%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average:
Looking at the chart above, IYH's low point in its 52 week range is $137.30 per share, with $160.58 as the 52 week high point - that compares with a last trade of $156.13. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IYH, in trading today Medtronic PLC (Symbol: MDT) is down about 0.1%, Lilly (Eli) & Co (Symbol: LLY) is down about 0.3%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $137.30 per share, with $160.58 as the 52 week high point - that compares with a last trade of $156.13. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IYH, in trading today Medtronic PLC (Symbol: MDT) is down about 0.1%, Lilly (Eli) & Co (Symbol: LLY) is down about 0.3%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $137.30 per share, with $160.58 as the 52 week high point - that compares with a last trade of $156.13. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IYH, in trading today Medtronic PLC (Symbol: MDT) is down about 0.1%, Lilly (Eli) & Co (Symbol: LLY) is down about 0.3%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $39.0 million dollar outflow -- that's a 2.1% decrease week over week (from 12,050,000 to 11,800,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $137.30 per share, with $160.58 as the 52 week high point - that compares with a last trade of $156.13. | Among the largest underlying components of IYH, in trading today Medtronic PLC (Symbol: MDT) is down about 0.1%, Lilly (Eli) & Co (Symbol: LLY) is down about 0.3%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $39.0 million dollar outflow -- that's a 2.1% decrease week over week (from 12,050,000 to 11,800,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $137.30 per share, with $160.58 as the 52 week high point - that compares with a last trade of $156.13. |
33672.0 | 2017-03-28 00:00:00 UTC | 3 Things You Probably Didn't Know About AbbVie Inc. | ABT | https://www.nasdaq.com/articles/3-things-you-probably-didnt-know-about-abbvie-inc-2017-03-28 | nan | nan | Since its spinoff from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie (NYSE: ABBV) has become one of the hottest big biotech stocks on the market. When AbbVie was formed, its market cap was close to Abbott's. Now, however, the biotech's market cap is nearly 35% higher than that of its parent company.
There's much for investors to like about AbbVie now -- but there are also some reasons for concern. Here are three things you might not know about this successful biotech.
1. One of the fastest-growing dividends
You probably already know that AbbVie currently boasts the highest dividend yield of any biotech stock . The company's yield of 3.9% easily tops the next-best contenders, Gilead Sciences and Amgen .
But did you know that AbbVie's dividend growth is among the highest of any stock on the market, regardless of industry? Over the last three years, AbbVie's dividend increased by an average annual rate of more than 17%. If we include Abbott's dividend track record, AbbVie has increased its dividend for 45 years in a row.
Even better, AbbVie appears to be poised to keep the dividend hikes coming. The company currently uses less than 63% of its earnings to fund the dividend program. That leaves plenty of room for more increases, especially considering that AbbVie's earnings are expected to grow significantly in the coming years.
2. One of the strongest product portfolios
Since Abbott spun it off, AbbVie has primarily been known for its huge blockbuster autoimmune disease drug, Humira. Sales for the company's other products were so much smaller in comparison that I nicknamed AbbVie's lineup "Humira and the seven dwarfs." That moniker isn't applicable today.
The 2015 acquisition of Pharmacyclics allowed AbbVie to pick up Imbruvica. The cancer drug could generate annual revenue of $5 billion by 2020 with approval of additional indications. AbbVie's buyout last year of Stemcentrx brought another cancer drug, Rova-T, into its pipeline. Rova-T is expected to launch next year and could reach peak annual sales of up to $5 billion. AbbVie partnered with Roche to develop yet another cancer drug, Venclexta, which could hit annual sales of up to $2 billion by 2020.
Humira could be joined in the next couple of years by two experimental autoimmune-disease candidates in AbbVie's pipeline. The company expects to launch risankizumab in 2019 for treating psoriasis and ABT-494 the same year for treating rheumatoid arthritis. Additional indications could also follow for both drugs.
3. One of the biggest debt loads
The acquisitions of Pharmacyclics and Stemcentrx came at a cost. AbbVie now has a total debt of nearly $37 billion. The only drugmaker with a higher level of debt is Pfizer . However, if you counted only long-term debt, AbbVie would rank at the top among all biopharmaceutical companies.
The buyout of Stemcentrx last year caused Moody's Investor Service to downgrade AbbVie's senior unsecured long-term rating to Baa2 from Baa1, which reflects a moderate credit risk. AbbVie's shareholders probably don't want the company to take on much more debt.
However, AbbVie's strong earnings and cash flow should allow the biotech to easily service its current debt. Earnings growth could also enable AbbVie to retire some of the debt more quickly, if it chose to do so.
One thing no one knows
There's at least one thing that no one knows about AbbVie: When will Humira's sales begin to fall? That uncertainty could make some investors wary of buying the stock.
I think, though, with its strong dividend and portfolio full of potential winners, AbbVie remains a smart pick. Abbott's spinoff has paid off nicely so far. My take is that it will continue to pay off for at least a few years to come.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 6, 2017
Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: long June 2017 $70 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Since its spinoff from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie (NYSE: ABBV) has become one of the hottest big biotech stocks on the market. The company expects to launch risankizumab in 2019 for treating psoriasis and ABT-494 the same year for treating rheumatoid arthritis. One of the strongest product portfolios Since Abbott spun it off, AbbVie has primarily been known for its huge blockbuster autoimmune disease drug, Humira. | Since its spinoff from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie (NYSE: ABBV) has become one of the hottest big biotech stocks on the market. The company expects to launch risankizumab in 2019 for treating psoriasis and ABT-494 the same year for treating rheumatoid arthritis. AbbVie's buyout last year of Stemcentrx brought another cancer drug, Rova-T, into its pipeline. | Since its spinoff from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie (NYSE: ABBV) has become one of the hottest big biotech stocks on the market. The company expects to launch risankizumab in 2019 for treating psoriasis and ABT-494 the same year for treating rheumatoid arthritis. One of the fastest-growing dividends You probably already know that AbbVie currently boasts the highest dividend yield of any biotech stock . | Since its spinoff from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie (NYSE: ABBV) has become one of the hottest big biotech stocks on the market. The company expects to launch risankizumab in 2019 for treating psoriasis and ABT-494 the same year for treating rheumatoid arthritis. AbbVie's buyout last year of Stemcentrx brought another cancer drug, Rova-T, into its pipeline. |
33673.0 | 2017-03-20 00:00:00 UTC | Trump, Biogen and Amgen Hammer Healthcare ETFs | ABT | https://www.nasdaq.com/articles/trump-biogen-and-amgen-hammer-healthcare-etfs-2017-03-20 | nan | nan | After making a strong comeback in February, the U.S. healthcare sector again witnessed some pain in the last couple of sessions. The initial sell-off came after Trump's budget blueprint, which signaled higher regulatory costs for the sector and a cut in federal funding for medical research.
The President proposed to double U.S. Food and Drug Administration (FDA) medical product user fee to over $2 billion for 2018 and cut the National Institute of Health (NIH) funding by approximately $5.8 billion, which would push down the budget to $25.9 billion. This has swept away the positive sentiment in the space (read: Trump Unveils First Budget Blueprint: ETFs to Gain or Lose ).
Additionally, the downgrade of Biogen BIIB by two analysts on Thursday and the long-awaited trail results for Amgen's AMG N) anti-cholesterol drug Repatha on Friday resulted in lackluster trading.
Biogen in Focus
Biogen fell about 5% on Thursday and an additional 1% on Friday after two analysts - Leerink and Morgan Stanley - downgraded the stock and slashed the target price to market perform with a $300 price target and equal-weight with a $305 price target, respectively.
The move dragged down other health care stocks, including Pfizer PFE , Amgen, Celgene CELG , Abbott Laboratories ABT and Thermo Fisher Scientific TMO .
Amgen in Focus
While the clinical study, known as Fourier, was positive for Amgen, it raised concerns over the astronomical pricing of Repatha at $14,523 for one year of treatment. Repatha reduces the risk of heart attack by 27%, stroke by 21% and coronary revascularization by 22% in patients with heart disease, according to a recent study conducted on 27,564 patients. This is much better than any other cholesterol-lowering statin drugs (read: Time to Buy Biotech ETFs? ).
However, the drug will continue to face limited access by pharmacy benefit managers and health insurers due to its steep price. As a result, the trial results pushed down Amgen shares by 6.4% on Friday, and sent shockwaves amog biotech stocks and other drug makers with cholesterol-lowering therapies in development stage. In particular, Esperion Therapeutics ESPR and Medicines Company MDCO tanked 20.2% and 8%, respectively, at the close.
ETF Impact
While most of the healthcare ETFs were in the red over the past two days, VanEck Vectors Biotech ETF BBH was the largest loser shedding 2.8%. Other ETFs - iShares Nasdaq Biotechnology ETF IBB , PowerShares Dynamic Biotechnology & Genome Portfolio PBE , BioShares Biotechnology Products Fund BBP , PowerShares Dynamic Pharmaceuticals Fund PJP , and SPDR S&P Pharmaceuticals ETF XPH tumbled over 2% (see: all the Health care ETFs here ).
Broad healthcare ETFs Health Care Select Sector SPDR Fund XLV , Vanguard Health Care ETF VHT and iShares U.S. Healthcare ETF IYH lost at least 1.5% in the last two sessions.
What's Ahead?
Despite the slide, the outlook for the sector is promising. Encouraging industry trends including hopes of increased M&A activity, an accelerated pace of innovation, promising drug launches, growing importance of biosimilars, cost-cutting efforts, an aging population, expanding insurance coverage, growing middle class, an insatiable demand for new drugs, ever-increasing health care spending, and the proposed Trump's policy of lower corporate taxes will continue to fuel growth in the sector.
Additionally, healthcare ETFs seems cheap, making them attractive bets at present. Notably, XLV currently has a P/E ratio of 16.41 versus 18.41 for SPY. Added to this strength is its non-cyclical nature, which provides a defensive tilt to the portfolio. Amid all the uncertainty over Trump's policy implementation and fears of political instability, defensive stocks could be compelling choices for investors (read: Hit ETFs & Stocks from the Top Sector of February ).
Further, the health care funds have a Zacks ETF Rank of 3 or 'Hold' rating, suggesting room for upside in the coming months.
Given the solid outlook but somewhat bearish near-term sentiments, investors may want to consider staying on the sidelines for now. However, risk tolerant long-term investors may consider this recent slump as a buying opportunity, should they have the stomach for extreme volatility.
Want key ETF info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
Affiliated Managers Group, Inc. (AMG): Free Stock Analysis Report
ISHARES NDQ BIO (IBB): ETF Research Reports
The Medicines Company (MDCO): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Esperion Therapeutics, Inc. (ESPR): Free Stock Analysis Report
SPDR-HLTH CR (XLV): ETF Research Reports
VIPERS-HLTH CR (VHT): ETF Research Reports
ISHARS-US HLTHC (IYH): ETF Research Reports
PWRSH-DYN PHARM (PJP): ETF Research Reports
BIOSH-BIO PRD (BBP): ETF Research Reports
SPDR-SP PHARMA (XPH): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The move dragged down other health care stocks, including Pfizer PFE , Amgen, Celgene CELG , Abbott Laboratories ABT and Thermo Fisher Scientific TMO . Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Affiliated Managers Group, Inc. (AMG): Free Stock Analysis Report ISHARES NDQ BIO (IBB): ETF Research Reports The Medicines Company (MDCO): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Esperion Therapeutics, Inc. (ESPR): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports PWRSH-DYN PHARM (PJP): ETF Research Reports BIOSH-BIO PRD (BBP): ETF Research Reports SPDR-SP PHARMA (XPH): ETF Research Reports To read this article on Zacks.com click here. The initial sell-off came after Trump's budget blueprint, which signaled higher regulatory costs for the sector and a cut in federal funding for medical research. | The move dragged down other health care stocks, including Pfizer PFE , Amgen, Celgene CELG , Abbott Laboratories ABT and Thermo Fisher Scientific TMO . Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Affiliated Managers Group, Inc. (AMG): Free Stock Analysis Report ISHARES NDQ BIO (IBB): ETF Research Reports The Medicines Company (MDCO): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Esperion Therapeutics, Inc. (ESPR): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports PWRSH-DYN PHARM (PJP): ETF Research Reports BIOSH-BIO PRD (BBP): ETF Research Reports SPDR-SP PHARMA (XPH): ETF Research Reports To read this article on Zacks.com click here. Other ETFs - iShares Nasdaq Biotechnology ETF IBB , PowerShares Dynamic Biotechnology & Genome Portfolio PBE , BioShares Biotechnology Products Fund BBP , PowerShares Dynamic Pharmaceuticals Fund PJP , and SPDR S&P Pharmaceuticals ETF XPH tumbled over 2% (see: all the Health care ETFs here ). | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Affiliated Managers Group, Inc. (AMG): Free Stock Analysis Report ISHARES NDQ BIO (IBB): ETF Research Reports The Medicines Company (MDCO): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Esperion Therapeutics, Inc. (ESPR): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports PWRSH-DYN PHARM (PJP): ETF Research Reports BIOSH-BIO PRD (BBP): ETF Research Reports SPDR-SP PHARMA (XPH): ETF Research Reports To read this article on Zacks.com click here. The move dragged down other health care stocks, including Pfizer PFE , Amgen, Celgene CELG , Abbott Laboratories ABT and Thermo Fisher Scientific TMO . Other ETFs - iShares Nasdaq Biotechnology ETF IBB , PowerShares Dynamic Biotechnology & Genome Portfolio PBE , BioShares Biotechnology Products Fund BBP , PowerShares Dynamic Pharmaceuticals Fund PJP , and SPDR S&P Pharmaceuticals ETF XPH tumbled over 2% (see: all the Health care ETFs here ). | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Affiliated Managers Group, Inc. (AMG): Free Stock Analysis Report ISHARES NDQ BIO (IBB): ETF Research Reports The Medicines Company (MDCO): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Esperion Therapeutics, Inc. (ESPR): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports PWRSH-DYN PHARM (PJP): ETF Research Reports BIOSH-BIO PRD (BBP): ETF Research Reports SPDR-SP PHARMA (XPH): ETF Research Reports To read this article on Zacks.com click here. The move dragged down other health care stocks, including Pfizer PFE , Amgen, Celgene CELG , Abbott Laboratories ABT and Thermo Fisher Scientific TMO . ETF Impact While most of the healthcare ETFs were in the red over the past two days, VanEck Vectors Biotech ETF BBH was the largest loser shedding 2.8%. |
33674.0 | 2017-03-20 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABT | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2017-03-20 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
Another consideration with dividend growth stocks is just how much the dividend is growing . We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
These five stocks are part of our full Dividend Aristocrats List . The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com .
Get the latest Zacks research report on PPG - FREE
Get the latest Zacks research report on ABT - FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Get the latest Zacks research report on PPG - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . | Get the latest Zacks research report on PPG - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. | Get the latest Zacks research report on PPG - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. | Get the latest Zacks research report on PPG - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. |
33675.0 | 2017-03-20 00:00:00 UTC | Abbott Laboratories' MitraClip Outcome Positive for DMR | ABT | https://www.nasdaq.com/articles/abbott-laboratories-mitraclip-outcome-positive-for-dmr-2017-03-20 | nan | nan | Global health care major Abbott LaboratoriesABT recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S. MitraClip treats people with degenerative mitral regurgitation (DMR).
This serious condition, also known as leaky heart valve, is a dysfunction of the heart's mitral valve which regulates blood flow to the heart's main pumping chamber.
The study evaluated data from the Transcatheter Valve Therapy registry involving DMR patients. Following minimally-invasive implantation with MitraClip, most of the patients displayed significant improvement. In addition, MitraClip patients also remained free from heart failure re-hospitalization in the year after implantation.
For the last three months, Abbott has been trading above the Zacks categorized Large Cap Pharmaceuticals . In fact, the stock gained 18.2% during this period, compared with 7.7% for the industry. Following the colossal buyout of St. Jude Medical, the share price treaded higher. We expect the late-breaking data on MitraClip to complement Abbott's structural heart business and further boost the share price.
DMR is a critical disease causing blood to flow backward and leak into the left atrium of the heart during the cardiac cycle. The condition can cause irregular heartbeats, stroke and heart failure. Patients often may not be eligible for the standard-of-care surgery because of advanced age, frailty or other complicating factors.
Abbott Laboratories Price
Abbott Laboratories Price | Abbott Laboratories Quote
It is said that almost one in 10 people over the age of 75 years suffer moderate to severe MR, which is basically difficult to diagnose. Thus, Abbott's goal is to provide MitraClip therapy as a necessary solution for patients who have limited options. Per management, the consistency in data across multiple trials reinforces confidence regarding the effectiveness of MitraClip in DMR patients to lead fuller and longer lives.
The MitraClip System is currently available in the U.S. and in more than 50 countries.
As per a recent Allied Market Research market, the global structural heart devices market is expected to be worth $12.1 million by 2022, at a CAGR of 10.5%. Given the rising rate of cardiac ailments and a critical need to detect them, we believe Abbott is well positioned to cash in on the opportunities in this market.
Zacks Rank &Key Picks
Abbott currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical product sector are Inogen, Inc. INGN , Bovie Medical Corporation BVX and ResMed, Inc. RMD . Inogen sports a Zacks Rank #1 (Strong Buy) while the other two companies carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Inogen gained 83.2% in the last one year in comparison to the S&P 500's gain of 15.9%. The company has a stellar four-quarter average earnings surprise of over 49.08%.
Bovie Medical surged 65% in the last one year in comparison to the S&P 500. It has a four-quarter average earnings surprise of 28.7%.
ResMed gained over 27.5% in the past one year, better than the S&P 500 mark. It also has a trailing average earnings surprise of 0.31%.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
ResMed Inc. (RMD): Free Stock Analysis Report
Bovie Medical Corporation (BVX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Global health care major Abbott LaboratoriesABT recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S. MitraClip treats people with degenerative mitral regurgitation (DMR). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report Bovie Medical Corporation (BVX): Free Stock Analysis Report To read this article on Zacks.com click here. We expect the late-breaking data on MitraClip to complement Abbott's structural heart business and further boost the share price. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report Bovie Medical Corporation (BVX): Free Stock Analysis Report To read this article on Zacks.com click here. Global health care major Abbott LaboratoriesABT recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S. MitraClip treats people with degenerative mitral regurgitation (DMR). Abbott Laboratories Price Abbott Laboratories Price | Abbott Laboratories Quote It is said that almost one in 10 people over the age of 75 years suffer moderate to severe MR, which is basically difficult to diagnose. | Global health care major Abbott LaboratoriesABT recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S. MitraClip treats people with degenerative mitral regurgitation (DMR). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report Bovie Medical Corporation (BVX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price Abbott Laboratories Price | Abbott Laboratories Quote It is said that almost one in 10 people over the age of 75 years suffer moderate to severe MR, which is basically difficult to diagnose. | Global health care major Abbott LaboratoriesABT recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S. MitraClip treats people with degenerative mitral regurgitation (DMR). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report Bovie Medical Corporation (BVX): Free Stock Analysis Report To read this article on Zacks.com click here. This serious condition, also known as leaky heart valve, is a dysfunction of the heart's mitral valve which regulates blood flow to the heart's main pumping chamber. |
33676.0 | 2017-03-17 00:00:00 UTC | IXJ, ABT, TMO, DHR: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/ixj-abt-tmo-dhr-large-outflows-detected-etf-2017-03-17 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $26.0 million dollar outflow -- that's a 1.7% decrease week over week (from 14,600,000 to 14,350,000). Among the largest underlying components of IXJ, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.3%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price performance of IXJ, versus its 200 day moving average:
Looking at the chart above, IXJ's low point in its 52 week range is $92.25 per share, with $106.25 as the 52 week high point - that compares with a last trade of $103.75. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IXJ, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.3%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price performance of IXJ, versus its 200 day moving average: Looking at the chart above, IXJ's low point in its 52 week range is $92.25 per share, with $106.25 as the 52 week high point - that compares with a last trade of $103.75. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IXJ, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.3%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price performance of IXJ, versus its 200 day moving average: Looking at the chart above, IXJ's low point in its 52 week range is $92.25 per share, with $106.25 as the 52 week high point - that compares with a last trade of $103.75. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IXJ, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.3%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $26.0 million dollar outflow -- that's a 1.7% decrease week over week (from 14,600,000 to 14,350,000). For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price performance of IXJ, versus its 200 day moving average: Looking at the chart above, IXJ's low point in its 52 week range is $92.25 per share, with $106.25 as the 52 week high point - that compares with a last trade of $103.75. | Among the largest underlying components of IXJ, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.3%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $26.0 million dollar outflow -- that's a 1.7% decrease week over week (from 14,600,000 to 14,350,000). For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price performance of IXJ, versus its 200 day moving average: Looking at the chart above, IXJ's low point in its 52 week range is $92.25 per share, with $106.25 as the 52 week high point - that compares with a last trade of $103.75. |
33677.0 | 2017-03-17 00:00:00 UTC | 3 Reasons to Love Abbott Laboratories (ABT) Stock | ABT | https://www.nasdaq.com/articles/3-reasons-to-love-abbott-laboratories-abt-stock-2017-03-17 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Abbott Laboratories (NYSE: ABT ) is up 17% up so far this year and is beginning to look more like its old self. From early 2011 to the middle of 2015, ABT stock expanded from just $22 per share to over $50. Since that high, Abbott has been going sideways. The current run leaves Abbott at its highest point since the mid-2015 peak.
Source: Open Grid Scheduler Via Flickr
While some analysts believe Abbott stock is going to cool-off because of its recent run, I believe in its prospects going forward.
Abbott has an impressively diverse portfolio, solid growth on tap and an enviable dividend history.
Here are three reasons why you should still pursue Abbott Laboratories as a stock to buy , even with the gains it's already booked this year.
ABT Has Strong Sales Growth
Abbott has a wide-ranging healthcare portfolio full of names consumers and medical experts alike are quite familiar with. Heard of Pedialyte and Pediasure? That's Abbott. Need generic pharmaceuticals for hypothyroidism or Ménière's disease? Abbott. Need a vaccine for the flu? Abbott. That strong portfolio is one driver of growth for the company.
7 Dividend Stocks With Yields That Grow Like Weeds
While earnings have shrunk by 15% annually over the last half-decade, a double-digit annual expansion is expected for the five years looking forward. Sales growth is in part to thank - this year, sales are expected to expand by 25%.
Abbott Is Acquisition Savvy
That sales growth is in part thanks to Abbott's recent acquisition of St. Jude Medical, a medical device company that further rounds out the healthcare giant's portfolio. According to the company's most recent earnings release, Abbott now holds the first or second positions across several cardiovascular device areas.
Abbott also recently announced that it will not follow through on its acquisition of Alere. I like the fact that Abbott is willing to pivot in the face of what it sees as eroding value, and believe certainty around the acquisition (okay, well, the lack thereof) is good for investor morale.
ABT Stock Dividend
In addition to offering organic growth, Abbott also rewards loyal investors with a dividend. The company has paid a dividend for 373 straight quarters - a streak that dates back almost a century! On top of that, it's increased the payout for 45 straight years.
As the company noted on its website, that makes Abbott a member of the S&P 500 Dividend Aristocrats Index , which tracks companies that have annually increased their dividend for 25 consecutive years.
A Tesla Inc (TSLA) Cash Raise Gets ... A Hero's Welcome?
That gives ABT stock a yield north of 2.3% even in the wake of its recent run. You can bet that yield will grow with more increases.
Abbott stock's run so far this year is a solid base for further gains. While the 2015 peak may serve as resistance down the line, I think it will be easy climb until that point.
Hilary Kramer is the editor ofGameChangers,Breakout Stocks,High Octane Trader,Absolute Capital ReturnandValue Authority. She is an accomplished investment specialist and market strategist with more than 25 years of experience in portfolio management, equity research, trading, and risk management. She has extensive expertise in global financial management, asset allocation, investment banking and private equity ventures, and is regularly sought after to provide her analysis on Bloomberg, CNBC, Fox Business Network and other media.
More From InvestorPlace
10 Safe Dividend Stocks to Own During the Next Market Crash
7 IPOs That Were Done the Right Way
The post 3 Reasons to Love Abbott Laboratories (ABT) Stock appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT Has Strong Sales Growth Abbott has a wide-ranging healthcare portfolio full of names consumers and medical experts alike are quite familiar with. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) is up 17% up so far this year and is beginning to look more like its old self. From early 2011 to the middle of 2015, ABT stock expanded from just $22 per share to over $50. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) is up 17% up so far this year and is beginning to look more like its old self. ABT Has Strong Sales Growth Abbott has a wide-ranging healthcare portfolio full of names consumers and medical experts alike are quite familiar with. From early 2011 to the middle of 2015, ABT stock expanded from just $22 per share to over $50. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) is up 17% up so far this year and is beginning to look more like its old self. More From InvestorPlace 10 Safe Dividend Stocks to Own During the Next Market Crash 7 IPOs That Were Done the Right Way The post 3 Reasons to Love Abbott Laboratories (ABT) Stock appeared first on InvestorPlace . From early 2011 to the middle of 2015, ABT stock expanded from just $22 per share to over $50. | That gives ABT stock a yield north of 2.3% even in the wake of its recent run. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) is up 17% up so far this year and is beginning to look more like its old self. From early 2011 to the middle of 2015, ABT stock expanded from just $22 per share to over $50. |
33678.0 | 2017-03-16 00:00:00 UTC | Alere Delays Filing for 2nd Year in a Row | ABT | https://www.nasdaq.com/articles/alere-delays-filing-2nd-year-row-2017-03-16 | nan | nan | For the second year in a row, Alere Inc. ( ALR ) has delayed filing its annual financial report with the Securities and Exchange Commission, citing possible accounting errors.
On March 1, the health care diagnostic test producer notified the SEC it would not be able to submit its annual report within the allotted time and requested an extension, which was set for March 16.
The Massachusetts-based company then submitted another filing on March 15, saying it needed more time to prepare.
According to the company, it needs more time "to review certain aspects of revenue recognition at its Korean and Japanese locations, including inappropriate conduct at the Company's subsidiary in South Korea, Standard Diagnostics Inc."
The company said some revenue in each of the past four years may have been reported in the wrong quarter.
In 2013, revenue was reported at $2,608.64 million. In 2014, revenue was reported at $2,575.28 million. The company is expecting a change within the range of $0 to $5 million for these two years.
In 2015, revenue was $2,463.32 million. The company expects changes between $5 million and $10 million for 2015 and 2016.
The company said it does not expect overall revenue to be affected, but only "a shift of revenue between accounting periods."
The filing delay only adds to Alere's problems.The company is currenty in a legal dispute with Abbott Laboratories ( ABT ). After reaching a buyout agreement early in 2016, Abbott decided to back out after Alere's diabetes unit had its Medicare billing privileges revoked later that year. In response, Alere has appealed to the court system to force the transaction to continue.
If the judge rules in its favor, Alere will become a subsidiary of Abbott.
The company has a market capitalization of $3.24 billion with approximately 87 million shares outstanding. Alere closed at $37.23 Wednesday, up 22 cents or 0.59% from the previous trading day. The stock has lost 4.46% year to date. The company does not distribute dividends. It has a price-sales (P/S) ratio of 1.36 and a price-book (P/B) ratio of 2.25 times. The forward price-earnings (P/E) ratio is 16.33.
Abbott closed at $45.32 Wednesday, up 52 cents or 1.16% from the previous trading day. It has a P/S ratio of 3.76 and a P/B ratio of 3.25. The forward P/E ratio is 16.48. The health care company distributes an annual dividend of $1.06 for a yield of 2.37%.
Disclosure: I have no positioned in any stock mentioned in this article.
Start afree 7-day trial of Premium Membershipto GuruFocus.
Warning! GuruFocus has detected 3 Warning Signs with NKTR. Click here to check it out.
NKTR 15-Year Financial Data
The intrinsic value of NKTR
Peter Lynch Chart of NKTR
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The filing delay only adds to Alere's problems.The company is currenty in a legal dispute with Abbott Laboratories ( ABT ). For the second year in a row, Alere Inc. ( ALR ) has delayed filing its annual financial report with the Securities and Exchange Commission, citing possible accounting errors. After reaching a buyout agreement early in 2016, Abbott decided to back out after Alere's diabetes unit had its Medicare billing privileges revoked later that year. | The filing delay only adds to Alere's problems.The company is currenty in a legal dispute with Abbott Laboratories ( ABT ). Alere closed at $37.23 Wednesday, up 22 cents or 0.59% from the previous trading day. Abbott closed at $45.32 Wednesday, up 52 cents or 1.16% from the previous trading day. | The filing delay only adds to Alere's problems.The company is currenty in a legal dispute with Abbott Laboratories ( ABT ). According to the company, it needs more time "to review certain aspects of revenue recognition at its Korean and Japanese locations, including inappropriate conduct at the Company's subsidiary in South Korea, Standard Diagnostics Inc." The company said some revenue in each of the past four years may have been reported in the wrong quarter. The company expects changes between $5 million and $10 million for 2015 and 2016. | The filing delay only adds to Alere's problems.The company is currenty in a legal dispute with Abbott Laboratories ( ABT ). The company is expecting a change within the range of $0 to $5 million for these two years. GuruFocus has detected 3 Warning Signs with NKTR. |
33679.0 | 2017-03-02 00:00:00 UTC | IHI, ABT, TMO, DHR: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/ihi-abt-tmo-dhr-large-outflows-detected-etf-2017-03-02 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $136.5 million dollar outflow -- that's a 11.3% decrease week over week (from 7,950,000 to 7,050,000). Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.2%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.3%, and Danaher Corp (Symbol: DHR) is lower by about 0.6%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $115.30 per share, with $152.00 as the 52 week high point - that compares with a last trade of $151.06. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.2%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.3%, and Danaher Corp (Symbol: DHR) is lower by about 0.6%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $115.30 per share, with $152.00 as the 52 week high point - that compares with a last trade of $151.06. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.2%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.3%, and Danaher Corp (Symbol: DHR) is lower by about 0.6%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $115.30 per share, with $152.00 as the 52 week high point - that compares with a last trade of $151.06. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.2%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.3%, and Danaher Corp (Symbol: DHR) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $136.5 million dollar outflow -- that's a 11.3% decrease week over week (from 7,950,000 to 7,050,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $115.30 per share, with $152.00 as the 52 week high point - that compares with a last trade of $151.06. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.2%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.3%, and Danaher Corp (Symbol: DHR) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $136.5 million dollar outflow -- that's a 11.3% decrease week over week (from 7,950,000 to 7,050,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $115.30 per share, with $152.00 as the 52 week high point - that compares with a last trade of $151.06. |
33680.0 | 2017-02-27 00:00:00 UTC | Abbott Labs (ABT) Up 10.8% Since Earnings Report: Can It Continue? | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-up-10.8-since-earnings-report%3A-can-it-continue-2017-02-27 | nan | nan | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Shares have added about 10.8% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Recent Earnings
Abbott Laboratories reported fourth-quarter 2016 earnings from continuing operations of $0.65 per share, $0.01 higher than the Zacks Consensus Estimate and up 4.8% year over year. Full-year 2016 adjusted earnings came in at $2.20 per share, in line with the Zacks Consensus Estimate. However, it remained ahead of the year-ago number by 2.3%.
Fourth-quarter sales came in at $5.33 billion, up 2.8% year over year on a reported basis. The quarterly figure is almost in line with the Zacks Consensus Estimate. The top line was, however, impacted 1% by unfavorable foreign exchange movement.
Worldwide sales for the full year came in at $20.85 billion, up 2.2% year over year on a reported basis. However, the figure is nearly in line with the Zacks Consensus Estimate.
Quarter in Detail
Abbott Labs operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
EPD sales were up 10.6% on a reported basis to $979 billion. There was a negative impact of 2% due to currency fluctuations. Sales in key emerging markets increased 10.6% driven by double-digit growth in BRIC that comprises approximately 45% of Abbott's Established Pharmaceuticals sales, as well as strong growth in several countries throughout Latin America, including Colombia, Mexico, Peru and Argentina.
The Medical Devices business generated sales of $1.35 billion, up 4.2% year over year on a reported basis. Vascular product sales were up 2.9% on the back of double-digit growth in MitraClip. Also strong sales growth in Abbott's Endovascular business was driven by vessel closure products and Supera.
Diabetes Care sales increased 4.5% on a reported basis (there was unfavorable 1.5% effect of foreign exchange),driven by continued consumer uptake of FreeStyle Libre. Sales of Medical Optics were up 7.7% on a reported basis (there was a favorable 0.8% effect of foreign exchange),backed by the recent launch of the Tecnis Symfony intraocular lenses in the U.S.
Nutrition sales decreased 3.7% year over year on a reported basis to $1.73 billion. Unfavorable foreign exchange impacted sales by 1.1%. Pediatric Nutrition sales decreased 5.4% on a reported basis. Adult Nutrition sales decreased 1.4% on a reported basis led by year-over-year difficult comparison of Ensure.
Diagnostics sales increased 2.9% year over year to $1.26 billion. While Core Laboratory sales increased 3.6%, Point of Care Diagnostics sales increased 8.1% on a reported basis. Molecular Diagnostics sales were down 7.6% as growth in the infectious disease testing business was partially offset by the planned scale-down of the genetics business.
2017 Guidance
Abbott Labs provided full-year 2017 guidance. The company currently forecasts earnings per share from continuing operations to remain within the range of $0.92 to $1.02. Adjusting certain net specified items for the full year of approximately $1.48 per share, adjusted earnings per share from continuing operations is expected to stay within the range of $2.40 to $2.50. The current Zacks Consensus Estimate is pegged at $2.54, at the midpoint of the projected range.
The company has also provided its first-quarter 2017 earnings per share guidance. Excluding certain specified items of $0.23 a share, projected adjusted earnings per share from continuing operations is expected to remain within $0.42 and $0.44 for the first quarter. The current Zacks Consensus Estimate remains at $0.50 a share for the first quarter, ahead of the forecasted range.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed a downward trend in fresh estimates. There have been two revisions lower for the current quarter. In the past month, the consensus estimate has shifted 13.31% downward due to these changes.
Abbott Laboratories Price and Consensus
Abbott Laboratories Price and Consensus | Abbott Laboratories Quote
VGM Scores
At this time, Abbott Lab's stock has an average Growth Score of 'C', though it is lagging a lot on the momentum front with an 'F'. However, the stock was allocated a grade of 'B' on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregte VGM Score of 'C'. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is suitable for value and growth investors.
Outlook
Estimates have been broadly trending downward for the stock. The magnitude of this revision also indicates a downward shift. Notably, the stock has a Zacks Rank #3 (Hold). We are looking for an inline return from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Detail Abbott Labs operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics. | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Recent Earnings Abbott Laboratories reported fourth-quarter 2016 earnings from continuing operations of $0.65 per share, $0.01 higher than the Zacks Consensus Estimate and up 4.8% year over year. | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Recent Earnings Abbott Laboratories reported fourth-quarter 2016 earnings from continuing operations of $0.65 per share, $0.01 higher than the Zacks Consensus Estimate and up 4.8% year over year. | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Recent Earnings Abbott Laboratories reported fourth-quarter 2016 earnings from continuing operations of $0.65 per share, $0.01 higher than the Zacks Consensus Estimate and up 4.8% year over year. |
33681.0 | 2017-02-24 00:00:00 UTC | Acadia Healthcare (ACHC) Tops Q4 Earnings, Gives 2017 View | ABT | https://www.nasdaq.com/articles/acadia-healthcare-achc-tops-q4-earnings-gives-2017-view-2017-02-24 | nan | nan | Acadia Healthcare Company Inc.ACHC reported fourth-quarter 2016 adjusted earnings of 59 cents per share, which surpassed the Zacks Consensus Estimate by 4 cents. Earnings were flat year over year.
Quarter Details
The company registered 42% year-over-year growth in revenues in the quarter. However, the quarterly revenues of approximately $702 million missed the consensus mark by $5 million, failing to impress investors.
The year-over-year upside in revenues may be attributed to the addition of beds at Acadia's facilities and 6.3% increase in same facility revenues. The improvement in same facility revenues, in turn, can be attributed to a 6.1% rise in patient days. Notably, revenue per patient day inched up 0.1% on a year-over-year basis.
The U.S. same facility revenues were up 6.6% from the year-ago quarter. The company also recorded a 6.5% increase in patient days from 2015.
The U.K. same facility revenues inched up 4.2% year over year to $73 million. Number of patient days rose 4.7% from the year-ago quarter.
We note that revenues per patient day were up 0.1% in the U.S. but down 1.0% in the U.K.
Total expenses increased 49% year over year to $660.5 million.
Same facility adjusted EBITDA margin was 26.3% compared with 26.0% in the year-ago quarter.
2016 Highlights
Adjusted earnings came at $2.45 per share on revenues of $2.8 billion. While revenues grew 56%, the bottom line improved 10%.
Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise
Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise | Acadia Healthcare Company, Inc. Quote
Financial Update
Cash and cash equivalents at year-end 2016 were $57.1 million, up from $11.2 million at year-end 2015.
Long term debt increased to $3.2 billion from $2.2 billion at the end of 2015.
Net cash provided by operating activities of $361.5 million increased 49% from 2015.
2017 Guidance
Acadia Healthcare estimates adjusted earnings per diluted between $2.40 and $2.50 on revenues between $2.85 billion and $2.9 billion.
Adjusted EBITDA is expected between $625 million and $640 million.
For first quarter, adjusted earnings per diluted share is projected in the range of 45-47 cents.
Zacks Rank and Performance of Other Stocks
Acadia Healthcare carries Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Among other medical stocks, Abbott Laboratories ABT , Advanced Accelerator Applications S.A. AAAP and AmerisourceBergen Corporation (Holding Co) ABC have surpassed their respective Zacks Consensus Estimate in the last reported quarter.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017? Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AmerisourceBergen Corporation (Holding Co) (ABC): Free Stock Analysis Report
Acadia Healthcare Company, Inc. (ACHC): Free Stock Analysis Report
Advanced Accelerator Applications S.A. (AAAP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among other medical stocks, Abbott Laboratories ABT , Advanced Accelerator Applications S.A. AAAP and AmerisourceBergen Corporation (Holding Co) ABC have surpassed their respective Zacks Consensus Estimate in the last reported quarter. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AmerisourceBergen Corporation (Holding Co) (ABC): Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC): Free Stock Analysis Report Advanced Accelerator Applications S.A. (AAAP): Free Stock Analysis Report To read this article on Zacks.com click here. For first quarter, adjusted earnings per diluted share is projected in the range of 45-47 cents. | Among other medical stocks, Abbott Laboratories ABT , Advanced Accelerator Applications S.A. AAAP and AmerisourceBergen Corporation (Holding Co) ABC have surpassed their respective Zacks Consensus Estimate in the last reported quarter. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AmerisourceBergen Corporation (Holding Co) (ABC): Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC): Free Stock Analysis Report Advanced Accelerator Applications S.A. (AAAP): Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise | Acadia Healthcare Company, Inc. Quote Financial Update Cash and cash equivalents at year-end 2016 were $57.1 million, up from $11.2 million at year-end 2015. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AmerisourceBergen Corporation (Holding Co) (ABC): Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC): Free Stock Analysis Report Advanced Accelerator Applications S.A. (AAAP): Free Stock Analysis Report To read this article on Zacks.com click here. Among other medical stocks, Abbott Laboratories ABT , Advanced Accelerator Applications S.A. AAAP and AmerisourceBergen Corporation (Holding Co) ABC have surpassed their respective Zacks Consensus Estimate in the last reported quarter. Acadia Healthcare Company Inc.ACHC reported fourth-quarter 2016 adjusted earnings of 59 cents per share, which surpassed the Zacks Consensus Estimate by 4 cents. | Among other medical stocks, Abbott Laboratories ABT , Advanced Accelerator Applications S.A. AAAP and AmerisourceBergen Corporation (Holding Co) ABC have surpassed their respective Zacks Consensus Estimate in the last reported quarter. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AmerisourceBergen Corporation (Holding Co) (ABC): Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC): Free Stock Analysis Report Advanced Accelerator Applications S.A. (AAAP): Free Stock Analysis Report To read this article on Zacks.com click here. The improvement in same facility revenues, in turn, can be attributed to a 6.1% rise in patient days. |
33682.0 | 2017-02-22 00:00:00 UTC | Noteworthy ETF Outflows: IHI, ABT, TMO, DHR | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-ihi-abt-tmo-dhr-2017-02-22 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $22.4 million dollar outflow -- that's a 1.9% decrease week over week (from 8,100,000 to 7,950,000). Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.1%, and Danaher Corp (Symbol: DHR) is up by about 0.1%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $112.93 per share, with $149.50 as the 52 week high point - that compares with a last trade of $149.02. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.1%, and Danaher Corp (Symbol: DHR) is up by about 0.1%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $112.93 per share, with $149.50 as the 52 week high point - that compares with a last trade of $149.02. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.1%, and Danaher Corp (Symbol: DHR) is up by about 0.1%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $112.93 per share, with $149.50 as the 52 week high point - that compares with a last trade of $149.02. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.1%, and Danaher Corp (Symbol: DHR) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $22.4 million dollar outflow -- that's a 1.9% decrease week over week (from 8,100,000 to 7,950,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $112.93 per share, with $149.50 as the 52 week high point - that compares with a last trade of $149.02. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.1%, and Danaher Corp (Symbol: DHR) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $22.4 million dollar outflow -- that's a 1.9% decrease week over week (from 8,100,000 to 7,950,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $112.93 per share, with $149.50 as the 52 week high point - that compares with a last trade of $149.02. |
33683.0 | 2017-02-17 00:00:00 UTC | Daily Dividend Report: MPW, NHI, XRAY, XL, ABT, NKE, FDX | ABT | https://www.nasdaq.com/articles/daily-dividend-report-mpw-nhi-xray-xl-abt-nke-fdx-2017-02-17 | nan | nan | Medical Properties Trust ( MPW ) declared a regular quarterly cash dividend of $0.24 per share of common stock to be paid on April 13, 2017, to stockholders of record on March 16, 2017.
National Health Investors ( NHI ) will increase its quarterly dividend 5.5% in the first quarter of 2017 to $.95 per common share. Dividends are payable on May 10, 2017 to shareholders of record on March 31, 2017.
DENTSPLY SIRONA ( XRAY ) declared a quarterly cash dividend of $0.0875 per share of common stock, an indicated annual rate of $0.35 per share. This represents a 12.9% increase from the prior annual rate of $0.31 per share. The dividend is payable on April 13, 2017 to holders of record on March 31, 2017.
XL Group ( XL ) declared a quarterly dividend on February 16, 2017 of $0.22 per common share payable on the Company's common shares. This action increases the quarterly dividend to $0.22 per common share from $0.20 per common share. The dividend will be payable on March 31, 2017 to common shareholders of record as of March 15, 2017.
Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. The cash dividend is payable May 15, 2017, to shareholders of record at the close of business on Apr. 14, 2017.
NIKE (NKE) has declared a quarterly cash dividend of $0.18 per share on the company's outstanding Class A and Class B Common Stock payable on April 3, 2017, to shareholders of record at the close of business on March 6, 2017.
FedEx Corporation (FDX) declared a quarterly cash dividend of $0.40 per share on FedEx Corporation common stock. The dividend is payable April 3, 2017 to stockholders of record at the close of business on March 13, 2017.
VIDEO: Daily Dividend Report: MPW, NHI, XRAY, XL, ABT, NKE, FDX
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: Daily Dividend Report: MPW, NHI, XRAY, XL, ABT, NKE, FDX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. Medical Properties Trust ( MPW ) declared a regular quarterly cash dividend of $0.24 per share of common stock to be paid on April 13, 2017, to stockholders of record on March 16, 2017. | VIDEO: Daily Dividend Report: MPW, NHI, XRAY, XL, ABT, NKE, FDX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. NIKE (NKE) has declared a quarterly cash dividend of $0.18 per share on the company's outstanding Class A and Class B Common Stock payable on April 3, 2017, to shareholders of record at the close of business on March 6, 2017. | Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. VIDEO: Daily Dividend Report: MPW, NHI, XRAY, XL, ABT, NKE, FDX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Medical Properties Trust ( MPW ) declared a regular quarterly cash dividend of $0.24 per share of common stock to be paid on April 13, 2017, to stockholders of record on March 16, 2017. | Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. VIDEO: Daily Dividend Report: MPW, NHI, XRAY, XL, ABT, NKE, FDX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Medical Properties Trust ( MPW ) declared a regular quarterly cash dividend of $0.24 per share of common stock to be paid on April 13, 2017, to stockholders of record on March 16, 2017. |
33684.0 | 2017-02-10 00:00:00 UTC | Pharmaceutical ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/pharmaceutical-etf-experiences-big-inflow-2017-02-10 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Pharmaceutical ETF (Symbol: PPH) where we have detected an approximate $66.7 million dollar inflow -- that's a 28.8% increase week over week in outstanding units (from 4,338,138 to 5,588,138). Among the largest underlying components of PPH, in trading today Novartis (Symbol: NVS) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is trading flat, and GlaxoSmithKline plc (Symbol: GSK) is up by about 0.4%. For a complete list of holdings, visit the PPH Holdings page » The chart below shows the one year price performance of PPH, versus its 200 day moving average:
Looking at the chart above, PPH's low point in its 52 week range is $50.351 per share, with $62.22 as the 52 week high point - that compares with a last trade of $53.37. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of PPH, in trading today Novartis (Symbol: NVS) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is trading flat, and GlaxoSmithKline plc (Symbol: GSK) is up by about 0.4%. For a complete list of holdings, visit the PPH Holdings page » The chart below shows the one year price performance of PPH, versus its 200 day moving average: Looking at the chart above, PPH's low point in its 52 week range is $50.351 per share, with $62.22 as the 52 week high point - that compares with a last trade of $53.37. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of PPH, in trading today Novartis (Symbol: NVS) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is trading flat, and GlaxoSmithKline plc (Symbol: GSK) is up by about 0.4%. For a complete list of holdings, visit the PPH Holdings page » The chart below shows the one year price performance of PPH, versus its 200 day moving average: Looking at the chart above, PPH's low point in its 52 week range is $50.351 per share, with $62.22 as the 52 week high point - that compares with a last trade of $53.37. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of PPH, in trading today Novartis (Symbol: NVS) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is trading flat, and GlaxoSmithKline plc (Symbol: GSK) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Pharmaceutical ETF (Symbol: PPH) where we have detected an approximate $66.7 million dollar inflow -- that's a 28.8% increase week over week in outstanding units (from 4,338,138 to 5,588,138). For a complete list of holdings, visit the PPH Holdings page » The chart below shows the one year price performance of PPH, versus its 200 day moving average: Looking at the chart above, PPH's low point in its 52 week range is $50.351 per share, with $62.22 as the 52 week high point - that compares with a last trade of $53.37. | Among the largest underlying components of PPH, in trading today Novartis (Symbol: NVS) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is trading flat, and GlaxoSmithKline plc (Symbol: GSK) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Pharmaceutical ETF (Symbol: PPH) where we have detected an approximate $66.7 million dollar inflow -- that's a 28.8% increase week over week in outstanding units (from 4,338,138 to 5,588,138). For a complete list of holdings, visit the PPH Holdings page » The chart below shows the one year price performance of PPH, versus its 200 day moving average: Looking at the chart above, PPH's low point in its 52 week range is $50.351 per share, with $62.22 as the 52 week high point - that compares with a last trade of $53.37. |
33685.0 | 2017-02-04 00:00:00 UTC | Insider Buys Highlight for Week of Jan. 30 | ABT | https://www.nasdaq.com/articles/insider-buys-highlight-week-jan-30-2017-02-04 | nan | nan | General Electric Co. ( GE ): Senior Vice President Jeffrey S. Bornstein bought 5,000 shares
Bornstein bought 5,000 shares of GE stock on Jan. 31 at the average price of $29.63 per share. The price of the stock has increased by 0.17% since.
General Electric is an American international conglomerate corporation and operates through multiple segments, including Power & Water, Oil and Gas, Aviation, Healthcare and Transportation. The company has over 305,000 employees as of 2015 and ranked among the Fortune 500 as the 68th largest firm in the U.S. as of 2011. The company has a market cap of $262.74 billion, and as of Feb. 3 the company traded at $29.70.
On Feb. 2, General Electric announced that this year it will complete the modernization of Elektro Privreda Srbije's TPP Nikola Tesla, the largest coal-fired power plant in Serbia that generates a large portion of the power supply for the national Serbian power grid. The retrofit will help increase power output, reduce operation and maintenance costs, and lower the plant's carbon footprint through lower coal consumption.
Abbott Laboratories ( ABT ): Executive Vice President Stephen R. Fussell bought 12,200 shares
Fussell bought 12,200 shares of ABT stock on Jan. 31 at the average price of $40.77 per share. The price of the stock has increased by 4.86% since.
Executive Vice President Heather L. Mason sold 35,700 shares of ABT stock on Jan. 31 at the average price of $40.77. The price of the stock has increased by 4.86% since.
Abbott Laboratories is an American-based international health care company. It has more than 74,000 employees in 150 countries. Some of its products include pharmaceutical drugs, medical devices and nutritional products. The company has a market cap of $73.85 billion, and as of Feb. 3 it traded at $42.78.
On Feb. 2, Abbott Laboratories announced that the U.S. Federal Drug Administration has authorized its molecular test to detect Zika virus in whole blood collected alongside a patient-matched serum or plasma sample for emergency use. This is the first molecular test made by a commercial manufacturer authorized to detect Zika in whole blood samples.
WESCO International Inc. ( WCC ): SVP and CFO David S. Schulz bought 5,000 shares
Schulz bought 5,000 shares of WCC stock on Jan. 31 at the average price of $71.17 per share. The price of the stock has decreased by 1.01% since.
WESCO International Inc. is an American international holding company that provides electrical, industrial, communications, repair and original equipment product services. The company serves over 100,000 customers worldwide, including both commercial and government agencies. The company has a market cap of $3.46 billion, and as of Feb. 3 it traded at $71.30.
On Jan. 26, WESCO International Inc. reported financial results for the fourth quarter and full year 2016. Net sales were $1.78 billion for the quarter, compared to $1.86 billion for the fourth quarter of 2015, a decrease of 3.7%. Operating profit was $82.1 million for the current quarter, compared to $90 million for the fourth quarter of 2015.
Chemical Financial Corp. ( CHFC ): Director James R. Fitterling bought 1,500 shares
Fitterling bought 1,500 shares of CHFC stock on Jan. 30 at the average price of $48.57 per share. The price of the stock has increased by 1.98% since.
Director Ronald A. Klein sold 5,000 shares of CHFC stock on Jan. 31 at the average price of $48.88 per share. The price of the stock has increased by 1.33% since.
Chemical Financial is an American financial holding company that operates through one state-chartered traditional subsidiary bank. It is the largest banking company headquartered in Michigan, and offers both traditional banking and fiduciary products to residents and business customers through several states including Michigan, Ohio and Indiana. The company has a market cap of $3.5 billion, and as of Feb. 3 it traded at $49.53.
On Jan. 23, Chemical Financial announced that Jeffrey L. Tate, corporate auditor for the Dow Chemical company, was appointed to the board of directors. His appointment will increase the board size to 13 members and will be effective March 1. Tate began his Dow career in 1992 and has held a variety of accounting and controller roles in financial and leadership assignments in Dow Automotive and Investor Relations.
For the complete list of stocks that were bought by their company executives, go to: Insider Trades.
Disclosure: I do not own stock in any of the companies mentioned in the article.
Start a free seven-day trial of Premium Membership to GuruFocus.
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Executive Vice President Heather L. Mason sold 35,700 shares of ABT stock on Jan. 31 at the average price of $40.77. Abbott Laboratories ( ABT ): Executive Vice President Stephen R. Fussell bought 12,200 shares Fussell bought 12,200 shares of ABT stock on Jan. 31 at the average price of $40.77 per share. General Electric is an American international conglomerate corporation and operates through multiple segments, including Power & Water, Oil and Gas, Aviation, Healthcare and Transportation. | Abbott Laboratories ( ABT ): Executive Vice President Stephen R. Fussell bought 12,200 shares Fussell bought 12,200 shares of ABT stock on Jan. 31 at the average price of $40.77 per share. Executive Vice President Heather L. Mason sold 35,700 shares of ABT stock on Jan. 31 at the average price of $40.77. General Electric Co. ( GE ): Senior Vice President Jeffrey S. Bornstein bought 5,000 shares Bornstein bought 5,000 shares of GE stock on Jan. 31 at the average price of $29.63 per share. | Abbott Laboratories ( ABT ): Executive Vice President Stephen R. Fussell bought 12,200 shares Fussell bought 12,200 shares of ABT stock on Jan. 31 at the average price of $40.77 per share. Executive Vice President Heather L. Mason sold 35,700 shares of ABT stock on Jan. 31 at the average price of $40.77. General Electric Co. ( GE ): Senior Vice President Jeffrey S. Bornstein bought 5,000 shares Bornstein bought 5,000 shares of GE stock on Jan. 31 at the average price of $29.63 per share. | Executive Vice President Heather L. Mason sold 35,700 shares of ABT stock on Jan. 31 at the average price of $40.77. Abbott Laboratories ( ABT ): Executive Vice President Stephen R. Fussell bought 12,200 shares Fussell bought 12,200 shares of ABT stock on Jan. 31 at the average price of $40.77 per share. WESCO International Inc. is an American international holding company that provides electrical, industrial, communications, repair and original equipment product services. |
33686.0 | 2017-02-03 00:00:00 UTC | Mondrian Investment Partners LTD Buys Wells Fargo, Walgreens Boots Alliance, SK Telecom Co, ... | ABT | https://www.nasdaq.com/articles/mondrian-investment-partners-ltd-buys-wells-fargo-walgreens-boots-alliance-sk-telecom-co | nan | nan | Mondrian Investment Partners LTD
New Purchases: SKM , VEDL , AA , AAPL, ARNC, CYD,
Added Positions:PHI, WFC, PFE, WBA, CCK, C, INFY, AAC, ECOL, CXW,
Reduced Positions:BCE, BAP, ABT, JNJ, MA, MSFT, PG, CAE, YUM, RBA,
Sold Out:PAC, CIB, CCU, YUMC, DVMT, CLC, GK,
For the details of Mondrian Investment Partners LTD's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Mondrian+Investment+Partners+LTD
These are the top 5 holdings of Mondrian Investment Partners LTD
CAE Inc ( CAE ) - 14,798,688 shares, 8.03% of the total portfolio. Shares reduced by 5.21%
Credicorp Ltd ( BAP ) - 1,407,843 shares, 6.42% of the total portfolio. Shares reduced by 28.94%
Abbott Laboratories ( ABT ) - 5,158,314 shares, 5.72% of the total portfolio. Shares reduced by 26.35%
PLDT Inc ( PHI ) - 7,072,512 shares, 5.63% of the total portfolio. Shares added by 10.41%
Taiwan Semiconductor Manufacturing Co Ltd ( TSM ) - 6,668,574 shares, 5.54% of the total portfolio. Shares reduced by 1.26%
New Purchase: SK Telecom Co Ltd (SKM)
Mondrian Investment Partners LTD initiated holdings in SK Telecom Co Ltd. The purchase prices were between $20.71 and $22.6, with an estimated average price of $21.61. The stock is now traded at around $21.65. The impact to the portfolio due to this purchase was 0.14%. The holdings were 227,080 shares as of 2016-12-31.
New Purchase: Vedanta Ltd (VEDL)
Mondrian Investment Partners LTD initiated holdings in Vedanta Ltd. The purchase prices were between $10.64 and $14.31, with an estimated average price of $12.6. The stock is now traded at around $14.82. The impact to the portfolio due to this purchase was 0.11%. The holdings were 295,900 shares as of 2016-12-31.
New Purchase: Alcoa Corp (AA)
Mondrian Investment Partners LTD initiated holdings in Alcoa Corp. The purchase prices were between $21 and $32.05, with an estimated average price of $27.94. The stock is now traded at around $37.40. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 395 shares as of 2016-12-31.
New Purchase: China Yuchai International Ltd (CYD)
Mondrian Investment Partners LTD initiated holdings in China Yuchai International Ltd. The purchase prices were between $10.47 and $13.85, with an estimated average price of $12.06. The stock is now traded at around $14.01. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 1,898 shares as of 2016-12-31.
New Purchase: Arconic Inc (ARNC)
Mondrian Investment Partners LTD initiated holdings in Arconic Inc. The purchase prices were between $17.34 and $21.8, with an estimated average price of $19.77. The stock is now traded at around $25.30. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 1,186 shares as of 2016-12-31.
New Purchase: Apple Inc (AAPL)
Mondrian Investment Partners LTD initiated holdings in Apple Inc. The purchase prices were between $105.71 and $118.25, with an estimated average price of $113.4. The stock is now traded at around $128.89. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 515 shares as of 2016-12-31.
Added: Wells Fargo & Co (WFC)
Mondrian Investment Partners LTD added to the holdings in Wells Fargo & Co by 32.39%. The purchase prices were between $43.75 and $57.29, with an estimated average price of $50.28. The stock is now traded at around $56.51. The impact to the portfolio due to this purchase was 0.51%. The holdings were 1,300,415 shares as of 2016-12-31.
Added: Walgreens Boots Alliance Inc (WBA)
Mondrian Investment Partners LTD added to the holdings in Walgreens Boots Alliance Inc by 27.02%. The purchase prices were between $77.18 and $87.73, with an estimated average price of $82.69. The stock is now traded at around $81.05. The impact to the portfolio due to this purchase was 0.29%. The holdings were 577,899 shares as of 2016-12-31.
Added: AAC Holdings Inc (AAC)
Mondrian Investment Partners LTD added to the holdings in AAC Holdings Inc by 192.61%. The purchase prices were between $6.86 and $17.61, with an estimated average price of $11.44. The stock is now traded at around $8.09. The impact to the portfolio due to this purchase was 0.05%. The holdings were 398,060 shares as of 2016-12-31.
Added: Omnicell Inc (OMCL)
Mondrian Investment Partners LTD added to the holdings in Omnicell Inc by 37.65%. The purchase prices were between $31.2 and $37.95, with an estimated average price of $34.4. The stock is now traded at around $36.25. The impact to the portfolio due to this purchase was 0.04%. The holdings were 128,723 shares as of 2016-12-31.
Added: CoreCivic Inc (CXW)
Mondrian Investment Partners LTD added to the holdings in CoreCivic Inc by 47.48%. The purchase prices were between $13.18 and $25.38, with an estimated average price of $19.07. The stock is now traded at around $29.44. The impact to the portfolio due to this purchase was 0.04%. The holdings were 165,035 shares as of 2016-12-31.
Added: US Ecology Inc (ECOL)
Mondrian Investment Partners LTD added to the holdings in US Ecology Inc by 79.08%. The purchase prices were between $39.25 and $49.6, with an estimated average price of $45.19. The stock is now traded at around $52.75. The impact to the portfolio due to this purchase was 0.04%. The holdings were 73,461 shares as of 2016-12-31.
Sold Out: Grupo Aeroportuario del Pacifico SAB de CV (PAC)
Mondrian Investment Partners LTD sold out the holdings in Grupo Aeroportuario del Pacifico SAB de CV. The sale prices were between $78.43 and $104.65, with an estimated average price of $90.23.
Sold Out: BanColombia SA (CIB)
Mondrian Investment Partners LTD sold out the holdings in BanColombia SA. The sale prices were between $32.49 and $39.15, with an estimated average price of $36.53.
Sold Out: United Breweries Co Inc (CCU)
Mondrian Investment Partners LTD sold out the holdings in United Breweries Co Inc. The sale prices were between $19.83 and $21.72, with an estimated average price of $20.58.
Sold Out: Yum China Holdings Inc (YUMC)
Mondrian Investment Partners LTD sold out the holdings in Yum China Holdings Inc. The sale prices were between $24.25 and $29.98, with an estimated average price of $26.73.
Sold Out: Dell Technologies Inc (DVMT)
Mondrian Investment Partners LTD sold out the holdings in Dell Technologies Inc. The sale prices were between $46.72 and $57.29, with an estimated average price of $51.07.
Sold Out: G & K Services Inc (GK)
Mondrian Investment Partners LTD sold out the holdings in G & K Services Inc. The sale prices were between $94.38 and $96.77, with an estimated average price of $95.63.
Reduced: BCE Inc (BCE)
Mondrian Investment Partners LTD reduced to the holdings in BCE Inc by 99.98%. The sale prices were between $42.03 and $46.17, with an estimated average price of $44.14. The stock is now traded at around $44.00. The impact to the portfolio due to this sale was -3.75%. Mondrian Investment Partners LTD still held 458 shares as of 2016-12-31.
Reduced: Credicorp Ltd ( BAP )
Mondrian Investment Partners LTD reduced to the holdings in Credicorp Ltd by 28.94%. The sale prices were between $145.23 and $163.1, with an estimated average price of $153.16. The stock is now traded at around $163.38. The impact to the portfolio due to this sale was -2.14%. Mondrian Investment Partners LTD still held 1,407,843 shares as of 2016-12-31.
Reduced: Abbott Laboratories ( ABT )
Mondrian Investment Partners LTD reduced to the holdings in Abbott Laboratories by 26.35%. The sale prices were between $37.6 and $43.5, with an estimated average price of $39.65. The stock is now traded at around $42.75. The impact to the portfolio due to this sale was -1.91%. Mondrian Investment Partners LTD still held 5,158,314 shares as of 2016-12-31.
Reduced: Johnson & Johnson (JNJ)
Mondrian Investment Partners LTD reduced to the holdings in Johnson & Johnson by 99.88%. The sale prices were between $110.99 and $120.31, with an estimated average price of $115.51. The stock is now traded at around $113.10. The impact to the portfolio due to this sale was -1.17%. Mondrian Investment Partners LTD still held 500 shares as of 2016-12-31.
Reduced: Mastercard Inc (MA)
Mondrian Investment Partners LTD reduced to the holdings in Mastercard Inc by 38.49%. The sale prices were between $100.18 and $107.02, with an estimated average price of $103.52. The stock is now traded at around $106.04. The impact to the portfolio due to this sale was -1.03%. Mondrian Investment Partners LTD still held 660,253 shares as of 2016-12-31.
Reduced: Microsoft Corp (MSFT)
Mondrian Investment Partners LTD reduced to the holdings in Microsoft Corp by 21.3%. The sale prices were between $56.92 and $63.62, with an estimated average price of $60.15. The stock is now traded at around $63.31. The impact to the portfolio due to this sale was -0.73%. Mondrian Investment Partners LTD still held 1,903,212 shares as of 2016-12-31.
Warning! GuruFocus has detected 5 Warning Sign with WFC. Click here to check it out.
WFC 15-Year Financial Data
The intrinsic value of WFC
Peter Lynch Chart of WFC
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Mondrian Investment Partners LTD New Purchases: SKM , VEDL , AA , AAPL, ARNC, CYD, Added Positions:PHI, WFC, PFE, WBA, CCK, C, INFY, AAC, ECOL, CXW, Reduced Positions:BCE, BAP, ABT, JNJ, MA, MSFT, PG, CAE, YUM, RBA, Sold Out:PAC, CIB, CCU, YUMC, DVMT, CLC, GK, For the details of Mondrian Investment Partners LTD's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Mondrian+Investment+Partners+LTD These are the top 5 holdings of Mondrian Investment Partners LTD CAE Inc ( CAE ) - 14,798,688 shares, 8.03% of the total portfolio. Shares reduced by 28.94% Abbott Laboratories ( ABT ) - 5,158,314 shares, 5.72% of the total portfolio. Reduced: Abbott Laboratories ( ABT ) Mondrian Investment Partners LTD reduced to the holdings in Abbott Laboratories by 26.35%. | Mondrian Investment Partners LTD New Purchases: SKM , VEDL , AA , AAPL, ARNC, CYD, Added Positions:PHI, WFC, PFE, WBA, CCK, C, INFY, AAC, ECOL, CXW, Reduced Positions:BCE, BAP, ABT, JNJ, MA, MSFT, PG, CAE, YUM, RBA, Sold Out:PAC, CIB, CCU, YUMC, DVMT, CLC, GK, For the details of Mondrian Investment Partners LTD's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Mondrian+Investment+Partners+LTD These are the top 5 holdings of Mondrian Investment Partners LTD CAE Inc ( CAE ) - 14,798,688 shares, 8.03% of the total portfolio. Shares reduced by 28.94% Abbott Laboratories ( ABT ) - 5,158,314 shares, 5.72% of the total portfolio. Reduced: Abbott Laboratories ( ABT ) Mondrian Investment Partners LTD reduced to the holdings in Abbott Laboratories by 26.35%. | Mondrian Investment Partners LTD New Purchases: SKM , VEDL , AA , AAPL, ARNC, CYD, Added Positions:PHI, WFC, PFE, WBA, CCK, C, INFY, AAC, ECOL, CXW, Reduced Positions:BCE, BAP, ABT, JNJ, MA, MSFT, PG, CAE, YUM, RBA, Sold Out:PAC, CIB, CCU, YUMC, DVMT, CLC, GK, For the details of Mondrian Investment Partners LTD's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Mondrian+Investment+Partners+LTD These are the top 5 holdings of Mondrian Investment Partners LTD CAE Inc ( CAE ) - 14,798,688 shares, 8.03% of the total portfolio. Shares reduced by 28.94% Abbott Laboratories ( ABT ) - 5,158,314 shares, 5.72% of the total portfolio. Reduced: Abbott Laboratories ( ABT ) Mondrian Investment Partners LTD reduced to the holdings in Abbott Laboratories by 26.35%. | Mondrian Investment Partners LTD New Purchases: SKM , VEDL , AA , AAPL, ARNC, CYD, Added Positions:PHI, WFC, PFE, WBA, CCK, C, INFY, AAC, ECOL, CXW, Reduced Positions:BCE, BAP, ABT, JNJ, MA, MSFT, PG, CAE, YUM, RBA, Sold Out:PAC, CIB, CCU, YUMC, DVMT, CLC, GK, For the details of Mondrian Investment Partners LTD's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Mondrian+Investment+Partners+LTD These are the top 5 holdings of Mondrian Investment Partners LTD CAE Inc ( CAE ) - 14,798,688 shares, 8.03% of the total portfolio. Shares reduced by 28.94% Abbott Laboratories ( ABT ) - 5,158,314 shares, 5.72% of the total portfolio. Reduced: Abbott Laboratories ( ABT ) Mondrian Investment Partners LTD reduced to the holdings in Abbott Laboratories by 26.35%. |
33687.0 | 2017-02-02 00:00:00 UTC | Noteworthy ETF Outflows: IWB, PG, CSCO, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-iwb-pg-csco-abt-2017-02-02 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $25.4 million dollar outflow -- that's a 0.1% decrease week over week (from 134,500,000 to 134,300,000). Among the largest underlying components of IWB, in trading today Procter & Gamble Co. (Symbol: PG) is up about 0.6%, Cisco Systems Inc (Symbol: CSCO) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average:
Looking at the chart above, IWB's low point in its 52 week range is $99.92 per share, with $128.13 as the 52 week high point - that compares with a last trade of $126.80. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWB, in trading today Procter & Gamble Co. (Symbol: PG) is up about 0.6%, Cisco Systems Inc (Symbol: CSCO) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $99.92 per share, with $128.13 as the 52 week high point - that compares with a last trade of $126.80. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWB, in trading today Procter & Gamble Co. (Symbol: PG) is up about 0.6%, Cisco Systems Inc (Symbol: CSCO) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $99.92 per share, with $128.13 as the 52 week high point - that compares with a last trade of $126.80. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWB, in trading today Procter & Gamble Co. (Symbol: PG) is up about 0.6%, Cisco Systems Inc (Symbol: CSCO) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $25.4 million dollar outflow -- that's a 0.1% decrease week over week (from 134,500,000 to 134,300,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $99.92 per share, with $128.13 as the 52 week high point - that compares with a last trade of $126.80. | Among the largest underlying components of IWB, in trading today Procter & Gamble Co. (Symbol: PG) is up about 0.6%, Cisco Systems Inc (Symbol: CSCO) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $25.4 million dollar outflow -- that's a 0.1% decrease week over week (from 134,500,000 to 134,300,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $99.92 per share, with $128.13 as the 52 week high point - that compares with a last trade of $126.80. |
33688.0 | 2017-02-01 00:00:00 UTC | After Hours Most Active for Feb 1, 2017 : FB, LOGM, TGI, GE, QQQ, PFE, WFT, BIVVV, CSCO, AAPL, ABT, SYF | ABT | https://www.nasdaq.com/articles/after-hours-most-active-feb-1-2017-fb-logm-tgi-ge-qqq-pfe-wft-bivvv-csco-aapl-abt-syf-2017 | nan | nan | The NASDAQ 100 After Hours Indicator is up 4.28 to 5,156.97. The total After hours volume is currently 47,904,385 shares traded.
The following are the most active stocks for the after hours session :
Facebook, Inc. ( FB ) is +2.87 at $136.10, with 6,766,935 shares traded. Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2016. The consensus EPS forecast is $1.13. Market Realist Reports: What's Twitter Doing about Trolling?
LogMein, Inc. ( LOGM ) is unchanged at $106.60, with 6,124,848 shares traded. LOGM's current last sale is 96.04% of the target price of $111.
Triumph Group, Inc. ( TGI ) is +0.1 at $27.50, with 4,493,057 shares traded.TGI is scheduled to provide an earnings report on 2/2/2017, for the fiscal quarter ending Dec2016. The consensus earnings per share forecast is 1.24 per share, which represents a 139 percent increase over the EPS one Year Ago
General Electric Company ( GE ) is -0.02 at $29.67, with 2,519,652 shares traded. As reported by Zacks, the current mean recommendation for GE is in the "buy range".
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.08 at $125.51, with 1,541,064 shares traded. This represents a 32.34% increase from its 52 Week Low.
Pfizer, Inc. ( PFE ) is unchanged at $31.67, with 1,533,551 shares traded. PFE's current last sale is 83.34% of the target price of $38.
Weatherford International plc ( WFT ) is unchanged at $5.18, with 1,527,530 shares traded. Seeking Alpha Reports: Weatherford: Crisis Value
Bioverativ Inc. ( BIVVV ) is +0.95 at $45.40, with 1,203,150 shares traded.
Cisco Systems, Inc. ( CSCO ) is unchanged at $30.50, with 1,168,104 shares traded. As reported by Zacks, the current mean recommendation for CSCO is in the "buy range".
Apple Inc. ( AAPL ) is +0.15 at $128.90, with 1,124,649 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2017. The consensus EPS forecast is $1.85. , following a 52-week high recorded in today's regular session.
Abbott Laboratories ( ABT ) is unchanged at $42.33, with 1,062,372 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2017. The consensus EPS forecast is $0.68. As reported by Zacks, the current mean recommendation for ABT is in the "buy range".
Synchrony Financial ( SYF ) is unchanged at $36.00, with 781,708 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2017. The consensus EPS forecast is $0.73. As reported by Zacks, the current mean recommendation for SYF is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is unchanged at $42.33, with 1,062,372 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The following are the most active stocks for the after hours session : Facebook, Inc. ( FB ) is +2.87 at $136.10, with 6,766,935 shares traded. | Abbott Laboratories ( ABT ) is unchanged at $42.33, with 1,062,372 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The consensus earnings per share forecast is 1.24 per share, which represents a 139 percent increase over the EPS one Year Ago General Electric Company ( GE ) is -0.02 at $29.67, with 2,519,652 shares traded. | Abbott Laboratories ( ABT ) is unchanged at $42.33, with 1,062,372 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". LogMein, Inc. ( LOGM ) is unchanged at $106.60, with 6,124,848 shares traded. | Abbott Laboratories ( ABT ) is unchanged at $42.33, with 1,062,372 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The NASDAQ 100 After Hours Indicator is up 4.28 to 5,156.97. |
33689.0 | 2017-01-30 00:00:00 UTC | Health Care Sector Update for 01/30/2017: JNJ, PFE, ABT, MRK, AMGN, OCRX, CALA, EYEG | ABT | https://www.nasdaq.com/articles/health-care-sector-update-01302017-jnj-pfe-abt-mrk-amgn-ocrx-cala-eyeg-2017-01-30 | nan | nan | Top Health Care stocks:
JNJ: -0.3%
PFE: -0.7%
ABT: -0.1%
MRK: -1%
AMGN: -1.7%
Health care shares were lower at mid-day Monday.
In health care stocks news, Calithera Biosciences ( CALA ) shares surged 52.2% after it and Incyte ( INCY ) said Monday they struck a global collaboration and license agreement for the research, development and commercialization of Calithera's small molecule arginase inhibitor CB-1158 in hematology and oncology.
CB-1158 is currently being studied in a monotherapy dose escalation trial and additional studies are expected to evaluate CB-1158 in combination with immuno-oncology agents, including anti-PD-1 therapy.
Under the agreement, Calithera will receive an up-front payment of $45 million plus a $8 million equity investment from Incyte. Incyte will buy shares at a price of $4.65 each. Incyte will also receive worldwide rights to develop and commercialize CB-1158 in hematology and oncology; Calithera will retain certain rights to research, develop and commercialize certain other arginase inhibitors in certain orphan indications.
In other sector news,
(+) EYEG, (+13.9%) Reports 75% of subjects in pilot trial of its ocular bandage gel achieved complete wound closure by day three
(-) OCRX, (-68.3%) Says phase 2b study of intravenously-administered ornithine phenylacetate (OCR-002) did not show statistically significant results in the primary and secondary endpoints
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Calithera Biosciences ( CALA ) shares surged 52.2% after it and Incyte ( INCY ) said Monday they struck a global collaboration and license agreement for the research, development and commercialization of Calithera's small molecule arginase inhibitor CB-1158 in hematology and oncology. Incyte will also receive worldwide rights to develop and commercialize CB-1158 in hematology and oncology; Calithera will retain certain rights to research, develop and commercialize certain other arginase inhibitors in certain orphan indications. In other sector news, (+) EYEG, (+13.9%) Reports 75% of subjects in pilot trial of its ocular bandage gel achieved complete wound closure by day three (-) OCRX, (-68.3%) Says phase 2b study of intravenously-administered ornithine phenylacetate (OCR-002) did not show statistically significant results in the primary and secondary endpoints The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Calithera Biosciences ( CALA ) shares surged 52.2% after it and Incyte ( INCY ) said Monday they struck a global collaboration and license agreement for the research, development and commercialization of Calithera's small molecule arginase inhibitor CB-1158 in hematology and oncology. Incyte will also receive worldwide rights to develop and commercialize CB-1158 in hematology and oncology; Calithera will retain certain rights to research, develop and commercialize certain other arginase inhibitors in certain orphan indications. In other sector news, (+) EYEG, (+13.9%) Reports 75% of subjects in pilot trial of its ocular bandage gel achieved complete wound closure by day three (-) OCRX, (-68.3%) Says phase 2b study of intravenously-administered ornithine phenylacetate (OCR-002) did not show statistically significant results in the primary and secondary endpoints The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Calithera Biosciences ( CALA ) shares surged 52.2% after it and Incyte ( INCY ) said Monday they struck a global collaboration and license agreement for the research, development and commercialization of Calithera's small molecule arginase inhibitor CB-1158 in hematology and oncology. Incyte will also receive worldwide rights to develop and commercialize CB-1158 in hematology and oncology; Calithera will retain certain rights to research, develop and commercialize certain other arginase inhibitors in certain orphan indications. In other sector news, (+) EYEG, (+13.9%) Reports 75% of subjects in pilot trial of its ocular bandage gel achieved complete wound closure by day three (-) OCRX, (-68.3%) Says phase 2b study of intravenously-administered ornithine phenylacetate (OCR-002) did not show statistically significant results in the primary and secondary endpoints The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were lower at mid-day Monday. In health care stocks news, Calithera Biosciences ( CALA ) shares surged 52.2% after it and Incyte ( INCY ) said Monday they struck a global collaboration and license agreement for the research, development and commercialization of Calithera's small molecule arginase inhibitor CB-1158 in hematology and oncology. Incyte will also receive worldwide rights to develop and commercialize CB-1158 in hematology and oncology; Calithera will retain certain rights to research, develop and commercialize certain other arginase inhibitors in certain orphan indications. |
33690.0 | 2017-01-30 00:00:00 UTC | Analysts Expect IHI To Hit $156 | ABT | https://www.nasdaq.com/articles/analysts-expect-ihi-hit-156-2017-01-30 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Medical Devices ETF (Symbol: IHI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $155.71 per unit.
With IHI trading at a recent price near $140.53 per unit, that means that analysts see 10.80% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IHI's underlying holdings with notable upside to their analyst target prices are Omnicell Inc (Symbol: OMCL), Nevro Corp (Symbol: NVRO), and Abbott Laboratories (Symbol: ABT). Although OMCL has traded at a recent price of $35.75/share, the average analyst target is 22.61% higher at $43.83/share. Similarly, NVRO has 22.55% upside from the recent share price of $83.70 if the average analyst target price of $102.57/share is reached, and analysts on average are expecting ABT to reach a target price of $47.50/share, which is 15.85% above the recent price of $41.00. Below is a twelve month price history chart comparing the stock performance of OMCL, NVRO, and ABT:
Combined, OMCL, NVRO, and ABT represent 10.34% of the iShares U.S. Medical Devices ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of OMCL, NVRO, and ABT: Combined, OMCL, NVRO, and ABT represent 10.34% of the iShares U.S. Medical Devices ETF. Three of IHI's underlying holdings with notable upside to their analyst target prices are Omnicell Inc (Symbol: OMCL), Nevro Corp (Symbol: NVRO), and Abbott Laboratories (Symbol: ABT). Similarly, NVRO has 22.55% upside from the recent share price of $83.70 if the average analyst target price of $102.57/share is reached, and analysts on average are expecting ABT to reach a target price of $47.50/share, which is 15.85% above the recent price of $41.00. | Three of IHI's underlying holdings with notable upside to their analyst target prices are Omnicell Inc (Symbol: OMCL), Nevro Corp (Symbol: NVRO), and Abbott Laboratories (Symbol: ABT). Similarly, NVRO has 22.55% upside from the recent share price of $83.70 if the average analyst target price of $102.57/share is reached, and analysts on average are expecting ABT to reach a target price of $47.50/share, which is 15.85% above the recent price of $41.00. Below is a twelve month price history chart comparing the stock performance of OMCL, NVRO, and ABT: Combined, OMCL, NVRO, and ABT represent 10.34% of the iShares U.S. Medical Devices ETF. | Similarly, NVRO has 22.55% upside from the recent share price of $83.70 if the average analyst target price of $102.57/share is reached, and analysts on average are expecting ABT to reach a target price of $47.50/share, which is 15.85% above the recent price of $41.00. Three of IHI's underlying holdings with notable upside to their analyst target prices are Omnicell Inc (Symbol: OMCL), Nevro Corp (Symbol: NVRO), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of OMCL, NVRO, and ABT: Combined, OMCL, NVRO, and ABT represent 10.34% of the iShares U.S. Medical Devices ETF. | Below is a twelve month price history chart comparing the stock performance of OMCL, NVRO, and ABT: Combined, OMCL, NVRO, and ABT represent 10.34% of the iShares U.S. Medical Devices ETF. Three of IHI's underlying holdings with notable upside to their analyst target prices are Omnicell Inc (Symbol: OMCL), Nevro Corp (Symbol: NVRO), and Abbott Laboratories (Symbol: ABT). Similarly, NVRO has 22.55% upside from the recent share price of $83.70 if the average analyst target price of $102.57/share is reached, and analysts on average are expecting ABT to reach a target price of $47.50/share, which is 15.85% above the recent price of $41.00. |
33691.0 | 2017-01-30 00:00:00 UTC | After Hours Most Active for Jan 30, 2017 : VREX, ABT, BAC, F, CMCSA, TXN, SWN, SSI, GE, QQQ, YHOO, HBAN | ABT | https://www.nasdaq.com/articles/after-hours-most-active-jan-30-2017-vrex-abt-bac-f-cmcsa-txn-swn-ssi-ge-qqq-yhoo-hban-2017 | nan | nan | The NASDAQ 100 After Hours Indicator is down -.26 to 5,129.07. The total After hours volume is currently 43,370,780 shares traded.
The following are the most active stocks for the after hours session :
Varex Imaging Corporation ( VREX ) is -2.27 at $25.00, with 4,022,379 shares traded.
Abbott Laboratories ( ABT ) is unchanged at $41.01, with 2,916,345 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2017. The consensus EPS forecast is $0.67. As reported by Zacks, the current mean recommendation for ABT is in the "buy range".
Bank of America Corporation ( BAC ) is unchanged at $22.95, with 2,568,402 shares traded. Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017. The consensus EPS forecast is $0.35. As reported by Zacks, the current mean recommendation for BAC is in the "buy range".
Ford Motor Company ( F ) is unchanged at $12.37, with 2,101,198 shares traded. F's current last sale is 88.36% of the target price of $14.
Comcast Corporation ( CMCSA ) is unchanged at $75.34, with 1,960,966 shares traded. As reported by Zacks, the current mean recommendation for CMCSA is in the "buy range".
Texas Instruments Incorporated ( TXN ) is -0.01 at $77.89, with 1,643,502 shares traded. Over the last four weeks they have had 12 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017. The consensus EPS forecast is $0.83. TXN's current last sale is 97.36% of the target price of $80.
Southwestern Energy Company ( SWN ) is unchanged at $9.13, with 1,391,067 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017. The consensus EPS forecast is $0.27. SWN's current last sale is 65.21% of the target price of $14.
Stage Stores, Inc. ( SSI ) is unchanged at $2.80, with 1,303,640 shares traded. SSI's current last sale is 112% of the target price of $2.5.
General Electric Company ( GE ) is unchanged at $29.96, with 1,188,467 shares traded. As reported by Zacks, the current mean recommendation for GE is in the "buy range".
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.03 at $124.85, with 1,097,419 shares traded. This represents a 31.64% increase from its 52 Week Low.
Yahoo! Inc. ( YHOO ) is unchanged at $43.93, with 1,064,048 shares traded. YHOO's current last sale is 99.84% of the target price of $44.
Huntington Bancshares Incorporated ( HBAN ) is unchanged at $13.62, with 1,018,968 shares traded. HBAN's current last sale is 93.93% of the target price of $14.5.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is unchanged at $41.01, with 2,916,345 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The following are the most active stocks for the after hours session : Varex Imaging Corporation ( VREX ) is -2.27 at $25.00, with 4,022,379 shares traded. | Abbott Laboratories ( ABT ) is unchanged at $41.01, with 2,916,345 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017. | Abbott Laboratories ( ABT ) is unchanged at $41.01, with 2,916,345 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017. | Abbott Laboratories ( ABT ) is unchanged at $41.01, with 2,916,345 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The NASDAQ 100 After Hours Indicator is down -.26 to 5,129.07. |
33692.0 | 2017-01-27 00:00:00 UTC | Nutritional Segment Subdues Abbott's Q4'16 Growth, But Future Growth Prospects Remain Strong | ABT | https://www.nasdaq.com/articles/nutritional-segment-subdues-abbotts-q416-growth-future-growth-prospects-remain-strong-2017 | nan | nan | Abbott Laboratories ( ABT ) reported its results for Q4 2016 on January 25th. The company's sales in the quarter grew by 2.8 percent on a reported basis and 3.8 percent on an operating basis. Abbott's results in the quarter were subdued by a 3.7 percent decline in its nutritional segment revenues, which constitute roughly one-third of its overall revenues. This was primarily because of the challenges faced by its pediatric nutrition business in China. However, the company saw healthy growth across all other segments. Furthermore, the company completed the St. Jude acquisition in this quarter, which it anticipates will result in annual pre-tax synergies of $500 million by 2020. Additionally, Abbott launched a couple of products in the diagnostics segment, which is likely to have a positive impact on its top-line in the coming quarters.
We are in the process of updating our model for Abbott Labs
See our complete analysis for Abbott Labs
Near-Term Challenges To Continue To Affect Nutritional Segment Growth
At $1.7 billion, Abbott's worldwide nutritional sales decreased by 3.7 percent in Q1. Nutritional sales in this quarter were negatively impacted by a decline in pediatric nutrition revenues. The nutrition market is witnessing an oversupply situation in China caused by local players in the region in the wake of government's decision to implement new safety regulations. These players are offering significant discounts on their nutritional products to clear their inventory before the new safety regulation is implemented. For these reasons, the company appears to be losing nutritional segment market share in China to local label bands. Another reason for the weak performance is the shift in the sales channel to e-commerce, an area in which Abbott lags. According to the company, the transition to this new sales channel is not likely to be quick, and can weigh on its nutritional sales in the near term. Going ahead, we can expect the growth from the sales of PediaSure toddler brand and the first formula in the U.S. with a human milk oligosaccharide to partially offset the decline from China.
New Product Launches In Diagnostics To Drive International Growth
Abbott's witnessed 2.9 percent growth from its diagnostics sales, which was primarily led by its growth in Point-of-Care diagnostics and Core Laboratory diagnostics. The company saw its Point-of-Care revenues grow by 8.5 percent in the quarter, which was driven by strong adoption of the i-STAT handheld system in the U.S. and internationally. Furthermore, Abbott obtained CE mark for four new major diagnostics systems, which include "AlinityTM s" for blood and plasma screening, "Alinity i" for immunoassay diagnostics, "Alinity c" for clinical chemistry diagnostics and "i-STAT Alinity" for point of care blood testing. The approval of these products should result in incremental sales for the company in future quarters.
Medical Device Business Growth Driven By FreeStyle Libre; Abbott Now A Market Leader In CRM Market
Abbott's medical device revenues increased 4.4 percent in the quarter, which was led by its diabetes segment. The diabetes segment witnessed double-digit growth in international sales, primarily led by the strong adoption of FreeStyle Libre, which is continuous glucose monitoring system, eliminating the need for finger-sticks. Furthermore, Abbott completed the acquisition of St. Jude, which marks its entrance into the large cardiac rhythm management market. This acquistion will help Abbott in competing effectively against rivals, Medtronic and Boston Scientific. According to Abbott, the combined company will likely be a market leader in most of the areas of the large cardiac rhythm management market. Furthermore, the company anticipates realizing annual pre-tax synergies of $500 million by 2020, which include both revenue and cost synergies.
Please let us know your views by commenting in the box below.
See More at Trefis |View Interactive Institutional Research(Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) reported its results for Q4 2016 on January 25th. The nutrition market is witnessing an oversupply situation in China caused by local players in the region in the wake of government's decision to implement new safety regulations. Going ahead, we can expect the growth from the sales of PediaSure toddler brand and the first formula in the U.S. with a human milk oligosaccharide to partially offset the decline from China. | Abbott Laboratories ( ABT ) reported its results for Q4 2016 on January 25th. New Product Launches In Diagnostics To Drive International Growth Abbott's witnessed 2.9 percent growth from its diagnostics sales, which was primarily led by its growth in Point-of-Care diagnostics and Core Laboratory diagnostics. Medical Device Business Growth Driven By FreeStyle Libre; Abbott Now A Market Leader In CRM Market Abbott's medical device revenues increased 4.4 percent in the quarter, which was led by its diabetes segment. | Abbott Laboratories ( ABT ) reported its results for Q4 2016 on January 25th. We are in the process of updating our model for Abbott Labs See our complete analysis for Abbott Labs Near-Term Challenges To Continue To Affect Nutritional Segment Growth At $1.7 billion, Abbott's worldwide nutritional sales decreased by 3.7 percent in Q1. New Product Launches In Diagnostics To Drive International Growth Abbott's witnessed 2.9 percent growth from its diagnostics sales, which was primarily led by its growth in Point-of-Care diagnostics and Core Laboratory diagnostics. | Abbott Laboratories ( ABT ) reported its results for Q4 2016 on January 25th. Furthermore, the company completed the St. Jude acquisition in this quarter, which it anticipates will result in annual pre-tax synergies of $500 million by 2020. Nutritional sales in this quarter were negatively impacted by a decline in pediatric nutrition revenues. |
33693.0 | 2017-01-25 00:00:00 UTC | Abbott Labs (ABT) Tops Q4 Earnings Estimates, Sales In Line | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-tops-q4-earnings-estimates-sales-in-line-2017-01-25 | nan | nan | Abbott LaboratoriesABT reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate and up 4.8% year over year.
Full-year 2016 adjusted earnings came in at $2.20 per share, in line with the Zacks Consensus Estimate. However, it remained ahead of the year-ago number by 2.3%.
Fourth-quarter sales came in at $5.33 billion, up 2.8% year over year on a reported basis. The quarterly figure is almost in line with the Zacks Consensus Estimate. The top line was, however, impacted 1% by unfavorable foreign exchange movement.
Worldwide sales for the full year came in at $20.85 billion, up 2.2% year over year on a reported basis. However, the figure is nearly in line with the Zacks Consensus Estimate.
Quarter in Detail
Abbott Labs operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote
EPD sales were up 10.6% on a reported basis to $979 billion. There was a negative impact of 2% due to currency fluctuations. Sales in key emerging markets increased 10.6% driven by double-digit growth in BRIC that comprises approximately 45% of Abbott's Established Pharmaceuticals sales, as well as strong growth in several countries throughout Latin America, including Colombia, Mexico, Peru and Argentina.
The Medical Devices business generated sales of $1.35 billion, up 4.2% year over year on a reported basis. Vascular product sales were up 2.9% on the back of double-digit growth in MitraClip. Also strong sales growth in Abbott's Endovascular business was driven by vessel closure products and Supera.
Diabetes Care sales increased 4.5% on a reported basis (there was unfavorable 1.5% effect of foreign exchange),driven by continued consumer uptake of FreeStyle Libre. Sales of Medical Optics were up 7.7% on a reported basis (there was a favorable 0.8% effect of foreign exchange),backed by the recent launch of the Tecnis Symfony intraocular lenses in the U.S.
Nutrition sales decreased 3.7% year over year on a reported basis to $1.73 billion. Unfavorable foreign exchange impacted sales by 1.1%. Pediatric Nutrition sales decreased 5.4% on a reported basis. Adult Nutrition sales decreased 1.4% on a reported basis led by year-over-year difficult comparison of Ensure.
Diagnostics sales increased 2.9% year over year to $1.26 billion. While Core Laboratory sales increased 3.6%, Point of Care Diagnostics sales increased 8.1% on a reported basis. Molecular Diagnostics sales were down 7.6% as growth in the infectious disease testing business was partially offset by the planned scale-down of the genetics business.
2017 Guidance
Abbott Labs provided full-year 2017 guidance. The company currently forecasts earnings per share from continuing operations to remain within the range of 92 cents to $1.02. Adjusting certain net specified items for the full year of approximately $1.48 per share, adjusted earnings per share from continuing operations is expected to stay within the range of $2.40 to $2.50. The current Zacks Consensus Estimate is pegged at $2.54, at the midpoint of the projected range.
The company has also provided its first-quarter 2017 earnings per share guidance. Excluding certain specified items of 23 cents a share, projected adjusted earnings per share from continuing operations is expected to remain within 42 cents and 44 cents for the first quarter. The current Zacks Consensus Estimate remains at 50 cents a share for the first quarter, ahead of the forecasted range.
Our Take
We believe the strong performance of the EPD and Medical Devices segments were to some extent offset by sluggish Nutrition business.
The company also stands to benefit from the recently completed acquisition of St. Jude Medical, which will offer it an industry leading pipeline across cardiovascular, neuromodulation, diabetes and vision care.
Moreover, the sale of Abbott Medical Optics to Johnson & Johnson will help Abbott in reshaping its portfolio in order to focus on gaining leadership positions in cardiovascular devices and expanding diagnostics.
Abbott Labs currently carries a Zacks Rank #3 (Hold).
Stocks to Consider
Some better- ranked medical stocks include Cardiovascular Systems, Inc. CSII , Neogen Corp. NEOG and OraSure Technologies, Inc. OSUR . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Cardiovascular Systems rallied 179.7% in the past one year, way higher than the S&P 500's 19.77% gain. It has a positive average earnings surprise of 31.8%.
Neogen gained 22.7% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth of 16.7% for the next five years compared with the industry average of 15.2%.
OraSure Technologies surged 51.2% in the last one year, compared to the S&P 500. The company has a stellar four-quarter average earnings surprise of over 100%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report
Neogen Corporation (NEOG): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate and up 4.8% year over year. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Neogen Corporation (NEOG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Diabetes Care sales increased 4.5% on a reported basis (there was unfavorable 1.5% effect of foreign exchange),driven by continued consumer uptake of FreeStyle Libre. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Neogen Corporation (NEOG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate and up 4.8% year over year. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote EPD sales were up 10.6% on a reported basis to $979 billion. | Abbott LaboratoriesABT reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate and up 4.8% year over year. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Neogen Corporation (NEOG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote EPD sales were up 10.6% on a reported basis to $979 billion. | Abbott LaboratoriesABT reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate and up 4.8% year over year. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Neogen Corporation (NEOG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Fourth-quarter sales came in at $5.33 billion, up 2.8% year over year on a reported basis. |
33694.0 | 2017-01-25 00:00:00 UTC | Abbott Laboratories (ABT): Tops Q4 Earnings, Sales in Line | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt%3A-tops-q4-earnings-sales-in-line-2017-01-25 | nan | nan | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. The company has reshaped its portfolio through strategic acquisitions/divestitures in recent times. It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R&D, which has resulted in numerous new product launches across its businesses.
In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters. However, unfavorable movement in foreign currency rates is affecting the top line adversely.
Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 3.07%.
Currently, Abbott Labs has a Zacks Rank #3 (Hold), but that could definitely change following the company's fourth quarter 2016 earnings report which was just released. (You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. ) We have highlighted some of the key stats from this just-revealed announcement below:
Earnings : The Zacks Consensus Estimate remained steady at 64 per share over the last 60 days. Abbott Labs' fourth quarter 2016 earnings per share from continuing operations of 65 cents beat this estimate bya penny and up 4.83% year over year.
Full year adjusted earnings came in at $2.20 per share which is in line with the Zacks Consensus Estimate.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Revenues : Abbott Labs posted fourth quarter revenues of $5.33 billion which is closely in line with the Zacks Consensus Estimate for revenues of $5.36 billion.
Full year revenues came in at $20.85 billion which is nearly in line with the Zacks Consensus Estimate of $20.90 billion.
Key Stats: Worldwide Nutrition sales decreased 3.7% on a reported basis in the fourth quarter to $1.73 billion while worldwide Diagnostics sales increased 2.9% on a reported basis to $1.25 billion while total Established Pharmaceuticals sales increased 10.6% on a reported basis to $979 million. Revenues of Worldwide Medical Devices increased 4.4% on a reported basis to $5.23 billion.
Major Factors: Per management, in the fourth quarter, Abbott obtained CE Mark for four new major diagnostics systems which have reflected in the quarterly results. Management has also issued full-year 2017 guidance range for reported EPS from continuing operations in the range of $0.92-$1.02, including intangible amortization and integration expenses related to the acquisition of St. Jude Medical. It has also issued full-year 2017 adjusted EPS from continuing operations in the band of $2.40-$2.50.
Stock Price: Following the earnings release, share prices dropped 0.77% during the pre-market trading session.
Check back later for our full write up on this Abbott Labs earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Abbott Labs has a Zacks Rank #3 (Hold), but that could definitely change following the company's fourth quarter 2016 earnings report which was just released. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Abbott Labs has a Zacks Rank #3 (Hold), but that could definitely change following the company's fourth quarter 2016 earnings report which was just released. |
33695.0 | 2017-01-25 00:00:00 UTC | Earnings Reaction History: Abbott Laboratories, 50.0% Follow-Through Indicator, 2.4% Sensitive | ABT | https://www.nasdaq.com/articles/earnings-reaction-history-abbott-laboratories-500-follow-through-indicator-24-sensitive-1 | nan | nan | Expected Earnings Release: 01/25/2017, Premarket
Avg. Extended-Hours Dollar Volume: $626,846
Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 37.5%
Average next regular session additional gain: 2.4%
Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 100%
Average next regular session additional loss: 2.7%
Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $626,846 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $626,846 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $626,846 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $626,846 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. |
33696.0 | 2017-01-25 00:00:00 UTC | Abbott Laboratories Gains Despite Unimpressive Q4 Revenue Results | ABT | https://www.nasdaq.com/articles/abbott-laboratories-gains-despite-unimpressive-q4-revenue-results-2017-01-25 | nan | nan | Abbott Laboratories ABT just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion.
ABT closed at a gain of $0.56 to $40.32 a shareafter its earnings report was released this morning.
Currently, ABT has a Zacks Rank #3 (Hold), but it is subject to change following the release of the company's latest earnings report. Here are 5 key statistics from this just announced report below.
Company:
Beat earnings estimates. The company posted earnings of $0.65 cents per share, beating our Zacks Consensus Estimate of $0.64. Zacks estimates excluded $0.12 from non-recurring items.
Underperformed revenue estimates. The company saw revenue figures of $5.33 billion, not meeting our estimate of $5.357 billion.
Abbott Laboratories reported that in their fourth quarter Pediatric Nutrition sales decreased by 5.4% and worldwide Adult Nutrition sales fell 1.4%, on a reported basis. H | ABT closed at a gain of $0.56 to $40.32 a shareafter its earnings report was released this morning. Currently, ABT has a Zacks Rank #3 (Hold), but it is subject to change following the release of the company's latest earnings report. Abbott Laboratories ABT just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion. | Abbott Laboratories ABT just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion. ABT closed at a gain of $0.56 to $40.32 a shareafter its earnings report was released this morning. Currently, ABT has a Zacks Rank #3 (Hold), but it is subject to change following the release of the company's latest earnings report. | Abbott Laboratories ABT just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion. Currently, ABT has a Zacks Rank #3 (Hold), but it is subject to change following the release of the company's latest earnings report. ABT closed at a gain of $0.56 to $40.32 a shareafter its earnings report was released this morning. | Abbott Laboratories ABT just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion. Currently, ABT has a Zacks Rank #3 (Hold), but it is subject to change following the release of the company's latest earnings report. ABT closed at a gain of $0.56 to $40.32 a shareafter its earnings report was released this morning. |
33697.0 | 2017-01-25 00:00:00 UTC | After Hours Most Active for Jan 25, 2017 : SYMC, EBAY, GE, FTI, SVA, QCOM, MSFT, ABT, BAC, MAT, NOK, KO | ABT | https://www.nasdaq.com/articles/after-hours-most-active-jan-25-2017-symc-ebay-ge-fti-sva-qcom-msft-abt-bac-mat-nok-ko-2017 | nan | nan | The NASDAQ 100 After Hours Indicator is down -1.34 to 5,150.13. The total After hours volume is currently 53,550,285 shares traded.
The following are the most active stocks for the after hours session :
Symantec Corporation ( SYMC ) is unchanged at $27.26, with 12,054,613 shares traded.SYMC is scheduled to provide an earnings report on 2/1/2017, for the fiscal quarter ending Dec2016. The consensus earnings per share forecast is 0.21 per share, which represents a 22 percent increase over the EPS one Year Ago
eBay Inc. ( EBAY ) is +2.18 at $32.41, with 1,458,586 shares traded. Smarter Analyst Reports: All Eyes on eBay Inc ( EBAY ) Ahead of Earnings Today
General Electric Company ( GE ) is unchanged at $30.37, with 1,290,328 shares traded. As reported by Zacks, the current mean recommendation for GE is in the "buy range".
TechnipFMC plc ( FTI ) is unchanged at $35.27, with 1,288,743 shares traded. FTI's current last sale is 99.35% of the target price of $35.5.
Sinovac Biotech, Ltd. ( SVA ) is -0.09 at $5.75, with 1,250,500 shares traded.
QUALCOMM Incorporated ( QCOM ) is -1.3 at $55.60, with 1,194,254 shares traded. Smarter Analyst Reports: All Eyes on QUALCOMM, Inc. ( QCOM ) Ahead of Earnings This Evening
Microsoft Corporation ( MSFT ) is +0.1 at $63.78, with 1,085,387 shares traded.MSFT is scheduled to provide an earnings report on 1/26/2017, for the fiscal quarter ending Dec2016. The consensus earnings per share forecast is 0.79 per share, which represents a 78 percent increase over the EPS one Year Ago
Abbott Laboratories ( ABT ) is unchanged at $40.31, with 1,072,354 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017. The consensus EPS forecast is $0.5. Seeking Alpha Reports: Amazon, Apple, And Netflix Versus Liberty
Bank of America Corporation ( BAC ) is unchanged at $23.37, with 943,463 shares traded. Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017. The consensus EPS forecast is $0.35. As reported by Zacks, the current mean recommendation for BAC is in the "buy range".
Mattel, Inc. ( MAT ) is -3.31 at $28.25, with 905,556 shares traded. As reported by Zacks, the current mean recommendation for MAT is in the "buy range".
Nokia Corporation ( NOK ) is unchanged at $4.62, with 789,858 shares traded. NOK's current last sale is 90.59% of the target price of $5.1.
Coca-Cola Company (The) ( KO ) is unchanged at $42.12, with 742,702 shares traded. KO's current last sale is 95.73% of the target price of $44.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The consensus earnings per share forecast is 0.79 per share, which represents a 78 percent increase over the EPS one Year Ago Abbott Laboratories ( ABT ) is unchanged at $40.31, with 1,072,354 shares traded. The following are the most active stocks for the after hours session : Symantec Corporation ( SYMC ) is unchanged at $27.26, with 12,054,613 shares traded.SYMC is scheduled to provide an earnings report on 2/1/2017, for the fiscal quarter ending Dec2016. Smarter Analyst Reports: All Eyes on QUALCOMM, Inc. ( QCOM ) Ahead of Earnings This Evening Microsoft Corporation ( MSFT ) is +0.1 at $63.78, with 1,085,387 shares traded.MSFT is scheduled to provide an earnings report on 1/26/2017, for the fiscal quarter ending Dec2016. | The consensus earnings per share forecast is 0.79 per share, which represents a 78 percent increase over the EPS one Year Ago Abbott Laboratories ( ABT ) is unchanged at $40.31, with 1,072,354 shares traded. The consensus earnings per share forecast is 0.21 per share, which represents a 22 percent increase over the EPS one Year Ago eBay Inc. ( EBAY ) is +2.18 at $32.41, with 1,458,586 shares traded. Smarter Analyst Reports: All Eyes on eBay Inc ( EBAY ) Ahead of Earnings Today General Electric Company ( GE ) is unchanged at $30.37, with 1,290,328 shares traded. | The consensus earnings per share forecast is 0.79 per share, which represents a 78 percent increase over the EPS one Year Ago Abbott Laboratories ( ABT ) is unchanged at $40.31, with 1,072,354 shares traded. The consensus earnings per share forecast is 0.21 per share, which represents a 22 percent increase over the EPS one Year Ago eBay Inc. ( EBAY ) is +2.18 at $32.41, with 1,458,586 shares traded. Smarter Analyst Reports: All Eyes on QUALCOMM, Inc. ( QCOM ) Ahead of Earnings This Evening Microsoft Corporation ( MSFT ) is +0.1 at $63.78, with 1,085,387 shares traded.MSFT is scheduled to provide an earnings report on 1/26/2017, for the fiscal quarter ending Dec2016. | The consensus earnings per share forecast is 0.79 per share, which represents a 78 percent increase over the EPS one Year Ago Abbott Laboratories ( ABT ) is unchanged at $40.31, with 1,072,354 shares traded. The NASDAQ 100 After Hours Indicator is down -1.34 to 5,150.13. Smarter Analyst Reports: All Eyes on QUALCOMM, Inc. ( QCOM ) Ahead of Earnings This Evening Microsoft Corporation ( MSFT ) is +0.1 at $63.78, with 1,085,387 shares traded.MSFT is scheduled to provide an earnings report on 1/26/2017, for the fiscal quarter ending Dec2016. |
33698.0 | 2017-01-25 00:00:00 UTC | 3 Dividend Aristocrats to Buy for Income and Growth | ABT | https://www.nasdaq.com/articles/3-dividend-aristocrats-to-buy-for-income-and-growth-2017-01-25 | nan | nan | InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips
I'm kind of down on dividend stocks these days. That's not because dividend stocks are a bad idea, it's just that the market is about 20% overvalued, and the rush to replace meager bond income resulted in dividend stocks being bid up too far. So that's why I prefer to stick with Dividend Aristocrats.
Source: Shutterstock
Dividend Aristocrats have a slight advantage over what might be characterized as your standard blue-chip stock, in that they have been raising dividends annually for over 25 years straight.
That speaks to a high degree of success in the business, of course, but it also speaks to ongoing growth. It means that free cash flow is likely expanding from year to year, thus permitting more of that cash flow to be paid out as a dividend.
10 High-Yield Dividend Stocks That Are SOMEHOW Still Bargains
So here are three Dividend Aristocrats that I think pay a reasonable dividend, but also have a shot at capital gains.
Dividend Aristocrats to Buy: AbbVie (ABBV)
Source: Black Stripe via Wikimedia (Modified)
Dividend Yield: 4.2%
Long-Term Earnings Growth: 15%
The first choice for Dividend Aristocrats is one I frankly didn't expect, but after checking it's financials, I think it may have the best chance for per-share earnings growth in 2017 - AbbVie Inc (NYSE: ABBV ).
ABBV is a spinoff of the famous Abbott Laboratories (NYSE: ABT ). It primarily serves the oncology, immunology and virology therapeutic sectors, but it's moving into neuroscience.
It would stand to reason that a pharma play would have the best shot at growth. Even though blockbuster Humira is coming off patent, earnings are pegged to rise 13% this year and 15%-plus annually over the next five years. A new lymphoma drug just got approved , as well.
The quarterly dividend just got bumped 12% to 64 cents per share, giving ABBV a yield of about 4.4%. I think ABBV may be reasonably priced here, and I frankly don't see too much long-term risk.
Dividend Aristocrats to Buy: Cardinal (CAH)
Source: Via Wikimedia
Dividend Yield: 2.4%
Long-Term Earnings Growth: 10%
At 2.4%, Cardinal Health Inc (NYSE: CAH ) doesn't have a whopper of a yield as far as Dividend Aristocrats go, but it has a great opportunity for growth going forward. Distribution is one of the best areas to be invested. With its footprint and infrastructure, Cardinal's ability to distribute supplies of any kind (healthcare in this case) will net some pretty thick margins.
There's no fuss or muss regarding manufacturing or quality control. Distributors just need to get the product to the church on time. CAH has a massive 25,000 customer pharmacies it distributes to - everything from generics and OTC to specialty pharma. It also distributes consumer products and handles logistics involving inventory management, pricing, chargebacks and the like.
It also has a medical, surgical and lab products segment that distributes those products to relevant places.
10 Stocks to Buy to Survive a "Trumpsy-Turvy" 2017
CAH is a solid 10% earnings grower over the next five years, with well over $2.5 billion of free cash flow even after paying $465 million in annual dividends.
Dividend Aristocrats to Buy: Hormel (HRL)
Source: Mike Mozart via Flickr (Modified)
Dividend Yield: 1.9%
Long-Term Earnings Growth: 8%
It may sound wacky, but Hormel Foods Corp (NYSE: HRL ) may have a crack at 8% to 10% earnings growth going forward, on top of its 88 straight years of paying dividends - and raising it 51 years in a row. The 1.88% yield is nothing to get too excited about for one of these Dividend Aristocrats, but HRL may just have some bright per-share earnings gains coming even beyond what is projected.
Yes, Hormel is the company behind the famous Spam. But here's the key difference between HRL and the struggling snack food "blue-chips stocks": protein. HRL pushes meats as a snack. In fact, that's one of its catchphrases for marketing.
It makes Jennie-O meats and Skippy peanut butter, along with other protein products like Muscle Milk, Natural Choice Meats, Rev wraps and other popular bacon products.
Hormel is also making a big push into organics, which, as we know, is what grocery stores have been demanding, making the future look very protein-rich indeed for its bottom line.
Lawrence Meyers is the CEO of PDL Capital, and manager of the forthcoming Liberty Portfolio stock newsletter. As of this writing, has no position in any stock mentioned. He has 22 years' experience in the stock market, and has written more than 1,600 articles on investing. Lawrence Meyers can be reached at TheLibertyPortfolio@gmail.com.
The post 3 Dividend Aristocrats to Buy for Income and Growth appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBV is a spinoff of the famous Abbott Laboratories (NYSE: ABT ). With its footprint and infrastructure, Cardinal's ability to distribute supplies of any kind (healthcare in this case) will net some pretty thick margins. 10 Stocks to Buy to Survive a "Trumpsy-Turvy" 2017 CAH is a solid 10% earnings grower over the next five years, with well over $2.5 billion of free cash flow even after paying $465 million in annual dividends. | ABBV is a spinoff of the famous Abbott Laboratories (NYSE: ABT ). Dividend Aristocrats to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 4.2% Long-Term Earnings Growth: 15% The first choice for Dividend Aristocrats is one I frankly didn't expect, but after checking it's financials, I think it may have the best chance for per-share earnings growth in 2017 - AbbVie Inc (NYSE: ABBV ). Dividend Aristocrats to Buy: Cardinal (CAH) Source: Via Wikimedia Dividend Yield: 2.4% Long-Term Earnings Growth: 10% At 2.4%, Cardinal Health Inc (NYSE: CAH ) doesn't have a whopper of a yield as far as Dividend Aristocrats go, but it has a great opportunity for growth going forward. | ABBV is a spinoff of the famous Abbott Laboratories (NYSE: ABT ). Dividend Aristocrats to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 4.2% Long-Term Earnings Growth: 15% The first choice for Dividend Aristocrats is one I frankly didn't expect, but after checking it's financials, I think it may have the best chance for per-share earnings growth in 2017 - AbbVie Inc (NYSE: ABBV ). Dividend Aristocrats to Buy: Cardinal (CAH) Source: Via Wikimedia Dividend Yield: 2.4% Long-Term Earnings Growth: 10% At 2.4%, Cardinal Health Inc (NYSE: CAH ) doesn't have a whopper of a yield as far as Dividend Aristocrats go, but it has a great opportunity for growth going forward. | ABBV is a spinoff of the famous Abbott Laboratories (NYSE: ABT ). 10 High-Yield Dividend Stocks That Are SOMEHOW Still Bargains So here are three Dividend Aristocrats that I think pay a reasonable dividend, but also have a shot at capital gains. Dividend Aristocrats to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 4.2% Long-Term Earnings Growth: 15% The first choice for Dividend Aristocrats is one I frankly didn't expect, but after checking it's financials, I think it may have the best chance for per-share earnings growth in 2017 - AbbVie Inc (NYSE: ABBV ). |
33699.0 | 2017-01-24 00:00:00 UTC | 3 Stocks with Great Earnings Charts | ABT | https://www.nasdaq.com/articles/3-stocks-great-earnings-charts-2017-01-24 | nan | nan | Earnings season is heading into the spotlight. This week, over 400 companies are reporting including many in the S&P 500.
Tracey dug through all of the charts to find only the best.
Despite what you might think, it's not easy for companies to beat every quarter or nearly every quarter. It's only a select few who have this amazing track record.
But here are three large cap companies who have that great record and they're looking to do it again this week.
1. Abbott Labs ABT hasn't missed in 5 years but shares still lag. The Street is ignoring it. Is this a hidden gem?
2. Boeing BA has a great record with just 1 miss in in the last 5 years. Shares are breaking out to new 5-year highs. Can they hold onto the momentum?
3. Citrix Systems CTXS has beat every quarter for 5 years but the shares were stuck doing the see-saw until 2016 when they finally broke out of the narrow range and surged to new highs. Is there a new story for this stock?
What else should you know about these earnings charts? Tune into the short video to find out.
Want to Learn How to Trade Options During Earnings Season?
Dave Bartosiak takes you through the options trade this earnings season on Youtube on Zacks LIve Trader .
How'd he do on the Alibaba (BABA) trade?
Check it out below:
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +26% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 11X worse than the market. See these critical buys and sells free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boeing Company (The) (BA): Free Stock Analysis Report
Citrix Systems, Inc. (CTXS): Free Stock Analysis Report
Alibaba Group Holding Limited (BABA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ABT hasn't missed in 5 years but shares still lag. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boeing Company (The) (BA): Free Stock Analysis Report Citrix Systems, Inc. (CTXS): Free Stock Analysis Report Alibaba Group Holding Limited (BABA): Free Stock Analysis Report To read this article on Zacks.com click here. Citrix Systems CTXS has beat every quarter for 5 years but the shares were stuck doing the see-saw until 2016 when they finally broke out of the narrow range and surged to new highs. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boeing Company (The) (BA): Free Stock Analysis Report Citrix Systems, Inc. (CTXS): Free Stock Analysis Report Alibaba Group Holding Limited (BABA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in 5 years but shares still lag. Plus, you may download 220 Zacks Rank #5 "Strong Sells." | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boeing Company (The) (BA): Free Stock Analysis Report Citrix Systems, Inc. (CTXS): Free Stock Analysis Report Alibaba Group Holding Limited (BABA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in 5 years but shares still lag. Check it out below: The Best & Worst of Zacks Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boeing Company (The) (BA): Free Stock Analysis Report Citrix Systems, Inc. (CTXS): Free Stock Analysis Report Alibaba Group Holding Limited (BABA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in 5 years but shares still lag. Boeing BA has a great record with just 1 miss in in the last 5 years. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.